NOVEL INTEGRIN RECEPTOR ANTAGONISTS

Abstract: This invention relates to novel heterocycles including 3-[1-[3-(imidazolin-2-ylamino)propyl]indazol-5-ylcarbonylamino]-2-(benzyloxycarbonylamino)propionic acid, which are useful as antagonists of the alpha v beta 3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiongenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

Description: TITLE Novel Integnn Receptor Antagonists FIELD OF THE INVENTION This invention relates to novel heterocycles which are useful as antagonists of the α v β 3 integnn and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis. BACKGROUND ΩF THE INVENTION Angiogenesis or neovasculanzation is critical for normal physiological processes such as embryonic development and wound repair (Folkman and Shmg, J. Biol. Chem. 1992, 2£2: 10931-10934; D'Amore and Thompson, Ann. Rev. Physiol. 1987, 41:453-464). However, angiogenesis also occurs pathologically, for example, in ocular neovasculanzation (leading to diabetic retinopathy, neovascular glaucoma, retinal vein occlusion and blindness) , in rheumatoid arthritis and in solid tumors (Folkman and Shmg, J. Biol. Chem., 1992, 2 1'.10931-10934; Blood and Zetter, Biochim. Biophys. Acta., 1990, 1032:118-1281. Tumor dissemination, or metastasis, involves several distinct and complementary components, including the penetration and traversing of tumor cells through basement membranes and the establishment of self- sustaining tumor foci in diverse organ systems. To this end, angiogenesis is critical to tumor survival. Without neovasculanzation, tumor cells lack the nourishment to divide and will not be able to leave the primary tumor site (Folkman and Shmg, J. Biol. Chem., 1992, 2ϋZ: 10931-10934) . Inhibition of angiogenesis animal models of cancer has been shown to result tumor growth suppression and prevention of metastatic growth (Herblm et al., Exp. Opm. Ther. Patents, 1994, 1-14) . Many angiogenic inhibitors have been directed toward blocking initial cytokine-dependent induction of new vessel growth, e.g. antibodies to endothelial cell growth factors. However, these approaches are problematic because tumor and inflammatory cells can secrete multiple activators of angiogenesis (Brooks et al., Cell, 1994, 12.: 1157-1164) . Therefore, a more general approach that would allow inhibition of angiogenesis due to a variety of stimuli would be of benefit. The integnn ctvfo, sometimes called the vitronectin receptor, is preferentially expressed on angiogenic blood vessels m chick and man (Brooks et al., Science, 1994, 264:569-571: Enenste and Kramer, J. Invest. Der atol., 1994, l_H:381-386). <*vβ3 is the most promiscuous member of the integnn family, allowing endothelial cells to interact with a wide variety of extracellular matrix components (Hynes, Cell, 1992, iϋ: 11-25) . These adhesive interactions are considered to be critical for angiogenesis since vascular cells must ultimately be capable of invading virtually all tissues. While mtegrm ctv promotes adhesive events important for angiogenesis, this receptor also transmits signals from the extracellular environment to the intracellular compartment (Leavesley et al., J. Cell Biol., 1993, 121:163-170, 1993) . For example, the interaction between the otvβ 3 mtegrm and extracellular matrix components promotes a calcium signal required for cell motility. During endothelium injury, the basement membrane zones of blood vessels express several adhesive proteins, including but not limited to von Willebrand factor, fibronectin, and fibrm. Additionally, several members of the mtegrm family of adhesion receptors are expressed on the surface of endothelial, smooth muscle and on other circulating cells. Among these lntegrms is αvβ 3 , the endothelial cell, fibroblast, and smooth muscle cell receptor for adhesive proteins including von Willebrand factor, fibrinogen (fibrm), vitronectin, thrombospondin, and osteopontm. These integrins initiate a calcium-dependent signaling pathway that can lead to endothelial cell ar.d smooth muscle cell migration and, therefore, may play a fundamental role in vascular cell biology. Recently, an antibody to the c_vβ 3 mtegrm has been developed that inhibits the interaction of this mtegrm with agonists such as vitronectin (Brooks et al., Science, 1994, 264:569-571) . Application of this antibody has been shown to disrupt ongoing angiogenesis on the chick chonoallantoic membrane (CAM) , leading to rapid regression of histologically distinct human tumor transplanted onto the CAM (Brooks et al., Cell, 1994, 21:1157-1164) . In this model, antagonists of the αyβ 3 integnn induced apoptosis of the proliferating angiogenic vascular cells, leaving pre-existing quiescent blood vessels unaffected. Thus, <χvβ 3 mtegrm antagonists have been shown to inhibit angiogenesis and are recognized as being useful as therapeutic agents for the treatment of human diseases such as cancer, restenosis, thromoembolic disorders, rheumatoid arthritis and ocular vasculopathies (Folkman and Shmg, J. Biol. Chem., 1992, 267:10931-109341. Increasing numbers of other cell surface receptors have been identified which bind to extracellular matrix ligands or other cell adhesion ligands thereby mediating cell-cell and cell-matrix adhesion processes. Like the ctvβ 3 mtegrm, these receptors belong to the mtegrm gene superfamily and are composed of heterodimeric transmembrane glycoprotems containing α- and β-subunits. Integnn subfamilies contain a common β-subunit combined with different α-subunits to form adhesion receptors with unique specificity. The genes for eight distinct β-subumts have been cloned and sequenced to date. The mtegrm αvβ 3 is a member of the β integnn subfamily and has been described on platelets, endothelial cells, melanoma, smooth muscle cells, and osteoclasts (Horton and Davies, J. Bone Mm. Res. 1989, 1:803-808; Davies et al . , J. Cell. Biol. 1989, 102:1817- 1826; Horton, Int. J. Exp. Pat oi., 1990, 21:741-759). Like the major platelet mtegrm GPIIb/IIIa, the vitronectin receptor binds a variety of RGD-containing adhesive proteins such as vitronectin, fibronectin, von Willibrand factor, fibrinogen, osteopontm, bone sialoprote II and thrombospond in a manner mediated by the RGD sequence. A key event m bone resorption is the adhesion of osteoclasts to the matrix of bone. Studies with monoclonal antibodies have implicated the <Xvβ3 receptor this process and suggest that a selective ctvβ3 antagonist would have utility in blocking bone resorption in diseases such as osteoporosis (Horton et al., J. Bone Miner. Res., 1993, 8:239-247; Helfnch et al., J. Bone Miner. Res., 1992, 7:335-343) . PCT Patent Application Publication Number WO94/08962, published April 28, 1994 discloses fibrinogen receptor antagonists of the general formula shown below: European Patent Application Publication Number 655,439, published May 31, 1995 discloses fibrinogen receptor antagonists of the general formula shown below: PCT Patent Application Publication Number W095/17397, published June 29, 1995, discloses fibrinogen receptor antagonists of the general formula shown below: PCT Patent Application Publication Number WO96/20192, published July 4, 1996, discloses fibrinogen receptor antagonists of the general formula shown below: Co-pend g, commonly assigned U.S. Patent Application Serial Number 08/455,768 filed 5/31/95 discloses mtegrm inhibitors of the general formula shown below: None of the above references discloses or suggests the compounds of the present invention which are described in detail below. SUMMARY OF THE INVENTION The present invention provides novel nonpeptide compounds which bind to integnn receptors thereby altering cell-matrix and cell-cell adhesion processes. The compounds of the present invention are useful for the inhibition of cell adhesion and the treatment (including prevention) of angiogenic disorders, inflammation, bone degradation, cancer metastases, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis. One aspect of this invention provides novel compounds of Formula la, lb or Ic (described below) which are useful as antagonists of the ctvβ 3 integnn. The ctvβ 3 mtegrm is also referred to as the ctvβ 3 receptor or the vitronectin receptor. The compounds of the present invention inhibit the binding of vitronectin or other RGD-contaming ligands to α v β 3 and inhibit cell adhesion. The present invention also includes pharmaceutical compositions containing such compounds, and methods of using such compounds for the inhibition of angiogenesis, and/or for the treatment of disorders mediated by angiogenesis. Another aspect of the present invention comprises agents that inhibit the binding of vitronectin to the α v β 3 receptor for the treatment (including prevention) of thrombosis, which do not significantly alter hemostatic balance and do not significantly inhibit platelet aggregation and do not significantly inhibit coagulation. Also, the compounds of the current invention can be used for the treatment or prevention of restenosis. The present invention also provides novel compounds, pharmaceutical compositions and methods which may be used in the treatment or prevention of other diseases which involve cell adhesion processes, including, but not limited to, rheumatoid arthritis, asthma, allergies, adult respiratory distress syndrome, graft versus host disease, organ transplantation, septic shock, psoriasis, eczema, contact dermatitis, osteoporosis, osteoarthπtis, atherosclerosis, metastasis, wound healing, diabetic retinopathy, ocular vasculopathies, inflammatory bowel disease and other autoimmune diseases. Also included the present invention are pharmaceutical kits comprising one or more containers containing pharmaceutical dosage units comprising a compound of Formula la, ID or Ic, for the therapeutic inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis . DETAILED DESCRIPTION OF THE INVENTION The present invention provides novel compounds of Formula la, lb or Ic (described below) which bind to integnn receptors thereby altering cell-matrix and cell-cell adhesion processes. The compounds of the present invention are useful for the inhibition of cell adhesion and the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastases, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis, in a mammal. One aspect of this invention provides novel compounds of Formula la, lb or Ic (described below) which are useful as antagonists of the c-vfo tegrm. The α v β 3 integnn is also referred to as the ctv 3 receptor or the vitronectin receptor. The compounds of the present invention inhibit the binding of vitronectin or other RGD-containing ligands to αvβ 3 and inhibit cell adhesion. The present invention also includes pharmaceutical compositions containing such compounds of Formula la, lb or Ic, and methods of using such compounds for the inhibition of angiogenesis, and/or for the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastases, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis, in a mammal . [1] One aspect of the present invention comprises compounds of Formula la: la including stereoisomenc forms thereof, or mixtures of stereoisomenc forms thereof, or pharmaceutically acceptable salt or prodrug forms thereof, wherein: X 1 , X 2 , X 3 , and X 4 are independently selected from nitrogen or carbon provided that at least two of X 1 , X 2 , X 3 and X 4 are carbon; R 1 is selected from: -U(NR 6 ) ( A and B are independently -CH 2 -, -0-, -N(R 2 )-, or -C(=0)-; A 1 and B 1 are independently -CH 2 - or -N(R 3 )-; D s -N(R 2 )-, -0-, -S-, -C(=0)- or -S0 2 -; -C ( R ) 2 C ( R 5) 2 -; J, K, L and M are independently selected from -C(R 4 )-, -C(R 5 )- or -N-, provided that at least one of J, K, L and M is not -N-; R 2 is selected from: H, Ci-Cβ alkyl, (Ci-Cβ alkyl) carbonyl, (Ci-Cβ alkoxy) carbonyl; (Ci-Cβ alkyl)aminocarbonyl, C 3 -C 6 alkenyl, C -C 7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, heteroaryl (Ci-Cβ alkyl) carbonyl, heteroarylcarbonyl, aryl (Ci-C δ alkyl)-, (Ci-Cβ alkyl) carbonyl-, arylcarbonyl, Ci-Cβ alkylsulfonyl, arylsulfonyl, ary iCi-Ce alkyl) sulfonyl, heteroarylsulfonyl, heteroaryl (Ci-C δ alkyl) sulfonyl, aryloxycarbonyl , or aryl(Cι-Ce alkoxy) carbonyl, wherein said aryl groups are substituted with 0-2 substituents selected from the group consisting of C 1 -C4 alkyl, C 1 -C 4 alkoxy, halo, CF , and nitro; R 3 is selected from: H, C_-Cό alkyl, C 3 -C 7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl(Cι-C 6 alkyl)-, or heteroaryl (C -C 6 alkyl) - ; R 4 and R 5 are independently selected from: H, C 1 -C 4 alkoxy, NR 2 R 3 , halogen, N0 2 , CN, CF 3 , C]-C 6 alkyl, C -Cβ alkenyl, C -C 7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl (Cι-C 6 alkyl)-, (Ci-Cβ alkyl) carbonyl, (Ci-C δ alkoxy) carbonyl, arylcarbonyl, or alternatively, when substituents on adjacent atoms, R 4 and R 5 can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups selected from: C1-C4 alkyl, C 1 -C 4 alkoxy, halo, cyano, amino, CF 3 , or N0 2 ; U is selected from: - ( CH 2 ) n -, -(CH 2 ) n (CR 7 =CR 8 ) (CH 2 ) m -, -(CH 2 ) n (C≡C) (CH 2 ) m -, - ( CH 2 ) .Q ( CH 2 ) m-, -(CH 2 ) n O(CH 2 ) m -, -(CH 2 ) n N(R 6 ) (CH 2 ) m -, -(CH 2 )nC(=0) (CH 2 ) m -, - (CH 2 ) n (C=0)N(R 6 ) (CH 2 ) m - - (CH 2 ) n N(R 6 ) (C=0) (CH 2 ) m -, or - (CH2) n S(0)p(CH 2 ) m -; wnerein one or more of the methylene groups in U is optionally substituted with R 7 ; Q is selected from 1, 2-cycloalkylene, 1, 2-phenylene, 1, 3-phenylene, 1, 4-phenylene, 2, 3-pyrιdιnylene, 3 , 4-pyrιdmylene, 2 , 4-pyrldmyiene, or 3,4- pyridazinylene; R 6 is selected from: H, C 1 -C 4 alkyl, or benzyl; R 7 and R 8 are independently selected from: H, Cι-C 6 alkyl, C 3 -C 7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl(Cι-C6 alkyl)-, or heteroaryl (Co-C 6 alkyl)-. R 10 is selected from: H, C 1 -C 4 alkoxy substituted with 0- 1 R 21 , N(R 6 ) 2 , halogen, N0 2 , CN, CF 3 , C0 2 R 17 , C(=0)R 17 , CONR 17 R 20 , -S0 2 R 17 , -S0 2 NR 17 R 20 , Ci-Cβ alkyl substituted with 0-1 R 15 or 0-1 R 21 , C 3 -C 6 alkenyl substituted with 0-1 R 15 or 0-1 R 21 , C3-C7 cycloalkyl substituted with 0-1 R 15 or 0-1 R 21 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 or 0-1 R 21 , aryl substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 , or aryl(Cι-C δ alkyl)- substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 ; R 11 is selected from H, halogen, CF 3 , CN, N0 2 , hydroxy, NR 2 R 3 , C 1 -C 4 alkyl substituted with 0-1 R 21 , C1-C4 alkoxy substituted with 0-1 R 21 , aryl substituted with 0-1 R 21 , aryl(Cι-C 6 alkyl)- substituted with 0-1 R 21 , (C 1 -C 4 alkoxy) carbonyl substituted with 0-1 R 21 , (C1-C4 alkyl)carbonyl substituted with 0-1 R 21 , C1-C4 alkylsulfonyl substituted with 0-1 R 21 , or C1-C4 alkylammosulfonyl substituted with 0-1 R 21 ; W is selected from: - (C(R 12 ) 2 ) q C(=0)N(R 13 )-, or -C(=0)-N(R l3 )-(C(R 12 ) 2 ) q -; X is -C(R 12 ) (R 1 )-C(R 12 ) (R 15 ) -; or alternatively, W and X can be taken together to be R 12 is selected from H, halogen, Cι-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -Cβ alkynyl, C -C 7 cycloalkyl, C4-C10 cycloalkylalkyl, (C 1 -C 4 alkyl)carbonyl, aryl, or aryl(Cι-Cδ alkyl) -; R 13 is selected from H, Cι-C 6 alkyl, C 3 -C7 cycloalkylmethyl, or aryl(Cι-C 6 alkyl)-; R 14 is selected from: H, Ci-Ce alkylthιo(Cι-C 6 alkyl)-, aryl(Cι-Cιo alkylthioalkyl) - , aryl (C 1 -C 1 0 alkoxyalkyl) -, C1-C 1 0 alkyl, C 1 -C 10 alkoxyalkyl, CI-CΘ hydroxyalkyl, C 2 -Cιo alkenyl, C 2 -Cιo alkynyl, C -Cιo cycloalkyl, C 3 -C 10 cycloalkylalkyl, aryKCi-Cβ alkyl)-, heteroaryl (Ci-Ce alkyl) -, aryl, heteroaryl, CO 2 R 17 , C(=0)R 17 , or CONR 17 R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 0-1 R 16 or 0-2 R 11 ; R 15 is selected from: H, R 16 , Ci-Cio alkyl, Ci-Cio alkoxyalkyl, Ci-Cio alkylammoalkyl, Ci-C o dialkylaminoalkyl, (Ci-Cio alkyl) carbonyl, aryl (Co-Cβ alkyl ) carbonyl , Ci-Cio alkenyl, Ci-Cio alkynyl ,C 3 -Cιo cycloalkyl, C3-C10 cycloalkylalkyl, aryl(Cι-C 6 alkyl)-, heteroaryl (Ci-Ce alkyl) -, aryl, heteroaryl, C0 2 R 17 , C(=0)R 17 , C0NR 17 R 20 , S0 2 R 17 , or S0 NR 17 R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 0-2 R 11 ; Y is selected from: -COR 19 , -ΞO 3 H, -P0 3 H, tetrazolyl, -CONHNHS0 2 CF 3 , -CONHS0 2 R 17 , -CONHS0 2 NHR 17 , -NHCOCF 3 , -NHCONHSO 2 R 17 , -NHS0 2 R 17 , -OP0 3 H 2 , -OS0 3 H, -P0 3 H 2 , -S0 3 H, -S0 2 NHCOR 17 , -S0 2 NHC0 R 17 , R 16 is selected from: -N(R 20 )-C(=O)-O-R 17 , -N(R 20 )-C(=O)-R 17 , -N(R 20 )-C(=O)-NH-R 17 , -N(R 20 )S0 2 -R 17 , or -N(R 20 )SO 2 -NR 20 R 17 ; R 17 is selected from: C 1 -C 10 alkyl, C 3 -C 11 cycloalkyl, aryl(Cι-C 6 alkyl ) -, (Ci-Cβ alkyl)aryl, heteroaryl (Cι-C 6 alkyl) -, (Cι-C 6 alkyl)heteroaryl, biaryl (Cι-C 6 alkyl) - , heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C alkyl, C1-C4 alkoxy, aryl, heteroaryl, halo, cyano, ammo, CF 3 , and NO2; R 1 is selected from: H, -C(=0)-0-R 17 , -C(=0)-R 17 , -C(=0)-NH-R 17 , -S0 2 -R 17 , or -SO 2 -NR 0 R 17 ; R 19 is selected from: hydroxy, C1-C 10 alkyloxy, C 3 -C 11 cycloalkyloxy, aryloxy, aryl (Cι-C 6 alkoxy)-, C3-C10 alkylcarbonyloxyalkyloxy, C -Cιo alkoxycarbonyloxyalkyloxy, C 2 -Cιo alkoxycarbonylalkyloxy, C5-C1 0 cycloalkylcarbonyloxyalkyloxy, C5-C1 0 cycloalkoxycarbonyloxyalkyloxy, C 5 -C1 0 cycloalkoxycarbonylalkyloxy, C7-C11 aryloxycarbonylalkyloxy, C 8 -C12 aryloxycarbonyloxyalkyloxy, Cg-Ci2 arylcarbonyloxyalkyloxy, C5-C10 alkoxyalkylcarbonyloxyalkyloxy, C5-C1 0 (5-alkyl-l, 3-dioxa-cyclopenten-2-one- yDmethyloxy, C 10 -C14 (5-aryl-l, 3-dioxa-cyclopenten- 2-one-yl)methyloxy, or (R 11 ) (R 12 )N- (C1-C10 alkoxy) -; R 20 is selected from: H, Cι-C 6 alkyl, C -C7 cycloalkyl, C4-C11 cycloalkylalkyl, aryl, aryl (C1-C6 alkyl) -, or heteroaryl (Ci-Cδ alkyl) - ; R 21 is selected from: COOH or NR 6 2; m is 0-4; and with the following provisos: (1) r , n, and q are chosen such that the number of atoms connecting R 1 and Y s in the range of 10-14; and (2) n and m are chosen such that the value of n plus m is greater than one ^ r.leεs " T is - 'CH?. -O ' H- '.(,-• [2] Preferred compounds of the invention as described above are compounds of the Formula la: la including stereoisomenc forms thereof, or mixtures of stereoisomeric forms thereof, or pharmaceutically acceptable salt or prodrug forms thereof, wherein: X 1 , X 2 , X 3 , and X 4 are independently selected from nitrogen or carbon provided that at least two of X 1 , X 2 , X 3 and X 4 are carbon; R 1 is selected from: A and B are independently -CH 2 -, -0- , -N(R 2 )-, or -C(=0)-; A 1 and B 1 are independently -CH 2 - or -N(R 3 )-; D is -N(R 2 )-, -0-, -S-, -C(=0)- or -S0 2 -; E-F is -C(R )=C(R 5 )-, -N=C(R 4 )-, -C(R 4 )=N-, or -C(R ) 2 C(R 5 ) 2 -; J, K, L and M are independently selected from -C(R 4 )-, -C(R 5 )- or -N-, provided that at least one of J, K, L and M is not -N-; R 2 is selected from: H, Cι-C 6 alkyl, (Cι-C 6 alkyl)carbonyl, (Ci-C δ alkoxy) carbonyl, Cχ-C6 alkylaminocarbonyl, C 3 -C 6 alkenyl, C 3 -C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, heteroaryl (Ci-Cβ alkyl)carbonyl, heteroarylcarbonyl, aryl (Ci-Cβ alkyl)-, (Ci-C δ alkyl)carbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, aryKCi-C δ alkyl) sulfonyl, heteroarylsulfonyl, heteroaryl (Ci- Cβ alkyl)sulfonyl, aryloxycarbonyl, or aryl (Cι-C 6 alkoxy) carbonyl, wherein said aryl groups are substituted with 0-2 substituents selected from the group consisting of C 1 -C4 alkyl, C 1 -C 4 alkoxy, halo, CF 3 , and nitro; R 3 is selected from: H, Ci-Cβ alkyl, C 3 -C 7 cycloalkyl, C4-C11 cycloalkylalkyl, aryl, aryl(Cι-C 6 alkyl)-, or heteroaryl (C1-C0 alkyl)-,. R 4 and R 5 are independently selected from: H, C 1 -C 4 alkoxy, NR 2 R 3 , halogen, N0 2 , CN, CF 3 , Cι-C 6 alkyl, 3 -Cβ alkenyl, C3-C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl (Cι-C 6 alkyl) -, C 2 -C 7 alkylcarbonyl, arylcarbonyl or alternatively, when substituents on adjacent atoms, R 4 and R 5 can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups selected from: C 1 -C4 alkyl, C 1 -C 4 alkoxy, halo, cyano, ammo, CF 3 , or N0 2 ; U is selected from: -(CH 2 ) n -, -(CH 2 ) n (CR 7 =CR 8 ) (CH 2 ) m -, -lCH 2 ) t Q(CH?) ,,-, -(CH 2 ) n O(CH 2 ) m -, -(CH 2 ) n N(R 6 ) (CH 2 ) m -, -(CH 2 ) n C(=0) (CH 2 ) m -, or -(CH 2 )nS ( 0 ) p ( CH 2 ) m-; wherein one or more of the methylene groups in U s optionally substituted with R 7 ; 0 s selectei frc τ n 1, 2-cr.εry_.e.-.e, 1, 3-pher.y-.ene, 2,3- pyndinylene, 3 , 4-tyriJir.y.r.e, or 2,4- R 6 is selected from: H, C 1 -C 4 alkyl, or benzyl; R 7 and R 8 are independently selected from: H, Ci-Cβ alkyl, C 3 -C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl(C_-C6 alkyl)-, or heteroaryl (Co-C ό alkyl)-,- R 10 is selected from: H, C 1 -C 4 alkoxy substituted with 0-1 R 21 , N(R 6 ) 2 , halogen, N0 2 , CN, CF 3 , C0 2 R 17 , C(=0)R 17 , CONR 17 R 20 , -S0 2 R 17 , -S0 2 NR 17 R 20 , Cχ-C 5 alkyl substituted with 0-1 R 15 or 0-1 R 21 , C 3 -C 6 alkenyl substituted with 0-1 R 15 or 0-1 R 21 , C 3 -C 7 cycloalkyl substituted with 0-1 R 15 or 0-1 R 21 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 or 0-1 R 21 , aryl substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 , or aryKC -Cβ alkyl)- substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 ; R 11 is selected from: H, halogen, CF 3 , CN, N0 , hydroxy, NR 2 R 3 , C 1 -C 4 alkyl substituted with 0-1 R 21 , C1-C4 alkoxy substituted with 0-1 R 21 , aryl substituted with 0-1 R 21 , aryl(Cι-C 6 alkyl)- substituted with 0-1 R 21 , (C 1 -C 4 alkoxy) carbonyl substituted with 0-1 R 21 , (C 1 -C 4 alkyl) carbonyl substituted with 0-1 R 21 , C 1 -C 4 alkylsulfonyl substituted with 0-1 R 21 , or C 1 -C4 alkylammosulfonyl substituted with 0-1 R 21 ; X is -C(R 12 ) (R 14 )-C(R 12 ) (R 15 )-; alternatively, W and X can be taken together to be R 12 is H or Cι-C 6 alkyl; R 13 is selected from: H, Ci-Ce alkyl, C3-C7 cycloalkylmethyl, or aryl(Cι-C 6 alkyl)-; R 14 is selected from: H, Ci-Cβ alkylthioalkyl, aryl(Cι-Cιo alkylthioalkyl) -, aryl (C1-C 1 0 alkoxyalkyl) -, C 1 -C 10 alkyl, Cχ-Cιo alkoxyalkyl, Ci-Ce hydroxyalkyl , C 2 -Cιo alkenyl, C 2 -Cχ 0 alkynyl, C 3 -C 10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl(Cι-C 6 alkyl)-, heteroaryl (Cχ-C6 alkyl)-, aryl, heteroaryl, C0 2 R 17 , C(=0)R 17 , or CONR 17 R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be substituted independently with 0-1 R 16 or 0-2 Rll; R 15 is selected from: H, R 16 , C1-C10 alkyl, C 1 -C 1 0 alkoxyalkyl, C1-C 1 0 alkylaminoalkyl, C 1 -C 10 dialkylaminoalkyl, C 1 -C10 alky1carbonyl, aryl (Co-Ce alkyl) carbonyl, C -Cιo alkenyl, C -Cιo alkynyl ,C 3 -C 10 cycloalkyl, C 3 -C 10 cycloalkylalkyl, aryl(Cι-C 6 alkyl)-, heteroaryl (Ci-Cβ alkyl)-, aryl, heteroaryl, C0 2 R 17 , C(=0)R 17 , CONR 17 R 20 , S0 2 R 17 , or Sθ 2 R 17 R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be substituted independently with 0-2 R 11 ; Y is selected from: R 16 is selected from: -N(R 20 ) -C(=0)-0-R 17 , -N(R 20 )-C(=O) -R 17 , -N(R 20 ) -C(=0)-NH-R 17 , -N(R 20 )S0 2 -R 17 , or -N(R 20 ) SO 2 -NR 20 R 17 ; R 17 is selected from: Ci-Cio alkyl, C3-C11 cycloalkyl, aryl (Cχ-C 6 alkyl)-, (Ci-Cδ alkyl)aryl» heteroaryl (Ci-Cβ alkyl)-, (Cχ-C 6 alkyl) heteroaryl, biaryKCi-Cβ alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, heteroaryl, halo, cyano, ammo, CF 3 , and N0 2 ; R lθ is selected from: H, -C(=0)-0-R 17 , -C(=0)-R 17 , -C(=0)-NH-R 17 , -SO2-R 17 , or -SO 2 -NR 20 R 17 ; R 19 is selected from: hydroxy, C 1 -C 10 alkyloxy, C 3 -C 11 cycloalkyloxy, Cβ-Cio aryloxy, C 7 -C 11 aralkyloxy, C 3 -C 10 alkylcarbonyloxyalkyloxy, C 3 -C 10 alkoxycarbonyloxyalkyloxy, C 2 -Cιo alkoxycarbonylalkyloxy, C5-C 1 0 cycloalkylcarbonyloxyalkyloxy, C 5 -C 10 cycloalkoxycarbonyloxyalkyloxy, C5-C10 cycloalkoxycarbonylalkyloxy, C7-C 11 aryloxycarbonylalkyloxy, Ca-Cχ 2 aryloxycarbonyloxyalkyloxy, δ ~ ι 2 arylcarbonyloxyalkyloxy, C5-C10 alkoxyalkylcarbonyloxyalkyloxy, C5-C10 (5-alkyl-l, 3-dιoxa-cyclopenten-2-one- yD ethyloxy, C 10 -C14 (5-aryl-l, 3-dιoxa-cyclopenten- 2-one-yl)methyloxy, or (R 11 ) (R 12 ) N- (Cχ-Cιo alkoxy)-; R 20 selected from: H, Cι~C 6 alkyl, C 3 -C 7 cycloalkyl, C 4 - Cn cycloalkylalkyl, aryl(Cχ-C6 alkyl)-, or heteroaryl (Cχ-C6 alkyl) -• R 21 is selected from COOH or NR 6 ; and [3] Further preferred compounds of the invention as described above are compounds of the Formula Ila or lib: Ila lib including stereoisomenc forms tnereof, or mixtures of stereoisomenc forms thereof, or pharmaceutically acceptable salt or prodrug forms thereof wherein: Xi and X3 are independently selected from nitrogen or carbon; R 1 is selected from: wherein the above heterocycles are optionally substituted with 0-2 substituents selected from the group consisting of: NH 2 , halogen, NO2, CN, CF3, C - C4 alkoxy, Ci-Cβ alkyl, and C3-C7 cycloalkyl; U is -(CH 2 )n-, - ( CH? ) L Q l CH? . n - or -C (=0) (CH 2 ) n -l"- wherein one of the methylene groups is optionally substituted with R 7 ; Q s selected frcrπ 1 , 2-phεr.yle:.e, 1 , 3 -pheny ene, 2,3- pyridmylene, 3 , 4- .yndinyier.e, or 2,4- pyridinyierie; R 6 is selected from: H, C1-C4 alkyl, or benzyl; R7 is selected from: Ci-Cβ alkyl, C 3 -C 7 cycloalkyl, C4- C 1 1 cycloalkylalkyl, aryl, aryl (Ci-Cβ alkyl) , heteroaryl, or heteroaryl (Ci-Cβ alkyl) ; R 10 is selected from: H, Cχ-C alkoxy substituted with 0-1 R 21 , halogen, C0 2 R 17 , CONR 17 R 20 , Cχ-C 6 alkyl substituted with 0-1 R 15 or 0-1 R 21 , C3-C 7 cycloalkyl substituted with 0-1 R 15 or 0-1 R 21 , C4-C11 cycloalkylalkyl substituted with 0-1 R 15 or 0-1 R 21 , or aryl(Cι-C 6 alkyl)- substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 ; R 11 is selected from: H, halogen, CF 3 , CN, N0 2 , hydroxy, NR 2 R 3 , C 1 -C4 alkyl substituted with 0-1 R 21 , Cχ-C alkoxy substituted with 0-1 R 21 , aryl substituted with 0-1 R 21 , aryl(Cι-C 6 alkyl)- substituted with 0-1 R 21 , (C1-C4 alkoxy) carbonyl substituted with 0-1 R 21 , (C1-C4 alkyl) carbonyl substituted with 0-1 R 21 , C1-C4 alkylsulfonyl substituted with 0-1 R 21 , or C1-C4 alkylaminosulfonyl substituted with 0-1 R 21 ; W is -C(=0)-N(R 13 )-; X is -CH(R 1 )-CH(R 15 )-; R 13 is H or CH 3; R 14 is selected from: H, C1-C1 0 alkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C4 alkyl, C1-C4 alkoxy, aryl, halo, cyano, ammo, CF 3 , and N0 2 ; R 16 is selected from: -NH(R 20 )-C(=O)-O-R 17 , -N(R 20 )-C(=O)-R 17 , -N(R 20 )-C(=O)-NH-R 17 , -N(R 20 )SO 2 -R 17 , or -N(R 20 )SO 2 -N(R 20 )R 17 ; R 17 is selected from: C1-C10 alkyl, C3-C11 cycloalkyl, aryl(Cι-C 6 alkyl)-, (Cχ-C 6 alkyl)aryl, heteroaryl (Ci-Cβ alkyl)-, (Cι~C 6 alkyl) heteroaryl, biaryl(Cι-C 6 alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C1-C4 alkyl, C1-C4 alkoxy, aryl, heteroaryl, halo, cyano, amino, CF3, and N0 ; R 19 is selected from: hydroxy, Cχ-Cιo alkoxy, methylcarbonyloxymethoxy-, ethylcarbonyloxymethoxy-, t-butylcarbonyloxymethoxy-, cyclohexylcarbonyloxymethoxy- , 1- (methylcarbonyloxy) ethoxy-, 1- (ethylcarbonyloxy) ethoxy- , 1- (t-butylcarbonyloxy) ethoxy- , 1- (cyclohexylcarbonyloxy) ethoxy-, i-propyloxycarbonyloxymethoxy- , t-butyloxycarbonyloxymethoxy- , 1- (l-propyloxycarbonyloxy)ethoxy-, 1- (cyclohexyloxycarbonyloxy) ethoxy- , 1- ( t-butyloxycarbonyloxy) ethoxy-, dimethylammoethoxy-, diethylammoethoxy-, (5-methyl-l, 3-dιoxacyclopenten-2-on-4-yl) ethoxy-, (5- ( -butyl) -1, 3-dιoxacyclopenten-2-on-4- yl)methoxy-, (1 , 3-dιoxa-5-phenyl-cyclopenten-2-on-4-yl)methoxy-, or 1- (2- (2-methoxypropyl) carbonyloxy) ethoxy-; R 21 is selected from COOH or NR 6 ; [4] Still further preferred compounds of the above invention are compounds of the Formula Ila or lib: Ila U including stereoisomeric forms thereof, or mixtures of stereoisomenc forms thereof, or pharmaceutically acceptable salt or prodrug forms thereof wherein: Xi and X 3 are independently selected from nitrogen or carbon, provided that at least one of X_ and X 3 is carbon; R 1 is selected from: CN HON .' wherein the above heterocycles are optionally substituted with 0-2 substituents selected from the group consisting of: NH 2 , halogen, N0 2 , CN, CF 3 , C 1 -C 4 alkoxy, Ci-Ce alkyl, and C 3 -C 7 cycloalkyl; U is -(CH 2 ) n -/ - ( CH 2 ,. L Q;CH ? : M - or -C (=0) (CH 2 ) n -l" > wherein one of the methylene groups is optionally substituted with R 7 ; Q s selected from 1, 2-phenylere, 1, 3-ρnenyierιe, 2,3- pyridmylene, 3 , 4-pyπdmyler.e, or 2,4- pynd ylene; R 6 is selected from: H, C 1 -C 4 alkyl, or benzyl; R7 is selected from: Cχ-C 6 alkyl, C 3 -C 7 cycloalkyl, C4-C11 cycloalkylalkyl, aryl, aryKCi-Cβ alkyl) , heteroaryl, or heteroaryl (Ci-Cβ alkyl); R 10 is selected from: H, C 1 -C 4 alkoxy substituted with 0-1 R- 1 , halogen, C0 R 17 , C0NR 17 R 20 , Ci-Cβ alkyl substituted with 0-1 R 15 or 0-1 R 21 , C 3 -C 7 cycloalkyl substituted with 0-1 R 15 or 0-1 R 21 , C4-C1 1 cycloalkylalkyl substituted with 0-1 R 15 or 0-1 R 21 , or aryl(Cι-C 6 alkyl)- substituted with 0-1 R 15 or 0-2 R or 0-1 R 21 ; R 11 is selected from: H, halogen, CF 3 , CN, N0 2 , hydroxy, NR 2 R 3 , C 1 -C 4 alkyl substituted with 0-1 R 21 , C 1 -C 4 alkoxy substituted with 0-1 R 21 , aryl substituted with 0-1 R 21 , aryl(C -C 6 alkyl)- substituted with 0-1 R 21 , (C 1 -C 4 alkoxy)carbonyl substituted with 0-1 R 21 , (Cχ-C 4 alkyl) carbonyl substituted with 0-1 R 21 , C 1 -C 4 alkylsulfonyl substituted with 0-1 R 21 , or C -C 4 alkyla inosulfonyl substituted with 0-1 R 21 ;W W IS -C(=0)-N(R 13 )-; X is -CH(R 1 )-CH(R 15 )-; R 13 is H or CH 3; R 14 is selected from: H, C 1 -C 10 alkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, halo, cyano, am o, CF3, and N0 2 ; R 16 is selected from: -N(R 20 )-C(=O) -O-R 17 , -N(R 20 )-C(=O)-R 17 , -N(R 20 )-C(=O)-NH-R 17 , -N(R 20 )SO 2 -R 17 , or -N(R 20 )SO 2 -NR 20 R 17 ; R 17 is selected from: Ci-Cio alkyl, C 3 -Cn cycloalkyl, aryl (Cι-C 6 alkyl)-, (Cχ-C 6 alkyl) aryl, heteroaryl (Cχ-C ό alkyl)-, (Ci-Cβ alkyl)heteroaryl, biaryKCi-Cβ alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, heteroaryl, halo, cyano, ammo, CF 3 , and N0 2 ; R 19 is selected from: hydroxy, Cj-Cio alkoxy, methylcarbonyloxymethoxy-, ethylcarbonyloxymethoxy- , t-butylcarbonyloxymethoxy-, cyclohexylcarbonyloxymethoxy-, 1- (methylcarbonyloxy) ethoxy-, 1- (ethylcarbonyloxy) ethoxy-, 1- (t-butylcarbonyloxy) ethoxy-, 1- (cyclohexylcarbonyloxy)ethoxy-, i-propyloxycarbonyloxymethoxy-, t-butyloxycarbonyloxymethoxy-, 1- (l-propyloxycarbonyloxy)ethoxy-, 1- (cyclohexyloxycarbonyloxy) ethoxy- , 1- (t-butyloxycarbonyloxy) ethoxy-, dimethylaminoethoxy-, diethylaminoethoxy-, ( 5-methyl-1, 3-dιoxacyclopen en-2-on-4-yl)methoxy-, (5- (t-butyl) -1,3-dιoxacyclopenten-2-on-4- yl)methoxy-, ( 1, 3-d oxa-5-phenyl-cyclopenten-2-on-4-yl)methoxy-, or 1- (2- (2-methoxypropyl)carbonyloxy)ethoxy-; R 21 s selected from COOH or NR 6 2 ; m s , or _.; t - '- or 1. [5] Specifically preferred compounds of the invention as described above are compounds of Formula la, including enantiomenc or diastenomenc forms thereof, or mixtures of enantiomenc or diastenomenc forms thereof, or pharmaceutically acceptable salt or prodrug forms thereof, selected from the group consisting of: 3- [1- [3- (ιmιdazolm-2-ylamιno)propyl] ιndazol-5- ylcarbonylamino]-2- (benzyloxycarbonylammo)- propionic acid, 3- [1-[3- (ιmιdazolιn-2-ylamιno)propyl] mdazol-5- ylcarbonylammo]-2- (2,4,6-trιmethylbenzene- sulfonylammo)propionic acid, 3- [1- [3- (i idazolin-2-ylammo)propyl] ιndazol-5- ylcarbonylammo]-2- (benzenesulfonylamino) propionic acid, 3- [1-[3- (imidazolin-2-ylamino)propyl]mdazol-5- ylcarbonylamino] -2- (2,6-dιchlorobenzene- sulfonylammo)propionic acid, 3- [1- [3- (imidazolin-2-ylamino)propyl] mdazol-5- ylcarbonylammo]-2- (3,5-dιmethylιsoxazol-4- ylsulfonylam o) propionic acid, 3- [1- [3- (imidazolin-2-ylammo)propyl] indazol-5- ylcarbonylammo] -2- (2, 6-dιmethylbenzene- sulfonylammo(propionic acid, 3- [1- [3- (ιmιdazolm-2-ylamino)propyl] mdazol-5- ylcarbonylammo] -2- (2, 6-dιmethyl-4-phenyl- benzenesulfonylamino)propionic acid, 3- [1- [3- (imidazolin-2-ylammo)propyl] mdazol-5- ylcarbonylamino] -2- (4-phenylbenzenesulfonyl- ammo)propionic acid, 3- [1- [3- (tetrahydropyrιmιd-2-ylammo)propyl] - mdazol-5-ylcarbonylamιno]-2- (benzyloxy- carbonylammo)propionic acid, 3- [1- [3- (tetrahydropyrιmιd-2-ylamino)propyl] - mdazol-5-ylcarbonylammo]-2- (2,4,6-trιmethyl- benzenesulfonylam o)propionic acid, 3- [1- [3- (tetrahydropyrιmιd-2-ylamino)propyl]- mdazol-5-ylcarbonylammo]-2- (benzenesulfonyl- a o) propionic acid, 3- [1-[3- (tetrahydropyπmιd-2-ylammo)propyl] - indazol-5-ylcarbonylammo] -2- (2, 6-dιchloro- benzenesulfonylam o)propionic acid, 3- [1- [3- (tetrahydropyrιmιd-2-ylammo)propyl] - mdazol-5-ylcarbonylammo]-2- (3,5-dιmethyl- ιsoxazol-4-ylsulfonylamino) ropionic acid, 3- [1- [3- (tetrahydropyrιmιd-2-ylammo)propyl] - mdazol-5-ylcarbonylammo] -2- (2, 6-dimethyl- benzenesulfonylamino)propionic acid, 3- [1- [3- (tetrahydropyrιmιd-2-ylamino)propyl]- mdazol-5-ylcarbonylammo] -2- (2,6-dιmethyl-4- phenylbenzenesulfonylamino)propionic acid, 3- [1- [3- (tetrahydropyrιmιd-2-ylammo)propyl]- indazol-5-ylcarbonylammo]-2-(4-phenylbenzene- sulfonylamino)propionic acid, 3- [1- [3- (imidazol-2-ylamino) propyl] mdazol-5-yl¬ carbonylammo] -2- (benzyloxycarbonylammo) - propionic acid, 3- [1- [3- (ιmιdazol-2-ylammo)propyl] mdazol-5-yl- carbonylammo] -2- (2,4, 6-tπmethylbenzene- sulfonylamino) propionic acid, 3- [1- [3- (imidazol-2-ylamino) propyl] mdazol-5-yl- carbonylammo] -2- (benzenesulfonylamino) - propionic acid, 3- [1- [3- (imidazol-2-ylamino) propyl] mdazol-5-yl¬ carbonylammo] -2- (2 , 6-dιchloroben∑ene- sulfonylamino) ropionic acid, 3- [1- [3- (imidazol-2-ylamino) propyl] mdazol-5-yl- carbonylammo] -2- (3, 5-dιmethylιsoxazol-4- ylsulfonylamino) propionic acid, 3- [1- [3- (imidazol-2-ylamino)propyl] mdazol-5-yl- carbonylammo] -2- (2 , 6-dιmethylbenzene- sulfonylamino)propionic acid, 3- [1- [3- (imidazol-2-ylammo) propyl] ιndazol-5-yl- carbonylammo] -2- (2, 6-dιmethyl-4-phenyl- benzenesulfonylamino) propionic acid, 3- [1- [3- (imidazol-2-ylammo)propyl] mdazol-5-yl¬ carbonylammo] -2- (4-phenylbenzenesulfonyl¬ amino)propionic acid, 3- [1- [3- (pyridm-2-ylammo)propyl] ιndazol-5-yl- carbonyla mo] -2- (benzyloxycarbonylammo) - propionic acid, 3- [1- [3- (pyridm-2-ylamino) propyl] ιndazol-5-yl- carbonyla o] -2- (2,4, 6-trιmethylbenzene- sulfonylamino) ropionic acid, 3- [1- [3- (pyrid -2-ylamino) propyl] mdazol-5-yl- carbonylamino] -2- (benzenesulfonylamino) - propionic acid, 3- [1- [3- (pyrid -2-ylammo)propyl] mdazol-5-yl- carbonylammo] -2- (2, 6-dιchlorobenzene- sulfonylamino)propionic acid, 3- [1- [3- (pyrιdm-2-ylammo) propyl] mdazol-5-yl- carbonylammo] -2- (3, 5-dιmethylιsoxazol-4- ylsulfonylamino) propionic acid, 3- [1- [3- (pyrιdm-2-ylammo) propyl] mdazol-5-yl- carbonylammo] -2- (2, 6-dιmethylbenzene- sulfonylamino) ropionic acid, 3- [1- [3- (pyrιdm-2-ylammo) propyl] mdazol-5-yl- carbonylammo] -2- (2, 6-dimethyl-4-phenyl- benzenesulfonylamino) ropionic acid, 3- [1- [3- (pyrιdm-2-ylammo) propyl] ιndazol-5-yl- carbonylammo] -2- (4-phenylbenzenesulfonyl¬ amino) propionic acid, 3- [1- [3- (ιmιdazolιn-2-ylammo)propyl] ιndazol-4- ylcarbonylammo] -2- (benzyloxycarbonylammo) - propionic acid, 3- [1- [3- (ιmιdazolιn-2-ylamιno) ropyl] ιndazol-4- ylcarbonylammo] -2- (2,4, 6-trιmethylbenzene- sulfonylammo) propionic acid, 3- [1- [3- (imidazolin-2-ylammo) propyl] mdazol-4- ylcarbonylammo] -2- (benzenesulfonylamino) propionic acid, 3- [1- (3- (ιmιdazolιn-2-ylam o) propyl] mdazol-4- ylcarbonylammo] -2- (2 , 6-dιchlorobenzene- sulfonylamino) propionic acid, 3- [1- [3- (imidazolin-2-ylammo) propyl] mdazol-4- ylcarbonylammo] -2- (3 , 5-dιmethylιsoxazol-4- ylsulfonylamino) propionic acid, 3- [1- [3- (imidazolin-2-ylammo)propyl] mdazol-4- ylcarbonylammo] -2- (2, 6-dιmethylbenzene- sulfonylamino) propionic acid, 3- [1- [3- (ιmιdazolιn-2-ylamino)propyl] ιndazol-4- ylcarbonylammo] -2- (2, 6-dimethyl-4-pnenyl- benzenesulfonylairu.no)propionic acid, 3- [1- [3- (ιmιdazolιn-2-ylamino) ropyl] mdazol-4- ylcarbonylammo] -2- (4-phenylbenzenesulfonyl ¬ amino) propionic acid, 3- [1- [3- (tetrahydropyrimid-2-ylammo)propyl] - ιndazol-4-ylcarbonylammo] -2- (benzyloxy¬ carbonylammo)propionic acid, 3- [1- [3- (tetrahydropyrιmιd-2-ylammo)propyl] - mdazol-4-ylcarbonylammo] -2- (2,4, 6-tπmethyl- benzenesulfonylamino)propionic acid, 3- [1- [3- (tetrahydropyrimid-2-ylammo)propyl]- mdazol-4-ylcarbonylammo]-2- (benzenesulfonyl¬ amino) propionic acid, 3- [1- [3- (tetrahydropyrιmιd-2-ylamino)propyl] - ιndazol-4-ylcarbonylamιno] -2- (2, 6-dιchloro- benzenesulfonylamino)propionic acid, 3- [1- [3- (tetrahydropyrimid-2-ylammo)propyl]- mdazol-4-ylcarbonylammo] -2- (3, 5-dιmethyl- ιsoxazol-4-ylsulfonylamino)propionic acid, 3- [1- [3- (tetrahydropyrimid-2-ylammo)propyl] - mdazol-4-ylcarbonylammo]-2- (2,6-dιmethyl- benzenesulfonylamino)propionic acid, 3- [1-[3- (tetrahydropyrιmιd-2-ylamιno)propyl] - indazol-4-ylcarbonylammo]-2- (2,6-dιmethyl-4- phenylbenzenesulfonylammo)propionic acid, 3- [1-[3- (tetrahydropyrιmιd-2-ylammo)propyl] - indazol-4-ylcarbonylammo] -2- (4-phenylbenzene- sulfonylamino)propionic acid, 3- [1- [3- (ιmιdazol-2-ylamιno)propyl]ιndazol-4-yl- carbonylamino]-2- (benzyloxycarbonylammo)- propionic acid, 3- [1-[3- (imidazol-2-ylamino)propyl] ιndazol-4-yl- carbonylamino]-2- (2,4, 6-trιmethylbenzene- sulfonylammo)propionic acid, 3- [1-[3- (imidazol-2-ylamino)propyl]indazol-4-yl¬ carbonylammo]-2- (benzenesulfonylamino)- propionic acid, 3- [1-[3- (imidazol-2-ylammo)propyl]ιndazol-4-yl- carbonylammo]-2- (2,6-dιchlorobenzene- sulfonylamino)propionic acid, 3- [1- [3- (ιmιdazol-2-ylammo) propyl] mdazol-4-yl- carbonylammo] -2- (3 , 5-dιmethylιsoxazol-4- ylsulfonylamino) propionic acid, 3- [1- [3- (ιmιdazol-2-ylammo) propyl] ιndazol-4-yl- carbonylammo] -2- (2 , 6-dιmethylbenzene- sulfonylamino) propionic acid, 3- [1- [3- (ιmιdazol-2-ylammo)propyl] mdazol-4-yl- carbonylammo] -2- (2 , 6-dιmethyl-4-phenyl- benzenesulfonylamino) ropionic acid, 3- [1- [3- (imidazol-2-ylammo) propyl] indazol-4-yl¬ carbonylammo] -2- (4-phenylbenzenesulfonyl¬ amino) propionic acid, 3- [1- [3- (pyrιdιn-2-ylammo) propyl] mdazol-4-yl- carbonylam o] -2- (benzyloxycarbonylammo) - propionic acid, 3- [1- [3- (pyrid -2-ylamino) propyl] mdazol-4-yl- carbonylammo] -2- (2, 4, 6-trιmethylbenzene- sulfonylamino)propionic acid, 3- [1- [3- (pyridin-2-ylammo)propyl] mdazol-4-yl- carbonylammo] -2- (benzenesulfonylamino) - propionic acid, 3- [1- [3- (pyrιdιn-2-ylammo) propyl] mdazol-4-yl- carbonylamino] -2- (2, 6-dιchlorobenzene- sulfonylamino)propionic acid, 3- [1- [3- (pyπd -2-ylammo) propyl] mdazol-4-yl- carbonylamino] -2- (3, 5-dιmethylιsoxazol-4- ylsulfonylamino) ropionic acid, 3- [1- [3- (pyrιdm-2-ylamino)propyl] mdazol-4-yl- carbony1amino] -2- (2, 6-dιmethylbenzene- sulfonylamino)propionic acid, 3- [1- [3- (pyrιdιn-2-ylammo) propyl] mdazol-4-yl- carbonylamino] -2- (2, 6-dιmethyl-4-phenyl- benzenesulfonylamino) propionic acid, and 3- (1- [3- (pyrιdιn-2-ylamino)propyl] mdazol-4-yl- carbonylammo] -2- (4-phenylbenzenesulfonyl¬ amino)propionic acid. Also specifically preferred are ester prodrugs of the specifically preferred compounds of Formula la, said esters being chosen from the group consisting Of: methyl, ethyl, isopropyl, n-butyl, isobutyl, benzyl, methylcarbonyloxymethyl, ethylcarbonyloxymethyl, tert-butylcarbonyloxymethyl, cyclohexylcarbonyloxymethyl, tert-butyloxycarbonyloxymethyl, di ethylammoethyl, diethylaminoethyl, πicrpho11noethy1, pyrrol dir.oethyl, and tr me zh 1 mmonIoethy1. [6] Another aspect of the present invention comprises compounds of Formula lb: lb including stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, or pharmaceutically acceptable salt or prodrug forms thereof, wherein: X 1 , X 2 , X 3 , and X 4 are independently selected from nitrogen or carbon provided that at least two of X 1 , X 2 , X 3 and X 4 are carbon; R 1 is selected from: A and B are independently -CH 2 -, -0-, -N(R 2 )-, or -C(=0)- ; A 1 and B 1 are independently -CH 2 - or -N(R 3 )-; D is -N(R 2 )-, -0-, -S-, -C(=0)- or -S0 2 -; -C ( R 4) 2 C ( R 5) 2 -; J, K, L and M are independently selected from: -C(R 4 )-, -C(R 5 )- or -N-, provided that at least one of J, K, L and M is not -N-; R 2 is selected from: H, Ci-Cβ alkyl, (Ci-Cβ alkyl)carbonyl, (Ci-Cβ alkoxy)carbonyl; (Ci-Cβ alkyl)aminocarbonyl, C 3 -C 6 alkenyl, C3-C 7 cycloalkyl, C4-C11 cycloalkylalkyl, aryl, heteroaryl (Cι-C 6 alkyl) carbonyl, heteroarylcarbonyl, aryl Cχ-C 6 alkyl, (Cχ-C 6 alkyl) carbonyl, or arylcarbonyl, Cχ-C 6 alkylsulfonyl, arylsulfonyl, aryl(Cι-C 6 alkyl) sulfonyl, heteroarylsulfonyl, heteroaryl (Ci-Cβ alkyl) sulfonyl, aryloxycarbonyl, or aryl(Cι-Cβ alkoxy) carbonyl, wherein said aryl groups are substituted with 0-2 substituents selected from the group consisting of Cχ-C4 alkyl, C1-C4 alkoxy, halo, CF 3 , and nitro; R 3 is selected from: H, Ci-Ce alkyl, C 3 -C 7 cycloalkyl, C -C 1 cycloalkylalkyl, aryl, aryKCi-Cβ alkyl)-, or heteroaryl (Ci-Cβ alkyl)-,- R 4 and R 5 are independently selected from: H, C1-C4 alkoxy, NR 2 R 3 , halogen, N0 , CN, CF 3 , Ci-C δ alkyl, C3-C 6 alkenyl, C 3 -C7 cycloalkyl, C4-C11 cycloalkylalkyl, aryl, aryl (Ci-Cβ alkyl)-, (Cι-C 6 alkyl) carbonyl, (Ci-Cβ alkoxy) carbonyl, arylcarbonyl, or alternatively, when substituents on adjacent atoms, R 4 and R 5 can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups selected from: C1-C4 alkyl, C1-C4 alkoxy, halo, cyano, ammo, CF3, or N0 2 ; U is selected from: -(CH 2 ) n (CR 7 =CR 8 ) (CH 2 ) m - -(CH 2 ) n (C=C) (CH 2 ) m - - ( CH 2 ) t Q ( CH 2 ) m- - ( CH 2 ) n N(R 6) ( CH 2 ) m -, -(CH 2 ) n C(=0) (CH 2 ) m -, -(CH 2 ) n (C=0)N(R 6 ) (CH 2 ) m - - ( CH 2 ) n N ( R 6) ( C=0 ) ( CH 2 ) m -, or -(CH 2 ) n S(0) p (CH 2 ) rn -; wherein one of the methylene groups is optionally substituted with R 7 ; Q is selected from: 1, 2-cycloalkylene, 1, 2-phenylene, 1, 3-phenylene, 1, 4-phenylene, 2, 3-pyridinylene, 3, 4-pyrιdιnylene, 2 , 4-pyπdιr.ylene, or 3,4- pyndazmylene; R 6 is selected from: H, C 1 -C 4 alkyl, or benzyl; R 7 and R 8 are independently selected from: H, Ci-Cβ alkyl, C 3 -C 7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl (Ci-Ce alkyl)-, or heteroaryl (Co-Cδ alkyl)-,. R 9 is selected from: H, C0 2 R 17 , C(=0)R 17 , CONR 17 R 20 , -S0 R 17 , -S0 NR 17 R 20 , Cι-C 6 alkyl substituted with 0- 1 R 15 or 0-1 R 21 , C 3 -C 6 alkenyl substituted with 0-1 R 15 or 0-1 R 21 , C 3 -C 7 cycloalkyl substituted with 0- 1 R 15 or 0-1 R 21 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 or 0-1 R 21 , aryl substituted with 0-1 R 15 or 0-2 R i or 0-1 R 21 , or aryl(Cι-C 6 alkyl) - substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 ; R 11 is selected from H, halogen, CF 3 , CN, N0 2 , hydroxy, NR 2 R 3 , Cι-C 4 alkyl substituted with 0-1 R 21 , C1-C4 alkoxy substituted with 0-1 R 21 , aryl substituted with 0-1 R 21 , aryKCi-C ό alkyl)- substituted with 0-1 R 21 , (C1-C4 alkoxy) carbonyl substituted with 0-1 R 21 , (C1-C4 alkyl) carbonyl substituted with 0-1 R 21 , C1-C4 alkylsulfonyl substituted with 0-1 R 21 , or C1-C4 alkylammosulfonyl substituted with 0-1 R 21 ; W is selected from: -(C(R 12 ) 2 ) q C(=0)N(R 13 )-, or -C(=0)-N(R 13 )-(C(R 12 ) 2 ) q - ; X is -C(R 12 ) (R 1 )-C(R 12 ) (R 15 )-; or alternatively, W and X can be taken together to be R 12 is selected from: H, halogen, Ci-Cβ alkyl, C 2 -Cβ alkenyl, C 2 -C 6 alkynyl, C 3 -C7 cycloalkyl, C 4 -C 10 cycloalkylalkyl, (C 1 -C 4 alkyl) carbonyl, aryl, or aryl(Cι-C 6 alkyl)-; R 13 is selected from: H, Cι-C 6 alkyl, C3-C7 cycloalkylmethyl, or aryl(Cχ-Cβ alkyl)-; R 14 is selected from: H, Ci-Cβ alkylthιo ( Cι-Cβ alkyl ) -, aryl ( Cι-Cιo alkylthioalkyl)-, aryl (C 1 -C 10 alkoxyalkyl) -, C1-C10 alkyl, C 1 -C 10 alkoxyalkyl, Ci-C δ hydroxyalkyl, C 2 -Cιo alkenyl, C 2 -Cχo alkynyl, C3-C10 cycloalkyl, C 3 -C 10 cycloalkylalkyl, aryKCi-Cβ alkyl)-, heteroaryl (Cι-C 6 alkyl) -, aryl, heteroaryl, C0 2 R 17 , C(=0)R 17 , or C0NR 17 R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 0-1 R 16 or 0-2 R 11 ; R 15 is selected from: H, R 16 , Ci-Cio alkyl, Cχ-Cι 0 alkoxyalkyl, Ci-Cio alkylam oalkyl, Cχ-Cιo dialkylammoalkyl, (Ci-Cio alkyl) carbonyl, aryl(Co-C 6 alkyl) carbonyl, Ci-Cio alkenyl, Cχ-Cιo alkynyl ,C 3 -C 10 cycloalkyl, C3-C10 cycloalkylalkyl, aryKCi-Ce alkyl)-, heteroaryl (Cχ-C 6 alkyl) -, aryl, heteroaryl, C0 2 R 17 , C(=0)R 17 , CONR 17 R 20 , S0 2 R 17 , or S0 2 NR 17 R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 0-2 R 11 ; Y is selected from: -COR 19 , -SO3H, -PO 3 H, tetrazolyl, -CONHNHS0 2 CF 3 , -CONHS0 R 17 , -CONHS0 2 NHR 17 , -NHCOCF3, -NHCONHS0 2 R 17 , -NHS0 2 R 17 , -0PO 3 H 2 , -OSO3H, -P0 3 H 2 , -SO3H, -S0 2 NHCOR 17 , -S0 2 NHC0 2 R 17 , R 16 is selected from: -N(R 20 )-C(=O) -O-R 17 , -N(R 20 )-C(=O)-R 17 , -N(R 20 )-C(=O)-NH-R 17 , -N(R 20 )SO 2 -R 17 , or -N(R 20 )SO 2 -NR 20 R 17 ; R 17 is selected from: C1-C10 alkyl, C3-C11 cycloalkyl, aryl(Cι-C6 alkyl)-, (Ci-Cβ alkyl)aryl. heteroaryl (Cχ-C 6 alkyl)-, (Cι-C 6 alkyl) heteroaryl, biaryl (Ci-Cβ alkyl) -, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C1-C4 alkyl, C1-C4 alkoxy, aryl, heteroaryl, halo, cyano, amino, CF 3 , and N0 2 ; R 18 is selected from: H, -C(=0)-0-R 17 , -C(=0)-R 17 , -C(=0)-NH-R 17 , -SO2-R 17 , or -SO2-NR 20 R 17 ; R 19 is selected from hydroxy, C1-C10 alkyloxy, C3-C1 1 cycloalkyloxy, aryloxy, aryl(Cι-C 6 alkoxy)-, C3-C10 alkylcarbonyloxyalkyloxy, C3-C10 alkoxycarbonyloxyalkyloxy, C 2 -Cιo alkoxycarbonylalkyloxy, C5-C1 0 cycloalkylcarbonyloxyalkyloxy, C5-C10 eyeloalkoxycarbonyloxyalkyloxy, C5-C 10 cycloalkoxycarbonylalkyloxy, C7-C11 aryloxycarbonylalkyloxy, s-Cι 2 aryloxycarbonyloxyalkyloxy, Cg-Ci2 arylcarbonyloxyalkyloxy, C5-C1 0 alkoxyalkylcarbonyloxyalkyloxy, C5-C10 (5-alkyl-l, 3-dioxa-cyclopenten-2-one- yDmethyloxy, C1 0 -C 14 (5-aryl-l, 3-dioxa-cyclopenten- 2-one-yl)methyloxy, or (R 11 ) (R 12 )N- (C1-C10 alkoxy) -; R 20 is selected from: H, Ci-Cβ alkyl, C3-C7 cycloalkyl, C4-C11 cycloalkylalkyl, aryl, aryl (Cι-C 6 alkyl) -, or heteroaryl (Ci-Cδ alkyl)-; R 21 is selected from COOH or NR 6 2 ; and with the following provisos: (1) t, n, m and q are chosen such that the number of atoms connecting R 1 and Y is in the range of 10-14; and (2) n and m are chosen such that the value of n plus m is greater than one unless U is -(CH;) Ϊ Q.'CH?).,,-. [7] Preferred compounds of the invention as described above are compounds of the Formula lb: lb including stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, or pharmaceutically acceptable salt or prodrug forms thereof, wherein: X 1 , X 2 , X 3 , and X 4 are independently selected from nitrogen or carbon provided that at least two of X 1 , X 2 , X 3 and X 4 are carbon; R 1 is selected from: A and B are independently -CH 2 -, -0-, -N(R 2 )-, or -C(=0)-; A 1 and B 1 are independently -CH 2 - or -N(R 3 )-; D is -N(R 2 )-, -0-, -S-, -C(=0)- or -S0 2 -; -C(R ) 2 C(R 5 ) -; J, K, L and M are independently selected from -C(R 4 )-, -C(R 5 )- or -N-, provided that at least one of J, K, R 2 is selected from: H, Cι-C 6 alkyl, (Ci-Cβ alkyl)carbonyl, (Ci-Cβ alkoxy) carbonyl, Ci-Cβ alkylaminocarbonyl, C 3 -C 6 alkenyl, C 3 -C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, heteroaryl (Ci- δ alkyl) carbonyl, heteroarylcarbonyl, aryl (Ci-Cβ alkyl)-, (Ci-Ce alkyl) carbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, aryl(Cι-C6 alkyl)sulfonyl, heteroarylsulfonyl, heteroaryl (Cχ-C 6 alkyl) sulfonyl, aryloxycarbonyl, aryKCi-Cβ alkoxy)carbonyl, wherein said aryl groups are substituted with 0-2 substituents selected from the group consisting of C -C 4 alkyl, C 1 -C 4 alkoxy, halo, CF 3 , and nitro; R 3 is selected from: H, Ci-Cβ alkyl, C 3 -C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl(Cχ-Ce alkyl)-, or heteroaryl (C 1 -C6 alkyl)-,- R 4 and R 5 are independently selected from: H, C 1 -C 4 alkoxy, NR 2 R 3 , halogen, N0 , CN, CF 3 , Cχ-C 0 alkyl, C 3 -C 6 alkenyl, C 3 -C 7 cycloalkyl, C4-C 11 cycloalkylalkyl, aryl, aryl(Cχ-C 6 alkyl)-, C 2 -C7 alkylcarbonyl, arylcarbonyl or alternatively, when substituents on adjacent atoms, R 4 and R 5 can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups selected from: C1-C4 alkyl, C -C 4 alkoxy, halo, cyano, ammo, CF 3 , or N0 2 ; U is selected from: -(CH 2 ) n -, -(CH 2 ) n (CR 7 =CR 8 ) (CH 2 ) m - -lCH 2 ) c QfCH ? ) „-, -(CH 2 )nO(CH 2 ) m -, -(CH 2 ) n N(R 6 ) (CH 2 )m-, -(CH 2 ) n C(=0) (CH 2 )m-/ or -(CH 2 ) n S(0)p(CH2)m-; wherein one of the methylene groups is optionally substituted with R 7 ; Q s selected from i, 2-phεr.yler.e, , 3 -p eny_.er.e, 2,3- pyr idiny lene , 3,4 - yr dmy ier.e , or 2,4- pyridinyi ne; R 6 is selected from: H, C 1 -C 4 alkyl, or benzyl; R 7 and R 8 are independently selected from: H, Cχ-C 6 alkyl, C3-C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl (Ci-Cβ alkyl ) -, or heteroaryl (Co-Cβ alkyl)-,- R 9 is selected from: H, C0 2 R 17 , C(=0)R 17 , CONR 17 R 20 , -S0 2 R 17 , -S0 2 NR 17 R 20 , Ci-Cβ alkyl substituted with 0- 1 R 15 or 0-1 R 21 , C 3 -C 6 alkenyl substituted with 0-1 R 15 or 0-1 R 21 , C 3 -C7 cycloalkyl substituted with 0- 1 R 15 or 0-1 R 21 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 or 0-1 R 21 , aryl substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 , or aryl(Cι-C 6 alkyl) - substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 ; R 11 is selected from: H, halogen, CF 3 , CN, N0 2 , hydroxy, NR 2 R 3 , C 1 -C 4 alkyl substituted with 0-1 R 21 , C1-C4 alkoxy substituted with 0-1 R 21 , aryl substituted with 0-1 R 21 , aryl(Cι-C 6 alkyl)- substituted with 0-1 R 21 , (C 1 -C 4 alkoxy) carbonyl substituted with 0-1 R 21 , (C 1 -C 4 alkyl) carbonyl substituted with 0-1 R 21 , C 1 -C 4 alkylsulfonyl substituted with 0-1 R 21 , or C 1 -C 4 alkylaminosulfonyl substituted with 0-1 R 21 ; W is -C(=0)-N(R 13) -(C(R 12 ) 2 ) q-; X is -C(R 12 ) (R 14 )-C(R 12 ) (R 15 )-; alternatively, W and X can be taken together to be R 12 is H or Ci-Ce alkyl; R 13 is selected from: H, Ci-Cβ alkyl, C 3 -C7 cycloalkylmethyl, or aryl (Cχ-Ce alkyl)-; R 14 is selected from: H, C -C 6 alkylthioalkyl, aryl(Cχ-Cι 0 alkylthioalkyl)-, aryl(Cι-Cχo alkoxyalkyl)-, C 1 -C 10 alkyl, Cχ-Cιo alkoxyalkyl, Cχ-C 6 hydroxyalkyl, C 2 -Cχo alkenyl, C -Cχo alkynyl, C 3 -Cχo cycloalkyl, C 3 -C 10 cycloalkylalkyl, aryl(Cι-C 6 alkyl)-, heteroaryl (Cχ-C6 alkyl)-, aryl, heteroaryl, C0 2 R 17 , C(=0)R 17 , or CONR 17 R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 0-1 R 16 or 0-2 R 11 ; R 15 is selected from: H, R 16 , C 1 -C 10 alkyl, Cχ-Cιo alkoxyalkyl, Cχ-Cιo alkylaminoalkyl, C 1 -C 10 dialkylaminoalkyl, C 1 -C 10 alkylcarbonyl, aryl (C 0 -C 6 alkyl) carbonyl, C 2 -C 10 alkenyl, C2-C 10 alkynyl ,C 3 -C10 cycloalkyl, C 3 -C 10 cycloalkylalkyl, aryl (C -Ce alkyl)-, heteroaryl (Cχ-Cβ alkyl)-, aryl, heteroaryl, C0 2 R 17 , C(=0)R 17 , CONR 17 R 20 , S0 2 R 17 , or S0 2 NR 17 R 2 °, provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 0-2 R 11 ; Y is selected from: -COR 19 , -SO 3 H, R lδ is selected from: -N(R 20 )-C(=O)-O-R 17 , -N(R 20 )-C(=O)-R 17 , -N(R 20 )-C(=O)-NH-R 17 , -N(R 20 )SO 2 -R 17 , or -N(R 20 )SO 2 -NR 20 R 17 ; R 17 is selected from: Ci-Cio alkyl, C 3 -Cu cycloalkyl, aryl(Cι-C 6 alkyl)-, (Cι-C 6 alkyl)aryl, heteroaryl (Cι-C 6 alkyl)-, (Ci-Cβ alkyl) heteroaryl, biaryl(Cχ-Ce alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, C -C 4 alkoxy, aryl, heteroaryl, halo,cyano, ammo, CF 3 , and N0 2 ; R 18 is selected from: H, -C(=0)-0-R 17 , -C(=0)-R 17 , -C(=0)-NH-R 17 , -SO 2 - R 20 R 17 ; .19 is selected from hydroxy, C 1 -C 1 0 alkyloxy, C 3 -C 11 cycloalkyloxy, Ce-Cio aryloxy, C 7 -C 11 aralkyloxy, C 3 -C 10 alkylcarbonyloxyalkyloxy, C 3 -C 10 alkoxycarbonyloxyalkyloxy, C 2 -Cιo alkoxycarbonylalkyloxy, 5 -C1 0 cycloalkylcarbonyloxyalkyloxy, C 5 -C 10 cycloalkoxycarbonyloxyalkyloxy, C 5 -C 1 0 cycloalkoxycarbonylalkyloxy, C7-C 11 aryloxycarbonylalkyloxy, C 8 -Cχ 2 aryloxycarbonyloxyalkyloxy, C 8 - 12 arylcarbonyloxyalkyloxy, Cs-C o alkoxyalkylcarbonyloxyalkyloxy, C5-C 0 (5-alkyl-l, 3-dioxa-cyclopenten-2-one- yDmethyloxy, C10-C14 (5-aryl-l, 3-dioxa-cyclopenten- 2-one-yl)methyloxy, or (R 11 ) (R 12 ) N- (C 1 -C 10 alkoxy) -; R20 selected from: H, Cχ-Ce alkyl, C 3 -C 7 cycloalkyl, C 4 - Cii cycloalkylalkyl, aryl (C -C 6 alkyl)-, or heteroaryl (Cχ-C6 alkyl)-,. R 21 is selected from COOH or NR 6 2 ; and [8] Further preferred compounds of the invention as described above are compounds of the Formula lie or lid: including stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, or pharmaceutically acceptable salt or prodrug forms thereof, wherein: Xi and X3 are independently selected from nitrogen or carbon; R 1 is selected from: NH 2 NH 2 N-( N-^ / NH2 N__=( →~ J ' - U -or — J . wherein the above heterocycles are optionally substituted with 0-2 substituents selected from the group consisting of: NH 2 , halogen, N0 2 , CN, CF3, Ci- C 4 alkoxy, Ci-Cβ alkyl, and C 3 -C7 cycloalkyl; U is -(CH 2 ) n -z - ;CH 2 ) t Q(CH-;-- or -C (=0) (CH 2 ) n -l" , wherein one of the methylene groups is optionally substituted with R 7 ; Q s selected from I, 2-phenyle e, 1, ?-pheny_e e, 2,3- pyrid ylene, 3 , 4-pyr dmyler.e, or 2,4- pyridinyiene; R δ is selected from: H, C -C 4 alkyl, or benzyl; R7 is selected from: Cχ-Ce alkyl, C 3 -C 7 cycloalkyl, C 4 - C 11 cycloalkylalkyl, aryl, aryKCi-Cβ alkyl) , heteroaryl, or heteroaryl (C -C 6 alkyl); R 9 is selected from: H, -S0 2 R 17 , -S0 2 NR 17 R 20 , Cχ-C 6 alkyl substituted with 0-1 R 15 or 0-1 R 21 , C 3 -C 7 cycloalkyl substituted with 0-1 R 15 or 0-1 R 21 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 or 0-1 R 21 , aryl substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 , or aryl(Cι-C 6 alkyl)- substituted w th 0-1 R 15 or 0-2 R 11 or 0-1 R 21 ; R 11 is selected from: H, halogen, CF , CN, N0 2 , hydroxy, NR 2 R 3 , C 1 -C 4 alkyl substituted with 0-1 R 21 , C 1 -C 4 alkoxy substituted with 0-1 R 21 , aryl substituted with 0-1 R 21 , aryl(Cχ-C 6 alkyl)- substituted with 0-1 R 21 , (C 1 -C 4 alkoxy)carbonyl substituted with 0-1 R 21 , (C 1 -C 4 alkyl) carbonyl substituted with 0-1 R 21 , C -C 4 alkylsulfonyl substituted with 0-1 R 21 , or C 1 -C 4 alkylaminosulfonyl substituted with 0-1 R 21 ; W is -C(=0)-N(R 13 )-; X is -CH(R 14 )-CH(R 15 )-; R 13 is H or CH 3; R 14 is selected from: H, C 1 -C 10 alkyl, aryl/ or heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, Cχ-C 4 alkoxy, aryl, halo, cyano, amino, CF 3 , and N0 2 ; R 16 is selected from: -NH(R 20 )-C(=O)-O-R 17 , -N(R 20 )-C(=O)-R 17 , -N(R 20 )-C(=O)-NH-R 17 , -N(R 20 )SO 2 -R 17 , or -N(R 20 )SO 2 -N(R 20 )R 17 ; R 17 is selected from: C1-C10 alkyl , C3-C11 cycloalkyl , aryl (Cι-C6 alkyl ) - , (C -C 6 alkyl)aryl, heteroaryl (Ci-Cβ alkyl)-, (Cι-C 6 alkyl) heteroaryl, biaryKCi-Cβ alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, heteroaryl, halo, cyano, amino, CF 3 , and N0 2 ; R 19 is selected from: hydroxy, C1-C 1 0 alkoxy, methylcarbonyloxymethoxy-, ethylcarbonyloxymethoxy-, t-butylcarbonyloxymethoxy-, cyclohexylcarbonyloxymethoxy-, 1- (methylcarbonyloxy)ethoxy-, 1- (ethylcarbonyloxy)ethoxy-, 1- (t-butylcarbonyloxy) ethoxy-, 1- (cyclohexylcarbonyloxy)ethoxy-, i-propyloxycarbonyloxymethoxy-, t-butyloxycarbonyloxymethoxy- , 1- (i-propyloxycarbonyloxy)ethoxy-, 1- (cyclohexyloxycarbonyloxy) ethoxy-, 1- (t-butyloxycarbonyloxy) ethoxy-, dimethylammoethoxy-, diethylammoethoxy-, (5-methyl-1, 3-dιoxacyclopenten-2-on-4-yl)methoxy-, (5- ( t-butyl) -1, 3-dιoxacyclopenten-2-on-4- yl)methoxy- , (1, 3-dioxa-5-phenyl-cyclopenten-2-on-4-yl) ethoxy-, or 1- (2- (2-methoxypropyl) carbonyloxy) ethoxy-; R 21 is selected from COOH or NR 6 ; and [9] Still further preferred compounds of the above invention are compounds of the Formula lie or lid: including stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, or pharmaceutically acceptable salt or prodrug forms thereof, wherein: Xx and X3 are independently selected from nitrogen or carbon, provided that at least one of Xi and X 3 is carbon; R 1 is selected from: wherein the above heterocycles are optionally substituted with 0-2 substituents selected from the group consisting of: NH 2 , halogen, N0 2 , CN, CF 3 , Ci- C 4 alkoxy, C -C 6 alkyl, and C 3 -C7 cycloalkyl: U is -(CH 2 ) n -, -:CH ? κQ(CH 7 π - or -C (=0) (CH 2 ) n _ι-, wherein one of the methylene groups is optionally substituted with R 7 ; Q s selected from 1, 2-phenylene, 1, 3-pherιylene, 2,3- pyπdmylene, 3 , 4-pyndιr.vler.e, or 2,4- pyrιdιny_ene; R 6 is selected from: H, C 1 -C 4 alkyl, or benzyl; R7 is selected from: Ci-Cβ alkyl, C3-C 7 cycloalkyl, C 4 - C11 cycloalkylalkyl, aryl, aryl(Cι-C 6 alkyl) , heteroaryl, or heteroaryl fC -C 6 alkyl); R 9 is selected from: H, -S0 2 R 17 , -S0 NR 17 R 20 , ι -C 6 alkyl substituted with 0-1 R 15 or 0-1 R 21 , C3-C 7 cycloalkyl substituted with 0-1 R 15 or 0-1 R 21 , C 4 -C 1 1 cycloalkylalkyl substituted with 0-1 R 15 or 0-1 R 21 , aryl substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 , or aryl(Cι-C 6 alkyl)- substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 ; R 11 is selected from H, halogen, CF 3 , CN, N0 2 , hydroxy, NR 2 R 3 , C1-C4 alkyl substituted with 0-1 R 21 , C1-C4 alkoxy substituted with 0-1 R 21 , aryl substituted with 0-1 R 21 , aryl(Cχ-C 6 alkyl)- substituted with 0-1 R 21 , (Cχ-C4 alkoxy) carbonyl substituted with 0-1 R 21 , (C -C4 alkyl) carbonyl substituted with 0-1 R 21 , C -C4 alkylsulfonyl substituted with 0-1 R 21 , or C -C 4 alkylammosulfonyl substituted with 0-1 R 21 ;W X is -CH(R 1 )-CH(R 15 )-; R 14 is selected from: H, C1-C10 alkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C1-C4 alkyl, C1-C4 alkoxy, aryl, halo, cyano, amino, CF3, and N0 2 ; Y is -COR 19 ; R 16 is selected from: -N(R 20 ) -C(=0)-0-R 17 , -N(R 20 )-C(=O)-R 17 , -N(R 20 )-C(=O)-NH-R 17 -N(R 20 )SO 2 -R 17 , or -N(R 20 )SO 2 -NR 20 R 17 ; R 17 is selected from: Ci-Cio alkyl, C3-C11 cycloalkyl, aryl(Cι-C 6 alkyl)-, (Cχ-C 6 alkyl)aryl, heteroaryl (Cι-C 6 alkyl)-, (Ci-Cβ alkyl) heteroaryl, biaryKCi-Cβ alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, heteroaryl, halo, cyano, amino, CF 3 , and N0 2 ; R 19 is selected from: hydroxy, C1-C10 alkoxy, methylcarbonyloxymethoxy-, ethylcarbonyloxymethoxy- , t-butylcarbonyloxymethoxy-, cyclohexylcarbonyloxymethoxy- , 1- (methylcarbonyloxy)ethoxy-, 1- (ethylcarbonyloxy) ethoxy-, 1- (t-butylcarbonyloxy) ethoxy-, 1- (cyclohexylcarbonyloxy)ethoxy-, i-propyloxycarbonyloxymethoxy-, t-butyloxycarbonyloxymethoxy-, 1- (i-propyloxycarbonyloxy)ethoxy-, 1- (cyclohexyloxycarbonyloxy) ethoxy-, 1- (t-butyloxycarbonyloxy)ethoxy-, dimethylaminoethoxy-, diethylam oethoxy- , (5-methyl-1, 3-dιoxacyclopenten-2-on-4-yl)methoxy-, (5- (t-butyl) -1, 3-dιoxacyclopenten-2-on-4- yl)methoxy-, (1, 3-dιoxa-5-phenyl-cyclopenten-2-on-4-yl)methoxy-, or 1- (2- (2-methoxypropyl) carbonyloxy) ethoxy-; R 20 is H or CH 3 ; R 21 is selected from COOH or NR 6 2 ; and [10] Specifically preferred compounds of the invention as described above are compounds of Formula lb, including enantiomeric or diastenomeric forms thereof, or mixtures of enantiomeric or diastenomenc forms thereof, or pharmaceutically acceptable salt or prodrug forms thereof, selected from the group consisting of: 3- [3- [3- (imidazolin-2-ylamino)propyl] mdazol-6- ylcarbonylammo] -2- (benzyloxycarbonylammo) - propionic acid, 3- [l-methyl-3- [3- (imidazolin-2-ylamino)propyl] - indazol-6-ylcarbonylammo] -2- (2, 4, 6-trιmethyl- benzenesulfonylamino)propionic acid, 3- [3- [3- (imidazolin-2-ylamino) propyl] mdazol-6- ylcarbonylamino] -2- (benzenesulfonylamino) propionic acid, 3- [l-methyl-3- [3- (imidazolin-2-ylammo) propyl] - indazol-6-ylcarbonylammo] -2- (2, 6-dichloro- benzenesulfonylamino) propionic acid, 3- [3- [3- (ιmιdazolm-2-ylammo)propyl] ιndazol-6- ylcarbonylamino] -2- (3,5-dιmethylιsoxazol-4- ylsulfonylamino) propionic acid, 3- [l-methyl-3- [3- (imidazolin-2-ylamino)propyl] - indazol-6-ylcarbonylammo]-2- (2, 6-dimethyl- benzenesulfonylamino)propionic acid, 3- [3- [3- (ιmιdazolm-2-ylamino)propyl]ιndazol-6- ylcarbonylammo] -2- (2,6-dimethyl-4-phenyl- benzenesulfonylamino)propionic acid, 3- [l-methyl-3- [3- (imidazolin-2-ylamino)propyl] - mdazol-6-ylcarbonylammo] -2- (4-phenylbenzene- sulfonylamino)propionic acid, 3- [3- [3- (tetrahydropyrimid- -ylammo)propyl] - indazol-6-ylcarbonylammo]-2- (benzyloxy- carbonylammo)propionic acid, 3- [l-methyl-3- [3- (tetrahydropyrιmιd-2-ylammo) - propyl] indazol-6-ylcarbonylammo]-2- (2,4,6- trimethylbenzenesulfonylamino)propionic acid, 3- [3- [3- (tetrahydropyrιmιd-2-ylamino)propyl]- ιndazol-6-ylcarbonylamιno]-2- (benzenesulfonyl¬ amino) propionic acid, 3- [l-methyl-3- [3- (tetrahydropyrιmιd-2-ylammo)- propyl]mdazol-6-ylcarbonylammo]-2- (2,6- dichlorobenzenesulfonylamino)propionic acid, 3- [3- [3- (tetrahydropyrimid-2-ylam o)propyl] - mdazol-6-ylcarbonylammo]-2- (3,5-dιmethyl- isoxazol-4-ylsulfonylamino)propionic acid, 3- [l-methyl-3-[3-(tetrahydropyrιmιd-2-ylammo)- propyl]mdazol-6-ylcarbonylammo]-2- (2, 6- dimethylbenzenesulfonylanu.no)propionic acid, 3- [3- [3- (tetrahydropyrιmιd-2-ylammo)propyl]- mdazol-6-ylcarbonylammo]-2-(2,6-dιmethyl-4- phenylbenzenesulfonylamino)propionic acid, 3- [l-methyl-3-[3-(tetrahydropyrimid-2-ylamino)- propyl] -mdazol-6-ylcarbonylammo]-2-(4- phenylbenzenesulfonylamino)propionic acid, 3- [3- [3- (imidazol-2-ylamino)propyl] indazol-6-yl¬ carbonylammo] -2- (benzyloxycarbonylammo) - propionic acid, 3- [l-methyl-3- [3- (imidazol-2-ylamino)propyl] - indazol-6-ylcarbonylammo] -2- (2,4, 6-trimethyl- benzenesulfonylamino)propionic acid, 3- [3- [3- (imidazol-2-ylamino)propyl] indazol-6-yl- carbonylamino] -2- (benzenesulfonylamino) - propionic acid, 3- [l-methyl-3- [3- (imidazol-2-ylamino)propyl] - indazol-6-ylcarbonylamino] -2- (2, 6-dichloro- benzenesulfonylamino)propionic acid, 3- [3- [3- (imidazol-2-ylamino)propyl] indazol-6-yl- carbonylamino] -2- (3, 5-dimethylisoxazol-4- ylsulfonylamino)propionic acid, 3- [l-methyl-3- [3- (imidazol-2-ylamino)propyl] - indazol-6-ylcarbonylammo] -2- (2, 6-dimethyl- benzenesulfonylamino)propionic acid, 3- [3- [3- (imidazol-2-ylamino)propyl] indazol-6-yl- carbonylamino] -2- (2, 6-dimethyl-4-phenyl- benzenesulfonylamino)propionic acid, 3- [l-methyl-3- [3- (imidazol-2-ylamino)propyl] - indazol-6-ylcarbonylammo] -2- (4-phenylbenzene- sulfonylamino)propionic acid, 3- [3- [3- (pyridin-2-ylamino)propyl] indazol-6-yl- carbony1amino] -2- (benzyloxycarbonylammo) - propionic acid, 3- [l-methyl-3- [3- (pyridin-2-ylamino)propyl] indazol- 6-ylcarbonylammo] -2- (2,4, 6-trimethylbenzene- sulfonylamino)propionic acid, 3- [3- [3- (pyridin-2-ylamino)propyl] indazol-6-yl- carbonylamino] -2- (benzenesulfonylamino) - propionic acid, 3- [l-methyl-3- [3- (pyridin-2-ylamino)propyl] indazol- 6-ylcarbonylamino] -2- (2, 6-dichlorobenzene- sulfonylamino)propionic acid, 3- [3- [3- (pyπdm-2-ylamιno)propyl] ιndazol-6-yl- carbonylam o]-2- (3, 5-dιmethylιsoxazol-4- ylsulfonylamino)propionic acid, 3- [l-methyl-3- [3- (pyridm-2-ylam o)propyl] mdazol- 6-ylcarbonylammo]-2- (2,6-dιmethyloenzene- sulfonylamino)propionic acid, 3- [3- [3- (pyridin-2-ylammo)propyl] indazol-6-yl¬ carbonylammo] -2- (2,6-dιmethyl-4-phenyl- benzenesulfonylamino)propionic acid, 3- [l-methyl-3- [3- (pyrιdm-2-ylammo)propyl]mdazol- 6-ylcarbonylammo]-2- (4-phenylbenzenesulfonyl¬ amino)propionic acid, 3- [3- [3- (ιmιdazolm-2-ylamιno)propyl]ιndazol-7- ylcarbonylammo] -2- (benzyloxycarbonylammo) - propionic acid, 3- [l-methyl-3-[3- (ιmιdazolm-2-ylammo)propyl] - mdazol-7-ylcarbonylammo]-2- (2,4, 6- trimethylbenzenesulfonylamino)propionic acid, 3- [3- [3- (imidazolin-2-ylamino)propyl]indazol-7- ylcarbonylammo] -2- (benzenesulfonylamino) propionic acid, 3- [l-methyl-3-[3- (ιmιdazolιn-2-ylamιno)propyl] - mdazol-7-ylcarbonylammo]-2- (2,6-dιchloro- benzenesulfonylamino)propionic acid, 3- [3-[3- (ιmιdazolιn-2-ylamino)propyl]ιndazol-7- ylcarbonylammo]-2- (3,5-dιmethylιsoxazol-4- ylsulfonylamino)propionic acid, 3- [l-methyl-3- [3- (ιmιdazolm-2-ylammo)propyl] - mdazol-7-ylcarbonylammo] -2- (2,6-dimethyl- benzenesulfonylamino)propionic acid, 3- [3- [3- (ιmιdazolm-2-ylamino)propyl] mdazol-7- ylcarbonylamino]-2- (2,6-dιmethyl-4-phenyl- benzenesulfonylamino)propionic acid, 3- [l-methyl-3- [3- (ιmιdazolm-2-ylammo)propyl]- ιndazol-7-ylcarbonylammo]-2- (4-phenylbenzene- sulfonylamino)propionic acid, 3- [3- [3- (tetrahyαropynmid-2-ylamino)propyl] - mdazol-7-ylcarbonylammo]-2- (benzyloxy¬ carbonylammo)propionic acid, 3- [l-methyl-3- [3- (tetrahydropyrιmιd-2-ylamιno) - propyl] ιndazol-7-ylcarbonylamιno] -2- (2,4, 6- tπmethylbenzenesulfonylamino)propionic acid, 3- [3- [3- (tetrahydropyrimid-2-ylammo)propyl] - mdazol-7-ylcarbonylammo]-2- (benzenesulfonyl¬ amino)propionic acid, 3- [l-methyl-3- [3- (tetrahydropyrimid-2-ylamino) - propyl] mdazol-7-ylcarbonylammo] -2- (2, 6- dichlorobenzenesulfonylamino)propionic acid, 3- [3- [3- (tetrahydropyrιmιd-2-ylamino)propyl]- indazol-7-ylcarbonylammo]-2- (3,5-dιmethyl- ιsoxazol-4-ylsulfonylammo)propionic acid, 3- [l-methyl-3- [3- (tetrahydropyrimid-2-ylamino)- propyl]ιndazol-7-ylcarbonylammo] -2- (2,6- dimethylbenzenesulfonylamino)propionic acid, 3- [3- [3- (tetrahydropyrimid-2-ylammo)propyl] - indazol-7-ylcarbonylammo]-2- (2, 6-dιmethyl-4- phenylbenzenesulfonylamino)propionic acid, 3- [l-methyl-3- [3- (tetrahydropyrιmιd-2-ylamino) - propyl] dazol-7-ylcarbonylammo]-2- (4- phenylbenzenesulfonylarru.no)propionic acid, 3- [3- [3- (imidazol-2-ylammo)propyl]mdazol-7-yl- carbonylammo] -2-(benzyloxycarbonylammo)- propionic acid, 3- [l-methyl-3- [3- (imidazol-2-ylamino)propyl] - mdazol-7-ylcarbonylammo]-2- (2,4, 6-trιmethyl- benzenesulfonylamino)propionic acid, 3- [3- [3- (ιmιdazol-2-ylammo)propyl]mdazol-7-yl- carbonylammo]-2-(benzenesulfonylamino)- propionic acid, 3- [l-methyl-3- [3- (imidazol-2-ylammo)propyl]- mdazol-7-ylcarbonylammo]-2- (2, 6-dιchloro- benzenesulfonylamino)propionic acid, 3- [3- [3- (ιmιdazol-2-ylamιno) propyl] ιndazol-7-yl- carbonyla mo] -2- (3 , 5-dιmethylιsoxazol-4- ylsulfonylamino) propionic acid, 3- [l-methyl-3- [3- (ιmιdazol-2-ylammo) propyl] - mdazol-7-ylcarbonylammo] -2- (2, 6-dιmethyl- benzenesulfonylamino) propionic acid, 3- [3- [3- (imidazol-2-ylammo) propyl] mdazol-7-yl¬ carbonylammo] -2- (2 , 6-dimethyl-4-phenyl- benzenesulfonylamino) propionic acid, 3- [l-methyl-3- [3- (imidazol-2-ylammo) propyl] - mdazol-7-ylcarbonylammo] -2- (4-phenylbenzene- sulfonylamino) propionic acid, 3- [3- [3- (pyrιdιn-2-ylammo) propyl] mdazol-7-yl- carbonylammo] -2- (benzyloxycarbonylammo) - propionic acid, 3- [l-methyl-3- [3- (pyridin-2-ylamino)propyl] mdazol- 7-ylcarbonylammo] -2- (2,4, 6-trιmethylbenzene- sulfonylamino) propionic acid, 3- [3- [3- (pyridm-2-ylamino)propyl] mdazol-7-yl- carbonylammo] -2- (benzenesulfonylam o) - propionic acid, 3- [l-methyl-3- [3- (pyridm-2-ylamino)propyl] indazol- 7-ylcarbonylammo] -2- (2 , 6-dιchlorobenzene- sulfonylamino)propionic acid, 3- [3- [3- (pyridm-2-ylammo) propyl] mdazol-7-yl- carbonylammo] -2- (3 , 5-dιmethylιsoxazol-4- ylsulfonylamino)propionic acid, 3- [l-methyl-3- [3- (pyridin-2-ylammo) propyl] mdazol- 7-ylcarbonylammo] -2- (2, 6-dιmethylbenzene- sulfonylammo) propionic acid, 3- [3- [3- (pyrιdιn-2-ylamιno)propyl] mdazol-7-yl- carbonylammo] -2- (2, 6-dimethyl-4-phenyl- benzenesulfonylammo) propionic acid, and 3- [l-methyl-3- [3- (pyridm-2-ylammo) propyl] mdazol- 7-ylcarbonylammo] -2- (4-phenylbenzenesulfonyl¬ amino)propionic acid. [11] Also specifically preferred are ester prodrugs of the specifically preferred compounds of Formula lb, said esters being chosen from the group consisting Of: methyl, ethyl, isopropyl, n-butyl, isobutyl, benzyl , methylcarbonyloxymethyl , ethylcarbonyloxymethyl, tert-butylcarbonyloxymethyl, cyclohexylcarbonyloxymethyl, tert-butyloxycarbonyloxymethyl, dimethylaminoethyl, and diethylaminoethyl, morphc1inoethy1, pyrrolidir.oemyl, and tri e~hy1ammonloethy1. [12] Yet another aspect of the present invention comprises compounds of Formula Ic: Ic including stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, or pharmaceutically acceptable salt or prodrug forms, thereof wherein: X 1 , X 2 , X 3 , and X 4 are independently selected from nitrogen or carbon provided that at least two of X 1 , X 2 , X 3 and X 4 are carbon; R 1 is selected from: A and B are independently -CH 2 -, -0-, -N(R 2 )-, or -C(=0)-; A 1 and B 1 are independently -CH 2 - or -N(R 3 )-; D is -N(R 2 )-, -0-, -S-, -C(=0)- or -S0 2 -; E-F is -C(R 4 )=C(R 5 )-, -N=C(R 4 )-, -C(R 4 )=N-, or -C(R 4 ) 2 C(R ) 2 -; J, K, L and M are independently selected from -C(R 4 )-, -C(R 5 )- or -N-, provided that at least one of J, K, L and M is not -N-; R 2 is selected from: H, Cχ-C 6 alkyl, (Cχ-Ce alkyl) carbonyl, (Cχ-C & alkoxy) carbonyl; (Cχ-C ό alkyl)aminocarbonyl, C 3 -C 6 alkenyl, C 3 -C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, heteroaryl (Cχ-C6 alkyl) carbonyl, heteroarylcarbonyl, aryl Ci-Cδ alkyl, (Ci-Ce alkyl) carbonyl, or arylcarbonyl, Cχ-C δ alkylsulfonyl, arylsulfonyl, aryl (Cχ-C 6 alkyl) sulfonyl, heteroarylsulfonyl, heteroaryl (C1-C6 alkyl) sulfonyl, aryloxycarbonyl, or aryKCi-Ce alkoxy)carbonyl, wherein said aryl groups are substituted with 0-2 substituents selected from the group consisting of C 1 -C 4 alkyl, Cχ-C alkoxy, halo, CF 3 , and nitro; R 3 is selected from: H, C -Cβ alkyl, C 3 -C7 cycloalkyl, C 4 -C 1 cycloalkylalkyl, aryl, aryl(Cχ-C6 alkyl)-, or heteroaryl (C -C6 alkyl)-,- R 4 and R 5 are independently selected from: H, C -C4 alkoxy, NR 2 R 3 , halogen, N0 2 , CN, CF 3 , Cι-C 6 alkyl, C 3 -C 6 alkenyl, C 3 -C 7 cycloalkyl, C 4 -C 1 cycloalkylalkyl, aryl, aryl (Ci-Cβ alkyl)-, (Cχ-Cδ alkyl) carbonyl, (C -C 6 alkoxy) carbonyl, arylcarbonyl, or alternatively, when substituents on adjacent atoms, R 4 and R 5 can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups selected from: C1-C4 alkyl, C -C 4 alkoxy, halo, cyano, ammo, CF3, or N0 2 ; U is selected from: - (CH 2 ) n -, - (CH 2 ) n (CR =CR 8 ) (CH 2 )m- - (CH 2 )n(C≡C) (CH 2 ) m - - (CH 2 )rQ(CH 2 ) m - - (CH 2 ) n O(CH 2 ) m -, - (CH 2 ) n N(R 6 ) (CH 2 ) m -, - (CH 2 ) n C(=0) (CH 2 ) m -, - (CH 2 ) n (C=0)N(R 6 ) (CH 2 ) m - - (CH 2 ) n N(R 6 ) (C=0) (CH 2 ) m -, or - (CH 2 )nS(0)p(CH 2 ) m -; wherein one of the methylene groups is optionally substituted with R 7 ; Q is selected from 1,2-cycloalkylene, 1,2-phenylene, 1, 3-phenylene, 1, 4-phenylene, 2, 3-pyrιdmylene, 3 , 4-pyrιdmylene, 2 , or 3,4- pyndazinylene; R 6 is selected from: H, C 1 -C 4 alkyl, or benzyl; R 7 and R 8 are independently selected from: H, Cχ-Ce alkyl, C 3 -C 7 cycloalkyl, C 4 -C 1 cycloalkylalkyl, aryl, aryl(Cι-C6 alkyl)-, or heteroaryl (C0-C6 alkyl)-,- R 9 is selected from: H, C0 2 R 17 , C(=0)R 17 , C0NR 17 R 20 , -S0 2 R 17 , -S0 2 NR 17 R 20 , Cχ-C 6 alkyl substituted with 0- 1 R 15 or 0-1 R 21 , C 3 -C 6 alkenyl substituted with 0-1 R 15 or 0-1 R 21 , C 3 -C7 cycloalkyl substituted with 0- 1 R 15 or 0-1 R 21 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 or 0-1 R 21 , aryl substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 , or aryl (Ci-Cβ alkyl)- substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 ; R 11 IS selected from H, halogen, CF3, CN, N0 , hydroxy, NR 2 R 3 , C -C4 alkyl substituted with 0-1 R 21 , Cχ-C4 alkoxy substituted with 0-1 R 21 , aryl substituted with 0-1 R 21 , aryl(Cι-C 6 alkyl)- substituted with 0-1 R 21 , (C -C4 alkoxy) carbonyl substituted with 0-1 R 21 , (C1-C4 alkyl (carbonyl substituted with 0-1 R 21 , C1-C4 alkylsulfonyl substituted with 0-1 R 21 , or C1-C4 alkylammosulfonyl substituted with 0-1 R 21 ; W is selected from: - (C(R 12 ) 2 )qC(=0)N(R 13 )-, or -C(=0)-N(R 13 )-(C(R 12 ) 2 ) q -; X is -C(R 12 ) (R 14 )-C(R 12 ) (R 15 )-; or alternatively, W and X can be taken together to be R 12 is selected from: H, halogen, Cχ-Ce alkyl, C 2 -Ce alkenyl, C 2 -C 6 alkynyl, C3-C7 cycloalkyl, C4-C10 cycloalkylalkyl, (C1-C4 alkyl) carbonyl, aryl, or aryl(Cι-C6 alkyl)-; R 13 is selected from: H, Cι-C 6 alkyl, C3-C7 cycloalkylmethyl, or aryl(Cχ-C 6 alkyl)- R 14 is selected from: H, C -C 6 alkylthιo(Cι-C 6 alkyl)-, aryl(Cι-Cιo alkylthioalkyl)-, aryl (C -C 10 alkoxyalkyl) -, C1-C10 alkyl, C1-C10 alkoxyalkyl, Ci-Cβ hydroxyalkyl, C2- 10 alkenyl, C 2 -Cιo alkynyl, C3-C10 cycloalkyl, C 3 -C1 0 cycloalkylalkyl, aryl(Cι-C6 alkyl)-, heteroaryl (Cχ-C ό alkyl) -, aryl, heteroaryl, C0 2 R 17 , C(=0)R 17 , or CONR 17 R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 0-1 R 16 or 0-2 R 11 ; R 15 is selected from: H, R 16 , Cχ-C 10 alkyl, C -C 10 alkoxyalkyl, Ci-Cio alkylam oalkyl, Cχ-Cιo dialkylammoalkyl, (Ci-Cio alkyl) carbonyl, aryl(Co-C6 alkyl) carbonyl, Ci-Cio alkenyl, Cχ-Cιo alkynyl ,C 3 -Cχo cycloalkyl, C 3 -Cχ 0 cycloalkylalkyl, aryl (Cχ-C 6 alkyl) -, heteroaryl (Cχ-Cβ alkyl) -, aryl, heteroaryl, C0 2 R 17 , C(=0)R 17 , CONR 17 R 20 , S0 2 R 17 , or S0 2 NR 17 R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 0-2 R 11 ; Y is selected from: -COR 19 , -SO3H, -PO3H, tetrazolyl, -CONHNHΞO2CF3, -CONHS0 2 R 17 , -CONHS0 2 NHR 17 , -NHCOCF3, -NHCONHS0 2 R 17 , -NHS0 2 R 17 , -OPO3H2, -OSO3H, -P0 3 H 2 , -SO 3 H, -S0 2 NHCOR 17 , -S0 2 NHC0 2 R 17 , R 16 is selected from: -N(R 0 )-C(=O)-O-R 17 , -N(R 20 )-C(=O)-R 17 , -N(R 20 )-C(=O)-NH-R 17 , -N(R 20 )SO 2 -R 17 , or -N(R 20 )SO2-NR 20 R 17 ; R 17 is selected from: Cχ-Cιo alkyl, C3-C11 cycloalkyl, aryl (Cι-C 6 alkyl) -, (Ci-Cβ alkyl ) aryl. heteroaryl (Cι-C 6 alkyl ) -, (Cχ-C 6 alkyl) heteroaryl, biaryl (Ci-Cβ alkyl) - , heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C1-C4 alkyl, C1-C4 alkoxy, aryl, heteroaryl, halo, cyano, amino, CF 3 , and N0 2 ; R 18 is selected from: H, -C(=0)-0-R 17 , -C(=0)-R 17 , -C(=0)-NH-R 17 , -S0 2 -R 17 , or -SO 2 -NR 20 R 17 ; R 19 is selected from hydroxy, Cχ-Cιo alkyloxy, C 3 -Cιχ cycloalkyloxy, aryloxy, aryl(Cι-C6 alkoxy)-, C -Cχo alkylcarbonyloxyalkyloxy, C -Cχo alkoxycarbonyloxyalkyloxy, C 2 -Cιo alkoxycarbonylalkyloxy, C5-C1 0 cycloalkylcarbonyloxyalkyloxy, C 5 -CX 0 cycloalkoxycarbonyloxyalkyloxy, C5-C1 0 cycloalkoxycarbonylalkyloxy, C 7 -C 1 aryloxycarbonylalkyloxy, C 8 -C 2 aryloxycarbonyloxyalkyloxy, C 8 -C12 arylcarbonyloxyalkyloxy, C5-C10 alkoxyalkylcarbonyloxyalkyloxy, C5-C10 (5-alkyl-1, 3-dιoxa-cyclopenten-2-one- yDmethyloxy, C10-C14 (5-aryl-l, 3-dioxa-cyclopenten- 2-one-yl)methyloxy, or (R 11 ) (R 12 ) N- (Cχ-Cχo alkoxy) -; R 20 is selected from: H, Cχ-C 6 alkyl, C3-C7 cycloalkyl, C4-C11 cycloalkylalkyl, aryl, aryl(Cι-C6 alkyl)-, or heteroaryl (Cχ-C6 alkyl)-,- R 2 is selected from COOH or NR 6 2 ; and with the following provisos: (1) t, n, m and q are chosen such that the number of atoms connecting R 1 and Y is in the range of 10-14; and (2) n and m are chosen such that the value of n plus m is greater than one __r.less is - !CH- ) L Q{CH 7 ) τr. [13] Preferred compounds of the invention as described above are compounds of the Formula Ic: IC including stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, or pharmaceutically acceptable salt or prodrug forms thereof wherein: X 1 , X 2 , X 3 , and X 4 are independently selected from nitrogen or carbon provided that at least two of X 1 , X 2 , X 3 and X 4 are carbon; R 1 is selected from: A and B are independently -CH -, -0-, -N(R 2 )-, or -C(=0)-; A 1 and B 1 are independently -CH 2 - or -N(R 3 )-; D is -N(R 2 )-, -0-, -S-, -C(=0)- or -S0 2 -; E-F is -C(R 4 )=C(R 5 )-, -N=C(R 4 )-, -C(R 4 )=N-, or -C(R 4 ) C(R 5) 2 -; J, K, L and M are independently selected from: -C(R 4 )-, -C(R 5 )- or -N-, provided that at least one of J, K, L and M is not -N-; R 2 is selected from: H, Ci-Cβ alkyl, (Ci-Cβ alkyl)carbonyl, (Cχ-Cβ alkoxy)carbonyl, C -Cβ alkylaminocarbonyl, C 3 -C 6 alkenyl, C 3 -C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, heteroaryl(C -Cβ alkyl)carbonyl, heteroarylcarbonyl, aryKCi-Ce alkyl)-, (C 1 -C 6 alkyl)carbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, aryl(Cι-C 6 alkyl) sulfonyl, heteroarylsulfonyl, heteroaryl (Cχ-C6 alkyl) sulfonyl, aryloxycarbonyl, aryl(Cι-C6 alkoxy) carbonyl, wherein said aryl groups are substituted with 0-2 substituents selected from the group consisting of C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo, CF 3 , and nitro; R 3 is selected from: H, Cχ-C6 alkyl, C3-C7 cycloalkyl, C4-C 1 1 cycloalkylalkyl, aryl, aryl(Cι-C 6 alkyl)-, or heteroaryl (Cχ-C 6 alkyl) -,- R 4 and R 5 are independently selected from: H, C -C 4 alkoxy, NR 2 R 3 , halogen, N0 2 , CN, CF 3 , C -C 6 alkyl, C 3 -C 6 alkenyl, C 3 -C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl(Cι-C6 alkyl)-, C 2 -C7 alkylcarbonyl, arylcarbonyl or alternatively, when substituents on adjacent atoms, R 4 and R 5 can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups selected from: C1-C4 alkyl, C -C 4 alkoxy, halo, cyano, amino, CF , or N0 2 ; U is selected from: -(CH 2 ) n (CR 7 =CR 8 ) (CH 2 ) m - - lCH 2 ),.Q;CH 2 ) -, -(CH2)nO(CH 2 ) m -, -(CH 2 ) n N(R 6 ) (CH 2 )m-. -(CH 2 ) n C(=0) (CH 2 )m-. or -(CH 2 ) n S(0)p(CH 2 ) m -; wherein one of the methylene groups is optionally substituted with R 7 ; Q is selected from i , 2- her.yler.e, 1, -phenylene, 2,3- yr d ylene, 2 , 4-pyrιdmyier.e, or 2,4- py idiny e e; R 6 is selected from: H, C 1 -C 4 alkyl, or benzyl; R 7 and R 8 are independently selected from: H, Ci-Cβ alkyl, C3-C7 cycloalkyl, C 4 ~C cycloalkylalkyl, aryl, aryl(Cχ-C6 alkyl)-, or heteroaryl (C0-C6 alkyl)-,- R 9 is selected from: H, C0 2 R 17 , C(=0)R 17 , CONR 17 R 20 , -S0 2 R 17 , -S0 2 NR 17 R 20 , Ci-Cβ alkyl substituted with 0- 1 R 15 or 0-1 R 21 , C 3 -Ce alkenyl substituted with 0-1 R 15 or 0-1 R 21 , C -C 7 cycloalkyl substituted with 0- 1 R 15 or 0-1 R 21 , C 4 -C X1 cycloalkylalkyl substituted with 0-1 R 15 or 0-1 R 21 , aryl substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 , or aryl (Cχ-Ce alkyl) - substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 ; R 11 is selected from: H, halogen, CF 3 , CN, NO 2 , hydroxy, NR 2 R 3 , C 1 -C 4 alkyl substituted with 0-1 R 21 , C -C 4 alkoxy substituted with 0-1 R 21 , aryl substituted with 0-1 R 21 , aryl(Cι-C 6 alkyl)- substituted with 0-1 R 21 , (C 1 -C 4 alkoxy)carbonyl substituted with 0-1 R 21 , (C1-C 4 alkyl)carbonyl substituted with 0-1 R 21 , C 1 -C4 alkylsulfonyl substituted with 0-1 R 21 , or C 1 -C 4 alkylaminosulfonyl substituted with 0-1 R 21 ; W is -C(=0 ) -N(R 13) - ( C ( R 12) 2 ) q-; X is -C(R 12 ) (R 1 )-C(R 12 ) (R 15 )-; alternatively, W and X can be taken together to be R 12 is H or Cι-C 5 alkyl; R 13 is selected from: H, Ci-Cβ alkyl, C3-C7 cycloalkylmethyl, or aryl(Cι-C 6 alkyl)-; R 14 is selected from: H, Cχ-C 6 alkylthioalkyl, aryl(C -Cιo alkylthioalkyl)-, aryl(Cχ-Cχo alkoxyalkyl)-, Cι-Cχ 0 alkyl, Cχ-Cχo alkoxyalkyl, Cχ-C 6 hydroxyalkyl , C 2 -Cχo alkenyl, C 2 -Cχo alkynyl, C3-C 1 0 cycloalkyl, C 3 -Cχo cycloalkylalkyl, aryl(Cχ-Ce alkyl)-, heteroaryl (Ci-Cβ alkyl)-, aryl, heteroaryl, C0 2 R 17 , C(=0)R 17 , or CONR 17 R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 0-1 R 16 or 0-2 R 11 ; R 15 is selected from: H, R 16 , C 1 -C 10 alkyl, Cι-Cχo alkoxyalkyl, C 1 -C 10 alkylammoalkyl, Cχ-Cιo dialkylaminoalkyl, C 1 -C 10 alkylcarbonyl , aryl(Co-C 6 alkyl) carbonyl, C 2 -C 10 alkenyl, C -Cιo alkynyl ,C3-Cιo cycloalkyl, C 3 -C 10 cycloalkylalkyl, aryl(Cι-C6 alkyl)-, heteroaryl (Ci-C δ alkyl)-, aryl, heteroaryl, C0 2 R 17 , C(=0)R 17 , CONR 17 R 20 , S0 2 R 17 , or S0 2 NR 17 R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 0-2 R 11 ; Y is selected from: -COR 19 , -SO 3 H, R 16 is selected from: -N(R 20 )-C(=O) -O-R 17 , -N(R 20 )-C(=O) -R 17 , -N(R 20 ) -C(=0) -NH-R 17 , -N(R 20 )SO 2 -R 17 , or -N(R 20 )SO 2 -NR 20 R 17 ; R 17 is selected from: Cχ-Cχ 0 alkyl, C 3 -C 1 cycloalkyl, aryl(Cι-C 6 alkyl)-, (Cχ-C 6 alkyl) aryl, heteroaryl (Ci-Cβ alkyl)-, (Cι-C 6 alkyl)heteroaryl, biaryKCi-Cβ alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C -C 4 alkyl, C -C 4 alkoxy, aryl, heteroaryl, halo, cyano, amino, CF 3 , and N0 ; R 18 is selected from: H, -C(=0)-0-R 17 , -C(=0)-R 17 , -C(=0)-NH-R 17 , -S0 2 -R 17 , or -SO 2 -NR 20 R 17 ; R 19 is selected from: hydroxy, C 1 -C10 alkyloxy, C 3 -C 11 cycloalkyloxy, C 6 -C o aryloxy, C 7 -C ι aralkyloxy, C 3 -C 10 alkylcarbonyloxyalkyloxy, C3-C 0 alkoxycarbonyloxyalkyloxy, C 2 -Cχo alkoxycarbonylalkyloxy, C5-C10 cycloalkylcarbonyloxyalkyloxy, C5-C10 cycloalkoxycarbonyloxyalkyloxy, C 5 -C 1 0 cycloalkoxycarbonylalkyloxy, C7-C 11 aryloxycarbonylalkyloxy, Cs-C 2 aryloxycarbonyloxyalkyloxy, Cg-Cχ 2 arylcarbonyloxyalkyloxy, C 5 -C 0 alkoxyalkylcarbonyloxyalkyloxy, C 5 -C 0 (5-alkyl-l, 3-dιoxa-cyclopenten-2-one- yD ethyloxy, C 1 0-C 14 (5-aryl-l, 3-dioxa-cyclopenten- 2-one-yl)methyloxy, or (R 11 ) (R 12 )N- (C 1 -C 10 alkoxy)-; R 20 selected from: H, C -C6 alkyl, C3-C7 cycloalkyl, C 4 - C cycloalkylalkyl, aryl(Cι-C6 alkyl)-, or heteroaryl (C1-C6 alkyl)-,. R 21 is selected from COOH or NR 6 2 ; and [14] Further preferred compounds of the invention as described above are compounds of the Formula lie or Ilf: lie Ilf including stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, or pharmaceutically acceptable salt or prodrug forms thereof, wherein: R 1 is selected from: wherein the above heterocycles are optionally substituted with 0-2 substituents selected from the group consisting of: NH 2 , halogen, N0 2 , CN, CF 3 , C1-C4 alkoxy, Ci-Cβ alkyl, and C 3 -C7 cycloalkyl; U is -(CH 2 ) n -, -(CH2)tQ(CH 2 )m- or -C (=0) (CH 2 ) n -ι-, wherein one of the methylene groups is optionally substituted with R 7 ; Q s ≤electei from . , 2-crery-.e..e, 1, ? -p..eny..er.e, 2,3- pyr di ylene, 3 , _imy_. r.e, :r 2,4- pyrιdιny_. πe; R 6 is selected from: H, Cχ-C alkyl, or benzyl; R7 is selected from: C -C6 alkyl, C 3 -C 7 cycloalkyl, C4-C11 cycloalkylalkyl, aryl, aryl(Cχ-C 6 alkyl), heteroaryl, or heteroaryl (Cχ-C 6 alkyl); R 9 is selected from: H, -S0 2 R 17 , -S0 2 R 17 R 20 , Ci-Cβ alkyl substituted with 0-1 R 15 or 0-1 R 21 , C 3 -C7 cycloalkyl substituted witn 0-1 R 15 or 0-1 R 21 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 or 0-1 R 21 , aryl substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 , or aryl(Cχ-C6 alkyl)- substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 ; R 11 is selected from H, halogen, CF 3 , CN, N0 2 , hydroxy, NR 2 R 3 , C 1 -C 4 alkyl substituted with 0-1 R 21 , C1-C4 alkoxy substituted with 0-1 R 21 , aryl substituted with 0-1 R 21 , aryKCi-Ce alkyl)- substituted with 0-1 R 21 , (C 1 -C4 alkoxy) carbonyl substituted with 0-1 R 21 , (C 1 -C 4 alkyl ) carbonyl substituted with 0-1 R 21 , C 1 -C 4 alkylsulfonyl substituted with 0-1 R 21 , or C 1 -C 4 alkylammosulfonyl substituted with 0-1 R 21 ; X is -CH(R 14 )-CH(R 15 )-; R 14 is selected from: H, C 1 -C 10 alkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C -C 4 alkyl, C -C 4 alkoxy, aryl, halo, cyano, ammo, CF 3 , and N0 2 ; R 16 is selected from: -NH(R 20 )-C(=O)-O-R 17 , -N(R 20 )-C(=O)-R 17 , -N(R 20 ) -C(=0) -NH-R 17 , -N(R 20 )SO 2 -R 17 , or -N(R 20 )SO 2 -N(R 20 )R 17 ; R 17 is selected from: Cχ-C 10 alkyl , C3-C 11 cycloalkyl , aryl (Cχ -C 6 alkyl ) - , (Cχ-C 6 alkyl)aryl, heteroaryl (Cι-C 6 alkyl)-, (Cχ-C 6 alkyl) heteroaryl, bιaryl(Cχ-C 6 alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, C -C 4 alkoxy, aryl, heteroaryl, halo, cyano, amino, CF3, and N0 2 ; R 19 is selected from: hydroxy, Cχ-Cιo alkoxy, methylcarbonyloxymethoxy-, ethylcarbonyloxymethoxy-, t-butylcarbonyloxymethoxy-, cyclohexylcarbonyloxymethoxy-, 1- (me hylcarbonyloxy)ethoxy-, 1- (ethylcarbonyloxy)ethoxy-, 1- (t-butylcarbonyloxy) ethoxy-, 1- (cyclohexylcarbonyloxy)ethoxy-, i-propyloxycarbonyloxymethoxy-, t-butyloxycarbonyioxymethoxy- , 1- (i-propyloxycarbonyloxy) ethoxy- , 1- (cyclohexyloxycarbonyloxy) ethoxy- , 1- ( t-butyloxycarbonyloxy) ethoxy-, dimethylam oethoxy-, diethyla inoethoxy-, ( 5-methyl-1, 3-dioxacyclopenten-2-on-4-yl)methoxy-, (5- ( t-butyl) -1, 3-dιoxacyclopenten-2-on-4- yl)methoxy-, (1,3-dioxa-5-phenyl-cyclopenten-2-on-4-yl)methoxy-, or 1- (2- (2-methoxypropyl)carbonyloxy) ethoxy-; R 20 is H or CH 3 ; R 21 is selected from COOH or NR 6 2 ; and [15] Still further preferred compounds of the above described are compounds of the Formula lie or Ilf: He Ilf including stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, or pharmaceutically acceptable salt or prodrug forms thereof, wherein: R 1 is selected from: wherein the above heterocycles are optionally substituted with 0-2 substituents selected from the group consisting of: NH 2 , halogen, N0 2 , CN, CF3, C -C 4 alkoxy, Ci-Cβ alkyl, and C 3 -C 7 cycloalkyl: U is -(CH 2 ) n -/ - ;CH 2 itQ' H-;^- or -C(=0) (CH 2 ) n -ι~, wherein one of the methylene groups is optionally substituted with R 7 ; s selected from 1,2-phenylene, 1, -phenylene, 2,3- pyridinylene, 2 , -pyr dιnylene, or 2,4- pyridinyiene; R 6 selected from: H, C 1 -C 4 alkyl, or benzyl; R7 is selected from Ci-Cβ alkyl, C 3 -C7 cycloalkyl, C4-C11 cycloalkylalkyl, aryl, aryKCi-Cβ alkyl), heteroaryl, or heteroaryl(Ci-Cβ alkyl); R 9 is selected from: H, -S0 2 R , -S0 2 NR 17 R 20 , Cχ-C alkyl substituted with 0-1 R 1 - 5 or 0-1 R 21 , C 3 -C 7 cycloalkyl substituted with 0-1 R 15 or 0-1 R 21 , C4-C11 cycloalkylalkyl substituted with 0-1 R 15 or 0-1 R 21 , aryl substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 , or aryKCi-Ce alkyl)- substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 ; R 11 is selected from H, halogen, CF , CN, N0 2 , hydroxy, NR 2 R 3 , C 1 -C4 alkyl substituted with 0-1 R 21 , C 1 -C 4 alkoxy substituted with 0-1 R 21 , aryl substituted with 0-1 R 21 , aryl(Cχ-Ce al yl)- substituted with 0-1 R 21 , (C -C 4 alkoxy) carbonyl substituted with 0-1 R 21 , (Cχ-C 4 alkyl) carbonyl substituted with 0-1 R 21 , C 1 -C 4 alkylsulfonyl substituted with 0-1 R 21 , or C -C 4 alkylammosulfonyl substituted with 0-1 R 21 ;W IS -C(=0)-N(R 13 )-; X is -CH(R 1 )-CH(R 15 )-; R 13 IS H or CH3; R 14 is selected from: H, C1-C1 0 alkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C1-C4 alkyl, C1-C4 alkoxy, aryl, halo, cyano, ammo, CF3, and N0 2 ; R 15 IS H or R 16 ; Y is -COR 19 ; Riό is selected from: -NH(R 0 )-C(=O! -0-R " , -N(R 2 0)-C(=O)-R^, -N(R 0)-C(=O)-NH-R 17 , -N(R20)S0 2 -R 17 , or -N(R 20 )SO 2 -NR 20 R 1'7 ; R 17 is selected from: Ci-Cio alkyl, C3-C11 cycloalkyl, aryl(Cι-C 6 alkyl)-, ( Ci-Ce alkyl ) aryl, heteroaryl (Cχ-C 6 alkyl)-, (C -C 6 alkyl ) heteroaryl, bιaryl(Cι-Ce alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, heteroaryl, halo, cyano, ammo, CF 3 , and N0 2 ; R 19 is selected from: hydroxy, C 1 -C 1 0 alkoxy, methylcarbonyloxymethoxy-, ethylcarbonyloxymethoxy-, t-butylcarbonyloxymethoxy-, cyclohexylcarbonyloxymethoxy-, 1- (methylcarbonyloxy)ethoxy-, 1- (ethylcarbonyloxy) ethoxy-, 1- (t-butylcarbonyloxy) ethoxy- , 1- (cyclohexylcarbonyloxy)ethoxy-, i-propyloxycarbonyloxymethoxy-, t-butyloxycarbonyloxymethoxy-, 1- (i-propyloxycarbonyloxy)ethoxy-, 1- (cyclohexyloxycarbonyloxy) ethoxy-, 1- ( t-butyloxycarbonyloxy)ethoxy-, dimethylaminoethoxy-, diethylaminoethoxy-, (5-methyl-1, 3-dιoxacyclopenten-2-on-4-yl)methoxy-, (5- (t-butyl) -1,3-dioxacyclopenten-2-on-4- yl)methoxy-, ( 1 , 3 -dιoxa- 5-phenyl-cyclopenten-2 -on-4 -yl ) met oxy- , or 1- ( 2 - ( 2 -methoxypropyl ) carDonyloxy) ethoxy- ; R 21 is selected from COOH or NR 6 2 ; and m _3 _ c r _ ; In the present invention it has been discovered that the compounds of Formula la, lb or Ic above are useful as inhibitors of cell-matrix and cell-cell adhesion processes. The present invention includes novel compounds of Formula la, lb or Ic and methods for using such compounds for the prevention or treatment of diseases resulting from abnormal cell adhesion to the extracellular matrix which comprises administering to a host m need of such treatment a therapeutically effective amount of such compound of Formula la, lb or Ic. In the present invention it has also been discovered that the compounds of Formula la, lb or Ic above are useful as inhibitors of ctvfo. The compounds of the present invention inhibit the binding of vitronectin to oivfo and inhibit cell adhesion. The present invention also provides pharmaceutical compositions comprising a compound of Formula la, lb or Ic and a pharmaceutically acceptable carrier. The compounds of Formula la, lb or Ic of the present invention are useful for the treatment (including prevention) of angiogenic disorders, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula la, lb or Ic described above. The term "angiogenic disorders" as used herein includes conditions involving abnormal neovasculanzation, such as tumor metastasis and ocular neovasculanzation, including, for example, diabetic retinopathy, neovascular glaucoma, age-related macular degeneration, and retinal ve n occlusion. The compounds of Formula la, lb or Ic of the present invention are also useful for the treatment (including prevention) of thromboembolic disorders, comprising administering to a mammal n need of such treatment a therapeutically effective amount of a compound of Formula la, lb or Ic described above. The term "thromboembolic disorders" as used herein includes conditions involving platelet activation and aggregation, such as arterial or venous cardiovascular or cerebrovascular thromboembolic disorders, including, for example, thrombosis, unstable angina, first or recurrent myocardial infarction, lschemic sudden death, transient lschemic attack, stroke, atherosclerosis, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary and cerebral arterial thrombosis, myocardial infarction, cerebral embolisms, kidney embolisms, pulmonary embolisms, or such disorders associated with diabetes. The compounds of Formula la, lb or Ic of the present invention may also be useful for the treatment or prevention of other diseases which involve cell adhesion processes, including, but not limited to, inflammation, bone degradation, restenosis, rheumatoid arthritis, asthma, allergies, adult respiratory distress syndrome, graft versus host disease, organ transplantation rejection, septic shock, psoriasis, eczema, contact dermatitis, osteoporosis, osteoarthritis, atherosclerosis, inflammatory bowel disease and other autoimmune diseases. The compounds of Formula la, lb or Ic of the present invention may also be useful for wound healing. The compounds of the present invention may be used for ether ex vi vo applications to prevent cellular adhesion in biological samples. The compounds of the present invention can also be administered in combination with one or more additional therapeutic agents selected from: antI-coagulant or coagulation inhibitory agents, such as heparin or warfarin; anti-platelet or platelet inhibitory agents, such as aspirin, piroxicam, or ticlopidine; thrombin inhibitors such as boropeptides, hirud or argatroban; or thrombolytic or fibrmolytic agents, such as plasminogen activators, anistreplase, urokinase, or streptokinase. The compounds of Formula la, lb or Ic of the present invention can be administered m combination with one or more of the foregoing additional therapeutic agents, thereby to reduce the doses of each drug required to achieve the desired therapeutic effect. Thus, the combination treatment of the present invention permits the use of lower doses of each component, with reduced adverse, toxic effects of each component. A lower dosage minimizes the potential of side effects of the compounds, thereby providing an increased margin of safety relative to the margin of safety for each component when used as a single agent. Such combination therapies may be employed to achieve synergistic or additive therapeutic effects for the treatment of thromboembolic or other disorders. By "therapeutically effective amount" is meant an amount of a compound of Formula la, lb or Ic that when administered alone or in combination with an additional therapeutic agent to a cell or mammal is effective to prevent or ameliorate the disease condition or the progression of the disease. By "administered in combination" or "combination therapy" it is meant that the compound of Formula la, lb cr Ic and one or more additional therapeutic agents are administered concurrently to the mammal being treated. When administered in combination each component may be administered at the same time or sequentially in any order at different points time. Thus, each component may be administered separately but sufficiently closely time so as to provide the desired therapeutic effect. The term antI-coagulant agents (or coagulation inhibitory agents) , as used herein, denotes agents that inhibit blood coagulation. Such agents include warfarin sodium crystalline clathrate and heparin. The term anti-platelet agents (or platelet inhibitory agents) , as used herein, denotes agents that inhibit platelet function such as by inhibiting the aggregation, adhesion or granular secretion of platelets. Such agents include the various known non-steroidal anti- flammatory drugs (NSAIDS) such as aspirin, lbuprofen, naproxen, sulindac, mdomethacin, mefenamate, droxicam, diclofenac, sulf pyrazone, and piroxicam, including pharmaceutically acceptable salts or prodrugs thereof. Other suitable anti-platelet agents include ticlopid e, including pharmaceutically acceptable salts or prodrugs thereof. Ticlopidme is also a preferred compound since it is known to be gentle on the gastro-intestinal tract in use. Still other suitable platelet inhibitory agents include thromboxane- A2~receptor antagonists and thromboxane-A2-synthetase inhibitors, as well as pharmaceutically acceptable salts or prodrugs thereof. The phrase thrombin inhibitors (or anti-thrombm agents) , as used herein, denotes inhibitors of the serine protease thrombin. By inhibiting tnrombm, various thromb -mediated processes, such as thrombin-mediated platelet activation (that is, for example, the aggregation of platelets, and/or the granular secretion of plasminogen activator inhibitor-1 and/or serotonin) and/or fibrm formation are disrupted. Such inhibitors include boroarginme derivatives and boropeptides, hirudin and argatroban, including pharmaceutically acceptable salts and prodrugs thereof. Boroargmine derivatives and boropeptides include N-acetyl and peptide derivatives of boronic acid, such as C-termmal α-ammoboronic acid derivatives of lys e, ormthme, argmme, homoarginine and corresponding isothiouronium analogs thereof. The term hirudm, as used herein, includes suitable derivatives or analogs of hirudin, referred to herein as hirulogs, such as disulfatohirudin. Boropeptide thrombin inhibitors include compounds described in Kettner et al., U.S. Patent No. 5,187,157 and European Patent Application Publication Number 293 881 A2, the disclosures of which are hereby incorporated herein by reference. Other suitable boroargmine derivatives and boropeptide tnrombm inhibitors include those disclosed in PCT Application Publication Number 92/07869 and European Patent Application Publication Number 471 651 A2, the disclosures of which are hereby incorporated herein by reference, in their entirety. The phrase thrombolytics (or fibr olytic) agents (or thrombolytics or fibrinolytics) , as used herein, denotes agents that lyse blood clots (thrombi) . Such agents include tissue plasminogen activator, amstreplase, urokinase, retivase or streptokinase, including pharmaceu ically acceptable salts or prodrugs thereof. Tissue plasminogen activator (tPA) is commercially available from Genentech Inc., South San Francisco, California. The term amstreplase, as used herein, refers to anisoylated plasminogen streptokinase activator complex, as described, for example, in European Patent Application No. 028,489, the disclosures of which are hereby incorporated herein by reference herein, in their entirety. The term urokinase, as used herein, is intended to denote both dual and single chain urokinase, the latter also being referred to herein as prourokinase. The compounds of the present invention are also useful as standard or reference compounds, for example as a quality standard or control, in tests or assays involving the binding of vitronectin or fibrinogen to otvβ3 ■ Such compounds may be provided in a commercial kit, for example, for use in pharmaceutical research involving ctvfo. The compounds of the present invention may also be used in diagnostic assays involving αyβs. The compounds herein described may have asymmetric centers. Unless otherwise indicated, all chiral, diastereomeric and racemic forms are included in the present invention. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. It will be appreciated that compounds of the present invention that contain asymmetrically substituted carbon atoms may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis, from optically active starting materials. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomer form is specifically indicated. When any variable (for example but not limited to, R 2 , R 4 , R 6 , R 7 , R 8 , R 12 ,and R 14 , n, etc.) occurs more than one time any constituent or in any formula, its definition on each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-3 R 4 , then said group may optionally be substituted with up to three R 4 and R 4 at each occurrence is selected independently from the defined list of possible R 4 . Also, by way of example, for the group -N(R 5a ) 2 , each of the two R 5a substituents on N is independently selected from the defined list of possible R 5a . Similarly, by way of example, for the group -C(R 7 ) -, each of the two R 7 substituents on C is independently selected from the defined list of possible R 7 . When a bond to a substituent is shown to cross the bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a bond joining a substituent to another group is not specifically shown or the atom in such other group to which the bond joins is not specifically shown, then such substituent may form a bond with any atom on such other group. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of Formula la, lb or Ic, then such substituent may be bonded via any atom m such substituent. For example, when the substituent is piperaz yl, piperidinyl, or tetrazolyl, unless specified otherwise, said piperazmyl, piperidinyl, tetrazolyl group may be bonded to the rest of the compound of Formula la, lb or Ic via any atom in such piperazmyl, piperidinyl, tetrazolyl group. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. By stable compound or stable structure it is meant herein a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. The term "substituted", as used herein, means that any one or more hydrogen on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substitent is keto (i.e., =0), then 2 hydrogens on the atom are replaced. As used herein, "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms (for example, "Co-C 10 " denotes alkyl having 0 to 10 carbon atoms; Co denotes a direct bond between the groups linked by the Co group; also by way of example, "Ci to C4" denotes methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-methylpropyl, 1-methylpropyl, 1,1-dιmethyl ethyl); "haloalkyl" is intended to include both branched and straight-cham saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen (for example -C v F w where v = 1 to 3 and w = 1 to (2v+D); "alkoxy" represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge; "cycloalkyl" is intended to include saturated ring groups, including mono-,bι- or poly-cyclic ring systems, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and adamantyl; and "biycloalkyl" is intended to include saturated bicyclic ring groups such as [3.3.0]bicyclooctane, [4.3.0]bιcyclononane, [4.4.0]bιcyclodecane (decalm) , [2.2.2]bιcyclooctane, and so forth. "Alkenyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl, propenyl and the like; and "alkynyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more triple carbon-carbon conds which may occur in any stable point along the chain, such as ethynyl, propynyl and the like. The terms "alkylene", "alkenylene" , "phenylene", and the like, refer to alkyl, alkenyl, and phenyl groups, respectively, which are connected by two bonds to the rest of the structure of Formula la, lb or Ic. Such "alkylene", "alkenylene", "phenylene", and the like, may alternatively and equivalently be denoted herein as "-(alkyl)-", "- (alkyenyl) -" and "-(phenyl)-", and the like. "Halo" or "halogen" as used herein refers to fluoro, chloro, bromo and lodo; and "countenon" is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, sulfate and the like. As used herein, "aryl" or "aromatic residue" is intended to mean phenyl or naphthyl; the term "arylalkyl" represents an aryl group attached through an alkyl bridge. As used herein, "carbocycle" or "carbocyclic residue" is intended to mean any stable 3- to 7- membered monocyclic or bicyclic or 7- to 14-membered bicyclic or tricyclic or an up to 26-membered polycyclic carbon ring, any of which may be saturated, partially unsaturated, or aromatic. Examples of such carbocyles include, but are not limited to, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, biphenyl, naphthyl, mdanyl, adamantyl, or tetrahydronaphthyl (tetralm) . As used herein, the term "heterocycle" or "heterocyclic" is intended to mean a stable 5- to 7- membered monocyclic or bicyclic or 7- to 10-membered bicyclic heterocyclic ring which may be saturated, partially unsaturated, or aromatic, and which consists of carbon atoms and from 1 to 4 heteroatoms independently selected from tne group consisting of N, 0 and S and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. Examples of such heterocycles include, but are not limited to, pyridyl (pyridinyl) , pyrimidinyl, furanyl (furyl), thiazolyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, benzothiophenyl, indolyl, mdolenyl, isoxazolmyl, isoxazolyl, qumolmyl, isoquinolmyl, benzimidazolyl, piperidinyl, 4-pιperιdonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolmyl, tetrahydrofuranyl, tetrahydroqumolinyl, tetrahydroisoquinol yl, decahydroqumol yl or octahydroisoqu olmyl, azocinyl, tnazinyl, 6H-1,2,5- thiadiazinyl, 2H, 6H-1 , 5,2-dιthιazmyl, thianthrenyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxathnnyl, 2H-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolmyl, isoxazolyl, oxazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizmyl, isoindolyl, 3H-indolyl, indolyl, lH-indazolyl, purinyl, 4f/-quιnolιzmyl, isoquinolmyl, qumolmyl, phthalazmyl, naphthyndmyl, quinoxalmyl, qu azolmyl, cinnolmyl, ptendmyl, 4aH-carbazole, carbazole, β-carbolinyl, phenanthridmyl, acridmyl, perimid yl, phenanthrolinyl, phenazinyl, phenarsazmyl, phenothiazinyl, furazanyl, phenoxazmyl, isochromanyl, chromanyl, pyrrolidinyl, pyrrolmyl, lmidazolidinyl, lmidazolmyl, pyrazolidmyl, pyrazolmyl, piperidinyl, piperazmyl, indolinyl, isoindolinyl, qumuclidmyl, morpholinyl or oxazolidinyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles. As used herein, the term "heteroaryl" refers to aromatic heterocyclic groups. Such heteroaryl groups are preferably 5-6 membered monocyclic groups or 8-10 membered fused bicyclic groups. Examples of such heteroaryl groups include, but are not limited to pyridyl (pyridinyl), pyrimidinyl, furanyl (furyl), thiazolyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, mdolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, benzofuranyl, benzothienyl, benzimidazolyl, qumolmyl, or isoquinolmyl. As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound of Formula la, lb or Ic is modified by making acid or base salts of the compound of Formula la, lb or Ic. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. "Prodrugs" are considered to be any covalently bonded carriers which release the active parent drug according to Formula la, lb or Ic in vivo when such prodrug is administered to a mammalian subject. Prodrugs of the compounds of Formula la, lb or Ic are prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compounds . Prodrugs include compounds of Formula la, lb or Ic wherein hydroxyl, amino, sulfhydryl, or carboxyl groups are bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxy1, am o, sulfhydryl, or carboxyl group respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of Formula la, lb or Ic, and the like. Examples of representative carboxyl and ammo prodrugs are included under the definition of R 2 , R 3 , and Y. The pharmaceutically acceptable salts of the compounds of Formula la, lb or Ic include the conventional non-toxic salts or the quaternary ammonium salts of the compounds of Formula la, lb or Ic formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethaneεulfomc, ethanedisulfonic, oxalic, lsethionic, and the like. The pharmaceutically acceptable salts of the present invention can be synthesized from the compounds of Formula la, lb or Ic which contain a basic or acidic moiety by conventional chemical methods. Generally, the salts are prepared by reacting the free base or acid with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents. The pharmaceutically acceptable salts of the acids of Formula la, lb or Ic may be prepared by reacting the acid with an appropriate amount of a base, such as an alkali or alkaline earth metal hydroxide e.g. sodium, potassium, lithium, calcium, or magnesium, or an organic base such as an amine, e.g., dioenzyletnylenediam e, tnmethylamine, piperidme, pyrrolidine, benzylamme and the like, or a quaternary ammonium nydroxide such as tetramethylammonium hydroxide and the like. As discussed above, pharmaceutically acceptable salts of the compounds of the invention can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid, respectively, m water or in an organic solvent, or m a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, .et-.a--c-, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington ' s Pharmaceu ical Sci ences, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference. The disclosures of all of the references cited herein are hereby incorporated herein by reference in their entirety. Synthesis The compounds of the present invention can be prepared in a number of ways well known to one skilled m the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. All references cited herein are hereby incorporated in their entirety herein by reference. Compounds of Formula la, lb or Ic wherein X 1 , X 2 , X 3 and X 4 are all carbon and W is C(=0)NH can be prepared from appropriately substituted 4-, 5-, 6-, or 7- alkoxycarbonyl mdazoles, Ilia, wherein R is an alkyl group such as methyl, ethyl or tert-butyl. Ilia "* The requisite indazoles can be conveniently prepared from the commercially available nitrotoluic acids according to the example shown m Scheme 1. Conversion of the acid la to a suitable ester, such as the ethyl ester lb, may be carried out by one of many methods well-known to one skilled in the art of organic synthesis, for example treatment with a suitable base, such as sodium bicarbonate, in a suitable solvent, such as N,N-dιmethylformamιde, followed by treatment with an alkyl halide, such as lodoethane. Reduction of the nitro group of lb can be effected in a number of ways known to one skilled in the art of organic synthesis, including treatment with tm'IIi chloride m ethanol. The resulting aniline derivative can be converted to the desired substituted dazole Ilia according to the method of Bartsch and Yang [J. Heterocycl . Chem. 1984, 21(4) : 1063-1064) . A variation of trie conversion of the aniline lc to the mdazole Ilia proceeds t rc gπ an N- acylated intermediate Id, followed by cyclization and deacetyla ion, according to tie method reported by chardt and Haεsmar.n Li ebigs Ann . Chem. 1980, 903- 927) . The order of the esterification and reduction steps may be reversed, such that the nitrotoluic acid s first converted to an ammotoluic acid, which is then esterified. In some cases other intermediates related to those shown in Scheme 1 are commercially available or may be prepared using methods described in the literature of organic chemistry; in these cases ransformations similar to those shown m Scheme 1 may be used to prepare the desired compounds Ilia. For example, commercially available methyl 3-ammo-4- methylbenzoate may be directly transformed into 6- ethoxycarbonylmdazole. Scneme 1 la lb lc Ilia te Id Compounds of Formula la or lb wherein one or more of X 1 , X 2 , X 3 or X 4 are nitrogen may be prepared from the corresponding alkoxycaroonylmdazoles Illb in which the appropriate carbon atom or atoms have been replaced by nitrogen. These may in turn be prepared by substitution of the appropriately substituted heterocycle for the nitrotoluic acids, nitrotoluic acid esters, or am otoluic acid esters in Scheme 1 above. The starting heterocycles could be obtained by following the procedures and methods in references outlined below, along with implementation of standard functional group transformations well known to one skilled in the art. Illb Functionalized pyrazines could be prepared according to procedures outlined in The Chemistry of Heterocyclic Compounds : The Pyrazines, Vol. 41 (Arnold Weissberger and Edward C. Taylor, Eds.), John Wiley and Sons (New York: 1982). Preparation of appropriately functionalized pyndazmes could be achieved using the methods described in The Chemistry of Heterocyclic Compounds : Condensed Pyridazmes Including Cinnolines and Phthalazines, Vol. 27 (Arnold Weissberger and Edward C. Taylor, Eds.), John Wiley and Sons (New York: 1973) and The Chemistry of Heterocyclic Compounds : Pyridazines, Vol. 28 (Arnold Weissberger and Edward C. Taylor, Eds.), John Wiley and Sons (New York: 1973). For the synthesis of functionalized pyrimidmes one could follow procedures in The Chemistry of Heterocyclic Compounds : The Pyrimidines, (Arnold Weissberger, Consulting Ed.) John Wiley and Sons (New York: 1962), The Chemistry of Heterocyclic Compounds : The Pyrimidines, Supplement I, (Arnold Weissberger and Edward C. Taylor, Consulting Eds.) John Wiley and Sons (New York: 1970), and The Chemistry of Heterocyclic Compounds : The Pyrimidines , Supplement II, Vol. 16 ( Arnold Weissberger and Edward C. Taylor, Consulting Eds.) John Wiley and Sons (New York: 1985) . Functionalized pyπdmes which can serve as starting materials in Scheme 1 could be made by the methods described in The Chemistry of Heterocyclic Compounds : Pyridine and Its Deri vatives, Part Four, (Arnold Weissberger, Consulting Ed.) John Wiley and Sons (New York: 1964) , The Chemistry of Heterocyclic Compounds : Pyridine and Its Deri vatives , Supplement Part Two, (Arnold Weissberger and Edward C. Taylor, Consulting Eds.) John Wiley and Sons (New York: 1974), The Chemistry of Heterocyclic Compounds : Pyridine and Its Deri vatives, Supplement Part Three, Vol. 14 (Arnold Weissberger and Edward C. Taylor, Consulting Eds.) John Wiley and Sons (New York: 1974), The Chemistry of Heterocyclic Compounds : Pyridine and Its Derivatives, Supplement Part Four, Vol. 14 (Arnold Weissberger and Edward C. Taylor, Consulting Eds.) John Wiley and Sons (New York: 1975), and The Chemistry of Heterocyclic Compounds : Pyridine and Its Deri vatives, Part Five, Vol. 14 (Arnold Weissberger and Edward C. Taylor, Consulting Eds.) John Wiley and Sons (New York: 1984) . One example of the preparation of an appropriately substituted pyridine starting material is the preparation of 2-methyl-3-amιnopyridine-5-carboxylιc acid half-sulfate salt, as described by Argoudelis and Kummerow (J. Org. Chem. 1961, 2£: 3420-3422) . Compounds of Formula la wherein R 10 is not hydrogen may be prepared from appropriately substituted alkoxycarbonylindazoles. Some such substituted alkoxycarbonylindazoles may be prepared using the method outlined in Scheme 1. For example, methyl 4-amino-3- ethylbenzoate may be prepared as described by Witte and Boekelheide (J. Org. Chem. 1972, 22 (18) : 2849-2853) . This compound may be converted to the diazonium fluoroborate and cyclized to 3-methyl-5- methoxycarbonylmdazole using the method outlined in Scheme 1. This compound may be used as a starting material for preparation of the corresponding compounds of Formula la wherein R 10 is methyl. Other substituted alkoxycarbonylindazoles may be prepared from unsubstituted alkoxycarbonylindazoles using the methods outlined in Scheme 2. For example, an ethoxycarbonylmdazole may be brommated by treatment with bromine m a suitable solvent, such as acetic acid, to provide the corresponding 3-bromo-ethoxycarbonyl- mdazole IIIc. This compound may be coupled with a suitable reagent, alternatively followed by additional synthetic manipulations, to provide the desired 3- substituted-ethoxycarbonylmdazole. For example, coupling with phenylboronic acid in the presence of tetrakis- (triphenylphosphine)palladium and triethylamine in N,N-dιmethylformamιde, using the method of Miyaura, Sugmome and Suzuki ( Tetrahedron 1983, !__,: 3271) provides the corresponding 3-phenyl-ethoxycarbonyl- dazole Hid. Similar methods, starting from compounds of Formula Illb, may be used to prepare the corresponding compounds wherein one or more of the ring carbons (corresponding to those designated X 1 , X 2 , X 3 and X 4 m Formula la) are replaced by nitrogen. Scheme 2 s COjEt IUa Br PhCCH mc As another example, also shown in Scheme 2, coupling of IIIc with phenylacetylene in the presence of bis- (triphenylphosphine)palladiu (II) chloride, copper(I) chloride, and triethylamine in pyridine according to the method of Melissaris and Litt (J. Org. Chem. 1992, 52: 6998-6999) provides the corresponding 3- (2-phenylethynyl) -ethoxycarbonyl dazole Hie, which may be reduced using hydrogen in the presence of palladium on charcoal to provide the corresponding 3-(2-phenyl- ethyl) ethoxycarbonylmdazole Illf. Similar methods, starting from compounds of Formula Illb, may be used to prepare the corresponding compounds wherein one or more of the ring carbons (corresponding to those designated X 1 , X 2 , X 3 and X 4 in Formula la) are replaced by nitrogen. Compounds IIIc, Hid, Hie and IHf may be used in the preparation of compounds of Formula la in which R 10 is phenyl, 2-phenylethynyl, or 2-phenylethyl, respectively. Alternatively, further manipulations of the substituent may be accomplished at a later stage in the synthesis of the compound of Formula la. For example, the 2-phenylethynyl mdazoles Hie may be used in a synthetic sequence during the course of which the acetylene will be reduced, providing ultimately compounds of Formula la in which R 10 is 2-phenylethyl. Other appropriately substituted alkoxycarbonyl¬ indazoles, for use the preparation of compounds of Formula la wherein R 10 is not hydrogen, may be prepared using other methods known in the art of organic synthesis, such as those outlined in The Chemistry of Heterocyclic Compounds : Pyrazoles, Pyrazolines, Pyrazolidines, Indazoles and Condensed Rings, Vol. 22 (Arnold Weissberger, Ed. ) , John Wiley and Sons (New York: 1967), Chapter 10. Hereinafter, unless otherwise specified, phrases such as "mdazoles III" and "mdazoles of Formula III" are meant to include simple mdazoles Ilia, mono- or diazaindazoles Illb, and substituted mdazoles such as but not restricted to IIIc, Hid, Hie and IHf. Substituted mono- and diazaindazoles such as but not restricted to mono- and diaza analogs of IIIc, Hid, Hie and IHf are also included. Compounds of Formula la may be prepared from indazoles III as outlined in Scheme 3. Alkylation of the mdazoles of Formula III with a suitably functionalized alkyl halide can oe effected in a variety of ways known to one skilled in the art. For example, using a method similar to that described by Granger et al. ( Chi . Ther. 1970, jj.: 24 ), an mdazole of Formula III is treated with a suitable base, such as potassium bis (trimethylsilyl) amide, followed by addition of the alkyl halide, for example, 3-bromopropylphthalιmιde. Alternately, the alkylation can be carried out utilizing Mitsunobu conditions (Mitsunobu, Synthesis, 1981, 1-28) by addition of the corresponding alcohol, 3- hydroxypropylphthaliira.de, to a mixture of diethyl azodicarboxylate and triphenylphosphine in a suitable solvent, usually dry tetrahydrofuran, followed by addition of the mdazole III. Separation, if necessary, of the mixture of 1- and 2-substituted isomers by chromatography provides the desired 1-alkylated product 3a. Removal of the phthalimide may be achieved by treatment with anhydrous hydrazme to give the primary amine 3b. Scheme 3 NH 2 NH 2 CF 3 COOH As further shown in Scheme 3, 2-imidazolinyl- aminoalkylindazoles may be prepared by treatment of the amine 3b with a suitable reagent such as 2-methylthio- 4, 5-dihydroimidazoliurn iodide. Hydrolysis of the ester, using conventional methods known to one skilled in the art of organic synthesis, may be followed by coupling of the resulting acid to an appropriately substituted α- or β-amino ester such as a compound of Formula IV, to provide an intermediate which, after deprotection, affords compounds of Formula la wherein R 1 is 2- imidazolinylaminoalkyl. The coupling may be carried out using any of the many methods for the formation of amide bonds known to one skilled the art of organic synthesis. Those methods include, but are not limited to, use of standard coupling procedures such as the azide method, mixed carbonic acid anhydride (isobutyl chloroformate) method, carbodiimide (dicyclohexyl- carbodiimide, diisopropylcarbodiiiru.de, or water-soluble carbodiimides (WSCDI) ) method, active ester (p- mtrophenyl ester, N-hydroxysuccinic imido ester) method, or by the use of one of many other known coupling reagent such as BOP-Cl. Some of these methods (especially the carbodiimide method) can be enhanced by the addition of 1-hydroxybenzotrιazole to the reaction mixture. An alternative method for preparing amines 3b wherein n=3 is outlined in Scheme 4. Alkylation of the mdazole III may be achieved by treatment with an optionally substituted acrylonitrile in the presence of a catalytic amount of a base such as sodium ethoxide or sodium bis (tnmethylsilyl)amide, in a suitable solvent such as ethanol, to provide the intermediate itπle 4a. This may be converted to the amine 3b by reduction using any of a number of methods known to one skilled in the art of organic synthesis, such as by treatment with hydrogen in the presence of a catalyst such as palladium on charcoal. An acid such as aqueous hydrochloric acid may be added to the reaction mixture to minimize side reactions during the reduction. Scheme 4 NC \ * CN - COjEt /*Vv NaN(TMS). EiOH m Y — CO j Et R'° 4a H,. Pd/C EtOH. HO Appropriately substituted racemic β-amino acids IV (used in Scheme 3) may be purchased commercially or, as is shown in Scheme 5, Method 1, prepared from the appropiate aldehyde, malonic acid and ammonium acetate according to the procedure of Johnson and Livak (J. Am. Chem. Soc . , 1936, __£, 299 ) . Racemic β-substituted-β- am o esters may be prepared through the reaction of dialkylcuprates or alkyllithiums with 4-benzoyloxy-2- azetidinone followed by treatment with anhydrous ethanol (Scheme 5, Method 2) or by reductive animation of β-keto esters as is described in WO93/16038 (also see Rico et al., J. Org. Chem. , 1993, 5_ , 7948-51) . Enantiomerically pure β-substituted-β-amino acids can be obtained through the optical resolution of the racemic mixture or can be prepared using numerous methods, including: Arndt- Eistert homologation of the corresponding α-amino acids as shown in Scheme 5, Method 3 (see Meier and Zeller, Angew. Chem. Int . Ed. Engl . , 1975 IA, 32; Rodriguez et al., Tetrahedron Let . , 1990, (31), 5153; Greenlee, J. Med. Chem. 1985, 23, 434 and references cited within); and through an enan ioseiect ve hydrogenation of a dehydroammo acid as is shown m Scheme 5, Method 4 (see Asymmetric Synthesis, Vol. 5, (Morrison, ed. ) Academic Press, New York: 1985) . A comprehensive treatise on the preparation of β-amino acid derivatives may be found m Patent Application WO 93/07867, the disclosure of which is hereby incorporated by reference. Scheme 5 Method 1 Method 2 Method 3 BOCH Method 4 OgMe The synthesis of N -subst t ted diaminopropiomc acid derivatives IV can be carried cut via Hoffmann rearrangement of a wide variety of asparagme derivatives as described, for example, by Waki et al . .Synthesis 1981, 266-267) or by Moore et al . (J. Med. Chem. 1976, 12.(6), 766-772). An example s shown m Scheme 6, Method 1. They may also be prepared by manipulations, which will be familiar to one skilled in the art of organic synthesis, of the commercially available 3-ammo-2-benzyloxycarbonylamιnopropιonιc acid. An example is shown m Scheme 6, Method 2. Scheme 6 Method 1 *,C0 2 H 1 NaOθr HsNCCr^^ H2N - COOH NHSOaP i HCl, H j O NHSθ2P H_S0 4 NHS0 2 Ph Method 2 jP l.H 2 , PdC 2. PhSO_Ci Et N COO β H ^ 3. CF 3 COOH NHSOaPh Compounds of Formula la above wherein R 1 is 2-pyridιnylammoalkyl may be prepared by the method outlined in Scheme 7. Treatment of the intermediate am oalkylindazole 3b from Scheme 3 (or the corresponding salt from Scheme 4) with 2-chloropyrιdιne N-oxide hydrochloride, using a modification of the method described by Misra, et al. (Bioorg. and Med. Chem. Let ters , 1994, A, 2165-2170), and subsequent reduction of the resulting N-oxide derivative 7a provides a 2-pyπdιnylamιnoalkyl intermediate 7b. This reduction may be performed using a number of methods known to one skilled in the art of organic synthesis, such as that using ammonium formate in the presence of 10% palladium on charcoal m refluxing ethanol, as described by Balicki ( Synthesis , 1989, 645-646), or by reduction with hydrogen in the presence of a catalyst such as palladium on charcoal or Raney nickel, or by treatment with triphenylphosphine. The resulting 2- aminopyrid e moiety of 7b may be optionally protected, for example by treatment with di-t-butyldicarbonate in dry tetrahydrofuran in the presence of a suitable base, such as triethylamine or N,N-dimethylammopyridme, using the method of Iwanowicz { Synth . Commun . , 1993, 21(10), 1443-1445), to provide intermediate 7c. Ester hydrolysis, coupling and deprotection as outlined in Scheme 3 can then provide the desired compounds of Formula la. Scheme 7 see Scheme 3 An alternative route to 1- (heteroarylaminoalkyl) indazoles of Formula la is outlined in Scheme 8. A suitable indazole III can be alkylated with an alkyl halide bearing a protected aldehyde, such as a 1,3- dioxolane, using conditions described above (see Scheme 3) to provide 8a. Deprotection to the aldehyde 8b, for example by treatment with aqueous acid, may be followed by reductive amination with a heteroarylamine such as 2- aminopyridine or a suitably protected 2-aminoimidazole, such as l-triphenylmethyl-2-aminoimidazole, in the presence of a reducing agent such as sodium triacetoxyborohydride or sodium cyanoborohydride, to provide the 1- (heteroarylaminoalkyl) indazole 8c. The intermediates 8c can then be elaborated to the corresponding compounds of Formula la, for example as described in Scheme 3. Scheme 8 8a (CHa . CHO HOAc. H,0 1 Hα-NH, Vv TF° # NaBWOAc), 8b (Het = appropriate aromatic heterocycle) A route to 1- (heteroarylaminocarbonylethyl) indazoles of Formula la is outlined in Scheme 9. A suitable indazole III can be alkylated by treatment with an acrylic acid ester such as tert-butyl acrylate, using a method such as that described in Scheme 4. Removal of the ester of 9a may be followed by conversion to a heteroaryl amide by treatment with a heteroaryl amme using any of a number of methods well known to one skilled in the art of organic synthesis. The resulting 1- (heteroarylam ocarbonylethyl) mdazole 9b can then be elaborated to the corresponding compounds of Formula la, for example as described m Scheme 3. Scheme 9 9b (Het = appropriate aromatic heterocycle) Compounds of Formula lb may be prepared according to the method outlined in Scheme 10. Thus, the appropriate indazole III may be alkylated by treatment with a suitable base, for example sodium hydride, followed by addition of a suitable alkylating agent such as an alkyl halide R 9 -Br or R 9 -I. Bromination of the intermediate 10a using, for example, bromine in acetic acid, provides the corresponding 3-bromo derivative 10b. (The order of these two synthetic steps may also be reversed. That is, the mdazole III may be brominated, and resulting bromoindazole may be alkylated, to provide similar products 10b. ) Coupling of 10b with, for example, 3, 3-diethoxy-l-propyne, under conditions similar to those described by Sa amoto et al. { Synthesis 1992, 746-748) provides a functionalized alkynyl derivative 10c. Reduction of the acetylenic bond of 10c using, for example, hydrogen in the presence of a catalyst such as palladium on charcoal, followed by nydroiysis of the acetal with aqueous acid provides an aldehyde intermediate lOd which, using methods analogous to those outlined in Scheme 8, may be elaborated to an intermediate lOβ containing a heteroarylaminoalkyl substituent at the 3-position. This intermediate may then in turn be elaborated to the desired compounds of Formula lb, for example using methods described m Scheme 3. Scheme 10 CFjCOOH sec Scheme 3 (Het = heteroaromat-c group) Compounds of Formula lb may alternatively be prepared from the intermediate 10b according to the method described in Scheme 11. Thus, coupling of 10b under conditions similar to those described by Murakami et al. (Heterocycles, 1990, .11.(8), 1505-11) can provide a 3-allyl derivative Ila. Hydroboration as described by Brown and Subba Rao (J. Am. Chem. Soc. fi , 6428-6433) can provide the alcohol lib, which may be subjected to the Mitsunobu reaction { vide supra) with phthalimide followed by deprotection to provide an amine intermediate lie which, analogously to the method shown m Schemes 10 and 3, can be elaborated to the desired compounds of Formula lb. Alternatively, the intermediate lib may be prepared by reduction of the aidenyde lOd shown in Scheme 10. Other methods can be used for the conversion of intermediates lOd and lib to the primary amine lie which are known to those skilled in the art of organic synthesis. Scheme 11 lib lie Compounds of Formula Ic may be prepared according to methods outlined in Scheme 12. Treatment of the appropriate dazole starting material 12a with zinc bromide and vmylmagnesium bromide followed by dιchloro(l,l'-bιs (diphenylphosphino) ferrocene] palladium (II) , using a procedure similar to that described by Brown, et al. (U.S. Patent 4,898,863), can provide the desired 3-vinyl derivative 12b. Treatment of this compound with ozone (F. J. Brown, et al. Ibid . ) , can provide an aldehyde 12c. Oxidation using silver(I) oxide, as described by Campaigne and LeSuer ( Organic Syntheses , 1963, Coll. Vol. 4, 919), can provide the αes red carboxylic acid 12d. Estenfication and deprotection of the ether oxygen of 12e using boron tribromide, by a method analogous to that detailed by Manson and Musgrave (J. Chem. Soc. 1011 (1963)), can provide the hydroxy intermediate 12f. Mitsunobu coupling, { vide supra ) , followed by further transformations of 12g similar to those shown m Scheme 3, can provide compounds of Formula Ic. Scheme 12 12a 3. ιch]oro(l.l-bιs- ( iphenylp oβphiDO)- feroceaei palla-UunVII) i. Ph,Prt>EΛD 1 3-hydro-ypιo yl- pht-aliπude 12e I2 Additional alcohols useful for the preparation of compounds of Formula la, lb and Ic through the Mitsunobu reaction described in the above schemes may be prepared as described in Scheme 13. Scheme 13 1. PhjP-CHCO j a J. Carbo. Chem. Q, 715-756(1994). 3 . (SO -0 l.dUHQ ♦ BOCN^N^ _ ZNaBH4 \ * _^ ' W Various compounds of Formula la, lb or Ic may be prepared from a common derivative of the corresponding compounds of Formula la, lb or Ic by functional grcup manipulations familiar to one skilled the art of organic synthesis. As one example, preparation of compounds of Formula la having different sulfonamide substituents at R 16 may be achieved as outlined in Scheme 14. Thus, the compound of Formula la having a benzyloxycarbonylammo group at R 16 (14a) may be hydrogenolyzed using, for example, hydrogen the presence of a catalyst such as palladium on charcoal to provide the primary amine derivative 14b. This may be reacted with a sulfonylatmg agent such as R 17 S0 C1 in the presence of an amme such as triethylamine to provide, after deprotection of the ester, the desired compound of Formula la. In place of the sulfonyl chloride, use of a carboxylic acid, acid chloride or acid anhydride can provide the corresponding amide derivative, use of a chloroformate can provide the corresponding carbamate derivative, use of a sulfamoyl chloride can provide the corresponding sulfamide derivative, and use of an lsocyanate can provide the corresponding urea derivative. Scheme 14 As another example, compounds of Formula la with different variations in R 1 may be prepared from a common precursor as outlined in Scheme 15. Thus, the amine intermediate 3b may be reacted, for example, with benzyl chloroformate to provide the benzyl carbamate. Hydrolysis of the ester, for example with lithium hydroxide, can provide the acid intermediate 15a. Using methods described earlier, 15a may be reacted with, for example, a suitable beta-amino ester, followed by removal of the benzyl carbamate, for example by hydrogenolysis, to provide the amine intermediate 15b. Using, for example, steps analogous to those shown in Schemes 3 or 7, the amine may be converted to an aminoheterocyclic group. After deprotection of the ester, the desired compound of Formula la may be obtained. Scheme 15 15b CFjCOOH The example outlined in Scheme 15 will also serve to demonstrate that the order in which the different substituents are elaborated to give the compounds of Formula la, lb and Ic may be varied from that in the examples shown in Schemes 1 through 14. This example will also serve to demonstrate the use of protecting groups to temporarily protect a functional group in the course of a synthetic sequence when that functional group is not compatible with one or more of the synthetic transformations that are to be accomplished . Such use of protecting groups, while not always explicitly shown in Schemes 1 through 15, is well known to one skilled in the art of organic synthesis. Many examples of protecting groups may be found, for example, in Greene, "Protective Groups in Organic Syntheses", Wiley (New York) , 1981. The detailed processes for preparing the compounds of Formula la, lb or Ic are illustrated by the following Examples. It is, however, understood that this invention is not limited to the specific details of these examples. Reactions were run under an atmosphere of nitrogen unless otherwise indicated. Solvent removal from reaction mixtures, extracts, and the like was performed under vacuum on a rotary evaporator. Flash chromatography refers to the medium-pressure column chromatography method described by Still et al. (J. Org. Chem. 1978, 11(14), 2923-2925) . Melting points (mp) are uncorrected. Proton nuclear magnetic resonance spectra (NMR) were measured in chloroform-d (CDCI3) , dimethyl sulfoxιde-d 6 (DMSO-d 6 ) or methanol-d 4 (MeOH-d 4 ) and the peaks are reported in parts per million downfield from tetramethylsilane (δ) . The coupling patterns are reported as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; b, broad. Mass spectra were measured using electrospray ionization (ESI) , ammonia chemical ionization (NH3-CI) , fast-atom bombardment from a glycol matrix (FAB) , or electron impact ionization (El) . Sxamn- 1035b 3- f1- ! 3- (N-irr.i azeL- 7.-v1amnoi nronvl ' -1 -riazol- - vl arhnrvl -ammol -2 t. S ) - f2.6-dimer.hvl-4-r»hpr.vlbenzftne- sι.lfrmvlamιι.0) -t.rr.pior.it. acid rrifluπr acetate A. rgrr-Bur.vl 3- FI - fl- ( K- π -rr Λnh-.nvl.nar.hvl -.mιdazol-2- yl ; -■.ffl-.-.o) PΓQPY - indazol -^-V- rarfronvleminQl -2 ( Si - ( 2 . 4 . S - - n Tier. hvl ben ^npc ,. ι f nv l. mno , πron r.are . A mixture of tne product rep r according to Ξ:-.amp e 1350e Part K (215 m , 37 μ-χi,, the product prepared according to Example 11 " 3b Part Ξ ; 140 r.g, 407 μ oi. , 1-hydroxybenzotriazole hydrate iS "7 r.ς, 407 μmcl: and .V-i-d rethyiformamide :? ;τιL) was treated with dicy lor.exylcarrcd imide (3 7 0 mg, 4C *7 μmo ' and stirred at rcoTT. temperature for 24 h. The mixture was poured _.nto vά er ( 7 5 ;:L) and extracted w t.n ethyl acetate ',3 κ 5 .nι_- . The organic pnaεe was dried (MgSO * ; and .cri entrated under vacuum. The residue was flash cr.romatcgraphed 'toluene:ethyl icetate, step gradient from 50:5.3 to 13:90, to provide the title product (252 g, 5%', as a co_.or_.ess glassy foam: ^H NMR 'CDCI3) δ S.17 [s , 1H>, 7.97 d, IHi , 7.^3 vdd, IH) , 7.4-"M 5Hι, 6.99 id, H), 0.94 ,s, 2H) , .85 (bt, IH: , 6.68 (d, IH: , β.42 (d, IH), 5.82 (bd, IH) , 4.07 * , 2H) , 3.93 tm, IK) , 3.83 m, IK' , 3.62 in, IH) , 3.04 ιm, IK) , 2.97 im, 2Hι , 2.65 <Ξ, όHj , 2.26 <s, 3H) , 1.32 (π, 2H; , 1.32 (s, _*«); Mass spectrum (ESI* m z 852.4 (100%, M+H * > . Alternative.y, a solution of the product prepared according to Example 1050e Part K (1.108 g, 2.1 mmol) u, M-dimethylfcrmamide (15 nL> was treated with the product prepared according to Example 11 8 Part E (719 mg, 2.1 πmcl), 3CP reagent 1 7 5 mσ, 2.2 mmol, and di sopropylethyi-a me (543 mg, 4.2 mmol; and the mixture was stirred at room temperature overnight. Tne mixture was concentrated under vacuum and the residue was partitioned between etnyl acetate (100 mL; and water (25 mL) . The aqueous phase was extracted with additional ethyl acetate (3 x 25 mL) and the combined organic phases were washed with hydrochloric acid ( 1.0 K; 10 mL) , water (2 x 10 mL) , saturated aqueous sodium bicarbonate (10 mL) and brine v2 x 10 mL! . then were dried !MgSθ4) and concentrated under vacuum. This material was combined with the crude product from another tun, starting from 10.β g of the product prepared according tc Ex m le 1 le Part . Z Z . rrcl , tc provide the title product as a :r_de πateπa- (23.0 g,' which was used m the next step without purification. 3 indazo-.-5-vlcarn nvl .rmr.πl -? r. ς - - i2.fi- iner. vl-..- s.ianvlber.zar.e-su onv ' .-.ninn' πrnmrr.ar?. τ!-e roduct prepared according tc Example 1035b Fart A '3.3 σ, 3.9 mπ l> was coαcir.ed witn methanol (IDC mL) and acetic i i '.-.0 :r ι and the mixture was heated at reflux overnigh . The mixture was concentrated under vac-urn, and tne residue was flash chromatographed <chloroform: methanol : queous a πcnia 130:10:15 to provide the product as a glassy foam.. This was combined -with the product from another run, starting from ..9.3 of the product prepared according to Example 1035b Fart A (22.3 m oli, to provide tne title product ;4.5 gj . Impure mater al frc the co_.urnr. was re-chromatographed ichloroform: methanol:aqueous ammonia 100:5:0.5: to provide additional pure title prcduct ι'δ.5 g; total con.b-.ned yie.d 31%): : H NMR (MeOH-d4, δ 5.17 (d, H) , 8.13 (d, H), .76 (dd, IH) , 7.57 id, 1H\ 6.85 is, IH) , 6.51 is, 2H), 4.53 (t, 2Hι , 4.06 (dd, IH) , 3.70 (dd, IH:, 3.50 (dd, IH) , 3.17 { z , H) , 2.59 (s, 6n) , 2. S ( , 2H1 , 2.10 (s, 3H5 , 1.22 (s, ?H ) . C. T-:i--3- -ιτr.ιdazo1-?-v1.3πi'nn,nronvl ' -uιd..zol-5-vl- carh nvlamino1 - iSi - (2. S-d τre hvl-4- nheπvlhenzenefluLfonv! -imnni nrr.monic ac d rr fine,roar rat.a. A solution of the product prepared according to Example 1035b Part 3 (430 g, 788 μmol: m dichloromethane (30 mL) was treated with trifluoroacetic ac d (5 mL) and stirred for 1 h at room temperature. The solution was concentrated under vacuum, and the residue was dissolved m methar.cl (3 L/ and purified by preparative reverse-pr.ase HPLC to provide, after lyophilization, the title product (432 rr.σ, 82%j aε an amorphous white solid: HPLC TR 12.33 mi:: ;95%); -H NMR ι ' MeOH-d4i δ 3.12 (s, 2H; , ".72 (dd, IK), 7.5 (<j, : ;;,, 6. ^ * s, 2H ) , 5.7?. ; 5 , 2H) , 4.53 (t, 2Hi , 4.15 (dd, IH; , I X i ;dd, IHi , 3.4? ( id, IH) , 3.23 (t, 2H) , 2.56 is, όH: , 2.22 (Γ , 2H! , 1.98 [ s , 2H! ; High resolution mass pectr π ;FA3) calculated ;V.+H + ) 554.2135, found 554.2195. Alternatively, a solution of the product prepared according to Example 1035b Part A (249 g, 291 μmol: m t ifluoroace ic acid (2.5 rti.) was heated at reflux for 60 min. The mixture was coded and concentrated, and the residue was purified by preparative reverse-phase HPLC to provide, after lyophilization, the title product (153 r.ς, 78%; as a white powder. Example. IQ'iOft - f 1 - n - ι N- mi daznT -3 -vl aιniπn ϊ nrnpyl 1 i ndazol-5- sulfonyl-urdnoi prnpioniπ acid r.rifl nroacftt ar.fi A. Er.hvl 3- prhvl-4-n t.rr>hen7.nare. A mixture of 3- :nethyl-4-nitrobenzoιc acid (1) f362.3 g, 2.0 mol) , N,N- dimethylfor amide (2000 ml) , sodium bicarbonate ( 200 g, 2.33 mol) and iodoethane (623.9 g, 4.0 mol) was stirred at " 0 "C for 18 h. The mixture was allowed to cool to room temperature a d poured into water (2000 mL; . The resulting solid was collected by filtration, washed with water and dried. The solid was washed further with he ane ϊnd dried to provide the title product (382.1 g, 91%) as an off-white solid: mp 51-52.5 °C; l H NMR (CDCI 3 ) 5 8.04-7.98 (m, 3H) , 4.42 (q, 2H) , 2.63 (s. 3H ) , 1.42 (t, 3H) ; Mass spectrum (NH3-CI) m/z 210 (100%, M+H + ) . B. Ethvl -τnethvl-4-am nobenzoate. A mixture of tr.- product prepared according tc Exaπple 1350e Part A ( 183. ? q , 380 πircl. , t n (II, chloride hydrate U 25 g, 4.54 noil and ethanol ;3500 mL, was neated at reflux for . . Ihe mixture was cooled ar.d diluted with water 3530 r. ) and the pH was adjusted tc 8.5. The mixture .v-as diluted further with additional water, ar.d extracted with ethy_ acetate. The organic extracts were dried .M SCi; , filtered and concentrated to provide the title product (13 .62 g, 8~%) as an off-white solid: mp 76-78 °C; 1 H NMR (CDCI 3 ) θ 7.78 (S, IH) , 7.76 (d, IH) , 6.63 (d, IH), 4.31 (q, 2H) , 3.99 (bs, 2H) , 2.19 (s, 3H) , 1.38 (t, 3H) ; High resolution mass spectrum ( H3-CI) calculated (M+H + ) 180.1025, found 180.1023. C. 5-Efhnxvcarbonvlindazole. A mixture of the product prepared according tc Example lϋ53e Part B (250.55 g, 1.4 mol), potassium acetate (143.3 g, 1.46 mol ) , acetic anhydride (285.9 g, 2.8 mol) and chloroform :ethano - free; 273 L, was stirred at room temperature. The temperature rose to 40 'C, then started to decline, at which time no starting πateriai was detected by TLC. A mixture of 18-crown-6 (75 g, 280 mmol: and n-amyl nitrite (364.5 g, 3.1 mol) was added and the mixture was heated at reflux overnight. The cooled mixture was washed with saturated aqueous sodium bicarbonate, then with water, and was dried (Mg3θ4), filtered and concentrated under vacuum. The residue was combined with that from another batch (711.3 g) and distilled through a 10 cm vigreaux column under vacuum to provide 1-Acetyl-5-ethoxycarbonyl-mdazole (576 g, 82%), bp 115- 155 * C (1.0 Torr: . This intermediate was combined with hydrochloric acid (6N; 2000 mL) and ethanol (20C0 mL ) , and the mixture was stirred overnight at rcom temperature. The mixture was concentrated under vacuum, and tne solid was combined with water. The pH of the mixture was ad -.st d to 8 witn aqueous ammcnia, ana the mixture was extracted w tn dichlcrcmethane. The organic phase was concentrated to provide a solid (460 g > . Th s was recrystallized from acetcn_.trile (1 CO mL; , and the rrystals were washed with et ancl, then hexar.e, and driεu to provide 5 (231 g, 60%) as a tan solid: p 122- 124 C C; l H NMR (CDC1 3 ) 5 10.23 (bs, IH) , 8.57 (s, IH) , 8.20 (s, IH), 8.10 (d, IH), 7.53 (d, IH) , 4.42 (q, 2H) , 1.42 (t, 3H) ; High resolution mass spectrum (NH 3 -CI) calculated (M+H + ); 191.0821, found 191.0838. D. 1- (2- (1.3-dιoxolan-2-vl)ethvl) -5-erhowoarbonvl- mdazole. A solution of the product prepared according to Example lCSOe Part C (74.5 g, 397 m o_.! _.__ anhydrous tet nydrofu n (1000 IOL) was treated sequentially with o i- t bis (tr methylsilyli m.ide tl.O M m tetrahydrofuran; 430 L, 430 mmol;, 13-crown-c vl.5 g) and 2- ;2-bromoethyl) -1, 3-dιoκoiane (90 g, 49β πrrπol) . The solution was heated at reflux for 20 h, then was cooled to room temperature. The solvent was removed under vacuum, and tne residue partitioned between toluene (2000 mL) and water '.1000 mL) . The aqueous phase was further extracted with tol-ene (3 x 200 mLi , and the combined organic phases were washed with water 13 x 2CO mL) and brine (2 :: 200 mL) . The organic phase was dried (MgSθ4) and concentrated under vacuum. The resulting oil was chronatcgraphed with toluene, then with 135:15 toluene-ethyl acetate, to provide the title product (71.0 g, 55%) : X H NMR (CDCI3) δ 8.49 (s, IH ) , 8.10 (S, IH), 8.06 (d, H) , 7.46 (d, IH) , 4.84 (t, IH ) , 4.55 (t, 2H), 4.41 (q, 2H) , 3.90 (m, 4H) , 2.31 ( , 2H ) , 1.42 (t, 3H) ; High resolution mass spectrum (NH3-CI ) calculated (M+H + ) 291.1345, found 291.1328. E. 1 - (3-nxonrnnvl) -5-erhπwrarhonvlindazole. A mixture of tr.e product prepared according to Example 1050e Part D v 7 3.C g, 256 nmci, , aceti.: acid 365 g; and water (1C20 πl ) was r.eate at " 0 * 0 tor 20 h. Tr.e mixture was cooled to room temperature, extracted with dichlorcmethane (E x 550 ΠILJ , and the combined orga ic layers were washed cautiously with saturated aquecis εodi- j -. b carrcnate ;until no πcre gases were evolved), then w tn water .'2 x 151 IULJ and brine '2 A 25 ' mL: . Tie orga-. c layer was dried ιM 3C ' , filtered ar.d concentiated under vacuu.ii to provide the title product 6C.9 g, 98%, as a _ιght yellow sc_ιd: T H NMR (CDCI 3 ) δ 9.87 (s, IH) , 8.50 (s, IH) , 8.10 (s+d, 2H) , 7.51 (d, IH), 4.70 (t, 2H) , 4.41 (q, 2H) , 3.19 (t, 2H) , 1.42 (t, 3H) ; High resolution mass spectrum (NH 3 -CI) calculated (M+H + ) 247.1083, found 247.1068. F. 2-Aιτnnoιmιdazole. 2-Aιr.ιno mιda:o_e sulfate (50 q, 378 rroTtolj was dissolved in rr.etnanol (1500 mL) and cooled to -78'C. Sodium methoxide (20.44 g, 3^& mmol was added port onwise over 60 mm. The mixture stirred at - 7 8'C for 30 mm, then at room temperature for 2.5 h. The solution was f -tered through Celite® and concentrated under vacuum to provide 2-ammeimidazole as a semi-solid (32.5 σ) which was used directly without further purification: 1 H NMR (DMSO-dβ) δ 6.32 (s, 2H), 5.0 (bs, 2H) . G. ?-Phfhalιmidoιτnidaτ:r>lP. A mixture of pnthalic anhydride (δ^.S g, 387.mmol) and the product prepared according to Example 1050e Part ? (32.5 g, 387 πnol) was heated with mechanical stirring tc 190-200 C C for 20 mm, then was placed under vacuum fcr 10 mm. The mixture was cooled to room temperature and dried under vacuum for 24 h. This material (83 g, 99%) was used without further purification. It could be purified y flash chromatography (chloroform: ethanol gradient from 95:5 to 80:20): X H NMR (DMSO-d 6 ) 6 12.35 (bs, IH) , 7.94-8.06 (m, 4H) , 7.16 (bs, 2H) ; Mass spectrum (ESI) m/z 214.2 (100%, M+H + ) . H. l-Trιnhf>nvlmerhvl-2-τ,hrhalιmιdQim da7.nlP A solut_.cn cr the product prepared according to Example 1350e Part 3 (3' - , 375 mmol ) in dichloromethane v2 00 mL: was treated with rr pr.er.y rr.et.nyl chloride (314 g, 1.125 mol' and tπet yianine !l51.3g, 1.5 mol: . The πiκture was heated at reflv.:: for 5.5 h, then cooled to room temperature ar.d concentrated .nder vacuum. The residue was extracted several times witr hexane/ethyl acetate < Z 2 ~ j ) . The residual solid was dissolved in dichloromethane and washed several times witn water, dried ( Mg5θ4: A concentrated. The residual solid was boiled i:. r.eκane, filtered, and the solid was wasned severa. times with het hexane until no trityl chloride was present ry TLC. This provided the title product .119 g, 70%): X H NMR (CDC1 3 ) δ 7.64 (s, 4H) , 7.28 (d. 6H) , 7.17 (m, 7H) , 7.06 (t, 3H) ,6.80 (d, IH) ; Mass spectrum (NH 3 -CI) m/z 456 (100%, M+H + ) . I. l-Triphenvlmethvl-2-..minoιmidazole. A mixture of the product prepared according to Example 1050e Part H ;114 g, 250 mmol), hydrazine PS. nL, 2.50 mol) and ethano. (3500 l; was neated at reflux for 2 h. The mixture was coded and the solvent was removed under vacuum. The solid residue was partitioned between water (500 :αL: a d chloroform (500 mL ) and tne aqueous phase was extracted further w th cnlcroform (3 x 200 mL) . The combined crgan c layers were washed with water (2 x 200 mL) , dried !MgS04) and concentrated to provide a sticky solid. This was heated with hexane and filtered to provide the title product (65 g, 80%) as a granular solid: 3-H NMR (DMSO-dβ) 67.33-7.44 (m, 9H) , 7.13 (d. 6H ) , 6.51 ( d, IH) , 6.26 (d, IH) ; Mass spectrum (NH3-CI) 326 (100%, M+H +) . j. 1- n- rw- (i-τriphenvlmgr.hvlimidr.zol-2-v- )amiriQl - propyll-5-Prhoxvcarbonvlindazole. A mixture of the product prepared according to Example 1050e Part E ( 10.0 g , 40.6 TO RCI) , the product prepared according to Example 1050e Part I 113.2 g, C.r nunol and toluene .500 m i was heated at refl :: under a Dean-Stark trap. Toluene (3 x ICO :τL ) was removed while adding fresh dry toluene. The mixture was then neated further for 20 n, when NMR analysis of an a_ quot showed the absence of aldehyde. Tr.e Mixture was cooled tc rccπ temperature and sodium triacetcxyborohydiiάe :34.42 g, 152.4 mmol) was added. The mixture was stirred at roo temperature for 20 h, men was oured into water '530 L- . The layers were separated and the aqueous phase was extracted with etnyl acetate (3 x 100 mL) . The combined organics were washed w th saturated aqueous sodium bicarbonate ι2 x 100 mL) , Λ'ater ;2 x IOC mL) and brine (2 x 100 mL: , tnen were dried ;MgSθ4), filtered and concentrated under vacuum to provide a crude product (25.0 g) . Th s was combined w th the crude product from another run ;startιr.g from . ~ l ~,l g of the product prepared according to Example lOSOe Part Ξ and 10.28 σ of the product prepared according to Example 1050e Part I) and was purified by flash chromatography (toluene:ethyl acetate, step gradient from 90:10 to 50:50) tc provide the title product (21.3 g, 52%) as an cil which slowly solidified: l H NMR (CDC1 3 ) 5 8.45 (s, IH) , 7.97 (s, IH) , 7.93 (d, IH) , 7.33 ( , 9H) , 7.21 (m, 6H) , 6.99 (d, IH) , 6.67 (d, IH) , 6.41 (d, IH) , 4.41 (q, 2H) , 4.06 (t. 2H) , 2.98 (m, 3H) , 1.81 (m, 2H) , 1.42 (t. 3H) ; High resolution mass spectrum (FAB) calculated (M+H + ) 556.2713, found 556.2725. K. 1-r3-fN-(l-Trinh nvlme hv-Limidazol-2-vl)amino1- nrnnvn-5-carhnxvinr1a7.nle. A mixture of the product prepared according to Example 1050e Part J (21.3 g, 37.8 mmol), ethanol (600 L) and aqueous sodium nydroxide (1.0 M; 209 mL, 209 mmol! was heated at reflux for 4 n. The mixture was cooled to room temperature and concentrated under vacuum to remove the ethanol. The pH of the residue was ad-j s si to 4, and the mixture was extracted with dι h-.cronethane and the combined organic phases were dried (Ma;_SC4, • ~h mixture was filtered and the solids were washed with N,N-dι.nethylformamide to lecov r precipitated product. The combined filtrates we_ ; ε concentrated under vacuum and the residue was washed w th ethanol and dried tc provide the title product :16.3 g, 35%) «s a white iolid: l H NMR (DMSO-d δ ) δ 8.39 (s, IH), 8.13 (s, IH) , 7.87 (d, IH) , 7.36 (m, 10H), 7.12 (d, 6H) , 6.51 (d, IH) , 6.28 (d, IH) , 4.05 (t, 2H) , 2.84 (m, 2H) , 1.63 (m, 2H) ; High resolution mass spectrum (FAB) calculated (M+H + ) 528.2400, found 528.2418. L. Metir.Y. 3-f1-[3-(N-(l-r.rinhfinγImeLhγliιπi-l--2Ql-2- v )amino)nrnnvl 1 indazol-5-vlπarbonvlam.nol-2 (Si - f2.6- dime hvl-4-nhenvlhPπ7PnPsu1fnnv amino)nronionar.e. A mixture of the product prepared according to Example 1050e Part K (293 mg, 556 μmol), methyl 3-amino-2- (S) - (2, 6-dimethy-4-phenylbenzenesulfonyl)aminopropionate hydrochloride (prepared according to the method of Example 3093 Parts J and K described below 290 mg, 727 μmol), N,N-dimethylformamide (7 mL) , dicyclohexyl- carbodiimide (115 mg, 557 μmol), 1-hydroxybenzotriazole hydrate (76 mg, 562 μmol) and triethylamine (230 μL, 1.65 mmol) was stirred at room temperature for 42 h. The mixture was concentrated under vacuum and the residue was purified by flash chromatography (ethyl acetate) to provide the title product (507 mg) contaminated with dicyclohexylurea, which was used in the subsequent reaction without further purification: H NMR (CDCI3) 6 8.13 (s, IH) , 8.02 (s, IH) , 7.70 ( d, IH), 7.60-7.15 (22H) , 6.98 (d, IH) , 6.87 (t, IH) , 6.67 (d, IH), 6.41 (d, IH), 6.08 (bs, IH) , 4.05 (t, 2H ) , 3.95 (m, IH), 3.75 (m, IH) , 3.65 (s, 3H) , 3.47 (m, IH ) , 2.95 (m, 2H) , 2.75 (s, 6H) , 1.79 (m, 2H) ; High resolution mass spectrum (FAB) calculated ' +H + ) 872.3594, found 872.3593. M. 3- ,l-r3- ( N-ιmιdazol-2-vlamιπo ) τ.ro-ιyl1 -indazol -5- vlcarbonylammo1 -2 (S) - (2.6-dιmethvI -4-nnenylbenzenP- s lfonvlamiπol roDionic acid tri luoroarer.ate. A mixture of the product prepared according to Example 1050e Part L (469 mg, 540 μmol), ethanol (13 mL) and aqueous sodium hydroxide (1.0 M; 2.7 mL, 2.7 mmol) was heated at reflux for 90 min. The mixture was cooled to room temperature and concentrated, and the residue was taken up in trifluoroacetic acid (6 mL) and heated at reflux for 90 mm. The mixture was cooled to room temperature and concentrated. The residue was purified by preparative reverse phase high pressure liquid chromatography (acetonitrile:water containing 0.05% trifluoroacetic acid; gradient from 10:90 to 90:10) to provide the title product (218 mg, 55%) as a white solid: X H NMR (MeOH-d 4 ) δ 8.06 (s, IH) , 7.95 (s, IH) , 7.63 (d, IH) , 7.34 (d, IH) , 7.28 (m, 5H) , 7.09 (S, 2H) , 6.75 (s, 2H) , 4.34 (t, 2H) , 4.27 (dd, 2H) ; 3.77 (dd, IH), 3.47 (dd, IH) , 3.17 (t, 2H) , 2.66 (S, 6H) , 2.12 (m, 2H) ; High resolution mass spectrum (FAB) calculated (M+H + ) 616.2342, found 616.2324. Example 1081 -ri-f3-(N-nvrιdιn-2-vlamιno)DrθL)vllιndazQl-5- vlcarbonylammo1 -2(5)- (benzvloxvcarbonvlamino)propionic acid trifluoroacetate A. 1- f3- (N-Dhthalιmιdo)propvll -5-ethoxvcarbonvl- dazole. A mixture of tetrahydrofuran (50 mL) and 18- crown-6 (100 mg) was stirred at room temperature. Potassium bis (trimethylsilyl)amide (0.5 M in toluene; 46.6 mL, 23.3 mmol) was added, followed by the product prepared according to Example 1050e Part C (4.43 g, 23.3 mmol ) dissolved n dry tetrahydrofuran (50 mL) . Then N- ( 3-bromopropyl ) phthalιmιde (6.24 g, 23.3 mmol) dissolved in dry tetrahydrofuran (50 mL) was added. The mixture was heated at reflux for 16 h. The mixture was allowed to cool to room temperature and poured into water (200 mL) . The layers were separated and the aqueous layer was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum. The residue was purified by flash chromatography (hexanes:ethyl acetate 50:50) to provide the title product (4.25 g, 48%) as a yellow solid: mp 122-124 °C; X H NMR (CDCI 3 ) δ 8.48 (s, IH) , 8.06 (s, IH) , 8.04 (d, IH) , 7.82 (m, 2H) , 7.71 (m, 2H) , 7.42 (d, IH) , 4.44 (t, 2H) , 4.40 (q, 2H) , 3.80 (t, 2H) , 2.40 (m, 2H) , 1.42 (t, 3H) ; High resolution mass spectrum (NH 3 -CI) calculated (M+H + ) 378.1454, found 378.1430. Also obtained (as a more polar fraction) was 2- [3- (N-phthalimido)propyl] -5-ethoxycarbonylιndazole (2,75 g, 31%) as a yellow solid: mp 133-135 °C; *H NMR (CDCI 3 ) δ 8.48 (S, IH) , 8.25 (s, IH) , 7.85 (d, IH) , 7.81 (m, 2H) , 7.70 (m, 2H) , 7.61 (d, IH) , 4.50 (t, 2H) , 4.40 (q, 2H), 3.78 (t, 2H) , 2.47 (m, 2H) , 1.43 (t, 3H) ? High resolution mass spectrum (NH 3 -CI) calculated (M+H + ) 378.1454, found 378.1430. B. 1-n-aπnnoτ.roπvl)-S-pr.hoxvrarhonvlιndazole. A mixture of the product prepared according to Example 1081 Part A (2.10 g, 5.6 mmol), ethanol (35 mL) , anhydrous tetrahydrofuran (35 mL) and anhydrous hydraz e (0.75 mL) was stirred at room temperature for 16 h. Dry tetrahydrofuran (100 mL) was added and the mixture was filtered. The filtrate was concentrated under vacuum. The residue was purified by flash chromatography (dichloromethane:methanol 90:10 containing 1% triethylamine) to provide the title product (1.25 g, 91%) as an orange syrup: l NMR (CDC1 3 ) δ 8.51 (s, IH), 8.10 (s, IH) , 8.06 (d, IH) , 7.46 (d, IH), 4.52 (t, 2H) , 4.41 (q, 2H) , 2.68 (t, 2H) , 2.06 (m, 2H) , 1.47 (bs, 2H) , 1.43 (t, 3H) ,- High resolution mass spectrum (NH3-CI) calculated (M+H + ) 248.1399, found 248.1392. C. 1- f3- ΓN- (l-oxido)pvridin-?-vlaττuno1nronyl 1 -5- ethoxvcarbonvlindazole. A mixture of the product prepared according to Example 1081 Part B (600 mg, 2.4 mmol), 2-chloropyridine-N-oxιde hydrochloride (806 mg, 4.9 mmol) , sodium bicarbonate (816 mg, 9.7 mmol) and n- butanol (7 mL) was stirred at 100 °C for 21 h. The mixture was allowed to cool to room temperature and was filtered. The filtrate was concentrated under vacuum. The residue was purified by flash chromatography (dichloromethane:methanol 95:5) to provide the title product (675 mg, 81%) as a pale yellow solid, mp 87-89 °C: ! H NMR (CDCI 3 ) δ 8.52 (s, IH), 8.15 (s, IH) , 8.13 (d, IH), 8.03 (d, IH) , 7.39 (d, IH) , 7.10 (t, IH) , 6.93 (bt, IH) , 6.56 (t, IH) , 6.41 (d, IH) , 4.57 (t, 2H) , 4.40 (q, 2H) , 3.24 (q, 2H) , 2.38 (m, 2H) , 1.40 (t, 3H) ; High resolution mass spectrum (NH 3 -CI) calculated (M+H + ) 341.1614, found 341.1622. D. l-r3-(N-Dvridm-2-vlamino)Dropvll-5-ethoxvcarbonvl- indazole. A mixture of the product prepared according to Example 1081 Part C (62 mg, 182 μmol), 10% palladium on charcoal (8 mg) and ethanol (0.5 mL) was stirred at room temperature. Ammonium formate (63 mg, 1.0 mmol) was added and the mixture heated to reflux for 30 min. Additional 10% palladium on charcoal (8 mg) and 6ammonium formate (63 mg, 1.0 mmol) were added and the reaction was continued at reflux for 4 h. The mixture was allowed to cool to room temperature, filtered through Celite ® and the solids were rinsed with ethanol. The solvent was evaporated from the filtrate under vacuum. The residue was purified by flash chromatography ιdichloromethane:methanol 95:5) to provide the title product (31 mg, 52%) as a glass: 1 H NMR ( CDCI3 ) δ 8.52 (s, IH) , 8.12 (s, IH) , 8.06 ( , 2H) , 7.38 (m, 2H), 6.55 (dd, IH) , 6.32 (d, IH) , 4.70 (bm, IH) , 4.53 (t, 2H) , 4.40 (q, 2H) , 3.30 (q, 2H) , 2.24 (m, 2H) , 1.42 (t, 3H) ; High resolution mass spectrum (NH 3 - CI) calculated (M+H + ) ; 325.1665, found 325.1659. E. 1- (3- (N-r.err.-hur.vloxvrarhonvl -N-nyridin-2- vlam o) nronvl1 - -et.hoxvcarhonvT m azol P A mixture of the product prepared according to Example 1081 Part D (80 mg, 246 μmol) , dry tetrahydrofuran (4 mL) , triethylamine (0.3 mL) and N,N-dιmethylammopyrιdιne (5 mg) was stirred at 0 °C. Di-tert-butyldicarbonate (130 mg, 2.4 equiv. ) was added and the mixture was stirred for 30 mm. The ice bath was removed and the mixture was stirred at room temperature for 16 h. Additional di-tert-butyldicarbonate (130 mg, 2.4 equiv. ) and N,N- dimethylammopyridme (5 mg) were added and the mixture was stirred at room temperature for 72 h. The solvent was evaporated under vacuum and the residue was purified by flash chromatography (hexanes:ethyl acetate 65:35) to provide the title product (70 mg, 66%) as a clear oil: l H NMR (CDCI 3 ) δ 8.50 (s, IH) , 8.28 (m, IH) , 8.08 (s, IH) , 8.04 (d, IH) , 7.60 (m, 2H) , 7.37 (d, IH) , 6.99 (in, IH) , 4.46 (t, 2H) , 4.41 (q, 2H) , 4.02 (t, 2H) , 2.34 ( , 2H) , 1.42 (t+s, 12H) ; High resolution mass spectrum (NH3-CI) calculated (M+H + ) ; 425.2189, found 425.2193. F. ι - n- (N-r.Prr-but.vloxvcarbonvl-N-nvrιdm-2- vlamιno)pronvll-5-carboxvmdazole. A mixture of the product prepared according to Example 1081 Part E (7.9 g, 18.6 mmol), water (100 mL) , ethanol (100 mL) and aqueous sodium hydroxide (1.0 M; 40 ml, 40 mmol) was stirred at reflux for 16 h. The mixture was allowed to cool to room temperature and aqueous hydrochloric acid (1.0 M; 43 mL, 43 mmol) was added. The solvent was decanted and the resulting gum was triturated several times with hexane to provide the title product (5.56 g, 75%) as a solid: mp 129-131 * C; X H NMR (CDCI 3 ) δ 8.59 (s, IH) , 8.30 (m, IH) , 8.12 (s, IH) , 8.07 (d, IH) , 7.61 (m, 2H) , 7.41 (d, IH) , 7.00 (m, IH) , 4.46 (t, 2H) , 4.01 (t, 2H) , 2.34 ( , 2H) , 1.42 (s, 9H) ; High resolution mass spectrum (NH3-CI) calculated (M+H + ) ; 397.1876, found 397.1878. G. r. rr.-Bur.vl 3- Tl- f3- (N- (terr-butvloxvcarbonvl-N- nyridin-2-v1 mino)oropvn ιndazol-5-vl arbonvlaminnl - (5)- fbenzvloxvcarbonvlamino)nronιonate. A mixture of the product prepared according to the procedure of Example 1081 Part F (1.19 g, 3.0 mmol), tert-butyl 3- amino-2 (S) - (benzyloxycarbonylammo)propionate (prepared according to Mokotoff and Logue, J. Med. Chem. 1981, 21, 554; 880 mg, 3.0 mmol), 1-hydroxybenzotriazole hydrate (410 mg, 3.0 mmol), and anhydrous tetrahydrofuran (20 mL) was stirred at room temperature. The mixture was treated with dicyclohexylcarbodiimide (660 mg, 3.2 mmol) and stirred for 24 h. The mixture was filtered and solvent was removed under vacuum. The residue was purified by flash chromatography (hexanes:ethyl acetate 50:50) to provide the title product (1.81 g, 89%) as a glass: H NMR (CDCI 3 ) δ 8.28 (d, IH) , 8.17 (s, IH) , 8.04 (S, IH) , 7.77 (d, IH) , 7.60 (d, 2H) , 7.4-7.25 (m, 6H) , 6.98 ( , 2H) , 5.88 (bd, IH) , 5.13 (s, 2H) , 4.47 (bm, IH), 4.46 (t, 2H) , 4.01 (t, 2H) , 3.87 (m, 2H) , 2.31 (m, 2H) , 1.48 (s, 9H) , 1.43 (s, 9H) ; High resolution mass spectrum (NH 3 -CI) calculated (M+H + ) 673.3350, found 673.3324. H. 3- fl- f3- ( N-Dvrιdιn-2-vlamτ.no, nrnpvll mdazol -5- y lcarbonvlaminol -2 ( S ) - ( benzvloxvcarhnnylamino) nroniomc acid tnfluoroacerar.e. A mixture of the product prepared according to Example 1081 Part G (32 mg, 47 μmol ) , dichloromethane (5 mL) and trifluoroacetic acid (300 μL) was stirred at room temperature for 16 h. The mixture was concentrated under vacuum and toluene was added. The solvent was evaporated and the residue was triturated with ether. The solvent was removed by decantation, and the residue was dried to constant weight under vacuum to provide the desired product (25 mg, 83% ) as a hygroscopic white solid: l H NMR (DMSO-dβ) δ 8.57 (bm, IH) , 8.53 (bt, IH) , 8.26 (S, IH) , 8.21 (s, IH), 7.82 ( , 3H) , 7.69 (d, IH) , 7.59 (d, IH) , 7.28 (m, 5H) , 6.93 (d, IH) , 6.78 (t, IH) , 4.99 (s, 2H) , 4.52 (t, 2H) , 4.23 (m, IH) , 3.60 (m, 2H) , 3.24 (m, 2H) , 2.15 (m, 2H) ,- High resolution mass spectrum (FAB) calculated (M+H + ) 517.2199, found 517.2213. Example 1Q94 3- ri- n- (N-nvr d n-2-vlam no)propvll ndazol-5-vl- carbonvlaminol -2 (S)- (ispbutvloxvcarbonvlaitu.no) propionic acid trifluoroacetate A. r.ert-Butvl 3- fl- f - (N-tert-burvloxvcarbonvl-N- pγrιdm-2-ylammo)pronvll mdazol- -vlcarbonvlamino1 - 2fS)-amιnor>ronιonate. A mixture of the product prepared according to the procedure of Example 1081 Part G (1.60 g, 2.33 mmol), 10% palladium on charcoal (160 mg) and ethanol (30 mL) was placed in a pressure bottle and stirred at room temperature under an atmosphere of hydrogen (1 atmosphere pressure). After 5 h, the mixture was filtered through Celite ® , the solids were rinsed with ethanol, and the filtrate was concentrated 'under vacuum to provide the title product (1.24 g, 97%) as a glass: i H NMR (CDCI 3 ) δ 8.28 id, IH) , 8.20 (S, IH! , 7.82 (d, IH) , 7.60 (m, 2H) , 7.38 (d, IH) , 6.98 ( , IH) , 6.93 (bt, IH) , 4.45 (t, 2H) , 4.00 (t, 2H) , 3.88 (m, IH) , 3.66 (m, IH) , 3.56 (m, IH) , 2.51 (m, 2H) , 2.05 (bs, ca. 2H1 , 1.48 (s, 9H), 1.42 (s, 9H) ; High resolution mass spectrum (NH 3 -CI) calculated (M+H + ) 539.2982, found 539.2998. B. tert-Bur.vl - f1- r - (N- ert-bu vloxvcarhonvl -N- πvridm-2-vlammo)proovl1 mdazol-5-vlcarbonylammo1 - 2 (S) - (isobut.vloxvcarbonvlamino)πropιonatp. A solution of the product prepared according to Example 1094 Part A (100 mg, 186 μmol) in N,N-dimethylformamide (5 mL) was treated with isobutyl chloroformate (27 μL, 205 μmol), 4- (N,N-dimethylamino) pyridine (10 mg) and pyridine (15 μL, 205 μmol) . The solution was stirred at room temperature for 16 h, then was concentrated under vacuum. The residue was purified by flash chromatography (dichloromethane:ethyl acetate 97:3) to provide the title product (106 mg, 89%) as a gum: 1 H NMR (DMSO-d 6 ) δ 8.51 (m, IH) , 8.28 (m, 2H) , 8.22 (s, IH) , 7.96 (s, IH), 7.90-7.50 (m, 3H) , 7.53 (d, 1H),7.11 (m, IH) , 4.46 (t, 2H) , 4.21 (m, IH) , 3.84 (m, 2H) , 3.75 (d, 2H), 3.69 (m, IH) , 3.56 (m, IH) , 2.13 (m, 2H) , 1.83 (m, IH) , 1.33 (s, 9H) , 1.30 (s, 9H) , 0.88 (d, 6H) ; High resolution mass spectrum (FAB) calculated (M+H + ) calculated 639.3480, found 639.3506. C. 3- fl- f - (N-nvridin-2-vlamino)PΓOPVII mdazol-5-vl- rarnonvTam nol -2(5)- l \sobutvloxvcarbonvlam no)Propionic acid trifluoroacetate Using the procedure of Example 1081 Part H, the product prepared according to Example 1094 Part B (106 mg, 166 μmol) was converted to the title product (76 mg, 76%) as a solid: *H NMR (DMSO-d 6 ) δ 8.56 (m, 2H) , 8.30 ' (s, IH) , 8.25 (s, IH) , 7.90-7.75 (m, 3H) , 7.72 (d, IH) , 7.44 (d, IH) , 6.96 (d, IH) , 6.80 (t, IH ) , 4.56 (t, 2H) , 4.24 (m, IH) , 3.73 id, 2H) , 3.52 im, 2H) , 3.28 ιm, 2H) , 2.17 (m, 2H) , 1.82 (m, IH) , 0.85 (d, 6H) ; High resolution mass spectrum (NH 3 -CI) calculated (M+H + ) calculated 483.2348, found 483.2356. Example lOqqh 3-ri- f3-(N-Dvrιdιn-2-vlamιno)nronvl 1 mdazol -5-vl- carbonvlammol-2- (5) - (E- rnhenvl erhenvl 1 rarhonylamino) - oronionic acid t.n f1uornar-prarp A. tert-Butvl 3- ri- f3- (N-tert-but.v oxvcarbonvl -N- nvrιdm-2-vlamιno)propvn ndazol-5-v1carbonv)ammo1- 2 (5) - (F- rnhpnvlethpnvllcarbonylammo)promonarP. A solution of the product prepared according to Example 1094 Part A (100 mg, 186 μmol) in tetrahydrofuran (3 mL) was treated with trans-cmnamic acid (28 mg, 186 μmol), 1-hydroxybenzotriazole hydrate (25 mg, 186 μmol) and dicyclohexylcarbodiimide (39 mg, 186 μmol) . The mixture was stirred at room temperature for 18 h, then was concentrated under vacuum. The residue was purified by flash chromatography (hexanes:ethyl acetate 70:30) to provide the title product (108 mg, 87%) as a gummy white solid: X H NMR (CDCI 3 ) δ 8.27 (d, IH) , 8.24 (s, IH) , 8.06 (S, IH) , 7.83 (d, IH) , 7.67 (d, J=17 Hz, IH) , 7.59 (m, IH), 7.55-7.35 (m, 6H) , 6.97 (m, IH) , 6.88 (d, IH) , 6.70 (d, J=17 Hz, IH) , 4.85 (m, IH) , 4.44 (t, 2H) , 4.02 (m, 3H), 3.47 (m, 2H) , 2.31 (m, 2H) , 1.52 (s, 9H) , 1.40 (s, 9H) ; High resolution mass spectrum (FAB) calculated (M+H+) 669.3401, found 669.3389. B. Wl - n- (N-nvπriτn-2-vlammo)oronvl1 mdazol -5-vl- rarbonylammo1 -2 (5) - (K- fπheπvlprhenvllcarbonylammo) - nromonic. arid r.r. flnoroaoetat.e Using the procedure of Example 1081 Part H, the product prepared according to Example 1099b Part A (100 mg, 150 μmol) was converted to the title product (90 mg, 96%) as a white solid: '-H NMR (DMSO-d δ ) δ 8.64 (t, IH) , 8.47 (d, IH) , 8.31 (s, IH) , 8.04 (s, IH), 7.90-7.80 (m, 3H) , 7.73 (d, IH) , 7.58 (d, IH), 7.50-7.35 (m, 6H) , 6.98 (d, IH) , 6.82 (t, IH) , 6.74 5 (d, J=17 Hz, IH), 4.63 (m, IH) , 4.55 (t, 2H) , 3.75-3.55 (m, 2H) , 3.27 (m, 2H) , 2.18 (m, 2H) ; High resolution mass spectrum (FAB) calculated (M+H + ) 513.2250, found 513.2239. 0 Example H ΩRb 3 - T l - f 3 - (N-Dvrιdιn-2 -vlammo ) nmpvl 1 mdazol -5 -yl- carbonvla mol -2 (S) - (cvclohexvlcarbonylammo)nropionir ac d trifluoroacetate ς A. 1- - (pyrιdιn-2-vlammo)propyl1 -5-carboxvmdazole. A mixture of the product prepared according to Example 1081 Part D (1.04 g, 3.19 mmol), ethanol (16 mL) and aqueous sodium hydroxide (1.0 M; 16 ml, 16 mmol) was 0 stirred at reflux for 20 h. The mixture was allowed to cool to room temperature and aqueous hydrochloric acid (1.0 M; 16 mL, 16 mmol) was added. The resulting solid was collected by filtration, washed with water and dried to provide the title product: l K NMR (DMSO-d 6 ) δ 8.42 5 (s, IH) , 8.22 (s, IH), 7.90 (m, 2H) , 7.76 (d, IH) , 7.38 (m, IH) , 6.58 (t, IH) , 6.42 (m, 2H) , 4.52 (t, 2H) , 3.20 (q, 2H) , 2.08 (m, 2H) ; Mass spectrum (ESI) m/z 297.3 (100%, M+H+) . 0 B. tart-Butyl 3- fl- (3- (pvrιdin-2-vlamino)pronvll - mdazol-5-vlcarbonvlammol -2 (S) - (benzvloxvcarbonvl¬ amino)propjonate. Using the procedure of 1081 Part G, the product prepared according to the procedure of Example 1108b Part A (740 mg, 2.5 mmol) was converted to 5 the title product (700 mg, 56%): X H NMR (CDC1 3 ) δ 8.19 (s, IH) , 8.08 (s, IH), 8.06 (m, IH) , 7.79 (d, IH ) , 7.45- 7.25 (m, 7H) , 7.02 (cm, IH) , 5.56 ( , IH) , 6.32 (d, IH) , 5.90 ( bm, IH) , 5.13 (s, 2H) , 4.52 (t, 2H) , 4.05 (bm, IH ) , 3.87 (m, 2H) , 3.47 (m, IH) , 3.28 (m, 2H) , 2.26 ( , 2H ) , 1.48 (s, 9H); Mass spectrum (ESI) m/z 573.4 (22%, M+H + ) . C. tert-Butvl 3- fl- f3-(nvn in-?-vlamint.)πrnpv11 - indazol-5-vlcarhonvlam-ιno! -2 (5) -ammopmn onarP. Using the procedure of 1094 Part A, the product prepared according to the procedure of Example 1108b Part B (700 mg, 1.22 mmol) was converted to the title product (500 mg, 93%) as a gummy solid: l K NMR (CDC1 3 ) δ 8.24 (s, IH), 8.09 (S, IH), 8.01 (d, IH) , 7.84 (d, IH) , 7.47 (d, IH) , 7.40 (t, IH), 7.10 (bm, IH) , 6.56 (t, IH) , 6.33 (d, IH) , 4.54 (t, 2H) , 4.11 ( , IH) , 3.86 (m, IH) , 3.59 (m, IH) , 3.25 (m, 2H) , 2.27 (m, 2H) , 1.49 (s, 9H) ; Mass spectrum (ESI) m/z 439.3 (100%, M+H + ) . D. terr-But.v 3- fl- f3- (pvridin- -vlamino)propvl - mdazol -S-vlcarbonvlammol -2(5) - (cvclohexvlcarbonvl - ammo) -nrooionate. Using the procedure of 1094 Part B, the product prepared according to the procedure of Example 1108b Part C (100 mg, 230 μmol) and cyclohexyl- carbonyl chloride (31 μL, 230 μmol) were converted to the title product (60 mg, 50%) : X H NMR (CDCI3) δ 8.22 (S, IH) , 8.10 (S, IH), 7.91 (d, IH) , 7.80 (d, IH) , 7.54 (d, IH) , 7.45 (m, 2H) , 6.72 (d, IH) , 6.57 (t, IH) , 6.32 (d, IH) , 4.72 (m, IH) , 4.58 (t, 2H) , 3.89 (m, IH) , 3.76 (m, IH), 3.19 (t, 2H), 2.30 (m, 3H) , 2.19 (m, IH) , 2.0- 1.2 (m, 10H) ; Mass spectrum (ESI) m/z 549.5 (100%, M+H + ) . E. -ri-r3-fMi -πvridin-?-vl mino)propvπ dazol-5-vl- rarhonvlamino1-2(5)-(rγr1ohexvlrarbonvlamino)r>ronionic acid trif1noroacerate. Using the procedure of Example 1081 Part H, the product prepared according to Example 1108b Part D (60 mg, 110 μmol) was converted to the title product: : H NMR (DMSO-d 6 ) δ 8.54 (m, IH) , 8.28 (s, IH) , 8.25 (s, IH) , 8.02 (d, IH) , 7.9-7.7 (m, 4H) , 6.90 (m, IH), 6.77 (m, IH) , 4.55 (t, 2H) , 4.44 (m, IH) , 3.61 ( , 2H) , 3.26 (m, 2H) , 2.16 (m, 3H) , 2.0-1.0 (m, 10H) ; High resolution mass spectrum (NH 3 -CI) calculated (M+H + ) 493.2563, found 493.2559. Example. lllQa 3- ri- f3- (N-Dvrιdιn-2-vlammo)nrnnvl 1 indazol -5- vlcarbonvlaminol -2 (S) - (nhenvlaimnncarhnπvlaimnn) - nropionic acid r.πfluoroarprarp A. tert-Butvl 3- fl- f3-(H-r.prr.-bu vIoxvcarhonvl-N- nvrid -2-vla moIpropvll mdazol-5-vlcarbonvlaminol - 2 (5) - fphenvlamιnocarhonvlaτmno)propιonate. A solution of the product prepared according to Example 1094 Part A (105 mg, 195 μmol) in dichloromethane (5 mL) was treated sequentially with diisopropylethylamine (69 μL, 385 μmol) and phenyl isocyanate (49 μl, 448 μmol) . The solution was stirred at room temperature for 1 h, then was concentrated under vacuum. The residue was purified by flash chromatography (hexanes:ethyl acetate, 50:50) to provide the title product (72 mg, 56%) : X H NMR (CDCI 3 ) δ 8.25 (d, IH) , 8.18 (s, IH) , (s, IH) , 7.75 (d, IH), 7.70 (bm, IH) (m, 3H) , 7.10 (m, 2H) , 6.95 (m, IH) , (m, IH), 4.79 (m, IH) , 4.34 (t, 2H) , (m, 2H) , 2.25 (m, 2H) , 1.46 (s, 9H) , resolution mass spectrum (FAB) calculated (M+H + ) 658.3353, found 658.3342. B. 3- n- T3- (N-pvrιdm-2-vTammo)nropvπ mdazol-5-vl- rarbonv1ammo1-2fS)-(phenvlammocarhonvlamιno)nronιonιc acid trifluoroacetate Using the procedure of Example 1081 Part H, the product prepared according to Example 1110a Part A (68 mg, 104 μmol) was converted to the title product (44 mg, 68%) as a white solid after preparative reverse phase high pressure liquid cnromatcgraphy (acetonιtπle:water containing 0.05% trifluoroacetic acid, gradient from 1:9 to 9:1) : l K NMR (MeOH-d ) δ 8.24 (s, IH) , 8.09 (s, IH) , 7.85-7.70 (m, 2H), 7.68 (d, IH), 7.55 (d, IH) , 7.29 (m, 2H) , 7.17 (t, 2H), 6.91 (m, 2H) , 6.79 (t, IH) , 4.66 (m, IH) , 4.54 (t, 2H), 3.88 (dd, IH) , 3.77 (dd, IH) , 3.27 (m, 2H) , 2.28 ( , 2H) ; High resolution mass spectrum (FAB) calculated (M+H + ) 502.2203, found 502.2196. Example 1129 3- fl- - (N-pvrιdιn-2-vlammolpropvll mdazol-5-vl- carbonvlammol -2 (5) - (1-naphrhalene-snlfonvla ino) - propionic acid trifl oroacetate A. 1- (2-cvanoer.hyl) -5-ethoxvrarbonvlmdazole. A mixture of the product prepared according to Example 1050e Part C (3.80 g, 20 mmol), acrylonitπle (7.9 mL, 120 mmol), sodium bis- (trimethylsilyl)amide (1.0 M in tetrahydrofuran; 1.0 mL, 1.0 mmol) and ethanol (40 mL) was heated to reflux. After 2 h, the solution was cooled to room temperature and treated with aqueous hydrochloric acid (1.0 M; 1.5 mL, 1.5 mmol) . After the mixture was partially concentrated under vacuum, a solid formed. Water (100 mL) was added and the mixture was stirred briefly. The resulting solid was collected by filtration, rinsed with water and dried to provide the title product (4.38 g, 90%) as a pale yellow fluffy solid: mp 106-109 * C; X H NMR (CDCI3) δ 8.54 (S, IH ) , 8.16 (S, IH) , 8.13 (d, IH) , 7.48 (d, IH) , 4.70 (t, 2H) , 4.42 (q, 2H) , 3.03 (t, 2H) , 1.43 (t, 3H) ; High resolution mass spectrum (NH 3 -CI) calculated (M+H+) 244.1086, found 244.1070. B. 1- (3-aminopropvl) - -e hoxvcarbonylindazo e h y drochloride. A mixture cf the product prepared according to Example 1120 Fart A (60 g, 260 raiol, , platinum oxide i . O g) , ethanol (1500 mL; and chloroform :..-0 ΓΛLJ was placed m a pressure bo tle and agitated under an atmosphere cf hydrogen ι 0 pεig; for 19 h. The mixture was filtered through Cent ^ and the sci ds were washed with ethanol. The filtrate was concentrated under vacuum and the residue was dissolved m aqueous sodium bicarocnate and washed with ethyl acetate. The aquecus phase was acidified with hydrochloric acid and concentrated to a solid. This was dissolved in hot ethanol, filtered, and the filtrate cooled. The resulting crystals were collected by filtration to provide the title product. Repeating the reaction twice more starting with 57 g of the nitriie provided a total of 115 g ;5~%; of the title product as a white solid: p 198-200 'C; *H NMR (DMSO-d 6 ) 6 8.49 (s, IH) , 8.32 (S, IH), 8.07 (bs, 3H) , 7.98 (d, IH) , 7.85 (d, IH) , 4.58 (t, 2H), 4.34 (q, 2H) , 2.80 (b , 2H) , 2.14 (m, 2H) , 1.34 (t, 3H) ,- High resolution mass spectrum (NH 3 -CI) calculated (M+H + ) 248.1399, found 248.1396. C. i-r3-rN-,l-oxido)pvridin-2-vlamino1propvl1-5- e hoxvcarbonvlindazo e. Using the procedure of Example 1081 Part C, the product prepared according to Example 1129 Part B (566 mg, 2.0 mmol) was converted to the title product (470 mg, 69%) . This product is the same as the product of Example 1081 Part C. D. l-r3-fN-(l-oχido)pvridin-2-vlaminolprθDvll-5- carboxyindazole. A mixture of the product prepared according to Example 1129 Part C (470 mg, 1.3 mmol), aqueous sodium hydroxide (1.0 M; 4.0 mL, 4.0 mmol) , water (10 mL) and ethanol (10 mL) was heated to reflux. After 30 h, additional aqueous sodium hydroxide (1.0 M; 2.0 mL ) was added and heating was continued. After 48 h more, the mixture was cooled to room temperature and treated with aqueous hydrochloric acid (1.0 M; 6.0 mL) to give a precipitate. The solid was collected by filtration, rinsed with water and dried to provide the title product (369 mg, 91%) as a white solid: : H NMR (DMSO-de) δ 12.70 (bs, IH) , 8.45 (s, IH) , 8.27 (s, IH) , 8.11 (d, IH), 7.92 (d, IH), 7.73 (d, IH) , 7.32 (bt, IH) , 7.15 (t, IH) , 6.70 (d, IH), 6.59 (t, IH) , 4.53 (t, 2H) , 3.24 (q, 2H) , 2.14 (m, 2H) ; High resolution mass spectrum (NH 3 -CI) calculated (M+H + ) 313.1301, found 313.1299. E. rerr-Bnrvl 3- ri- f3- (N- (1-oxιdo)pvrιdm-2-vlammo) - oropvll ιndazol-5-vlcarbonvlammo1-2- (S) -(henzvloxv- arbonyla inolpropionate. A mixture of the product prepared according to Example 1129 Part D (312 mg, 1.0 mmol), tert-butyl 3-am o-2 (S) -benzyloxycarbonylamino- propionate (prepared according to Mo itoff and Logue, J. Med. Chem. 1981, 21, 554; 294 mg, 1.0 mmol), 1- hydroxybenzotriazole hydrate (135 mg, 1.0 mmol), tetrahydrofuran (4 mL) and dry N, N-dimethylformamide (1 mL) was stirred on an ice bath. Dicyclohexylcarbo¬ diimide (227 mg, 1.1 mmol) was added, and the mixture was stirred for 1 h. The ice bath was removed and stirring was continued for 3.5 h more. The mixture was filtered, and the solid was rinsed with tetrahydrofuran. The filtrate was concentrated under vacuum, and the residue was taken up in ethyl acetate. The solution was washed with water, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by flash chromatography (dichloromethane/methanol; 96:4, then 94:6) to provide the title product (304 mg, 52%) as an off-white glass: *H NMR (CDCI3) δ 8.00 (s, IH) , 8.11 (d, IH) , 8.07 (s, IH), 7.75 (d, IH) , 7.4-7.2 (m, 5H) , 7.18 (bt, IH) , 7.12 (t, IH) , 6.95 (bt, IH) , 6.53 (t, IH) , 6.39 (d, IH) , 6.10 (d, IH) , 5.11 (s, 2H), 4.50 (t, 3H) ,3.88 (m, 2H) , 3.21 (q, 2H) , 2.31 (m, 2H) , 1.48 (s, 9H) ; High resolution mass spectrum (FAB) calculated (M+H + ) 589.2775, found 589.2804. F. tert-Butvl 3-fl- Fl- (N-nvrιdm-3-vlamino) -nronyl 1 - dazol-5-vlcarbonvlammol -2- (5) -aminonmmonarP. A mixture of the product prepared according to Example 1129 Part E (266 mg, 452 μmol) and 10% palladium on charcoal (65 mg) in ethanol (20 mL) was placed in a pressure bottle and agitated under an atmosphere of hydrogen (55 psig) for 100 h. The mixture was filtered through Celite ® and the solids were rinsed with ethanol. The filtrate was concentrated under vacuum, and the residue was purified by flash chromatography (dichloromethane:methanol, step gradient from 96:4, to 92.5:7.5) to provide the title product (100 mg, 50%) as a colorless glass: l R NMR (CDCI 3 ) δ 8.21 (s, IH) , 8.10 (S, IH), 8.07 (d, IH), 7.80 (d, IH) , 7.42 (d, IH) , 7.39 (t, IH), 6.88 (bt, IH) , 6.56 (t, IH) , 6.33 (d, IH) , 4.90 (bt, IH) , 4.53 (t, 2H) , 3.86 (m, IH) , 3.63 (m,lH), 3.52 (m, IH) , 3.28 (q, 2H) , 2.26 (m, 2H) , 1.90 (b, 2H) , 1.48 (s, 9H) ; High resolution mass spectrum (NH3- CI) calculated (M+H + ) 439.2458, found 439.2457. G. t-err-Butvl - r1- f - (M-nvn m-2-vlaπnno) -nropvl1 - ιndazol -S-vl rarbonvlaminol -2- (5) - (1-naphthalenesulfonvl- amin ) roo onate. A solution of the product prepared according to Example 1129 Part F (77 mg, 176 μmol) in dry tetrahydrofuran (2 mL) was treated with 4-(N,N- dimethylamino)pyridine (24 mg, 193 μmol), 1-naphthalene- sulfonyl chloride (44 mg, 193 μmol) and pyridine (16 μL, 193 μmol) . The mixture was stirred at room temperature for 20 h, then was concentrated under vacuum. The residue was purified by flash chromatography (dichloromethane-methanol, 96:4) and rotary thin-layer chromatography (dichloromethane-methanol, 96:4) to provide the title product (90 mg, 82%) as a colorless glass: l H NMR (CDCI3) δ 8.67 (d, IH) , 8.26 (d, IH) , 8.1- 8.0 (m, 4H) , 7.88 (d, IH) , 7.70 ( , 2H) , 7.55 (m, 2H) , 7.20 (m, 2H), 6.50 (m, 2H) , 5.34 (d, IH) , 6.10 (bs, IH) , 5.35 (bs, IH) , 4.53 (t, 2H) , 3.95 (b, IH) , 3.80 (m, IH) , 3.63 (m, IH) , 3.28 (q, 2H) , 2.28 (m, 2H) , 1.12 (s, 9H) ; High resolution mass spectrum (FAB) calculated (M+H + ) 629.2546, found 629.2526. H. 3- ri - f - (N-nvrιdιn-2-vlammo) -nropvl) mdazol-5- vTcarhonvla inol -2- (5) - (1-nanhthalenesulfonvlamιπo) - nropiomc acid trifluoroacetate. A solution of the product prepared according to Example 1129 Part G (77 mg, 122 μmol) dichloromethane (2 mL) was treated with trifluoroacetic acid (1 mL) and stirred at room temperature for 3 h. The solution was concentrated under vacuum, toluene was added, and the solvent was again removed under vacuum. The residue was triturated in ether, and the resulting solid was collected by filtration to provide the title product (81 mg, 96% ) as a white powder: l H NMR (DMSO-d 6 ) δ 8.60 (m, 3H) , 8.39 (bt, IH) , 8.21 (s, IH) , 8.09 (d, 2H) , 8.05 (s, IH) , 7.90 (t, 2H), 7.83 (t, IH), 7.67 (m, 3H) , 7.55 (m, 2H) , 6.97 (d, IH) , 6.81 (t, IH), 4.56 (t, 2H) , 4.08 (q, IH) , 3.53 (m, IH), 3.30 (m, 3H) , 2.18 (m, 2H) ; High resolution mass spectrum (FAB) calculated (M+H + ) 573.1947, found 573.1928. XrimnlP U29fl 3- fl- H- (N-nvrιdm-2-v1ammo)propvll mdazol -S-vl - carbonylammo1-2 (S) - (4-nhenvlbenzenesulfonylamιno) - propionic acid trifluoroacetate A. tert-3utvl 3- fl- f3- (N-tert-bu vloxvcarbonyl-N- ovrid -2-ylamino)oropvl1 mdazol-S-vlcarbonvlamino1 - 2 (S) - (4-phenvlbenzenesulfonvlamino)propιonate. Using the procedure of Example 1129 Part G, the product prepared according to Example 1094 Part A (86 mg, 159 μmol) and 4-phenylbenzenesulfonyl chloride were converted to the title product (116 mg, 97%) : T-H NMR (CDC1 3 ) δ 8.28 (m, IH) , 8.23 (2, IH) , 8.06 (s, IH) , 7.92 (d, 2H) , 7.81 (d, IH), 7.68 (d, 2H) , 7.60 (m, 2H) , 7.53 (m, 2H) , 7.45 (m, 3H) , 7.37 (d, IH) , 6.99 (m, IH) , 6.88 (bt, IH) , 5.75 (d, IH) , 4.45 (t, 2H) , 4.01 (m, 4H) , 3.62 (m, IH) , 2.31 (m, 2H) , 1.43 (s, 9H) , 1.30 (s, 9H) ; High resolution mass spectrum (FAB) calculated (M+H + ) 755.3227, found 755.3200. B. 3-fl-f3-(N-pγrιdm-2-vlammo)propvnmdazol-5-vl- carbonylammol -2 (S) - (4-phenvlbenzenesulfonvlamino) - propionic acid trifluoroacetate Using the procedure of Example 1129 Part H, the product prepared according to Example 1129a Part A (108 mg, 143 μmol) was converted to the title product: l H NMR (MeOH-d 4 ) δ 8.16 (s, IH) , 8.08 (s, IH) , 7.85 (d, 2H), 7.8-7.7 (m, 4H) , 7.58 (d, 2H) , 7.5-7.3 (m, 6H) , 6.9-6.75 (m, 2H) , 4.48 (t, 2H) , 4.23 (m, IH), 3.78 (dd, IH) , 3.50 (dd, IH) , 3.26 (m, 2H) , 2.26 (m, 2H) ; High resolution mass spectrum (FAB) calculated (M+H + ) 599.2077, found 599.2062. Example 1155 3-ri-f3-(N-nvrιd n-2-y1 mιno)DrQDvl1ιndazol-5-vl- carbonylaminol -2 (S) - (benzvlaminosulfonvlamino)propionic and rrifluoroacetate A. tert-Butvl - j -n- n-fN- ( rerr-butvloxvrarboπyl-N- nvridin-2-vlamm inropvl 1 nriazol-5-vlcarhonylaιτriπol - 2 ( S ) - ( benzvlammosulfonvlam noinropionarp A solution of the product prepared according to Example 1094 Part A (101 mg, 188 μmol) in anhydrous tetrahydrofuran (5 mL) was treated with N-benzylsulfamoyl chloride (prepared according to the procedures of Audrieth and Sveda, J. Org. Chem. 1944, 9_, 89-101, and Kloeck and Leschmsky, J. Org. Chem. 1976, 41, 4028-4029; 51 mg, 248 μmol), then with 4- (N,N-dimethylamino)pyridine (37 mg, 193 μmol) and pyridine (19 μL, 252 μmol) . The resulting mixture was stirred at room temperature for 24 h, then was concentrated under vacuum. The residue was purified by flash chromatography (hexanes:ethyl acetate 45:55) to provide the title product (92 mg, 70%) as a white solid: 1 H NMR (CDC1 3 ) δ 8.27 (m, IH) , 8.18 (s, IH) , 8.04 (s, IH), 7.78 (d, IH) , 7.60 (m, 2H) , 7.36 (d, IH) , 7.29 (m, 5H), 6.99 (m, IH) , 6.79 (bt, IH) , 5.62 (d, IH) , 4.75 (t, IH) , 4.44 (t, 2H) , 4.23 (t, 2H) , 4.15 (m, IH) , 4.00 (m, 2H) , 3.95 (m, IH) , 3.76 (m, IH) , 2.31 (m, 2H) , 1.48 (s, 9H) , 1.43 (s, 9H) ; High resolution mass spectrum (FAB) calculated (M+H + ) 708.3179, found 708.3205 B. -ri-r3-(N-pvridm-2-vl)am nopropvllindazol-5-vll- rarbonylam no-2 (S) -benzvlaminosulfonvla inonronioniC acid trifluoroacetate. Using the procedure of Example 1129 Part H, the product prepared according to Example 1155 Part A (21 mg, 30 μmol) was converted to the title product (19 mg, 96%) : X H NMR (DMSO-dβ) δ 8.56 (m, 2H ) , 8.33 (S, IH) , 8.24 (s, IH) , 7.90-7.70 (m, 4H) , 7.49 (d, IH), 7.43 (t, IH), 7.23 (m, 5H) , 6.96 (d, IH) , 6.80 ( t, IH) , 4.56 (t, 2H) , 4.20-3.60 (m, 5H) , 3.59 (m, 2H) , 2.18 (t, 2H) ; High resolution mass spectrum (FAB) calculated (M+H+) 552.2029, found 552.2042. "xamnle 1178b 3-n-n-,M- .4.5. fi-Tetrahvdroπvrimidin-2-vla ino) - propvll indazol-5-vlcarbonvlaminol -2 f5) - f 2 .4. fi-r.rimethvl- benzenesulfonylammo)propionic acid r.ri f1 noroacerarp A. 1 - (3-Benzvloxvcarbonvlaminopropvl ) - -e hoxvcarbonvl - \ ndazole. A mixture of the product prepared according to Example 1129 Part B (5.0 g, 18 mmol) and triethylamine (7.5 mL, 19 mmol) in dichloromethane (100 mL) was cooled on an ice bath and treated with benzyl chloroformate (2.7 mL, 19 mmol). The mixture was stirred at room temperature for 16 h, then was concentrated under vacuum. The residue was dissolved in dichloromethane and washed with water several times, then was dried over anhydrous magnesium sulfate, filtered and concentrated to provide the title product (3.4 g, 49%) as a white solid. While this material was suitable for further use, it could be purified by flash chromatography (dichloromethane:methanol 95:5) : X H NMR (CDCI 3 ) δ 8.50 (s, IH) , 8.06 (m, 2H) , 7.38 (m, 6H) , 5.20 (bm, IH) , 5.02 (s, 2H) , 4.42 ( , 4H) , 3.18 (m, 2H) , 2.18 (m, 2H) , 1.40 (m, 3H) ; Mass spectrum (ESI) m/z 382.5 (100%, M+H + ) . B. 1-(3-Benzv1oxvcarbonvlaminonropvl)-5-carbo v- indazole. A mixture of the product prepared according to Example 1178b Part A (3.08 g, 8.07 mmol), lithium hydroxide hydrate (678 mg, 16.2 mmol), ethanol (160 mL ) and water (40 mL) was stirred at room temperature. Tetrahydrofuran was added until the mixture was homogeneous, then stirring was continued for 5 days. The solution was concentrated, and the residue was taken up in water. The mixture was washed with ethyl acetate, and the aqueous phase was acidified to pH 4-5 with aqueous hydrochloric acid (1.0 M) . This mixture was then extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate, filtered and concentrated to provide the title product (1.6 g, 56%) as a sticky solid: l H NMR (DMSO-d 6 ) δ 8.44 (s, IH) , 8.26 (s, IH) , 7.93 (d, IH), 7.72 (d, IH) , 7.35 (m, 5H) , 5.00 (s, 2H) , 4.46 (t, 2H), 3.01 (m, 2H) , 1.98 ( , 2H) . C. M*- (2.4.6 trimethvlhenzenesulfonvi ) -T.-asn ramΠP L- Asparagme (20.0 g, 0.15 mol) was suspended in a mixture of tetrahydrofuran (130 mL) and water (250 mL) . Triethylamine (68 mL, 0.48 mol) was added, followed by mesitylenesulfonyl chloride (49.7 g, 0.23 mol) added over 20 nun. The reaction mixture became slightly warmer and the solids dissolved to yield a yellow solution. The reaction mixture was stirred for 3 h at room temperature, then washed twice with ether, and twice with dichloromethane. The aqueous layer was acidified to pH 1.5 with concentrated aqueous HCl, during which time a thick precipitate formed. After being stirred for 30 m the solid was collected by filtration, washed with water and dried to yield the title product (34.1 g, 72%) as a white solid: m.p.193.5- 195'C; l H NMR (DMSO-d 6 ) δl2.58 (bs, IH) , 7.82 (d, IH) , 7.32 (bs, IH) , 6.99 (s, 2H) , 6.88 (bs, IH) , 3.98 (m, IH), 2.55 (s, 6H) , 2.45 (dd, IH) , 2.28 (dd, IH) , 2.24 (s, 3H) ; Mass spectrum (ESI) m/z 315.2, (100%, M+H + ) . D. 3-Am no-2- (5) - (2.4.6-rrιmethvlbenzenesulfonvlamino) - propionic acid. Sodium hydroxide (32 g, 0.80 mol), was dissolved in water (200 mL) and cooled in an ice bath. Bromine (6.2 mL, 0.12 mol) was added dropwise over 5 mm and the mixture was allowed to stir for 15 min. The product prepared according to Example 1178b Part C (31.44 g, 0.10 mol) was added in several portions over a period of ca. 10 min, during which time the yellow color faded. After stirring for 15 min more, the reaction mixture was heated rapidly to an internal temperature of ca. 85 * C. After lh, the reaction mixture was allowed to cool to room temperature, then cooled in an ice bath. The reaction mixture was cautiously acidified to pH 6 with concentrated aqueous HCl, during which time a solid formed and gas was evolved. The solid was collected by filtration, washed with cold water, and allowed to dry overnight to provide the title product (23.9 g, 83%) as a white solid: 1 H NMR (DMSO-d 6 ) δ 7.06 (s, 2H) , 3.07 idd, IH), 3.35 (broad), 2.94 (dd, IH) , 2.80 (dd, IH) , 2.59 (s, 6H) , 2.26 (s, 3H); Mass spectrum (ESI) m/z 287.2 (100%, M+H + ) . E. tert-Butvl -ammo-2- (5) - (2.4. fi-rπ ethvlbpnzenp- snlfonvlamino)propionar.e. The product prepared according to Example 1178b Part D (11.45 g, 0.04 mol) was placed in a pressure bottle and dissolved in dioxane (170 mL) . Concentrated sulfuric acid (11 mL) was added and the reaction mixture was cooled in a dry lce- acetone bath. Liquid isobutylene (ca. 185 mL) was added, and the bottle was sealed and agitated for 114 h. The bottle was de-pressurized, then purged with nitrogen for a brief time. The reaction mixture was poured into a rapidly stirred mixture of water (225 mL) containing sodium hydroxide (17 g) and ether (600 mL) which had been pre-cooled in an ice bath. The layers were separated, and the aqueous layer was extracted with additional ether. These organic extracts were discarded. The pH of the aqueous layer was carefully adjusted with concentrated aqueous HCl to pH 11.0 and extracted four times with ether. The organic layers from the pH 11 extraction were combined, dried with anhydrous sodium sulfate, filtered and concentrated to yield the title product (8.64g, 63%) as a viscous oil which gradually solidified: l H NMR (CDC1 3 ) δ 6.95 (s, 2H ) , 3.69 (m, IH), 2.93 (m, 2H) , 2.67 (s, 6H) , 2.28 (s, 3H ) , 1.28 (s, 9H) ,- Mass spectrum (ESI) m/z 343.3 (100%, M+H + ) . F. tert-But.vl 3- f1- n-benzvloxvcarbonvlam nopropyl 1 - mdazol -5- y lcarbonvlammol -2 (S)- (2.4.6-rrιmPthylbPnzPnP- ulfony1amino) ropionate. Using the procedure of Example 1129 Part E, the product prepared according to Example 1178b Part B (100 mg, 283 μmol) and the product prepared according to Example 1178b Part E (107 mg, 283 μmol) were converted to the title product (130 mg, 68%) as a yellowish solid: X H NMR (CDC1 3 ) δ 8.24 (s, IH) , 8.09 (s, IH) , 7.85 (d, IH) , 7.42 (d, IH) , 7.36 (m, 5H) , 6.93 (s, 2H) , 6.83 (m, IH) , 5.78 (d, IH) , 5.09 (s, 2H) , 4.47 (t, 2H) , 4.02 (m, IH) , 3.84 (m, IH) , 3.7-3.4 (m, 2H) , 3.18 (m, 2H) , 2.66 (s, 6H) , 2.26 (s, 3H) , 2.15 (m, 2H), 1.21 (s, 9H) ,- Mass spectrum (ESI) m/z 678.4 (41%, M+H + ) . G. tert-Butvl 3- r1- (3-aτmnopropvl ) -indazol-5-vl- rarboπylaimnnl -2(5)- (2.4.6-rri erhvlbenzenesul onvl¬ amino) oromonate. A mixture of the product prepared according to Example 1178b Part F (50 mg, 74 μmol), palladium hydroxide on charcoal (Pearlman's catalyst; 15 mg) , 1,4-cyclohexa-dιene (1 mL) and methanol (2 mL) was heated at reflux. After 4 h, the mixture was cooled and filtered through Celite ® , and the solids were rinsed with methanol. The filtrate was concentrated under vacuum to provide the title product (34 mg, 85% ) as a solid which was used in subsequent reactions without further purification: *H NMR (CDCI3) δ 8.03 (s, IH ) , 7.80-7.65 (m, 3H) , 7.31 (d, IH) , 6.84 (s,H), 4.40 ( m, 2H), 4.02 ( , IH) , 3.78 (m, 2H) , 3.06 (m, 2H) , 2.63 ( m, IH), 2.59 (s, 6H) , 2.27 (m, 2H) , 2.19 (s, 3H) , 1.23 ( s, 9H) ; Mass spectrum (ESI) m/z 544.5 (100%, M+H +) . H. tert-Butvl 3-f. - r 3- (N-3.4.5.6-tetrahvdropvrιm dιn-2- vlammo) nropvll -indazol-5-Ylcarbonvlaminol -2 (5) - (2.4.5- r.rιmethvlbenz p nP.sulfonvlammo)propιonatP hvdnodide. A mixture of the product prepared according to Example 1178b Part G (100 mg, 184 μmol) and 2-methylthιo- 3, 4, 5, 6-tetrahydropyrιmιdme hydriodide (57 mg, 221 μmol) in pyridine (5 mL) was heated at 120 "C. After 15 h, the mixture was cooled to room temperature and concentrated under vacuum. The residue was purified by flash chromatography (dichloromethane:methanol, step gradient from 95:5 to 90:10) to provide the title product (37 mg, 27%) : i .H NMR (CDCI 3 ) δ 8.30 (s, IH) , 8.10 (b , IH) , 8.08 (s, IH) , 7.92 (d, IH) , 7.85 (t, IH) , 6.95 (s, 2H) , 4.47 ( , 2H) , , 3.61 (m, IH) , 3.44 (m, 4H) , 2.28 (s, 3H) , 2.15 (m, 2H) , Mass spectrum (ESI) m/z I. 3-fl-r3-(N-3.4.5.6-Te ahvdropvnmid n-2-vlamιno) - nropvll mdazol-5-ylcarbonylammo1 -2 (S) - (2.4.6-tnmethvl- benzenesulfonvlamino)prop onιc acid tri luoroacetate. Using the procedure of Example 1129 Part H, the product prepared according to Example 1178b Part H was converted to the title product: l H NMR (DMSO-dβ) δ 8.46 (bt, IH) , 8.24 (s, IH), 8.19 (s, IH) , 8.07 (d, IH) , 7.79 (d, IH) , 7.32 (bt, IH) , 6.84 (s, 2H) , 4.47 (t, 2H) , 4.02 (m, IH) , 3.6-3.4 (m, 2H), 3.21 (m, 4H) , 3.03 (m, 2H) , 2.52 (s, 6H), 2.07 (s, 3H), 2.05 (m, 2H) , 1.78 (m, 2H) ; Mass spectrum (ESI) m/z 570.5 (100%, M+H + ) . Example 1198 3-ri-r3-(N-4.5-Dihvdroimιdazol-2-vlammo)propvl1indazol- 5-ylcarbonvlaminol -2(5)- (benzvloxvcarbonvlamino) - propionic acid trifluoroacetate A. l-f -ammopropvl)-5-ethoxvcarhonγiιnria ol A mixture of the product prepared according to Example 1081 Part A (4.20 g, 11.1 mmol), ethanol (75 mL) , dry tetrahydrofuran (75 mL) and anhydrous hydrazine (1.5 mL) was stirred at room temperature for 16 h. Dry tetrahydrofuran (100 mL) was added, the mixture was filtered and the filtrate was concentrated to provide the title product, which was used directly in the subsequent reaction without purif cation: ~ : H NMR (CDC1 3 ) δ 8.51 (s, IH), 8.10 (s, IH), 8.06 (d, IH) , 7.46 (d, IH) , 4.52 (t, 2H) , 4.41 (q, 2H) , 2.68 (t, 2H) , 2.06 (m, 2H) , 1.72 (bs, 2H) , 1.43 (t, 3H) . B. 1-T3- fN-4.5-Dιhvdroιm dazol-2-vlammo)propvl1-S- ethoxycarbonylindazole hydriodide. The crude product of Example 1198 Part A was combined w th 2-methylthιo-4, 5- dihydroimidazole hydriodide (2.71 g, 11.1 mmol) and pyridine (125 mL) , and the mixture was heated at 80°C for 5 h. The mixture was allowed to cool to room temperature and concentrated under vacuum. The residue was purified by flash chromatography (dichloromethane: methanol 80:20) to provide the title product (3.73 g, 75%) as a gum: l H NMR (DMSO-d 6 ) δ 8.50 (s, IH) , 8.30 (s, IH), 8.24 (bs, IH) , 7.98 (d, IH) , 7.75 (d, IH) , 4.49 (t, 2H), 4.34 (q, 2H) , 3.57 (s, 4H) , 3.13 (m, 2H) , 2.05 (m, 2H) , 1.35 (t, 3H) ; High resolution mass spectrum (NH 3 - CI) calculated (M+H + ) 316.1774, found 316.1765. C. erf-Bn vl 3- fl- F3- (N-A.5-Dihvdroιmidazol-2-vl- amino)propyl 1 indazol-5-vlcarhonvlaτπmol -2(5)- (benzvloxvcarbonvlamino) promonate hydrochloride. A mixture of the product prepared according to Example 1198 Part B (3.39 g, 7.64 mmol), aqueous sodium hydroxide (1.0 M; 16 mL, 16 mmol) and ethanol (35 mL ) was stirred at reflux for 16 h. The mixture was allowed to cool to room temperature and was treated with aqueous hydrochloric acid (1.0 M; 16 mL, 15 mmol) . The solvent was evaporated under vacuum, benzene was added and solvent was again evaporated. A portion of the resulting residue (77 mg, 240 μmol) was combined with tert-butyl 3-ammo-2 (S) -benzyloxycarbonylamino- propionate (prepared according to Mokotoff and Logue, J. Med. Chem. 1981, 21, 554; 70 mg, 240 μmol), l-ethyl-3- ( 3-dimethylaminopropyl ) carbodiimide hydrochloride (60 mg, 313 μmol), 1-hydroxybenzotrιazole hydrate (10 mg) , dry N, -dimethylformamide (5 mL) and triethylamine (0.1 mL) , and the resulting mixture was stirred at room temperature for 16 h. The mixture was concentrated under vacuum and benzene (20 mL) was added. The solvent was evaporated and the residue was purified by flash chromatography (dichloromethane:methanol 90:10) to provide the title product (122 mg, 85%) as a yellow gum: r H NMR (DMSO-d 6 ) δ 8.53 (bt, IH) , 8.30 (s, IH) , 8.24 (s+m, 2H) , 7.88 (d, IH) , 7.71 (d, IH) , 7.70 (m, IH) , 7.34 (m, 5H) , 5.04 (s, 2H) , 4.47 (t, 2H) , 4.23 (m, IH) , 3.75-3.50 (m, 2H) , 3.55 (s, 4H) , 3.12 (q, 2H) , 2.06 (m, 2H) , 1.33 (s, 9H) ; High resolution mass spectrum (NH 3 - CI) calculated (M+H + ) 564.2934, found 564.2959. D. 3- M - T3- (N-4.5-Dihvdroimi azol-2-vlamino)nropvl1 - mdazol-5-ylcarbony ammo) -2 (5) - (benzvloxvcarbonvl¬ amino) -pronioni r. acid r.ri f1noroarer.a e. Using the procedure of Example 1081 Part H, the product prepared according to Example 1198 Part C (108 mg, 180 μmol) was converted to the title product (74 mg, 75%) as a hygroscopic, off-white solid: l H NMR (DMSO-dβ) δ 8.57 (bt, IH) , 8.31 (S, IH) , 8.28 (m, IH) , 8.24 (s, IH) , 7.88 (d, IH) , 7.72 (d, IH), 7.62 (m, IH) , 7.32 (m, 5H) , 5.02 (s, 2H) , 4.47 (t, 2H), 4.29 (m, IH) , 3.65 (m, 2H) , 3.55 (s, 4H) , 3.11 (q, 2H) , 2.06 (m, 2H) ; High resolution mass spectrum (FAB) calculated (M+H + ) 508.2308, found 508.2323. Example 1213 3-ri- ι3-(N-4.5-Dιhvdroιmιdazol-2-vlamιno)nropv11mdazol- 5-vlcarbonvlammo1-2 (S)- (benzenesulfonvlamino) propionic acid trifluoroacetate A. ert-Butvl 3-fl- f - (N-4.5-dιhvdro mιdazol-2-vl- am o) oropvll mdazol- -ylcarbonvlaminol -2 (S) - (benzene¬ sulfonylamino) prop onate hydrochloride. A mixture of tert-butyl 3-benzyloxycarbonylamιno-2- (S) -benzene¬ sulfonylam opropionate (200 mg, 460 μmol), methanol (15 mL) and 10% palladium on charcoal (25 mg) was stirred at room temperature. Hydrogen gas was bubbled through the solution for 5 minutes, and a hydrogen-filled balloon was then placed on the reaction flask. The mixture was stirred at room temperature for 3 h, then was filtered through Celite®. The solids were washed with methanol and the filtrate was concentrated. The residue was mixed with a portion of the intermediate residue obtained in Example 1198 Part C (149 mg, 460 μmol ) , 1- ethyl-3- (3-dιmethylamιnopropyl) carbodiimide hydrochloride (120 mg, 626 μmol), 1-hydroxybenzotriazole hydrate (20 mg) , dry N,N-dιmethylformamιde (10 mL) and triethylamine (0.2 mL) . The mixture was stirred at room temperature for 16 h. The solvent was removed under vacuum and the residue was purified by flash chromatography (dichloromethane:ethanol 75:25 ) to provide the title product (220 mg, 78%) as a gum: l tt NMR (CDCI 3 ) δ 8.66-7.04 (m, 13H) , 5.99 (bs, IH ) , 4.52- 1.98 (m, 15H), 1.30 (s, 9H) ; High resolution mass spectrum calculated (M+H + ) 570.2499, found 570.2503. B. 3- f1- n- ιN-4.5-Dιhvdroιmιdazol-2-vlamιno)proDvn - ndazol-5-ylcarbonvlammol -2 (5) - (benzenesulfonylammo) - p ro p ionic acid rrifluoroacetare. Using the procedure of Example 1081 Part H, the product prepared according to Example 1213 Part A (202 mg, 333 μmol) was converted to tne title product (151 mg, 82%) as a hygroscopic solid: ^ NMR (DMSO-de) δ 8.56-7.08 (m, 15H) , 4.54-2.01 (m, 13H) ; High resolution mass spectrum calculated (M+H + ) 514.1873, found 514.1879. Examp e 1216b 3-fl- (3- (N-4.5-D hvdroιm dazol-2-vl mιno)propyll mdazol- 5-ylcarbonvlaminol -2 (S) - (2.4, 6-trιmethylbenzenesulfonyl- amino)propionic acid trifluoroacetate A. tert-Butvl 3- \1- , 3- (N-4.5-dιhvdro mιdazol-2-vl- ammo)propvll mdazol-5-ylcarbonylammo-2 (S) -(2,4.6- t imethylbenzenesul£Qnylami_Q)propior.ate hydriodide, A mixture of the product prepared according to Example 1178b Part G (60 mg, 110 μmol), 2-methylthιoιmιdazolme hydriodide (32 mg, 130 μmol) and pyridine (5 mL) was heated on an oil bath at 120 * C. After 16 h, the mixture was cooled to room temperature and concentrated under vacuum. The residue was purified by flash chromatography (dichloromethane:methanol, step gradient from 98:2 to 90:10) to provide the title product (30 mg, 37%) : i H NMR (CDC1 3 ) δ 8.03 (S, IH) , 7.82 (s, IH) , 7.73 (d, IH), 7.70 (bm, IH) , 7.31 (d, IH) , 6.84 (s, IH) , 4.39 (m, 2H), 3.99 (m, IH) , 3.78 (m, 2H) , 3.48 (S, 4H) , 3.01 (m, 2H) , 2.60 (s, 6H), 2.21 (m, 2H) , 2.17 (s, 3H) , 1.24 (s, 9H) ; High resolution mass spectrum (FAB) calculated (M+H + ) 612.2968, found 612.2975. B. 3-ri-r3-(N-4.5-r>τhvdrotmιdazol-2-vlamιno)propvll- mdazol - 5-ylcarbonylajnιnol - 2 ( 5 ) - ( 2 . 4 . 6 - tπmethvlbenzene- sulfonvlamino)propionic acid rr: f1uoroacer. r.e. Using the procedure of Example 1129 Part H, followed by purification by preparative reverse phase high pressure liquid chromatography (acetonitrile:water containing 5 0.05% trifluoroacetic acid; gradient from 10:90 to 90:10 ) , the product prepared according to Example 1216b Part A was converted to the title product (15 mg, 48%) : l ' ή NMR (MeOH-d 4 ) δ 8.16 (s, 2H) , 7.79 (d, IH) , 7.59 (d, IH), 6.76 (s, 2H), 4.52 (t, 2H) , 4.16 (dd, IH) , 3.77 10 (dd, IH) , 3.59 (s, 4H) , 3.47 (dd, IH) , 3.16 (m, 2H) , 2.57 (s, 6H), 2.18 ( , 2H) , 2.02 (s, 3H) ; High resolution mass spectrum (FAB) calculated (M+H + ) 556.2372, found 556.2342. lb Example 1326b 3-ri-fl-(R5)-Methvl-3-(N-pvrιdm-2-ylamιno)propvl1- ιndazol-5-vlcarbonvlammol -2 (S) - (2, , 6-tπmethvlbenzene- sul onvlamino)propιonιc acid trifluoroacetate 20 A. l-(l-(RS)-methvl-2-cvanoethvl)-5-ethoxvcarbonvl- dazole. A mixture of the product prepared according to Example 1050e Part C (1.90 g, 10 mmol), crotono- nitπle (4.9 mL, 60 mmol), sodium bis(trimethylsilyl) - 25 amide (1.0 M tetrahydrofuran; 0.5 mL, 0.5 mmol) and ethanol (20 mL) was heated at reflux for 18 h. The solution was cooled to room temperature and treated with aqueous hydrochloric acid (1.0 M; 0.5 mL) . The solvent was removed under vacuum, and the residue was taken up 30 in dichloromethane and washed with water. The organic phase was dried over anhydrous magnesium sulfate, filtered, and concentrated under vacuum. The residue was purified by flash chromatography (hexanes:ethyl acetate 60:40) to provide the title product (2.49 g, 35 96%) as a viscous syrup which gradually solidified on standing: l K NMR (CDCI 3 ) δ 8.53 (s, IH) , 8.17 ( s, IH ) , 8.11 (d, IH), 7.45 (d, IH) , 5.03 , , IH) , 4.41 (q, 2H) , 3.05 (m, 2H) , 1.74 (d, 3H) , 1.43 (t, 3H) ; High resolution mass spectrum (NH 3 -CI) calculated (M+H+) 258.1243, found 258.1248. B. 1- (1- (RS) -methvl-3-amιnopropvl) -5-erhoxvrarhonvl - mdazole h y drochloride. Using the procedure of Example 1129 Part B, the product prepared according to Example 1326b Part A (2.0 g, 7.8 mmol) was converted into the title product (2.22 g, 96%) as a pale yellow, hygroscopic glass: 1 H NMR (DMSO-dβ) δ 8.48 (s, IH) , 8.33 (s, IH) , 8.10 (bs, 3H) , 7.96 (d, IH) , 7.88 (d, IH) , 5.11 (m, IH) , 4.34 (q, 2H) , 2.75 (bm, IH) , 2.45 (bm, IH) , 2.30 (bm, IH) , 2.15 (bm, IH) , 1.49 (d, 3H) , 1.35 (t, 3H) ; high resolution mass spectrum (NH 3 -CI) calculated (M+H + ) 262.1556, found 262.1561. C. 1- (1- (RS) -merhvl-3- TN- (1-oxιdo)pvrιdm-2-vl mmol - nropvl) -5-ethoxvcarbonvlmdazolP. Using the procedure of Example 1081 Part C, the product prepared according to Example 1326b Part B (596 mg, 2.0 mmol) was converted into the title product (312 mg, 44%) as a tan glass: 1 H NMR (CDCI 3 ) δ 8.52 (s, IH) , 8.18 (S, IH) , 8.09 (d, IH) , 7.98 (d, IH) , 7.38 (d, IH) , 6.99 (t, IH) , 6.82 (bt, IH) , 6.51 (d, IH) , 4.90 ( , IH) , 4.41 (q, 2H) , 3.12 (m, IH) , 2.95 (m, IH) , 2.61 (m, IH) , 2.22 (m, IH) , 1.62 (d, 3H) , 1.42 (t, 3H) ; High resolution mass spectrum (NH 3 -CI) calculated (M+H + ) 355.1770, found 355.1771. D. l-π-(R5)-merhvl-3-rN-nvπ ιn-2-v ammo1nronvl)-5- ethoxycarbonylindazole. A mixture of the product prepared according to Example 1326b Part C (292 mg, 824 μmol), polymer-supported triphenylphosphine (550 mg, ca. 1.65 mmol) and N,N-dιmethylformamιde (5 mL) was heated on an oil bath at 160 * C. After 18.5 h, an additional aliquot of polymer-supported triphenylphosphine (550 mg) was added, and tne reaction was neated for 24 h more. The m i xture was cooled to room temperature and filtered. The solid was washed with N,N-dιmethylformamιde, and the filtrate was concentrated under vacuum. The residue was purified by flash chromatography (dichloromethane: methanol 96:4 ) and rotary thin-layer chromatography (dichloromethane: methanol 97:3) to provide the title product (189 mg, 67%) as a pale yellow gum which gradually solidified on standing: X H NMR (CDCI3) δ 8.52 (s, IH ) , 8.16 (s, IH) , 8.05-8.00 (m, 2H) , 7.41 (d, IH) , 7.33 (t, IH) , 6.54 (t, IH) , 6.19 (d, IH) , 4.87 (m, IH) , 4.50-4.30 (m, 3H) , 3.16 (m, IH) , 3.05 (m, IH) , 2.45 (m, IH) , 2.23 (m, IH) , 1.61 (d, 3H) , 1.42 (t, 3H) ; High resolution mass spectrum (NH3-CI) calculated (M+H + ) 339.1821, found 339.1832. E. l-(l-(R5)-methvl-3-fN-pvrιdm-2-vlammo1propy] )-5- carboxymdazole. A mixture of the product prepared according to Example 1326b Part D (180 mg, 532 μmol) , aqueous sodium hydroxide (1.0 M; 2.13 mL, 2.13 mmol) and ethanol (4 mL) was heated to reflux. After 4.25 h, the solution was cooled to room temperature and concentrated under vacuum. The residue was used directly in the next reaction without purification or characterization. F. r.err-Bntvl 3- Tl- Tl- (R5) -mer.hvl-3- (N-pvrιdm-2- vlammo)nronvll ndazol -5-ylcarbonvlaminol -2- (5) -(2.4.6- m ethvlhenzenesul fonvlamino) oron onate. The product of Example 1326b Part E was combined with the product prepared according to Example 1178b Part E (183 mg, 535 μmol) , 1-hydroxybenzotrιazole hydrate (72 mg, 535 μmol), N,N-dιmethylformamιde (8 mL) , and triethylamine (1 drop) , and the mixture was treated with dicyclohexylcarbodiimide (121 mg, 589 μmol) and stirred at room temperature. After 21.75 h, the mixture was diluted with ethyl acetate and filtered. The filtrate was concentrated under vacuum, and the residue was purified by flash chromatography (dichloromethane: methanol 97:3) to provide the title product (286 mg, 85%) as a colorless glass: l H NMR (CDCI 3 ) δ 8.21 (s, IH) , 8.12 (s, IH) , 8.04 (dd, IH) , 7.77 (dt, IH) , 7.40 Id, IH ) , 7.33 (t, IH) , 6.93 (s, 2H) , 6.87 (bt, IH) , 6.53 (dd, IH) , 6.18 (d, IH), 6.01 (bs, IH) , 4.86 (bm, IH) , 4.51 (m, IH) , 4.0-3.8 (m, 2H) , 3.65 (m, IH) , 3.15 (m, IH) , 3.03 (m, IH), 2.66 (s, 6H) , 2.44 (m, IH) , 2.26 (s, 3H) , 2.22 (m, IH) 1.61 (d, 3H) , 1.30 (s, 9H) ; High resolution mass spectrum (FAB) calculated (M+H+) 635.3016, found 635.3019. G. 3-ri-ri-(R5)-Methvl-3-(N-pvrιdm-2-v1ammo)nropy11- ι.ndazol-5-vlcarbonvlammo1-2(S)-(2.4.6-r.rιmer.hvlbenzenP- sulfonvDa inoproPion c. acid tn fluoroacerate Using the procedure of Example 1129 Part H, the product prepared according to Example 1326b Part F (109 mg, 172 μmol) was converted to the title product (92 mg, 77%) as a white powder: l NMR (DMΞO-d 6 ) δ 8.43 (bt, 2H) , 8.27 (s, IH) , 8.17 (s, IH) , 8.06 (d, IH) , 7.8-7.6 (m, 4H) , 6.87 (d, IH), 6.82 (d, 2H) , 6.74 (t, IH) , 5.02 (m, IH) , 4.02 (q, IH), 3.57 (m, IH) , 3.40 (m, IH) , 3.07 (m, 2H) , 2.53 (s, 6H) , 2.37 (m, IH) , 2.21 (m, IH) , 2.05 (s, 3H) , 1.52 (d, 3H) ; High resolution mass spectrum (FAB) calculated (M+H + ) 579.2390, found 579.2405. Example 132fif 3-fl-r3-(N-nyrιdm-2-vlammo)pronvl1-^-nhPnvlmdazol-5- vlcarbonvl mol -2 (5) - (2.4. fi-rr rπethvlbenzenesulfonvl- aπnno)prop onic acid trifluoroacetate A. -Bromo- -prhoxvcarhonvlmdazole. A solution of the product prepared according to Example 1050e Part C (3.80 g, 20 mmol) in acetic acid (120 mL) was stirred at room temperature and treated with bromine (1.55 L, 30 mmol) . The mixture was stirred in the dark for 51 h, then was poured into water (600 mL) . The resulting slurry was stirred at room temperature and treated with small portions of solid sodium bisulfite, whereupon the original orange color faded to almost white. After stirring 20 min more, the solid was collected by filtration, rinsed with water and dried to provide the title product (5.14 g, 96%) as a white solid. While pure enough for use in subsequent reactions, this material could be purified further by flash chromatography (hexanes-.ethyl acetate 70:30) : X H NMR (DMSO-de) δ 13.80 (bs, IH) , 8.20 (d, IH) , 8.01 (dd, IH) , 7.69 (d, IH) , 4.36 (q, 2H) , 1.37 (t, 3H) ; Mass spectrum (NH 3 -CI) m/z 269 (100%), 271 (95%) (M+H + ) . B. -Phenvl - -erhoxvcarbonvl indazolp. A mixture of the product prepared according to Example 1326f Part A (2.69 g, 10.0 mmol), phenylboronic acid (1.71 g, 14.0 mmol), triethylamine (5.6 mL, 40.0 mmol), and N,N- dimethylformamide (20 mL) was purged of oxygen by bubbling with nitrogen for 20 mm. Tetrakis- (triphenylphosphine)palladium (580 mg, 500 μmol) was added, and the mixture was heated on an oil bath at 110 'C under nitrogen. After 48 h, the mixture was cooled to room temperature and diluted with water. The mixture was extracted with ethyl acetate, and the organic phase was dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum. The residue was purified by flash chromatography (hexanes:ethyl acetate 80:20) to provide the title product (542 mg, 20%) as a white solid: *H NMR (CDCI 3 ) δ 11.44 (bs, IH) , 8.78 ( s, IH ) , 8.06 (d, IH) , 8.01 (d, 2H) , 7.57 (t, 2H) , 7.49 (t, IH ) , 7.30 (d, IH) , 4.44 (q, 2H) , 1.43 (t, 3H) ; High resolution mass spectrum (NH 3 -CI) calculated (M+H +) 267.1134, found 267.1132. C. 1- ( 2-Cvanoethvl ) -3- p henvl-5-erhoxvcarbonvl indazole. Using the procedure of Example 1129 Part A, followed by purification by flash chromatography (hexanes:ethyl acetate 70:30) , the product prepared according to Example 1326f Part B (266 mg, 1.0 mmol) was converted to the title product (263 mg, 82%) as a white solid: mp 99-102 • C; l R NMR (CDC1 3 ) δ 8.77 (s, IH) , 8.16 (d, IH) , 7.96 (m, 2H) , 7.60-7.40 (m, 4H) , 4.73 (t, 2H) , 4.43 (q, 2H) , 3.10 (t, 2H) , 1.44 (t, 3H) ; High resolution mass spectrum (NH 3 -CI) calculated (M+H + ) 320.1399, found 320.1386. D. 1- (3-ammopropvl)-3-phpnvl-5-pthoxvcarbonvlmdazole hydrochloride. Using the procedure of Example 1129 Part B, the product prepared according to Example 1326f Part C (214 mg, 670 μmol) was converted to the title product (260 mg, >100%) as a tan solid which was not purified, but was used directly in subsequent reactions: X H NMR (DMSO-de) δ 8.64 (s, IH) , 8.05 (d, IH) , 8.0-7.9 (m) , 7.60 (t, 2H) , 7.49 (m, IH) , 4.63 (t, 2H) , 4.37 (q, 2H) , 2.90 (m, 2H) , 2.18 (m, 2H) , 1.36 (t, 3H) ; High resolution mass spectrum (ESI) calculated (M+H + ) 323.1634, found 323.1645. E. l-r3-fN-(l-ox do)pvrιdm-2-v1amιno)nropvn-3-Dhenvl- 5-ethoxyrarhonγlιπdazole. Using the procedure of Example 1081 Part C, the crude product of Example 1326f Part D was converted into the title product (122 mg, 43%) as a tan glass: X H NMR (CDCI 3 ) δ 8.78 (s, IH ) , 8.13 (d, IH), 8.07 (d, IH), 7.99 (d, 2H) , 7.55 (t, 2H) , 7.47 (d, IH) , 7.42 (d, IH), 7.09 (t, IH) , 6.97 (bt, IH) , 6.56 (t, IH) , 6.47 (d, IH), 4.59 (t, 2H) , 4.43 (q, 2H) , 3.32 (q, 2H) , 2.41 (m, 2H) , 1.43 (t, 3H) ; High resolution mass spectrum (NH 3 -CI) calculated (M+H + ) 417.1927, found 417.1918. F. ethoxvcarbonvl ndazol P. Using the procedure of Example 1129 Part F, the product prepared according to Example 1326f Part E (106 mg, 255 μmol) was converted to the title product (39 mg, 38%) as a glass: l R NMR (CDC1 3 ) δ 8.77 (s, IH) , 8.08 (m, 2H) , 7.98 (d, 2H) , 7.54 (t, 2H-) , 7.5-7.3 (m, 3H) , 6.56 (t, IH) , 6.32 (d, IH) , 4.77 (bt, IH ) , 4.55 (t, 2H) , 4.42 (q, 2H) , 3.35 (q, 2H) , 2.30 (m, 2H ) , 1.43 (t, 3H) ; High resolution mass spectrum (NH3- CI ) calculated (M+H + ) 401.1978, found 401.1977. G. tert-Butvl 3- Tl- f3- (N-Pvridin-2-vl mino) nroπvl 1 -?- nhenvlιndazol-5-vlcarbonvlarmnol - 2 (5) - ( 2 .4.6-trimethyl- benzenesulfonylammo)propionate. Using the procedures of Example 1326b Parts E and F, the product prepared according to Example 1326f Part F (38 mg, 95 μmol) was converted to the title product (59 mg, 89%) as a glass: H NMR (CDCI3) δ 8.57 (s, IH) , 8.08 (d, IH) , 8.01 (d, 2H), 7.85 (d, IH) , 7.53 (t, 2H) , 7.5-7.4 (m, 3H) , 6.97 (m, IH), 6.92 (s, 2H) , 6.57 (dd, IH) , 6.33 (d, IH) , 5.86 (d, IH) , 4.57 (t, 2H) , 3.98 (m, IH) , 3.83 (m, IH) , 3.53 (m, IH) , 3.35 (q, 2H) , 2.65 (s, 6H) , 2.31 (m, 2H) , 2.24 (s, 3H) , 1.31 (s, 9H) ; High resolution mass spectrum (FAB) calculated (M+H + ) 697.3172, found 692.3184. H. ^-π-f3-(N-pvridin-2-vl)aminopropvl1-3-phenvl- inriazo1-5-vllrarhonvlamino-2(S)-(2.4.6-trimer.hvlben2ene- sulfnπvDaininnnmninπir acid tri luoroacetate. Using the procedure of Example 1129 Part H, the product prepared according to Example 1326f Part G (44 mg, 63 μmol) was converted to the title product (32 mg, 80% ) as an off-white powder: X H NMR (DMSO-dβ) δ 8.61 (bt, IH) , 8.38 (s, IH) , 8.08 (d, IH) , 8.01 (d, 2H) , 7.88 (d, IH) , 7.82 (d, IH) , 7.75 (d, IH) , 7.71 (bm, IH) . 7.57 (t, 2H) , 7.47 (t, IH) , 6.86 (bd, IH) , 6.72 (bt, IH) , 6.70 (s, 2H), 4.61 (t, 2H), 4.07 ( m , IH) , 3.58 (m, IH) , 3.5-3.3 ( , 3H) , 2.51 (s, 6H) , 2.23 (m, 2H) , 1.92 (s, 3H) ; High resolution mass spectrum (FAB) calculated (M+H+) 641.2546, found 641.2569. Example.13.26a 3- fl- " 3- fN-pyrl.dm-2-vlammo)propvl1 -3- (2-phenvlethγl ) - dazol-5-ylcarbonvlam no1-2(5) -(2.4.6-trιmethvlbenzpn - .quifonvlammo) propionic acid trifluoroacetate A. -Phenylet.hvyl-5-ethQ-Wcacbon li dasol .. A mixture of the product prepared according to Example 1326f Part A (269 mg, 1.0 mmol), triphenylphosphine (21 mg, 80 μmol), copper(I) iodide (8 mg, 40 μmol), phenylacetylene (165 μL, 1.5 mmol) and diethylamme (5 mL) was purged of oxygen by bubbling with nitrogen for 35 min. Bis (tri¬ phenylphosphine)palladium(II) chloride (14 mg, 20 μmol) was then added, and the mixture was heated to reflux under nitrogen. After 16.5 h, the mixture was cooled to room temperature and concentrated under vacuum. The residue was purified by flash chromatography (hexanes:ethyl acetate 80:20) to provide the title product (227 mg, 78%) as a yellowish solid: 1 H NMR (CDCI 3 ) δ 8.66 (s, IH) , 8.13 (d, IH) , 7.68 (m, 2H ) , 7.55 (d, IH) , 7.42 (m, 3H), 4.45 (q, 2H) , 1.45 (t, 3H) ; High resolution mass spectrum (NH 3 -CI) calculated (M+H +) 291.1134, found 291.1111. B. 1- (2-Cvanoerhvl) -3- (2-nhenvlethvnvl) -5-ethθXV- carbonylindazole. Using the procedure of Example 1129 Part A, the product prepared according to Example 1326g Part A (278 mg, 958 μmol) was converted to the title product (254 mg, 77%) as a tan solid: mp 90-94 * C; X H NMR (CDCI 3 ) δ 8.63 (s, IH) , 8.17 (d, IH) , 7.67 (m, 2H ) , 7.52 (d, IH) , 7.42 (m, 3H) , 4.70 (t, 2H) , 4.45 (q, 2H) , 3.09 ( t, 2H) , 1.46 (t, 3H) ; High resolution mass spectrum (NH3-CI) calculated (M+H + ) 344.1399, found 344.1391. C 1- ( -Aminopro p vn -3- (2-DhenvlethvD-5-P how- car p onv dazole h y drochlor e. Using the procedure of Example 1129 Part B, the product prepared according to Example 1326g Part B (240 mg, 699 μmol) was converted to the title product (277 mg, >100%) as a pale yellow solid which was not purified, but was used directly in subsequent reactions: X H NMR (DMSO-dβ) δ 4.50 (m, 2H) , 3.28 (t, 2H), 3.05 (t, 2H) , 2.80 (m, 2H) , 2.10 (m, 2H) . D. 1- f3- r - (l-ox do)pvr dιn-2-ylam nolpronyl 1 -3- (2- ohenvlethvl) - -ethoxvcarbonvl indazole. Using the procedure of Example 1081 Part C, the crude product of Example 1326g Part C was converted into the title product (145 mg, 46%) as a pale yellow glass which was not purified but was used in subsequent reactions: Mass spectrum (ESI) m/z 445.4 (100%, M+H + ) . E. 1- r3-fN-pvr dιn-2-vlammolpropvll-3-(2-phenvlethvl)- 5-ethoxvcarbonvl dazole. Using the procedure of Example 1326b Part D, the impure product of Example 1326g Part D was converted to the title product (90 mg, 70%) as a yellow gum, which impure but was used subsequent reactions without further purificat on. F. tert.-Butv 3- f1- f3- (N-nvrιdιn-2-vlamιno)oropvll -3- ( -nhenvlprhvl)mdazol-5-vlrarbonvlammol-2(5)-(2.4.6- tnmethvlbenzenesulfonvlamino) nropionate. Using the procedures of Example 1326b Parts E and F, the impure product of Example 1326g Part E was converted to the title product (98 mg, 64%) as a glass, which was impure but was used without further purification in the subsequent reaction. G. 3-π- r (W-nvniii n-2-v 1 .a ιno) nmnvl 1-3- (2-phenvl - ethvl) mdazol.-5-vlcarhonvl mmol -2 (S) - f2.4.6-trιmethyl- benzenesulf nvl mino)propιon c acid tnf1 noroacet tp. Using the procedure of Example 1129 Part H, the impure product of Example 1326g Part F was converted to the title product. The crude material was purified by preparative reverse-phase high pressure liquid chromatography (acetomtrile-water containing 0.05% trifluoroacetic acid, gradient from 10:90 to 90:10) to provide the title product (20 mg, 20%) as an off-white powder: High resolution mass spectrum (FAB) calculated (M+H + ) 669.2859, found 669.2881. Example 1 27b 3-ri- r2-fN-Tmιdazol-2-vlam nocarbonvl)ethvllmdazol-5- γl carhonvlaminol -2 (5) - (2.4.6-trιmethvlbenzenesulfonvl- a moipropionic acid tri luoroacetate A. 1- (2-tert-But.vloxvcarbonγlethvl ) - -ethoxvcarbonvl- mdazole. A mixture of the product prepared according to Example 1050e Part C (2.0 g, 10.5 mmol), tert-butyl acrylate (9.3 mL, 63.5 mmol) and ethanol (21 mL) was treated with sodium bis (trimethylsilyl)amide (1.0 M in tetrahydrofuran; 530 μL, 530 μmol) . The resulting solution was heated at reflux for 3 h, then was cooled to room temperature. Aqueous hydrochloric acid (1.0 M; 550 μL, 550 μmol) was added, and the mixture was concentrated. The residue was partitioned between ether and water, and the aqueous phase was extracted further w th ether. The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by flash chromatography (hexanes:ethyl acetate 85:15) to provide the title product (830 mg, 25%): l K NMR (CDC1 3 ) δ 8.49 (s, IH) , 8.10 (s, IH) , 8.07 (d, IH) , 7.50 (d, IH) , 4.64 ( t, 2H), 4.41 (q, 2H) , 2.91 (t, 2H) , 1.42 (t, 3H) , 1.33 (s, 9H) ; high resolution mass spectrum (NH 3 -CI) calculated (M+H + ) 319.1658, found 319.1655. 3. l-(2-Carboxvethvl)-5-ethoxvcarbonvl mdazolP. A solution of the product prepared according to Example 1327b Part A (791 mg, 2.49 mmol) in dichloromethane (28 L) was treated with trifluoroacetic acid (6 mL) . The mixture was stirred at room temperature for 16 h, then was concentrated under vacuum. Addition of ether to the residue produced, after filtering and drying, the title product (571 mg, 88%) as a white solid: *H NMR (CDCI 3 ) δ 8.52 (s, IH) , 8.12 (s, IH) , 8.09 (d, IH) , 7.49 (d, IH) , 4.67 (t, 2H) , 4.41 (q, 2H) , 3.07 (t, 2H) , 1.42 (t, 3H) ; Mass spectrum (ESI) m/z 263.3 (100%, M+H + ) . C. l-(2-(N-ι ι zol-2-vlammocarbonvl)Pthvl)-5- ethoxvcarbonv indazole. A mixture of the product prepared according to Example 1327b Part B (352 mg, 1.34 mmol), 2-aminoimidazole sulfate (0.55 g, 4.15 mmol), diisopropylethylamine (1.17 mL, 6.7 mL) and N,N- dimethylformamide (7 mL) was treated with benzotriazol- 1-yloxy-trιs (dιmethylamιno)phosphonιum hexafluoro- phosphonate (BOP Reagent; 891 mg, 2.0 mmol) and warmed to 70 * C on an oil bath. The mixture was stirred at this temperature for 18 h, then was cooled to room temperature and diluted with water (75 mL) . The resulting precipitate was collected by filtration to provide the title product (310 mg, 71%) which was used m subsequent reactions without further purification: !H NMR (CDCI 3 ) δ 8.49 (S, IH) , 8.11 (S, IH) , 8.07 ( d, IH) , 7.88 (b, IH), 7.55 (d, IH) , 7.40 (b, IH) , 4.75 ( t, 2H) , 4.41 (q, 2H) , 3.01 (t, 2H) , 1.42 (t, 3H) ; high resolution mass spectrum (NH 3 -CI) calculated (M+H +) 328.1046, found 328.1031. D. 1- (2- (N-imidazol -2-vlaιmnorarhonv! )ethvl) -S- carboxvmdazol p . A mixture of the product of Example 1327b Part C (145 mg, 443 μmol) , tetrahydrofuran (2 mL) and water (2 mL) was treated with aqueous lithium nydroxide (1.0 M; 0.56 mL, 560 μmol) and stirred at room temperature for 21 h. The reaction was incomplete by thin-layer chromatography, so additional lithium hydroxide solution (a total of 1.35 mL) was added in four portions over the next 8 h. After stirring for 16 h more, the reaction was acidified with aqueous hydrochloric acid (1.0 M) and concentrated under vacuum. The residue was partitioned between water and dichloromethane, and the organic phase was dried over anhydrous magnesium sulfate, filtered and concentrated to provide the title product (49 mg, 37%) : l K NMR (DMSO-de) δ 8.41 (s, IH) , 8.24 (s, IH) , 7.94 (d, IH) , 7.76 (d, IH) , 6.67 (s, 2H) , 4.73 (t, 2H) , 3.00 (t, 2H) ; High resolution mass spectrum (NH 3 -CI) calculated (M+H + ) 300.1097, found 300.1097. E. tert-Butvl 3- fl- f2- (N-ιmιdazol-2-vl minocarbonvl) - ethvl 1 indazol-5-vlcarbonvlamιnol -2- (5) - (2.4.6-tnmethvl- benzenesulfonvlaminolpropionate. Using the procedure of Example 1326b Part F, the product prepared according to Example 1327b Part D (48 mg, 160 μmol) was converted to the title product (32 mg, 32%) : Mass spectrum (ESI) m/z 624.4 (100%, M+H + ) . F. 3-ri-r2-(N-Imιdazol-2-v1amιnocarbonvl )ethvl1 mdazol- -ylcarbonvl minol -2 (5) - (2. .6-rrιmethvibenzene- sulfonvlaminolnrop onic acid trifluoroacetate. Using the procedure of Example 1081 Part H followed by purification by preparative reverse phase high pressure liquid chromatography (acetomtrιle:water containing 0.05% trifluoroacetic acid, gradient from 10:90 to 90:10 ) , the product prepared according to Example 1327b Part E (32 mg, 52 μmol) was converted to the title product (28 mg, 95%) as a white powder after lyophilization: H NMR (MeOH-d 4 ) δ 8.11 (s, IH) , 8.09 is, IH ) , 7.77 (d, IH), 7.68 (d, IH) , 7.10 (s, 2H) , 6.73 (s, 2H), 4.81 (t, 2H), 4.14 (dd, IH) , 3.75 (dd, IH) , 3.47 (dd, IH) , 3.19 (t, IH) , 2.56 (s, 6H) , 1.97 (s, 3H) ; high resolution mass spectrum (FAB) calculated (M+H + ) 568.1978, found 568.1972. Example 2328 3-n-T4- (N-4.5-Dihydroimirtazol-2-vla.nlno)hutvl 1 mdazol- 4-ylcarbonvlaminol -2(5)- (benzvloxvcarhonvlammo) - propionic acid tri luoroacetate A. Met.hvl 2-methvl -3-amιnobenzoate. A mixture cf methyl 2-rτethyl-3-nιtrobenzoate <,30 g, 154 rural) , 1C% palladium cn charcoal !3.0 g) and ethano.. v350 L) was shaken under hydrogen at 50 ps g. After 4 h, the mixture was filtered through Celite® and the solids were washed with additional ethancl. The filtrate was concentrated to provide the title product (24.4 g, 96%) as a tan oil: l H NMR (CDC1 3 ) δ 7.18 (m, IH) , 7.06 ( m, IH) , 6.78 (m, IH) , 3.85 (s, 3H) , 2.34 (s, 3H) ; high resolution mass spectrum ( H3-CI) calculated ιM+H + ) 166.0868, found 166.C866. B. 4-Me hoxvcarhonvl indazole. The product prepared according to Example 2328 Part A v24.25 g, 147 mmol ) was combined with concentrated hydrochloric acid ύC.l ml ) and water <1"C mLj . Aruronium tetraflucroborate (20.62 g, 19" mmol) was added and the mixture was stirred at C * C. A solution of sodium nitrite (10.14 g, 147 mmol ) m water (25 ml) was added dropwise, and the mixture was stirred for 40 run after addition was complete. The wr.ite precipitate was collected ry f _tratιon ar.d washed with water '3 x 30 rL , tr.en with methane! '30 xl > a d finally w th etner !3 κ 60 ml; . The resulting solid was added to a stirred mixture of potassium acetate ιi .89 , 132 mr.cl>, 18-crown-6 (1.20 g, 4.5 mmol J ana cr._orcferm (360 Π J at rccm tenperature. Tne resulting mixture was stirred for 50 mm, then water [250 ml; / s uaded and the layers were separated. Tne organic phase was washed with water (250 ml ' , and onne (300 r '< , ana dried over anhydrous magnesium sulfate, filtered and cor.cer. rated under reduced pressure. The residue was t tuiated w th hexanes and filtered to provide after drying tne title product (16.95 g, 62% ■ as ar. orange solid: λ H NMR (CDCI3) δ 8.60 (s, IH) , 7.98 (d, IH) , 7.74 (d, IH) , 7.42 (t, IH) , 4.01 (s, 3H) ; High resolution mass spectrum (NH3-CI) calculated (M+H + ) 177.0664, found 177.0669. C. 1-T4- (N-nhthalimido)butvl 1 -4-methoxvcarbonvl- mdazole. Following the procedure of Example 1081 Part A, the product prepared according to Example 2328 Part B (2.97 g, 16.9 mmol) and N- (4-bromobutyl)phthalimide (4.99 g, 16.9 mmol) were converted to the title product (1.88 g, 29%) as an orange oil: T H NMR (CDCI3) δ 8.45 (s, IH) , 7.91 (d, IH), 7.82 (m, 2H) , 7.72 (m, 2H) , 7.66 (d, IH) , 7.43 (t, IH), 4.46 (t, 2H) , 4.02 (t, 3H) , 3.75 (t, 2H), 1.99 (m, 2H) , 1.72 (m, 2H) ; Mass spectrum (NH 3 - CI) m/z 378.0 (100%, M+H + ) . D. l- -fAminohutvl ) -4-methoxvcarboπvlindazole. Using the procedure of Example 1081 Part B, the product prepared according to Example 2328 Part C (1.81 g, 4.8 mmol) was converted to the title product (0.72 g, 60%) as a yellow oil: l H NMR (CDCI3) δ 8.48 (s, IH) , 7.93 (d, IH), 7.64 (d, IH) , 7.44 (t, IH) , 4.44 (t, 2H) , 4.02 (s, 3H) , 2.74 (t, 2H) , 2.00 (m, 2H) , 1.84 (bs, 2H) , 1.47 (m, 2H ) ; High resolution mass spectrum (NH 3 -CI) calculated (M+H + ); 248.1399, found 248.1391. E. 1- f4- (N-4, 5-Dιhvdroιm dazol -2-vlamιno) butyll -4- ethoxvcarbonvl dazole h y dr odide. Using the procedure of Example 1198 Part B, the product prepared according to Example 2328 Part D (247 mg, 1.0 mmol) was converted to the title product (223 mg, 50%) as a gum. X H NMR (DMSO-de) δ 8.37 (s, IH) , 8.11 (bs, IH) , 8.01 (d, IH) , 7.82 (d, IH), 7.51 (t, IH) , 4.46 (t, 2H) , 3.90 (s, 3H) , 3.53 (s, 4H) , 3.08 (m, 2H) , 1.81 (m, 2H) , 1.38 (m, 2H) ; High resolution mass spectrum (NH 3 -CI) calculated (M+H + ) 316.1774, found 316.1772. F. tert-Butyl 3- fl- f4- (N-4.5-dιhvdroιm dazol-2-yl- amι__Q)butγπ -ndazol-4-YlcarbonYlaminQl -2(S) - (benzyloxy ¬ carbonylammo)nropionate hydrochloride. Using the procedure of Example 1198 Part C, the product prepared according to Example 2328 Part E (215 mg, 485 μmol) was converted to the title product (178 mg, 59%) as a clear gum: l H NMR (DMSO-d 6 ) δ 8.52 (m, IH) , 8.32 (s, IH) , 8.13 (bm, IH) , 7.85 (d, IH) , 7.69 (d, IH) , 7.50 (t, 2H) , 7.45 (m, IH) , 7.30 (m, 5H) , 5.01 (s, 2H) , 4.44 (t, 2H) , 4,24 (m, IH), 3.75-3.50 (m, 2H) , 3.50 (s, 4H) , 3.19 (m, 2H) , 1.80 (m, 2H) , 1.37 (m, 2H) , 1.31 (s, 9H) ; High resolution mass spectrum (FAB) calculated (M+H + ); 578.3091, found 578.3119. G. 3- f1- T4- (N- .5-DιhvdroιmιdazoI-2-vlamιno) butvll - indazol-4-ylcarbonvlam nol -2 (£) - (benzvloxvcarbonvl¬ amino)propionic acid hydroch oride. Using the procedure of Example 1081 Part H, the product prepared according to Example 2328 Part F (121 mg, 197 μmol) was converted to the title product (88 mg, 80%) as a hygroscopic white solid: 1 H NMR (DMSO-d 6 ) δ 8.57 (m, IH) , 8.31 (s, IH ) , 8.18 (bm, IH) , 7.86 (d, IH) , 7.63 (d, IH) , 7.50-7.35 ( m, 3H) , 7.30 (m, 5H) , 5.00 (s, 2H) , 4.43 (t, 2H) , 4,28 (m, IH) , 3.75-3.40 ( , 6H) , 3.07 (m, 2H) , 1.78 (m, 2H) , 1.38 (m, 2H) ; High resolution mass spectrum (FAB) calculated (M+H + ); 522.2465, found 522.2484. Example 3093 3-ri-Methvl-3- n- (N-lmidazol -?-vlamino)nronvl 1 ndazol -fi- vlcarhonvlaminol -2 (S) - ( .6-dimethvlbenzenesulfonyl - amino)propionic acid r.rifluoroar tatP A. -Methoxvcarbonvlindazol P. Using the procedure of Example 2323 Part 3, methyl 3-amino-4-methylbenzoate (12.39 g, 75 mmol) was converted to the title product (8.85 g, 67%) which could be recrystallized from acetonitrile to give pale orange crystals: mp 142-144 • C; X H NMR (CDC1 3 ) δ 11.17 (bs, IH) , 8.30 (s, IH) , 8.18 (s, IH) , 7.83 (m, 2H) , 3.97 (s, 3H) ; Mass spectrum (NH 3 -CI) m/z 177 (100%, M+H + ) . B. 3-Bromo- f>-methoxvcarbonvl indazole. Using the procedure of Example 1326f Part A, the product prepared according to Example 3093 Part A (3.52 g, 20 mmol) was converted to the title product (4.46 g, 87%) as a light yellow powder: mp 186-189 'C; l K NMR (CDCI3) δ 8.24 (s, IH) , 7.91 (d, IH) , 7.70 (d, IH) , 3.92 (s, 3H) ; Mass spectrum (NH 3 -CI) m/z 255 (100%), 257 (96%) (M+H + ) ; High resolution mass spectrum (El) calculated (M + ) 253.9691, found 253.9694. C. 1 -Methvl -3-bromo-6-methoxvcarbQnvlindazole. Sodium hydride (60% in mineral oil; 600 mg, 15 mmol) was placed in a dry flask under nitrogen and suspended in dry N,N- dimethylformamide (20 mL) . The suspension was stirred on an ice bath and treated with a solution of the product prepared according to Example 3093 Part B (2.55 g, 10 mmol) in dry N,N-dιmethylfcrmamιde (20 mL) ever ca. 3 mm. The resulting yellow solution was stirred for 10 mm more, then was treated with lodo ethane (0.7 mL, 11 mmol) . The mixture was stirred at room temperature for 22.5 h, then was poured into water (ca. 600 ml, . After being stirred for 10 m , the suspension was filtered, and the solid was washed with water and dried to provide the title product (2.57 g, 95%) as a yellow solid, which could be recrystallized from ethanol: mp 122-125 * C; *H NMR (CDCI3) δ 8.16 (s, IH) , 7.87 (d, IH) , 7.65 (d, IH) , 4.13 (s, 3H) , 3.99 (s, 3H) ; Mass spectrum (NH3-CI) m/z 269 (100%), 271 (92%) (M+H + ); High resolution mass spectrum (NH 3 -CI) calculated 268.9926, found 268.9914. D. l-Methvl-3- (3.3-diethoxvpropvnvl) -6-methoxvcarbonvl- ι ndazole. A mixture of the product prepared according to Example 3093 Part C (1.93 g, 7.2 mmol) , 3,3- diethoxypropyne (1.65 mL, 11.5 mmol), triphenylphosphine (190 mg, 720 μmol) , copper(l) iodide (68 mg, 360 μmol) and triethylamine (60 mL) was purged of oxygen by bubbling with nitrogen for 25 min. Bis (triphenyl¬ phosphine) palladium(II) chloride (126 mg, 180 μmol) was added, and the mixture was heated at 100 "C. After 14 h, the mixture was concentrated under a nitrogen stream and cooled to room temperature. The residue was purified by flash chromatography (hexanes:ethyl acetate 85:15) to provide an orange, sticky solid. This was recrystallized (methanol) to provide the title product (1.26 g, 56%) as light yellow fibrous needles: mp 91-93 "C; l H NMR (CDCI3) δ 8.18 (s, IH) , 7.88 (d, IH ) , 7.83 (d, IH) , 5.59 (s, IH) , 4.14 (s, 3H) , 3.98 (s, 3H ) , 3.89 (m, 2H) , 3.72 (m, 2H) , 1.30 (t, 6H) ; Mass spectrum (ESI) m/z 317.4 (100%, M+H + ) . E. l-Methvl-3- (3.3-d etnoxvpror.v ) -fi-methoxvcarnonvl - mdazole. A mixture of the product prepared according to Example 3093 Part D (1.24 g, 3.92 mmol), 10% palladium on charcoal (130 mg) , methanol (40 mL) and tetrahydro uran (60 mL) was placed in a pressure bottle and shaken under an atmosphere of hydrogen (60 psig) . After 60 mm, the bottle was vented and the mixture was filtered through Celite. ® The solids were rinsed with methanol and tetrahydrofuran, and the filtrate was concentrated under vacuum to provide the title product (1.31 g, >100%) as a slightly cloudy oil which was not purified further: l ti NMR (CDCl 3 j δ 8.11 (s, IH) , 7.77 (d, IH) , 7.72 (d, IH), 4.57 (t, IH) , 4.08 (s, 3H) , 3.97 (s, 3H) , 3.69 (m, 2H) , 3.52 (m, 2H) , 3.06 (t, 2H) , 2.13 (m, 2H) , 1.22 (t, 6H) ; High resolution mass spectrum (NH 3 -CI) calculated (M+H + ) 321,1814, found 321.1830. F. l-Methvl-3-(3-oxopropvl)-6-methoxvcarbonvlιndazole. A mixture of the product prepared according to Example 3093 Part E (1.29 g, 4.0 mmol), acetic acid (20 mL) and water (30 mL) was heated on an oil bath at 80 "C. After 30 mm, the solvent was removed under vacuum, and the residue was dissolved in ethyl acetate. The solution was washed with saturated aqueous sodium bicarbonate, dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum to provide a light brown oil. On further concentration under vacuum, a tan solid slowly formed, which was the title product (982 mg, 98%): mp 80-83 * C; l U NMR (CDCI 3 ) δ 9.92 (s, IH) , 8.11 (S, IH), 7.79 (d, IH) , 7.71 (d, IH) , 4.07 (s, 3H) , 3.98 (s, 3H) , 3.31 (t, 2H), 3.03 (t, 2H) ; High resolution mass spectrum (NH 3 -CI) calculated (M+H + ) 247.1083, found 247.1077. G. l-Methyl-3-r3-fN-(l-triPhenvlmethvlιmιdazol-2-vl- ammo)PΓOPVI1 -6-methoxvcarhonvl1ndazole. A solution of the product prepared according to Example 3093 Part F ( 900 mg, 3.65 mmol) and the product prepared according to Example 1050e Part I \1.19 g, 3.65 mmol) in toluene ( 130 mL ) was heated at reflux under an empty Dean-Stark water trap. After 22.5 h, additional toluene (ca. 40 mL ; was removed by distillation, and the solution was cooled to room temperature under a nitrogen atmosphere. The solution was then cooled on an ice bath and treated with sodium triacetoxyborohydride (3.09 g, 14.6 mmol) and the mixture was stirred at room temperature for 21.75 h. Water (ca. 4 mL) was added cautiously and the mixture was stirred for 15 mm. Additional water (75 ml ) was added, and the layers were separated. The aqueous phase was extracted with ethyl acetate, and the combined organic phases were dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum. The residue was purified by flash chromatography (toluene:ethyl acetate 50:50) to provide the title product (1.56 g, 77%) as a pale tan glass: : H NMR (CDCI 3 ) δ 8.07 (s, IH) , 7.72 (d, IH) , 7.43 (d, IH) , 7.30 ( , 9H) , 7.20 (m, 6H) , 6.68 (d, IH) , 6.38 (d, IH) , 4.01 (S, 3H) , 3.97 (s, 3H) , 3.13 (q, 2H) , 2.96 (t, IH) , 2.61 (t, 2H) , 1.61 (m, 2H) ; High resolution mass spectrum (NH 3 -CI) calculated (M+H + ) 556.2713, found 556.2732. H. Methvl ?-aιmnn-2- fSI -henzovloxvcarbonvlammo- propionate. hydrochloride salt. A suspension of 3- amino-2- (S) -N-benzyloxycarbonyl-aminopropionic acid (11.0 g, 46.2 mmol) in methanol (165 mL) was stirred on an ice/acetone bath until the internal temperature was below 0 * C. Thionyl chloride (3.7 mL, 50.8 mmol) was added dropwise over 10 m . The mixture was stirred for an additional 10 mm at 0 'C, then for 17.25 h at room temperature. The mixture was concentrated under vacuum and the gummy residue was stirred in ether (300 mL) to provide a white solid. This was collected by filtration, rinsed with additional ether and dried to provide the title product (12.9 g, 97%) as a white powder: l rl NMR (DMSO-de) δ 8.32 (bs, 3H) , 7.94 (d, IH) , ~.37 (5H) , 5.07 (s, 2H) , 4.45 (m, IH) , 3.68 (s, 3H) , 3.22 m, IH) , 3.07 (m, IH) . I. Methvl 3- (tert-butvloxycarhonvl mino) -2- (h nzyloxy- carbonvl mino)nropionate. A suspension of the product prepared according to Example 3093 Part H (8.00 g, 27.7 mmol) in dichloromethane (140 mL) and saturated aqueous sodium bicarbonate (85 mL) was stirred at room temperature and treated with di-tert-butyldicarbonate (6.11 g, 28 mmol) . The mixture was stirred at room temperature for 16.5 h, then filtered and the layers were separated. The aqueous layer was extracted with additional dichloromethane, and the combined organics were washed with brine, dried over magnesium sulfate, and concentrated under vacuum. The resulting viscous oil was stirred hexane (ca. 200 mL) overnight. The resulting solid was collected by filtration, washed with hexane and dried to provide the title product (7.66 g, 78%) as a white powder: *H NMR (CDCI3) δ 7.36 (5H), 5.80 (bd, IH) , 5.12 (s, 2H) , 4.84 (b, IH) , 4.41 (b, IH) , 3.77 (s, 3H), 3.55 (b, 2H) , 1.42 (s, 9H) . J. Methvl - (tert-butvloxvc rbonvlam no) -2-amιno- propionate. A solution of the product prepared according to Example 3093 Part I (7.50 g, 21.3 mmol) in ethanol (200 mL) was treated with 10% palladium on charcoal (0.75 g) and stirred under hydrogen (1 atmosphere) for 8.5 h. The mixture was filtered through Celite® and the solids were rinsed with additional ethanol. The filtrate was concentrated to provide the title product (4.65 g, 100%) as a viscous oil: X H NMR (CDCI3) δ 5.02 (bs, IH; , 3.75 (s, 3H) , 3.59 (t, IH , 3.53 (m, IH) , 3.27 (m, IH) , 1.67 (bs, 2H) , 1.44 (s, 9H) . K. Methvl 3- ftert-butvloxvcarbor.vlammo) -2- (S) - (2. fi- dimetnvlbenzenesulfonvlamino) nrnpi nate A solution of tne product prepared according to Example 3093 Part J (6.24 g, 24.5 mmol), and diisopropylamine (6.34 g, 49 mmol) in dichloromethane (25 mL) was cooled on an ice bath. A solution of 2 , 6-dιmethyIbenzenesulfonyl chloride (prepared according to Wagenaar and Engberts, J. Royal Neth. Chem. Soc . 1982, 1101(5), 91-94; 5.01 g, 24.5 mmol) in dichloromethane (75 mL) was added over 15 min. The ice bath was removed and the mixture was stirred at room temperature for 18 h. Additional dichloromethane was added and the solution was washed with water. The organic phase was dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum. The residue was purified by flash chromatography (hexanes:ethyl acetate, step gradient from 80:20 to 60:40) to provide the title product (7.25 g, 76%) as a colorless gum: l H NMR (CDCI 3 ) δ 7.29 (t, IH) , 7.14 (d, 2H) , 5.78 (bd, IH) , 4.89 (bt, IH) , 3.92 (m, IH) , 3.55 (s, 3H) , 3.47 (m, 2H) , 2.68 (s, 6H) , 1.42 (s, 9H) . 1. Methyl 3-ammo-2- f£) - (2. fi-dimethvlhengenesulfonvl- ammo)nropionate (+) -camphorsul fonate. The product prepared according to Example 3093, Part K (7.25 g, 18.8 mmol) was dissolved in HCl/dioxane (4.0 M; 50 mL) and the solution was stirred at room temperature for 18 h. The mixture was concentrated under vacuum to yield a hygroscopic solid (6.63 g) which was dissolved in tetrahydrofuran and treated with triethylamine (1.0 equiv.) . The resulting solid was removed by filtration, and the filtrate was treated with (+) -camphorsulfonic acid (1.0 equiv.) . The mixture was stirred at room temperature for 15 min, and the resulting solid was collected by filtration, rinsed with tetrahydrofuran, and dried to provide the title product (6.63 g, 68%) as a white solid: l NMR (DMSO-d 6 ) δ 8.30 (bs, IH) , 7.94 ( bs, 3H ) , 7.33 (t, IH), 7.19 (d, 2H) , 4.09 (bt, IH) , 3.21 's, 3H), 3.10 (dd, IH) , 2.93 (dd, IH) , 2.83 (d, IH ) , 2.64 (t, IH) , 2.56 (s, 6H) , 2.34 (d, IH) , 2.20 (dm, IH), 1.90 (m, 2H), 1.80 (d, IH) , 1.24 (dd, 2H) , 1.31 (s, 3HJ , 0.70 3H) M. Methvl 3-ri-methvl-3-f -(N-(l-triphenv1 ethvl- mιdazol-2-vlamιno) nronvl 1 mdazol -S-vl carbonvlammo! - 2 (S) - (2.6-dιmet vlbenzenesulfonvlaιmno) pronionate. A mixture of the product prepared according to Example 3093 Part G (1.43 g, 2.57 mmol), aqueous sodium hydroxide (1.0 M; 13 mL, 13 mmol) and ethanol (32 mL) was heated at reflux. After 80 mm, the mixture was cooled to room temperature and aqueous hydrochloric acid (1.0 M; 13 mL, 13 mmol) was added. The mixture was concentrated under vacuum and dried. A portion of this material (which contains sodium chloride; 77 mg, 92 μmol) was combined with the product prepared according to Example 3093 Part L (52 mg, 101 μmol) , 1-hydroxy- benzotriazole hydrate (13 mg, 92 μmol), and triethyl- amine (25 μL, 184 μmol) in N,N-dimethylformamide (5 mL) and treated with dicyclohexylcarbodiinu.de (19 mg, 92 μmol) . The mixture was stirred at room temperature for 2.5 days, then was concentrated under vacuum. The residue was partially purified by flash chromatography (dichloromethane:methanol 95:5) to provide the title product (75 mg, 100%) which was impure but was used directly in the subsequent reaction. N. 3- f1 -Methvl-1- R- fN-imidazol-2-vlammo)propvll - ιndazol-5-vlcarbonvlammol-2(.ς)-(2.6-dιmet.hvlbenzene- su fonvl mino)propionic acid trifluoroacetate. Using tne procedure of Example 1050e Part M, the product prepared according to Example 3393 Part M (75 mg, 92 μmol) was converted to the title product as a white powder (after lyophilization) : 1 H NMR (MeOH-d 4 ) δ 7.90 's, IH) , 7.76 (d, IH) , 7.47 (d, IH) , 7.09 (m, IH) , 7.01 (m, 2H ) , 6.81 (s, 2H) , 4.16 ( , IH) , 4.04 (s, 3H) , 3.78 (dd, IH), 3.52 (dd, IH) , 3.34 (t, 2H) , 3.09 (t, 2H) , 2.62 (s, 6H) , 2.14 (m, 2H) ; High resolution mass spectrum (FAB) calculated (M+H + ) 554.2186, found 554.2184. Example ^1 ύ.7 3- ri-Methvl-3- f3- (N-Pvndm-2-vlamino)oropvl 1 ndazol-6- ylcarbonvlaminol -2 (S) - (2.4.6-tπmethvlbenzenesulfonvl¬ amino)propionic acid trifluoroacetate A. 1 -Methvl-3- R- rN-pvr dιn-2-vlamιno)propvll -6- methoxycarbonyl mdazole. A solution of the product prepared according to Example 3093 Part F (201 mg, 816 μmol) and 2-amιnopyrιdme (154 mg, 1.63 mmol) in dichloroethane (4 mL) was stirred at room temperature and treated with sodium triacetoxyborohydride (346 mg, 1.63 mmol) . After 16.5 h, the mixture was diluted with water (ca. 5 mL) and saturated aqueous sodium bicarbonate (ca. 2 mL) and stirred for 15 mm. The mixture was extracted three times with dichloromethane, and the combined organic phases were dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum. The residue was purified by flash chromatography (dichloromethane:isopropanol 95:5) to provide the title product (214 mg, 81%) as a white solid: mp 101-104 * C; l NMR (CDCI3) δ 8.13 (s, IH) , 8.07 (d, IH) , 7.76 (d, IH) , 7.67 (d, IH) , 7.39 (t, IH ) , 6.56 (dd, IH) , 6.36 (d, IH) , 4.65 (bt, IH) , 4.08 (s, 3H) , 3.98 (S, 3H) , 3.38 (q, 2H) , 3.10 (t, 3H) , 2.16 ( m, 2H) ; High resolution mass spectrum (NH 3 -CI; calculated (M+H + ) 325.1665, found 325.1653. B. tert-Butvl 3- fl-methvl-3- M- (N-PVΠdιn-2-ylammo) - nropvll indazol-6-ylcarbonvlaminol -2fS)- ( . .6-trιmethyl - benzenesulfonvllaminopropionate. Using the procedures of Example 1326b Parts E and F, the product prepared according to Example 3142 Part A (59 mg, 182 μmol) was converted to the title product (108 mg, 93%) as a colorless glass: l H NMR (CDCI3) δ 8.08 (d, IH) , 7.95 (s, 7.46 (d, IH) , 7.40 (m, IH) , 6.94 (s, 6.56 (m, IH) , 6.37 (d, IH) , 5.79 (d, 4.08 (s, 3H) , 3.95 (m, IH) , 3.83 (m, 3.38 (q, 2H), 3.10 (t, 2H) , 2.66 (s, , 2.16 (m, 2H) , 1.32 (s, 9H) ; High resolution mass spectrum (FAB) calculated (M+H + ) 635.3016, found 635.3028. C. 3- fl-Methvl-3- f3- (N-pvrιdιn-2-vlamιno)propvll- ιndazol-6-vlcarbonvlammol -2 (£) - (2. .6-tπmethvlbenzene- sulfonylamino) ropionic acid trifluoroacetate. Usmg the procedure of Example 1129 Part H, the product prepared according to Example 3142 Part B (100 mg, 158 μmol) was converted to the title product (84 mg, 77%) as a white powder: X H NMR (DMSO-d 6 ) δ 8.52 (m, 2H) , 8.08 (d, IH), 7.95 (S, IH), 7.90 (d, IH) , 7.82 (t, IH) , 7.77 (d, IH) , 7.46 (d, IH) , 6.97 (d, IH) , 6.79 (s+m, 3H) , 4.05 (m, IH) , 4.01 (s, 3H) , 3.59 (m, 2H) , 3.39 (m, 2H) , 3.03 (t, 2H), 2.52 (s, 6H) , 2.07 (m, 2H) , 2.00 (s, 3H) ; High resolution mass spectrum (FAB) calculated (M+H + ) 579.2390, found 579.2400. Example 3339 3- fl-Benzvl-3- \ 2 - (N-pvr dm-2-vlammo)πmnvl 1 mdazol -6- vlcarbonvlaminol -2 (S) -(2.4.6-trιmethvlbenzenesul onyl¬ amino) propionic acid trifluoroacetate A. 3- (3 , 3-Diethoxvpropvnvl) -6-methoxvcarbonvlmdazoi.e. Using the procedure of Example 3093 Part D, the product prepared according to Example 3093 Part B (2.55 g, 10 mmol) was converted to the title product (1.49 g, 49%) as a brown gum: X H NMR (CDCI 3 ) δ 8.28 (s, IH) , 7.90 (d, IH) , 7.85 (d, IH) , 5.61 (s, IH) , 3.98 (s, 3H) , 3.88 (m, 2H) , 3.75 (m, 2H) , 1.31 (t, 6H) ; Mass spectrum (NH 3 -CI) m/z 257 (100%, (M+H-EtOH) + ) . B. 3-(3.3-Dιethoxypropyl) -6-methoxvcarhonvlιndazole. Using the procedure of Example 3093 Part E, the product prepared according to Example 3339 Part A (263 mg, 870 μmol) was converted to the title product (106 mg, 40%) as an orange oil, which contained a contaminant but was used directly in the subsequent reaction: 1 H NMR (CDCI3 ) δ 8.20 (s, IH), 7.81 (d, IH) , 7.76 (d, IH) , 4.60 (t, IH) , 3.96 (s, 3H), 3.68 (m, 2H) , 3.51 (m, 2H) , 3.09 ( m, 2H), 2.17 (m, 2H) , 1.22 (t, 6H) ; High resolution mass spectrum (NH 3 -CI) calculated (M+H + ) 307.1658, found 307.1636. C. 1 -Benzyl-3- f .3-diet o vpropvl ) -6-methoxvcarbonvl- ■ yndazole. A solution of the product prepared according to Example 3339 Part B (230 mg, 750 μmol ) and benzyl chloride (95 μL, 826 μmol) in dry N,N-dimethylformamιde (4 mL) was stirred on an ice bath and treated with sodium hydride (60% in mineral oil; 36 mg, 900 μmol ) . The mixture was stirred 10 min, then was allowed to warm to room temperature and stirred for 23 h. The mixture was diluted with water and extracted three times with ethyl acetate. The combined organic phases were washed twice with water, then dried over magnesium sulfate, filtered and concentrated under vacuum. The residue was purified by flash chromatograpny (hexanes :ethyl acetate 85:15) to provide the title product (152 mg, 51%) as an oil, which was impure but was used directly in the subsequent reaction: X H NMR (CDCI3) δ 8.08 (s, IH) , 7.75 (m, 2H) , 7.25 (m, 3H) , 7.17 (m, 2H) , 5.59 (s, 2H) , 4.56 (t, IH) , 3.94 (s, 3H) , 3.67 (m, 2H) , 3.50 ( , 2H) , 3.08 (m, 2H) , 2.2-2.05 (m, 2H) , 1.22 (t, 6H) ; Mass spectrum (NH3-CI) m/z 397.5 (10%, M+H + ;, 351 (100%, (M+H-EtOH) + ) . D. l-Benzvl-3- (3-oxopropvl ) - -metho rarbonvl indazolP Using the procedure of Example 3093 Part F, the product of Example 3339 Part C (115 mg, 567 μmol) was converted to the title product (110 mg, 60%) as an oil which solidified on standing: H NMR (CDCI3) δ 9.91 (s, IH) , 8.08 (S, IH) , 7.78 (d, IH) , 7.72 (d, IH) , 7.27 (m, 3H) , 7.16 (m, 2H) , 5.57 (s, 2H) , 3.93 (s, 3H) , 3.33 (t, 2H) , 3.05 (t, 2H) ; Mass spectrum (ESI) m/z 323.4 (24%, M+H + ) . E. l-Benzvl-3- r.3- (N-pvπd n-3-vlamιno)πrnnvl 1 -fi- methoxvcarbonvlindazol . Using the procedure of Example 3142 Part A, the product prepared according to Example 3339 Part D (91 mg, 282 μmol) was converted to the title product (90 mg, 80%) as a viscous oil which solidified on standing. This material contained a contaminant but was used directly in the subsequent reaction: X H NMR (CDCI3) δ 8.08 (m, 2H) , 7.77 (d, IH) , 7.70 (d, IH) , 7.36 (m, IH) , 7.3-7.2 (m, 3H) , 7.17 (m, 2H) , 6.54 (dd, IH) , 6.30 (d, IH), 5.60 (s, 2H) , 4.65 (bt, IH) , 3.93 (s, 3H) , 3.37 (q, 2H) , 3.13 (t, 2H) , 2.16 (m, 2H) ; High resolution mass spectrum (FAB) calculated (M+H + ) 401.1978, found 401.1982. F. tert-Rutvl 3- r -benzvl -3- n- (N-nvridin-2-vlamino) - nropvll ιndazol-6-ylcarbonvlaπnnol - (S) - (2. . fi-trimethvl- benzenesul onvl ) a mopropionate. Using the procedure of Example 1326b Parts E and F, the product prepared according to Example 3339 Part E (81 mg, 202 μmol) was converted to the title product (162 mg, >100%) as a colorless glass which contained a contaminant but was used directly in the subsequent reaction: l H NMR (CDCI 3 ) δ 8.07 (m, IH), 7.94 (s, IH) , 7.71 (d, IH) , 7.47 (d, IH) , 7.38 (m, IH) , 7.26 (m, 5H) , 6.92 (s+bm, 3H) , 6.55 (m, IH) , 6.33 (d, IH) , 5.81 (d, IH) , 5.59 (s, 2H) , 4.69 (bt, IH) , 3.94 (m, IH) , 3.81 (m, IH) , 3.56 (m, IH) , 3.38 (q, 2H) , 3.13 (t, 2H) , 2.63 (s, 6H) , 2.26 (s, 3H) , 2.17 (m, 2H) , 1.29 (s, 9H) ,- High resolution mass spectrum (FAB) calculated (M+H + ) 711.3329, found 711.3341. G. 3- rl-Benzvl-3- f3- (N-pvrιdιn-2-vlammo)nropvll - mdazol- -ylcarbonvlaminol -2 (S) - (2.4.6-trιmethvl- benzenesulfonylammo)propιon c acid trifluoroacetate. Using the procedure of Example 1129 Part H, the product prepared according to Example 3339 Part F (136 mg, 191 μmol) was converted to the title product (110 mg, 75%) as a white powder: l R NMR (DMSO-d 6 ) δ 8.49 (t, IH) , 8.07 (d, IH), 8.05 (s, IH) , 7.92 (d, IH) , 7.81 (d, IH) , 7.72 (m, IH) , 7.45 (d, IH) , 7.35-7.20 (m, 5H) , 6.88 (d, IH) , 6.73 (s+m, 3H) , 5.62 (s, 2H) , 4.05 (m, IH) , 3.58 (m, IH), 3.5-3.3 (m, 3H) , 3.05 (t, 2H) , 2.52 (s, 6H) , 2.07 tm, 2H) , 1.95 (s, 3H) ; High resolution mass spectrum (FAB) calculated (M+H+) 655.2703, found 655.2701. Using the methods described above and modifications thereof known to one skilled in the art of organic synthesis, the following additional examples in Tables 1-8 can be prepared. Utility The compounds of Formula la, lb or Ic of the present invention possess activity as antagonists of integrins such as, for example, the civ or vitronectin receptor, ctvβs or ctsPi, and as such have utility the treatment and diagnosis of cell adhesion, angiogenic disorders, inflammation, bone degradation, cancer metastases, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis. The tegrm antagonist activity of the compounds of the present invention is demonstrated using assays which measure the binding of a specific mtegr to a native ligand, for example, using the ELISA assay described below for the binding of vitronectin to the c_vβ 3 receptor. The compounds of the present invention possess selectivity for the αvβ3 receptor relative to the GPIIb/IIIa receptor as demonstrated by their reduced activity m standard assays of platelet aggregation, such as the platelet aggregation assay described below. One of the ma.or roles of integrins in vi vo is to mediate cellular interactions with adjacent cells. Cell based adhesion assays can be used to mimic these interactions m vi tro . A cell based assay is more representative of the in vivo situation than an ELISA since the receptor is maintained in membranes in the native state. The compounds of the present invention have activity in cell-based assays of adhesion, for example as demonstrated in using the cell adhesion assays described below. The compounds of Formula la, lb or Ic of the present invention may be useful for the treatment or prevention of other diseases which involve cell adhesion processes, including, but not limited to, osteoporosis, rheumatoid arthritis, autoimmune disorders, bone degradation, rheumatoid arthritis, asthma, allergies, adult respiratory distress syndrome, graft versus host disease, organ transplantation, septic shock, psoriasis, eczema, contact dermatitis, osteoarthritis, atherosclerosis, metastasis, wound healing, inflammatory bowel disease and other angiogenic disorders. The compounds of Formula la, lb or Ic have the ability to suppress/inhibit angiogenesis in vivo, for example, as demonstrated using animal models of ocular neovascularization. The compounds provided by this invention are also useful as standards and reagents in determining the ability of a potential pharmaceutical to inhibit integrin-ligand binding. These may be provided in a commercial kit comprising a compound of this invention. As used herein "μg" denotes microgram, "mg" denotes milligram, "g" denotes gram, "μL" denotes microliter, "mL" denotes milliliter, "L" denotes liter, "nM" denotes nanomolar, "μM" denotes micromolar, "mM" denotes millimolar, "M" denotes molar and "nm" denotes nanometer. "Sigma" stands for the Sig a-Aldrich Corp. of St. Louis, MO. The utility of the compounds of the present invention may be assessed by testing in one or more of the following assays as described in detail below: Purified αv§ (human placenta) - Vitronectin ELISA, otvβ3-Vitronectin Binding Assay, Human Aortic Smooth Muscle Cell Migration Assay, In Vivo Angiogenesis Model, Pig Restenosis Model, Mouse Retinopathy Model. A compound of the present invention is considered to be active if it has an IC 50 or Ki value of less than about 10 μM for the inhibition of αyβ3-Vitronectin Binding Assay, with compounds preferably having Ki values of less than about 3 1 μM. Tested compounds of the present invention are active in the α,/β 3 -Vitronectin Binding Assay. Purified o .^ (human placenta) - Vitronectin RT.TSA The α.yj- 3 receptor was isolated from human placental extracts prepared using octylglucoside. The extracts were passed over an affinity column composed of antι-α v β 3 monoclonal antibody (LM609) bound to Affigel. The column was subsequently washed extensively at pH 7 and pH 4.5 followed by elution at pH 3. The resulting sample was concentrated by wheat germ agglutin chromatography to provide two bands by SDS gel electrophoresis which were confirmed as ctvfo by western blotting. Affinity purified protein was diluted at different levels and plated to 96 well plates. ELISA was performed using fixed concentration of biotinylated vitronectin (approximately 80 nM/well) . This receptor preparation contains the αvβ 3 with no detectable levels of ctvβs according to the gel and according to effects of blocking antibodies for the <Xvβ3 or c-vPs integrins in the ELISA. A submaximal concentration of biotinylated vitronectin was selected based on a concentration response curve with fixed receptor concentration and variable concentrations of biotinylated vitronectin. n-fa- itronectin Binding Assay The purified receptor is diluted with coating buffer (20 mM Tris HCl, 150 mM NaCl, 2.0 mM CaCl 2 , 1.0 mM MgCl 2 '6H 2 0, 1.0 mM MnCl2-4H 2 0) and coated (100 μL/well) on Costar (3590) high capacity binding plates overnight at 4°C. The coating solution is discarded and the plates washed once with blocking/binding buffer (B/B buffer, 50 mM Tris HCl, 100 mM NaCl, 2.0 mM CaCl 2 ,l-0 mM MgCl 2 -6H 2 O,1.0 mM MnCl ; -4H 2 C ) . Receptor is then blocked ( 200 μL/well) with 3.5% BSA m 3/B buffer for 2 hours at room temperature. After washing once with 1.0% BSA m B/B buffer, biotinylated vitronectin (100 μL) and either inhibitor ( 11 μL) or B/B buffer w/1.0% BSA (11 μL) is added to each well. The plates are incubated 2 hours at room temperature. The plates are washed twice with B/B buffer and incubated 1 hour at room temperature with anti-biot alkaline phosphatase (100 μL/well) in B/B buffer containing 1.0% BSA. The plates are washed twice with B/B buffer and alkaline phosphatase substrate (100 μL ) is added. Color is developed at room temperature. Color development is stopped by addition of 2N NaOH (25 μL/well) and absorbance is read at 405 nm. The IC 50 is the concentration of test substance needed to block 50% of the vitronectin binding to the receptor. Inteαrin Cell-Based Adhesion Assays In the adhesion assays, a 96 well plate was coated with the ligand (i.e., fibrinogen) and incubated overnight at 4° C. The following day, the cells were harvested, washed and loaded with a fluorescent dye. Test compounds and cells were added together and then were immediately added to the coated plate. After incubation, loose cells are removed from the plate, and the plate (with adherent cells) is counted on a fluorometer. The ability of test compounds to inhibit cell adhesion by 50% is given by the IC 50 value and represents a measure of potency of inhibition of integnn mediated binding. Compounds were tested for their ability to block cell adhesion using assays specific for c v fo, α,^ and c-sβi mtegr interactions. Platelet Aggregation Assay Venous blood was obtained from anesthetized mongrel dogs or from healthy human donors who were drug- and aspirin-free for at least two weeks prior to blood collection. Blood was collected into citrated Vacutainer tubes. The blood was centrifuged for 15 minutes at 150 x g ( 850 RPM in a Sorvall RT6000 Tabletop Centrifuge with H-1000 B rotor) at room temperature, and platelet- rich plasma (PRP) was removed. The remaining blood was centrifuged for 15 minutes at 1500 x g (26,780 RPM) at room temperature, and platelet-poor plasma (PPP) was removed. Samples were assayed on a PAP-4 Platelet Aggregation Profiler, using PPP as the blank (100% transmittance) . 200 μL of PRP (5xl0 8 platelets/mL) were added to each micro test tube, and transmittance was set to 0%. 20 μL of ADP (10 μM) was added to each tube, and the aggregation profiles were plotted (% transmittance versus time) . Test agent (20 μL) was added at different concentrations prior to the addition of the platelet agonist. Results are expressed as % inhibition of agonist-induced platelet aggregation. Human Aortic Smooth Muscle Cell. Migration Assay A method for assessing c-vβ 3 -mediated smooth muscle cell migration and agents which inhibit αyβ 3 -mediated smooth muscle cell migration is described in Liaw et al., J. Clin . Invest . (1995) 95: 713-724) . Tn Vivo Angiogenesis Model A quantitative method for assessing angiogenesis and antiangiogenic agents is described in Passaniti et al. Laboratory Investigation (1992) 67: 519-528 Pig Restenosis Model A method for assessing restenosis and agents which inhibit restenosis is described in Schwartz et al., J. Am. College of Cardiology (1992) 19: 267-274. Mouse Retinopathy Model A method for assessing retinopathy and agents which inhibit retinopathy is described in Smith et al.. Invest. Ophthal . & Visual Science (1994) 35: 101-111. Dosage ar.d FQrmu at-.nn The compounds of this invention can be administered by any means that produces contact of the active agent with the agent's site of action, the 0.^ 3 integnn, in the body of a mammal . They can be administered by any conventional means available for use in con]unction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents, such as a antiplatelet agent such as aspirin, piroxicam, or ticlopidme which are agonist-specific, or an ant1-coagulant such as warfarin or heparin, or a thrombin inhibitor such as a boropeptide, hirudin or argatroban, or a thrombolytic agent such as tissue plasminogen activator, amstreplase, urokinase or streptokinase, or combinations thereof. The compounds of the invention, or compounds of the invention in combination with other therapeutic agents, can be administered alone, but generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice. The dosage of the novel compounds of this invention administered will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration,- the age, health and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; and the effect desired. A daily dosage of active ingredient can be expected to be about 0.301 to 10 milligrams per kilogram of body weight. Dosage forms (compositions suitable for administration) contain from about 0.1 milligram to about 100 milligrams of active ingredient per unit. In these pharmaceutical compositions the active ingredient will ordinarily be present m an amount of about 0.5-95% by weight based on the total weight of the composition. The active ingredient can be administered orally solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions. It can also be administered by injection, in sterile liquid dosage forms. Gelatin capsules contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract. Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance. In general, water, a suitable oil, saline, aqueous dextrose (glucose) , and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary/ buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol. Suitable pharmaceutical carriers are described Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text n this field. Useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows: Capsules A large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each with 10 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate. soft Gelatin Capsules A mixture of active ingredient in a digestable oil such as soybean oil, cottonseed oil or olive oil is prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 10 milligrams of the active ingredient. The capsules are washed and dried. Tablets A large number of tablets are prepared by conventional procedures so that the dosage unit was 10 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatabil ty or delay absorption. The combination products of this invention, such as the novel αvβ 3 antagonist compounds of this invention combination with an ant1-coagulant agent such as warfarin or heparin, or an anti-platelet agent such as aspirin, piroxicam or ticlopidine, or a thrombin inhibitor such as a boropeptide, hirudin or argatroban, or a thrombolytic agent such as tissue plasminogen activator, amstreplase, urokinase or streptokinase, cr combinations thereof, can be in any dosage form, such as those described above, and can also be administered in various ways, as described above. In a preferred embodiment, the combination products of the invention are formulated together, in a single dosage form (that is, combined together in one capsule, tablet, powder, or liquid, etc.) . When the combination products are not formulated together in a single dosage form, the cvβ 3 antagonist compounds of this invention and the anti-coagulant agent, anti-platelet agent, thrombin inhibitor, and/or thrombolytic agent may be administered at the same time (that is, together) , or in any order, for example the compounds of this invention are administered first, followed by administration of the antl-coagulant agent, anti-platelet agent, thrombin inhibitor, and/or thrombolytic agent. When not administered at the same time, preferably the administration of the compound of this invention and any anti-coagulant agent, anti-platelet agent, thrombin inhibitor, and/or thrombolytic agent occurs less than about one hour apart, more preferably less than about 30 minutes apart, even more preferably less than about 15 minutes apart, and most preferably less than about 5 minutes apart. Preferably, administration of the combination products of the invention is oral. The terms oral agent, oral inhibitor, oral compound, or the like, as used herein, denote compounds which may be orally administered. Although t is preferable that the otv03 antagonist compounds of this invention and the antl-coagulant agent, anti-platelet agent, thrombin inhibitor, and/or thrombolytic agent are both administered in the same fashion (that is, for example, ooth orally) , if desired, they may each be administered in different fashions (that is, for example, one component of the combination product may be administered orally, and another component may be administered intravenously) . The dosage of the combination products of the invention may vary depending upon various factors such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration, the age, health and weight of the recipient, the nature and extent of the symptoms, the kind of concurrent treatment, the frequency of treatment, and the effect desired, as described aoove. As discussed above, where two or more of the foregoing therapeutic agents are combined or co-admmistered with the compounds of this invention, generally the amount of each component in a typical daily dosage and typical dosage form may be reduced relative to the usual dosage of the agent when administered alone, in view of the additive or synergistic effect which would be obtained as a result of addition of further agents m accordance with the present invention. Particularly when provided as a single dosage form, the potential exists for a chemical interaction between the combined active ingredients (for example, a novel compound of this invention and an antI-coagulant such as warfarin or heparin, or a novel compound of this invention and an anti-platelet agent such as aspirin, piroxicam or ticlopidme, or a novel compound of this invention and a thrombin inhibitor such as a ooropeptide, hirudin or argatroban, or a novel compound of this invention and a thrombolytic agent such as tissue plasminogen activator, amstreplase, urokinase or streptokinase, or combinations thereof) . For this reason, the preferred dosage forms of the combination products of this invention are formulated such that although the active ingredients are combined in a single dosage form, the physical contact between the active ingredients is minimized (that is, reduced) . In order to minimize contact, one embodiment of this invention where the product is orally administered provides for a combination product wherein one active ingredient is enteric coated. By enteric coating one of the active ingredients, it is possible not only to minimize the contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the gastrointestinal tract such that one of these components is not released in the stomach but rather is released m the intestines. Another embodiment of this invention where oral administration is desired provides for a combination product wherein one of the active ingredients is coated with a sustained-release material which effects a sustained-release throughout the gastrointestinal tract and also serves to minimize physical contact between the combined active ingredients. Furthermore, the sustained-released component can be additionally enteric coated such that the release of this component occurs only in the intestine. Still another approach would involve the formulation of a combination product in which the one component is coated with a sustained and/or enteric release polymer, and the other component is also coated with a polymer such as a low viscosity grade of hydroxypropyl methylcellulose (HPMC) or other appropriate materials as known in the art, in order to further separate the active components. The polymer coating serves to form an additional barrier to interaction with the other component. Dosage forms of the combination products of the present invention wherein one active ingredient is enteric coated can be in the form of tablets such that the enteric coated component and the other active ingredient are blended together and then compressed into a tablet or such that the enteric coated component is compressed into one tablet layer and the other active ingredient is compressed into an additional layer. Optionally, in order to further separate the two layers, one or more placebo layers may be present such that the placebo layer s between the layers of active ingredients. In addition, dosage forms of the present invention can be in the form of capsules wherein one active ingredient is compressed into a tablet or in the form of a plurality of microtablets, particles, granules or non-perils, which are then enteric coated. These enteric coated microtablets, particles, granules or non- perils are then placed into a capsule or compressed into a capsule along with a granulation of the other active ingredient . These as well as other ways of minimizing contact between the components of combination products of the present invention, whether administered in a single dosage form or administered in separate forms but at the same t me by the same manner, will be readily apparent to those skilled in the art, once armed with the present disclosure. Pharmaceutical kits useful in, for example, the inhibition of thrombus formation, the prevention of blood clots, and/or the treatment of thromboembolic disorders, which comprise a therapeutically effective amount of a compound according to the method of the present invention along with a therapeutically effective amount of an anti-coagulant agent such as warfarin cr heparin, or an antiplatelet agent such as aspirin, piroxicam or ticlopidme, or a tnrombm inhibitor such as a boropeptide, hirudin or argatroban, or a thrombolytic agent such as tissue plasminogen activator, amstreplase, urokinase or streptokinase, or combinations thereof, in one or more sterile containers, are also within the ambit of the present invention. Sterilization of the container may be carried out using conventional sterilization methodology well known to those skilled in the art. The sterile containers of materials may comprise separate containers, or one or more multi-part containers, as exemplified by the UNIVIAL™ two-part container (available from Abbott Labs, Chicago, Illinois) , as desired. The compounds according to the method of the invention and the antI-coagulant agent, anti-platelet agent, thrombin inhibitor, thrombolytic agent, and/or combinations thereof, may be separate, or combined into a single dosage form as described above. Such kits may further include, f desired, one or more of various conventional pharmaceutical kit components, such as for example, one or more pharmaceutically acceptable carriers, additional vials for mixing the components, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, may also be included in the kit. Table 1 , 10 , 13 3 1 3 15 MS H H H NHC0 CH2Ph I N H NHCO CH 2 C6H4- (2-CH 3 ) H NHCO2CH C6H4- O-CH3) H NHCO2CH2C6H4- (4-CH3) H NHC0 2 CH 2 (2-pyridinyl) H NHC0 2 CH2 ( 3-pyridinyl) H NHC0 2 CH (4-pyridinyl) H NHC0 2 CH 2 (2-thιazolyl) H NHC0 2 CH 2 (4-thιazolyl) H NHCO2CH2 (5-thιazolyl) H NHCO2CH 2 (4-isoxazolyi; 1013 imidazol -2-ylamino- ( CH 2 ) 3 NHC0 2 CHj (2-thιenyl) 1014 imidazol-2-ylamino- ( CH 2 ) 3 NHCO2CH 2 (5-ιsoxazolyi; 1015 imidazol -2-ylamino- (CH 2 ) 3 NHC0 2 n-Bu 1016 imidazol -2-ylamino- ( CH 2 ) 3 NHC0 2 ι-Bu 1017 imidazol -2-ylamino- ( CH 2 ) 3 NHC0 t-Bu 1017a imidazol -2-ylaroino- (CH 2 )3 NHCOPh 1018 imidazol -2-ylamino- (CH 2 ) 3 NHCOCH^Ph 1019 imidazol-2-ylamino- ( CH 2 ) 3 HCOCH 2 C6H -(2-CH3) 1020 imidazol-2-ylamino- ( CIU3 NHCOCH 2 C6H 4 -(3-CH 3 ) 1021 imidazol-2-ylamino- ( CH 2 ) 3 HCOCH C 6 H - U-CH3) 1021a imidazol-2-ylamino- (CH 2 ) 3 NHCOCH 2 CH Ph 1021b imidazol-2-ylamino- ( CH 2 ) 3 NHCOCH=CHPh 1022 imidazol-2-ylamino- (CH 2 ) 3 NHC0CH2(2-pyrιdinyl) 1023 imidazol-2-ylamino- (CH 2 )3 NHCOCH^ (3-pyridinyl) 1024 imidazol-2-ylamino- (CH 2 ) 3 NHCOCH^ ( -pyridinyl) 1025 imidazol-2-ylamino- <CH 2 )3 NHCOCH 2 (2-Chιazolyl) 1026 imidazol-2-ylamino- (CH 2 ) 3 NHCOCH^ (4-thιazolyl) 1027 imidazol-2-ylamino- (CH 2 ) 3 NHCOCH^ (5-thιazolyl) 1028 imidazol-2-ylamino- (CH 2 ) 3 NHCOCH2 (4-ιsoxazol) 1029 imidazol-2-ylamino- (CH 2 ) 3 NHCOCH2 (2-thienyl) 1029a imidazol-2-ylamino- (CH 2 ) 3 NHC0CH 2 (cyclohexy1) 1029b imidazol-2-ylamino- (CH 2 ) 3 NHCO-cyclohexyl 1030 imidazol-2-ylaroino- ( CH 2 ) 3 NHCOn-Bu NHCOt-Bu 1031 imidazol- 2-ylamino- (CH ) 3 1031a imidazol-2-ylamino- NHCONHPh (CH 2 )3 NHCONHCH 2 Ph 1031b imidazol-2-ylamino- (CH 2 )3 NHSOaPh 512.3 1032 imidazol- 2-ylamino- (CH 2 )3 NHSO C 6 H -(2-CH3) 1033 imidazol- -2-ylamino- (CH 2 ) 3 1034 imidazol- -2-ylamino- (CH 2 ) 3 NHSO2C6H4- (3-CH 3 ) 1035 imidazol- -2-ylamino-(CH 2 ) 3 NHSO^CβJ^- (4-CH 3 ) 2 C 6 H 3 -(2,6-CH 3 )2 540.4 1035a imidazol- -2-ylamino- NHS0 (CH 2 ) 3 NHS0 2 C 6 H 2 -(2,4,6-CH 3 ) 3 554.4 1035b i idazol- -2-ylamino- (CH 2 )3 NHS0 2 (2-pyridyl) 1036 imidazol- -2-ylamino- (CH 2 ) 3 1037 imidazol -2-ylamino- (CH 2 )3 NHS0_, (3-pyridyl) NHSO^l4-pyridyl) 1038 imidazol -2-ylam (CH 2 )3 NHS0 2 (2-thienyl) 1038a imidazol -2-ylamino (CH 2 )3 NHS0 2 -[3-(2,5- J 1038b imidazol -2-ylamino (CH 2 )3 o KJ dichloro ) thienyl ] I NHS0 2 ( 2 - thιaz-oly l ) 1039 imidazol-2-ylamino-(CH2) 3 1040 imidazol-2-ylamino-(CH 2 ) 3 NHSO^ - thiazoly l ) 1040a imidazol-2-ylamino-(CH 2 ) 3 NHSO2 - [ 5 - ( 4 -me hy 1 - 2 - amino) hiazolyl] NHS0 (4-isoxazolyl) 1041 imidazol-2-ylamino-(CH 2 ) 3 NHS0 2 [4-(3,5- 1042 imidazol-2-ylamino- (CH 2 ) 3 dimethy 1 ) isoxazoly l ] 1043 imidazol-2-ylamino- (CH 2 ) 3 NHSO C6H 4 - ( 2 -Br ) 1044 imidazol 2-ylamino- (CH 2 ) 3 HSO2C6H4- (3-Bι) 1045 imidazol 2-ylamino- (CH 2 )3 NHSO 6H4- (4-Br) 1046 imidazol- 2-ylamino- (CH 2 ) 3 NHSO C6H4- (2-F) 1047 imidazol 2-ylamino- (CH 2 ) 3 NHS0 2 C 6 H4-(3-F) 1048 imidazol 2-ylamino- (CH 2 )3 NHSO2C6H4- (4-F) 1048a imidazol- 2-ylamino- ( CH 2 ) 3 NHS0 2 C 6 H3-(2,6-Cl 2 ) 580.2 1049 imidazol- 2-ylamino- (CH 2 )3 NHS0 2 (2-naphthyl) 1050 imidazol 2-ylamino- ( CH 2 >3 NHSO_(l-naphthyl) 562.4 1050a imidazol 2-ylamino- ( CH 2 ) 3 NHS0 2 C6H4-(4-Ph) 588.4 1050b imidazol- 2-ylamino- ( CH 2 )3 NHS0 2 C 6 H4-4-(4- pyridyl) 1050c imidazol-2-ylamino-(CH 2 ) 3 NHS0 2 C 6 H4-4-(2- oxazolyl) I 1 o 1050d imidazol -2-ylamino- (CH ) 3 NHS0 2 C6H4-4-(3- J I pyrazolyl) 1050e imidazol-2-ylamino- (CH ) 3 NHS0 2 C 6 H2-4-Ph-2,6- 616.3 dimethyl 1050f imidazol-2-ylamino- (CH 2 )3 NHSO2C6H2- -O- pyridyl) -2, 6-dimethyl 1050g imidazol-2-ylamino- (CH2) 3 HSθ2CgH2-4- (2-oxa- zolyl) -2, 6-dimethyl 1050h imidazol-2-ylamιno-(CH2>3 NHSO2C6H2- - (3-pyra- zolyl) -2, 6-dimethyl 1050i imidazol-2-ylamino- (CH 2 ) 3 NHS0 2 C6H2- -Ph-2, 6- dichloio 1050j imidazol-2-ylamino-(CH 2 ) 3 NHSO2C6H4- - (2-£uryl) 578.3 1050k imidazol-2-ylamino-(CH 2 )3 NHS0 2 C6H 2 -4- (3-£uryl) 10501 imidazol-2-ylamino-(CH ) 3 HS0 2 C6H2-4- (3- pyridyl) 1050m imidazol-2-ylamino-(CH 2 )3 NHS02CgH2-4-(4- pyridyl) -2, 6-dimethyl 1050n imidazol-2-ylamino- ( CH 2 ) 3 NHS0 2 C 6 H 2 -4-(3-furyl) - 2, 6-dimethyl 1050o imidazol-2-ylamino- (CH2)3 NHS0 2 C6H2- - (2-furyl) - 2, 6-dichloro NHS0 2 CH=CHPh NHS0 2 CH^Ph NHS0^CH 2 CH=CH-Ph NHS0 2 -n-Bu NHS0 -i-Bu NHS0 -t-Bu NHS0 2 NHPh NHSO 2 HC6H4- (2-CH3) HSO2 HC6H4- (3-CH3) HS0^ HC6H4-(4-CH3) NHS0 2 NHC6C 3 - (2, 6-Me 2 ) 1060b imidazol-2-ylamino- (CH2)3 NHS0 2 NHC 6 C 2 -(2, 4, 6- imidazol- 2-ylamino- CH 2 )3 NHS0 2 NH(2-pyridyl) imidazol-2-ylamino- CH 2 )3 NHSOΛWt3-pyridyl) imidazol-2-ylaroino- CH 2 ) 3 NHS0 2 NH(4-pyridyl) imidazol-2-ylanιino- CH 2 ) 3 NHSO^NH(2-thiazolyl) imidazol-2-ylamino- CH 2 ) 3 NHS0 NH(4-thiazolyl) imidazol- 2-ylamino- CH 2 ) 3 NHS0 2 NH(4-isoxazoly1) imidazol-2-ylamino- CH 2 )3 NHS0 2 1 - (3.5- dimethyl) isoxazolyl ) imidazol- 2-ylamino- CH 2 )3 NHS0 2 NHC6H4~ (2-Br) imidazol-2-ylamino- CH 2 ) 3 HS0 2 NHC6H4- (3-Br) imidazol- 2-ylamino- CH 2 ) 3 NHS0 NHC6H4-(4-Br) imidazol- 2-ylamino- CH 2 ) 3 NHSO^NHCgH^- (3-F) imid zol 2-ylamino- CH 2 ) 3 NHSO NHC6H - (4-F) imidazol- 2-ylaraino- CH 2 )3 NHS0 2 NH(2-naphthyl) imidazol- 2-ylamino- CH 2 )3 NHS0 2 NH(1-naphthyl) imidazo - 2-ylamino- CH 2 )3 NHS0 NHCgH4-(4-Ph) imidazol 2-ylamino- CH 2 )3 NHSθ 2 NHCgH 2 - (4-Ph-2, 6- dimethyl) 1074c imidazol-2-ylamino- CH 2 ) 3 NHS0 2 NHC6H 2 - (4-Ph-2, 6- dichloro) 1075 imidazo1-2-ylamino- CH 2 ) 3 NHSθ 2 NHCH=CH-Ph imidazol -2 -ylamino imidazol -2 -ylamino imidazol -2 -ylamino NHSθ2NH-cyclohexyl imidazol -2 -ylamino NHSO ^ NH-n-Bu imidazol -2 -ylamino NHS0 2 NH-i-Bu imidazol -2 -ylamino NHSO ^ NH-t-Bu pyndιn-2-ylamιno- NHCO i CH 2 Ph 517.3 pyndιn-2 -ylamιno- NHCO2CH..C6H4- (2-CH3) pyndιn-2-ylamιno- NHC0 2 CH 2 C6H4-(3-CH3) pyr dιn-2-ylamιno- NHC0 2 CH C6H 4 -(4-CH3) pyndm-2-ylamιno- NHCO2CH2 (2-pyrιdιnyl) ρyrιdιn-2-ylamιno- NHCθ2CH^ ( 3-pyridinyl) pyrιdιn-2-ylamιno- NHCO2CH2 (4-pyrιdmyl) pyrιdιn-2-ylamιno- NHCO2CH 2 (2-thιazolyl) pyrιdιn-2-ylamιno- NHC0 2 CH^ (4-thιazolyl) 1090 pyrιdιn-2-ylamιno- HCO2CH2 (5-thιazolyl) 1091 py ridin -2 -ylamino - NHCO2CH2 (4-ιsoxazolyl) 1092 pyridm-2-ylamιno- NHCO2CH,, (2-thιenyl) 1093 pyrιdιn-2-ylamιno- NHCθ2n-Bu 1094 pyπdιn-2-ylamιno- NHC0 2 ι-Bu 483 5 1095 pyrιdιn-2-ylamιno- NHC0 2 t-Bu 1095a pyrιdιn-2-ylamιno- NHCOPh 487 3 1096 pyridin- 2 -ylamino- NHC0CH 2 Ph 501 4 2-ylamino- (CH 2 ) 3 NHCOCH 2 C 6 H4-(2-CH 3 ) 2-ylamino- ( CH 2 ) 3 NHC0CH 2 -C 6 H4- (3-CH 3 ) 2-ylamino- (CH 2 ) 3 NHC0CH CeH4-(4-CH3) 2-ylamino- ( CH 2 ) 3 NHC0CH 2 CH Ph 515.4 2-ylamino- (CH 2 ) 3 NHCOCH=CHPh 513.3 2-ylamino- (CH 2 ) 3 NHC0CH 2 (2-pyrιdιnyl) 2-ylamino- (CH 2 ) 3 NHC0CH 2 (3-pyridinyl) 2-ylamino- (CH 2 ) 3 NHCOCH z (4-pyrιdιnyl) 2-ylamιno- (CH 2 ) 3 NHCOCH^ (2-thιazolyl) 2-ylamino- <CH 2 >3 NHCOCH 2 (4-thιazolyl) 2-ylamιno- (CH 2 ) 3 NHCOCH 2 (5-thιazolyl) 2-ylamino- (CH 2 ) 3 NHC0CH 2 CH 2 CH(CH3 ) 2 481.4 2-ylamino- ( CH 2 ) 3 NHCOCH^ (4-ιsoxazolyl) 2-ylamino- (CH 2 ) 3 NHCOCH 2 (2-thιenyl) 2-ylamino- (CH 2 ) 3 NHC0CH 2 (cyclohexyl) 507.3 2-ylamino- (CH 2 ) NHCO-cyclohexyl 493.4 2-ylamino- (CH 2 ) 3 NHCOn-Bu 2-ylamino- (CH 2 ) 3 NHCOt-Bu 2-ylamino- ( CH 2 ) 3 NHCONHPh 2-yl-unino- (CH 2 ) 3 NHCONHCH Ph 2-ylamino- (CH 2 ) 3 NHS0 2 Ph 2-ylamino (CH 2 ) 3 HS0 2 C6H -(2-CH ) 2-ylamino- (CH 2 ) 3 NHS0 2 CgH4- (3-CH3) 114 pyrιdιn-2-ylammo- CH 2 ) 3 NHSO ^ C 6 H 4 -(4-CH3) 114a pyrιdιn-2-ylamino- CH 2 ) 3 NHS0 2 C 6 H 3 - ( 2,6-CH 3 ) 2 114b pyrιdιn-2-ylamino- CH 2 ) 3 NHS0 2 C 6 H 2 -(2,4,6-CH3)3 565 2 115 pyridin- 2 -ylamino- CH 2 ) 3 NHS0.,( 2 -pyridyl) 116 pyrιdιn-2-ylamιno- CH 2 ) 3 NHS0_( 3 -pyridyl) 117 pyrιdιn-2-ylamino- CH 2 ) 3 NHS0 2 (4-pyndyl) 117a pyrιdιn-2-ylamιno- CH 2 ) 3 NHSθ2<2-thιenyl) 529 2 117b pyrιdιn-2-ylamιno- CH 2 ) 3 NHS0 2 -[3-(2,5- 597 1 dichloroj hienyl) 118 pyrιdιn-2-ylamιno- CH 2 ) 3 NHS0^( 2 -thiazolyl) 119 ρyπdιn-2-ylamιno- CH 2 ) 3 NHS0 2 (4-thιazolyl) 119a pyπdιn-2-ylamιno- CH 2 ) 3 NHS0 2 -(5-(4-methyl-2- 559 2 amino) hiazolyl] ι < 1120 pyrιdιn-2-ylamιno- CH 2 ) 3 HSO^ (4-ιsoxazolyl) ? 1121 pyπdιn-2-ylamιno- CH 2 ) 3 NHS0^-[4-(3,5- 5 4 2 dimethyl) isoxazolyl] 1122 py ridin- 2 -ylamino - CH 2 ) 3 NHS0^C6H 4 -(2-Br) 1123 pyr ldm- 2 -ylamino - CH 2 ) 3 HSO2C6H4- (3-Br) 1124 pyrιdιn-2-ylamιno- CH 2 ) 3 NHS0 2 C6H 4 - (4-Br) 1125 pyrιdιn-2-ylamιno- CH 2 ) 3 NHS0^C6H - (2-F) 1126 pyrιdm-2-ylaroιno- CH 2 ) 3 HSO C6H 4 - (3-F) 1127 pyrιdιn-2-ylamιno- CH 2 ) 3 HS0 ^ CgH4- (4-F) 1127a pyrιdιn-2-ylamιno- CH 2 ) 3 NHS02C 6 H 3 -(2,6-Cl 2 ) 591.3 1128 pyrιdιn-2-ylamιno- ( CH 2 ) 3 NHSO ^ l 2 -naphthyl) 573 4 1129 pyrιdιn-2-ylamino- (CH 2 ) 3 NHSO 1 -naphthyl) 573.2 1129a pyrιdιn-2-ylamino-(CH 2 ) 3 NHS0 2 C 6 H4-(4-Ph) 599.4 1129b pyrιdιn-2-ylamino- (CH 2 ) 3 NHSθ2CgH4-4-(4- pyridyl) 1129c pyrιdιn-2-ylamino-(CH 2 )3 NHS0 2 C6H4-4-(2- oxazoly1) 1129d pyridin-2-ylamino- (CH 2 >3 NHS0 2 C 6 H 4 -4-(3- pyrazolyl) 1129e pyridin-2-ylamιno- (CH 2 ) 3 NHSθ2C6H2- -Ph-2, 6- dimethyl 1129f pyrιdin-2-yl-unιno- (CH 2 )3 NHSθ2C6H2- -(3- pyridyl) -2, 6-dimethyl I *° 1129g pyrιdιn-2-yl-tmιno- (CH2) 3 NHSθ2C6H " 2-4-(2-oxa- o so I zolyl) -2, 6-dimethyl 1129h pyndin-2-ylamino- (CH 2 ) 3 HSO2C6H2-4- (3-pyra¬ zolyl) -2, 6-dimethyl 1129i pyridιn-2-ylammo- (CH 2 ) 3 NHS0 2 C6H 2 -4-Ph-2, 6- dichloro 1129 3 pyrιdin-2-ylammo- (CH 2 ) 3 NHS0 2 C6H4-4-(2-£uryl) 1129k pyridin-2-ylamino-(CH 2 )3 NHSθ2CgH2-4-(3-furyl) 11291 pyridιn-2-ylamino- (CH 2 ) 3 NHS0 2 C6H2-4-(3- pyridyl) 1129m pyridin-2-ylamino- CH 2 )3 NHSθ2CgH2- - (4- pyridyl) -2, 6-dimethyl 1129n pyridin-2-ylamino- CH 2 ) 3 NHS0 2 C 6 H2-4-(3-furyl) 2, 6-dimethyl 1129o pyridin-2-ylamino- CH 2 ) 3 HS0 C6H -4- (2-£uryl) 2, 6-dichloro 1130 pyridin 2-ylamino- CH 2 )3 NHS0 2 CH=CH-Ph 1131 pyridin 2-ylamino- CH 2 ) 3 NHSO ^ CH^Ph 537.4 1132 pyridin •2-ylamino- CH 2 )3 NHS0 2 -CH^CH-:CH-Ph 1133 pyridin 2-ylamino- CH 2 )3 NHS0 2 -n-Bu 503.3 1134 pyridin -2-ylamino- CH 2 ) 3 NHS0 -i-Bu 1135 pyridin •2-ylamino- CH 2 ) 3 NHS0 2 -t-Bu 1136 pyridin -2-ylamino- CH 2 )3 NHS0 2 NHPh pyridin -2-ylamino- NHSO / NHC6H 4 - (2-CH3) t- J > 1137 CH 2 )3 ? 1138 pyridin -2-ylamino- CH 2 ) 3 HSO2NHC6H4- (3-CH3 ) 1139 pyridin -2-ylamino- CH 2 ) 3 NHS0 2 NHC6H 4 - ( -CH3) 1139a pyridin-2-ylamino- CH 2 )3 NHSO2NHC6C3- (2, 6-Me 2 ) 1139b pyridin -2-ylamino- CH 2 )3 NHS02NHC6C 2 -(2,4, 6- 580.3 Me 3 ) 1140 pyridin-2-ylamino- CH 2 ) 3 NHS0^NlU2-pyridyl) 1141 ρyridin-2-ylamino- CH 2 ) 3 NHS0 2 NH(3-pyridyl) 1142 pyridin-2-ylamino- CH 2 ) 3 NHS0^NH(4-pyridyl) 1143 pyridin-2-ylamino- CH 2 ) 3 NHS0 2 NH(2-thiazolyl) 1144 pyridιn-2-ylamino- CH 2 )3 NHSO_,NH- (4-thιazolyl) 1145 pyridin-2-ylamino- CH 2 ) 3 NHS0^NH(4-ιsoxazolyl) 1146 pyridin-2-ylamino- CH 2 )3 NHSO. ; -[4-(3,5- dimethyl ) isoxazolyl ] 1147 pyridin- 2-ylamino- CH 2 ) 3 NHSO2NHC6H4- (2-Br) 1148 pyridin- 2-ylamino- CH 2 ) 3 NHSO _, HC6H4 - ( 3 -Br ) 1149 pyridin- 2-ylamino- CH 2 )3 NHS0 NHC6H4- (4-Br) 1150 pyridin- 2-ylamino- CH 2 )3 NHSO NHC 6 H 4 -(3-F) 1151 pyridin 2-ylamino- CH 2 ) 3 NHSO..NHC6H4- (4-F) 1152 pyridin- 2-ylaroino- CH 2 )3 NHS0 2 NH(2-naphthy1) 1153 pyridin- 2-ylamino- CH 2 )3 NHS0 2 NH)1-naphthyl) 1153a pyridin- 2-ylamino- CH 2 ) 3 NHSO2NHC6H4- (4-Ph) 1153b pyridin 2-ylamino- CH 2 )3 NHS0 2 NHC6H2- (4-Ph-2, 6- I NJ dimethyl) 1153C pyridin-2-ylamino- CH 2 ) 3 NHS0 2 NHC6H - (4-Ph-2, 6- dichloro) 1154 pyridin-2-ylamino- CH 2 )3 NHSθ2NHCH=CH-Ph 1155 pyridin-2-ylamino- CH 2 ) 3 NHS0 2 NHCH z Ph 552.4 1156 pyridιn-2-ylamino- CH 2 ) 3 NHS0 NHCH 2 CH=CH-Ph 1156a pyridin-2-ylamino- CH 2 ) 3 NHS0 2 NH-cyclohexyl 544.4 1157 pyridin-2-ylamino- CH 2 )3 NHSO_NH-n-Bu 1158 pyridin-2-ylamino- CH 2 ) 3 NHSO^NH-i-Bu 518.4 1159 pyridin-2-ylamino- CH 2 ) 3 NHSO^NH-t-Bu 1160 tetrahydropyrimidin- NHCOOCH 2 Ph 1161 tetrahydropyrimidin- NHCθ2CH C6H -(2-CH 3 ) 1162 tetrahydropyrimidin- NHCO2CH2C6H4 - ( 3 -CH3 ) 1163 tetrahydropyrimidin- NHCθ2CH z C6H 4 -(4-CH 3 ) 1164 tetrahydropyrimidin- NHCO2CH,, (2-pyrιdinyl) 1165 tetrahydropyrimidin- NHC0 CH ( 3 -pyridinyl ) 1166 tetrahydropyrimidin- NHCO2CH.. (4-pyrιdιnyl) 1167 tetrahydropyrimidin- NHCO2CH.. (2-thiazolyl) 1168 tetrahydropyrimidin- NHCO2CH2 (4-thiazolyl) 1169 tetrahydropyrimidin- NHCθ2CH i > (5-thiazolyl) 1170 tetrahydropyrimidin- NHCO2CH2 (4-ιsoxazolyl) 117 1 tetrahydropyrimidin- NHCO2CH2 (2-thιenyl) 1172 tetrahydropyrimidin- NHC02n-Bu 1173 tetrahydropyrimidin- NHCO21-BU 1174 tetrahydropyrimidin- NHCθ2t-Bu 1175 tetrahydropyrimidin- NHS0 2 Ph 1176 tetrahydropyrimidin- NHS0 2 C6H 4 -(2-CH 3 ) 1177 tetrahydropyrimidin- NHS0 2 C 6 H -(3-CH3) 1178 tetrahydropyrimidin- HSO2C6H4- (4-CH3) 1178a tetrahydropyrimidin- NHSθ2C6H3-(2,6-Me 2 ) 1178b tetrahydropyrimidin- NHS0 2 C 6 H2-(2,4,6-Me3) 570.5 1179 tetrahydropyrimidin-2-ylamino- (CH 2 ) 3 NHS0^(2-pyridyl) 1180 tetrahydropyrimidin-2-ylamino- CH 2 )3 H NHS0 2 (3-pyrιdyl) 1181 tetrahydropyrimidin-2-ylamino- CH 2 ) 3 H NHS0_(4-pyrιdyl) 1181a tetrahydropyrimidin-2-ylamino- CH 2 ) 3 H NHS0 2 (2-thienyl) 1181b tetrahydropyriraidin-2-ylamino- CH 2 ) 3 H NHS0 2 -(3- (2,5- dichloro) hienyl] 1182 tetrahydropyrimid n-2-ylamino- CH 2 ) 3 H NHS0..(2-thιazolyl) 1183 tetrahydropyrimid n-2-ylamιno- CH 2 ) 3 H NHS0 2 (4-thiazolyl) 1184 tetrahydropyrimid n-2-ylamino- CH 2 ) 3 H NHSO ^ , (4-ιsoxazolyl) 1185 tetrahydropyrimid n-2-ylamino- CH 2 ) 3 H NHS0^-[4-(3,5- dimethyl) isoxazolyl] 1186 tetrahydropyrimidin-2-ylamino- CH 2 ) 3 H NHS0 2 C6H4-(2-Br) 1 ^ 1187 tetrahydropyrimιdιn-2-ylamino- CH 2 ) 3 H NHS0 Z C 6 H4- (3-Br) l I 1188 tetrahydropyrimidin-2-ylamino- CH 2 ) 3 H NHS0 2 C 6 H4-(2-F) 1189 tetrahydropyrimidin-2-ylamino- CH 2 ) 3 H NHS0 2 C6H4-(3-F) 1190 tetrahydropyrimidin-2-ylamino- CH 2 ) 3 H NHS0 2 C 6 H4-(4-F) 1190a tetrahydropyrimidin-2-ylamino- CH 2 ) 3 H NHS0 2 C 6 H 3 -(2,6-Cl 2 ) 1191 tetrahydropyrimidin-2-yla ino- CH 2 ) 3 H NHS0 2 (2-naphthyl) 1192 tetrahydropyrimidin-2-ylamino- CH 2 ) 3 H NHS0 2 (1-naphthyl) 1192a tetrahydropyrimidin-2-ylamino- CH 2 ) 3 H NHSθ2C6H4 - ( 4 - Ph ) 1192b tetrahydropyrimidin-2 ylamino- CH 2 ) 3 H HS0 2 C6H4 - - ( 4 - pyr idy l ) 1192c tetrahydropyrimidin-2-ylamino- (CH2) 3 H H H NHS0 2 C 6 H 4 -4-(2- oxazolyl ) 1192d tetrahydropyrimidin-2-ylamino- (CH2) 3 H H H NHS0 2 C6H4-4-(3- pyrazolyl) 1192e tetrahydropyrimidin-2-ylamino- (CH 2 ) 3 H H H NHSθ2C 6 H 2 -4-Ph-2,6- dimethyl 1192f tetrahydropyrimidin-2-ylaι_ino-(CH2) 3 H H H NHS0 C 6 H -4-(3- pyridyl) -2, 6-dimethyl 1192g tetrahydropyrimidin-2-ylamino- (CH2) 3 H H H NHS0 2 CgH 2 -4- (2-oxa- zolyl ) -2, 6-dimethyl 1192h tetrahydropyrimidin-2-ylamino- (CH2) 3 H H H NHS02CgH2-4- (3-pyra- zolyl) -2, 6-dimethyl 1192i tetrahydropyrimidin-2-ylamino- (CH 2 ) 3 H H H NHS0 2 CsH2-4-Ph-2, 6- 1 t dichloro T 1192j tetrahydropyrimidin-2-ylamino- (CH 2 ) 3 H NHSO2C6H4-4- (2-fury1) 1192k tetrahydropyrimidin-2-ylamino- (CH 2 ) 3 H NHS0 2 C6H2-4- (3-£uryl) 11921 tetrahydropyrimidin-2-ylamino-(CH ) 3 H NHSθ 2 C6h " 2-4-<3- pyridyl) 1192m tetrahydropyrimidin-2-ylamino- (CH 2 ) 3 H H H NHS02C6H2-4-(4- pyridyl) -2, 6-dimethyl 1192n tetrahydropyrimidin-2-ylamino- (CH 2 ) 3 H H H NHSθ2C6H2-4-(3-£uryl) - 2, 6-dimethyl 1192o tetrahydropyrimidin-2-ylamino- (CH2)3 NHS0 2 C6H 2 -4-(2-£uryl) 2, 6-dιchloro NHS0 2 CH=CHPh NHS0 2 CH Ph NHSO_CH 2 CH=CHPh NHSO_-n-Bu NHSO^-i-Bu NHSO ^ NHPh NHS0 ^ HC6H 4 - (2-CH3) NHSO NHC6H4- (3-CH3) NHSO2 HC6H4- (4-CH 3 ) NHSO2 HC6C3- (2, 6-Me 2 ) NHS02NHC6C2-(2,4, 6- NHSθ 2 [4- (3,5- dimethyl) isoxazolyl] NHS0 NH(2-naphthyl) NHSθ2NH(l-naphthyl) HSθ2NHC6H4-(4- h) NHSθ2NHC6H2-(4- h-2, 6- dimethyl) 1197n tetrahydropyrimidin-2-ylamino- (CH 2 ) 3 H NHSO2NHC6H2- (4-Ph-2, 6- dichloro) 1197p tetrahydropyrimidin-2-ylamino-(CH 2 ) 3 H NHS0 NHCH z Ph 1198 imidazolin-2-ylamino- (CH 2 ) 3 H NHCOOCH Ph 508.6 1199 imidazolin-2-ylamino- (CH 2 )3 H NHC0 2 CH z C6H4-(2-CH 3 ) 1200 imidazolin-2-ylaroino-(CH 2 )3 H NHC0 CH 2 C 6 H4-(3-CH3) 1201 imidazolin-2-ylamino- (CH 2 )3 H NHC0 2 CH 6H4- (4-CH3) 1202 imidazolin-2-ylamino-(CH )3 H NHC0 2 CH 2 (2-pyridinyl) 1203 imidazolin-2-ylamino-(CH 2 )3 H NHC0 2 CH 2 (3-pyridinyl) 1204 imidazolin-2-ylamino-(CH 2 ) 3 H NHC0 2 CH 2 (4-pyridinyl) 1205 imidazolin-2-ylamino- (CH 2 ) 3 H NHCO2CH (2-thiazolyl) 1206 imidazolin-2-ylamino- (CH2) 3 H NHCO2CH2 (4-thiazolyl) 1207 imidazolin-2 -ylamino- ( CH 2 ) 3 H NHCO2CH2 (5-thiazolyl) 1208 imidazolin-2-ylamino- ( CH ) 3 H NHCO2CH2 (4-isoxazolyl) cs 1209 imidazolin-2-ylamino- ( CH 2 ) 3 H NHCO2 H2 (2-thienyl) ? 1210 imidazolin-2-ylamino- ( CH 2 ) 3 H NHCθ2n-Bu 1211 imidazolin-2-ylamino- ( CH 2 ) 3 H NHCθ2i-Bu 1212 imidazolin-2-ylamino- ( CH 2 ) 3 H NHCθ2t-Bu 1213 imidazolin-2-ylamino- ( CH 2 ) 3 H NHS0 2 Ph 514.3 1214 imidazolin-2-ylamino- ( CH 2 ) 3 H NHS0 2 C 6 H4-(2-CH 3 ) 1215 imidazolin-2-ylamino- (CH 2 ) 3 H NHSO 2 C6H4-O-CH3) 1216 imidazolin-2-ylamino- <CH 2 )3 H NHS0 2 C6H -(4-CH3) 1216a imidazolin-2-ylamino- (CH 2 ) 3 H NHS0 2 C 6 H 3 -(2,6-Me 2 ) 1216b imidazolin-2-ylamino- (CH 2 ) 3 H NHSθ2C 6 H2-(2,4, 6-Mβ3) 556.4 1217 ιmιdazolιn-2-ylamino- (CH 2 ) 3 NHSO^( 2 -pyridyl) 1218 imidazolιn-2-ylamino- NHS0 2 ( 3 -pyridyl) 1219 imidazolin-2-ylamino- NHS0 2 (4-pyrιdyl) 1219a imιdazolin-2-ylamιno- NHS0 2 (2-thιenyl) 1219b imidazolin-2-ylamino- NHS0 2 -[3-(2, 5- dichloro) hienyl ) 1220 ιmιdazolin-2-ylamino- NHSO_(2-thιazolyl) 1220a imidazolin-2-ylamino- NHSO2 - [ - ( 4 -methy 1 -2 - amino) thiazolyl ] 1221 imidazolin-2-ylamιno- NHS0 2 (4-ιsoxazolyl) 1222 imidazolιn-2-ylamιno- NHS0 2 -[4-(3, 5- dimethyl) isoxazol l] i 1 22 3 imidazolin-2-ylamιno- NHS0 C 6 H4-(2-Br) i 1224 imidazolin-2-ylamιno- NHS0 2 C6H4-(3-Br) 1225 imidazolin-2-ylamino- NHS0 2 C6H -(2-F) 1226 imidazolin-2-ylamino- NHSO2C6H4- (3-F) 1227 imidazolin-2-ylamino- NHS0 2 C6H 4 - (4-F) 1227a imidazolin-2-ylamino- NHS0 2 C 6 H 3 -(2,6-Cl 2 ) 1228 ιmidazolιn-2-ylamιno- NHSO ^; (2-naphthyl) 1229 imidazolin-2-ylamino- NHS0 2 (1 -naphthyl) 1229a imidazolin-2-ylamino- NHS0 2 C 6 H 4 -(4-Ph) 1229b imidazolin-2-ylamino- (CH 2 )3 H H HSθ2C6H4-4-(4- pyridyl) 1229c imidazolin-2-ylamino-(CH 2 )3 H H NHSθ2C6H4-4-(2- oxazolyl) 1229d imidazolin-2-ylamino-(CH )3 H H NHS0 2 C 6 H4-4-(3- pyrazolyl) 1229e imidazolin-2-ylamino-(CH )3 H H NHSθ2C6H2-4-Ph-2, 6- di ethyl 1229£ imidazolin-2-ylamino-(CH2 ) 3 H H NHSO2C6H2- -O- pyridyl) -2, 6-dimethyl - 4 - ( 2 -oxa - 1229g imidazolin-2-ylamino- ( CH2 ) 3 H H NHSθ2CeH 2 zolyl) -2, 6-dimethyl 1229h imidazolin-2-ylamino-(CH 2 )3 H H NHS0 2 C6H 2 -4- (3-pyra- I to zolyl) -2, 6-dimethyl oo l 2 29i imidazolin-2-ylamιno-(CH )3 H H NHSO2C6H2 4-Ph-2, 6- dichloro NHSO2C6H4-4- (2-f uryl ) 1229 j imidazolin-2-ylamino- ( CH2 ) 3 1229k imidazolin-2-ylamino- (CH2) 3 NHS0 2 C6H 2 -4- (3-£uryl) N 12291 imidazolin-2-ylamino- ( CH 2 ) 3 HS0 2 C6H2-4-(3- pyridyl) 4- 1229m imidazolin-2-ylamino- ( CH2 ) 3 H H NHSθ2C6H2-4-( pyridyl) -2, 6-dimethyl l 2 29n imidazolin-- ylamino- (CH ) 3 NHS0 2 C_H2-4-(3-£uryl) ■ 2, 6-dimethyl l 2 29o imidazolin-2-ylamino- (CH 2 ) 3 NHS0 2 C6H 2 -4-(2-£uryl) 2, 6-dichloro 1230 l i Ldazoli 2-ylamino (CH 2 )3 H NHSO H=CHPh 1231 imidazolin 2-ylamino (CH 2 )3 H NHSO^CH Ph 1232 imidazolin 2-ylamino (CH 2 )3 H NHS0 2 CH2CH-:CHPh 1233 imidazolin 2-ylamino (CH 2 )3 H NHS0 , .-n-Bu 1234 imidazolin 2-ylamino (CH 2 ) 3 H NHS0 2 -i-Bu 1234a imidazolin 2-ylamino (CH 2 )3 H NHS0 NHPh 1234b imidazolin 2-ylamino (CH 2 )3 H NHSθ NHC6H4-(2-CH3) 1234c imidazolin 2-ylamino (CH 2 )3 H NHS0 2 NHC 6 H4-(3-CH3) 1234d imidazolm- 2-ylamino (CH 2 )3 H HSO2NHC6H - (4-CH 3 ) NJ 1234e imidazolin- 2-ylamino (CH 2 )3 H NHS0 2 NHC6C 3 - (2, 6-Me 2 ) SO T 1234£ imidazolin 2-ylamino (CH 2 )3 H NHSθ 2 NHC6C2-(2,4, 6- Me 3 ) 1234g imidazolin-2-ylamino- (CH2) 3 H NHS0 2 NH (2-naphthy1) 1234h imidazolin-2-ylamino- (CH2) 3 H NHSθ 2 NH) 1-naphthyl) 1234j imidazolin-2-ylamino- (CH 2 ) 3 H NHSθ2 HC6H4-(4- h) 1234m imidazolin-2-ylamino- (CH 2 ) 3 H NHSθ2NHCgH2-(4-Ph-2, 6- dimethyl) 1234n imidazolin-2-ylamino- (CH 2 ) 3 NHSO2NHC6H2- (4-Ph-2, 6- d ichloro ) NHS0 2 NHCH_Ph -2-ylamino- ( H2) 3 NHSOaPh -2-ylamino-(CH 2 )3 NHS0 CgH4-(2-CH3) -2-ylamino-(CH 2 ) 3 NHSO C 6 H4- O-CH3) -2-ylamino-(CH )3 NHSO 6H - (4-CH 3 ) -2-ylamino-(CH 2 )3 NHS0 2 C 6 H3-(2,6-Me 2 ) -2-ylamino-(CH 2 )3 NHS02C 6 H2-(2,4, 6-MΘ3] -2-ylamino-(CH 2 ) 3 NHS0 2 (2-pyridyl) -2-ylaroino- (CH ) 3 NHS0^(3-pyridyl) -2-ylamino- (CH 2 )3 NHSO_,(4-pyridyl) -2-ylamino- (CH2)3 NHSθ2(2-thienyl) -2-ylamino- (CH2) 3 NHS0 2 -[3-<2,5- dichloro) thienyl] -2-ylamino-(CH 2 )3 NHSO ^ , (2-thiazolyl) -2-ylamino-(CH 2 ) 3 NHSO2- [5-(4-methy1-2- amino) thiazolyl] -2-ylamino- (CH 2 ) 3 NHS0 2 (4-isoxazolyl) -2-ylamino- (CH 2 ) 3 NHS0 2 -(4-(3, 5- dimethy1) isoxazolyl] 1245 benzimidazo -2-ylamino- (CH 2 )3 NHS0 2 C6H4-(2-Br) 1246 benzimidazo -2-ylamino- (CH2)3 NHS0 2 C 6 H4- (3-Br) 1247 benzimidazo -2-ylamino-(CH 2 ) 3 NHSO^Cgri^- (2-F) 1248 benzimidazol-2-ylamino- NHSO2C6H4- (3-F) 1249 benzimidazol-2-ylaraino- NHSO C 6 H4-(4-F) 1249a benzimidazol-2-ylamino- NHS0 2 C 6 H3-(2,6-Cl 2 ) 1249b benzimidazol-2-yl.unino- NHS0,(2-naphthyl) 1249c benzimidazol-2-ylamino- NHS0 2 (1-naphthyl) 1249d benzimidazol-2-ylamino- NHS0 2 C 6 H -(4-Ph) 1249e benzimidazol-2-ylainino- NHS0 2 C 6 H2-(4-Ph-2,6- di ethyl) 1249£ benzimidazol-2-ylamino- CH 2 ) 3 NHS0 2 C 6 H2-(4-Ph-2,6- dichloro) benzimidazol -2-ylamino- CH 2 >3 H NHSθ 2 CH=CHPh benzimidazol -2-ylamino- CH 2 ) 3 H NHS0 2 CH 2 Ph benziimidazol -2-ylamino- CH 2 ) 3 H NHSθ 2 CH 2 CH=CHPh benzimidazol -2-ylamino- CH 2 ) 3 H NHS0 2 -n-Bu benzim dazol -2-ylamino- CH 2 ) 3 H NHS0 2 -i-Bu benziimidazol -2-ylamino- CH 2 ) 3 H NHS0 2 NHPh benzimidazol -2-ylamino- CH 2 ) 3 H NHSO 2 NHC6H4- (2-CH3) benzimidazol -2-ylamino- CH 2 ) 3 H NHS0 2 NHC6H -(3-CH3) benzimidazol -2-ylamino- CH 2 ) 3 H NHSO2NHC6H4- (4-CH 3 ) benzimidazol -2-ylamino- CH 2 ) 3 H NHSO2NHC6C3- {2, 6-Me2) benzimidazol -2-ylamino- CH 2 ) 3 H NHS0 2 NHC 6 C 2 -(2,4, 6- Me 3 ) 1249u benzimidazol-2-ylamino- (CH 2 ) 3 NHSO^NH ( 2 -naphthyl ) NHS0 2 NH) 1-naphthy1) 1249v benzimidazol-2-ylamino-(CH2 ) 3 NHSθ2NHC6H4-(4-Ph) 1249w benzimidazol-2-ylamino-(CH 2 )3 NHSO2 HC6H2- (4-Ph-2, 6- 1249x benzimidazol-2-ylamino-(CH 2 ) 3 dimethyl) NHSO2NHC6H2- (4-Ph-2, 6- 1249y benzimidazol-2-ylamino-(CH )3 dichloro) NHSθ 2 NHCH 2 Ph 1249z benzimidazol-2-ylamino- (CH 2 ) 3 HC02CH2Ph 1250 benzimidazol-2-ylamino-(CH 2 ) 3 NHCθ2n-Bu 1251 benzimidazol-2-ylamino- ( CH 2 ) 3 NHC0 2 i-Bu 1252 benzimidazol-2-ylamino- ( CH 2 ) 3 NHSθ2Ph 1253 2-aminopyridin-6-yl- (CH 2 ) 3 NHS0 2 C 6 H -(2-CH3) 1254 2-aminopyridin-6-yl- (CH ) 3 NHS0 2 C6H4- (3-CH3) 1255 2-aminopyridin-6-yl- (CH 2 ) 3 NHS0 z C6H4-(4-CH3> NJ 1256 2-aminopyridin-6-yl- (CH 2 ) 3 co t NHS0 2 C6H3-(2,6-Me 2 ) 1 1256a 2-aroinopyridin-6-yl- (CH 2 ) 3 NHSθ 2 C6H2-(2, 4,6-Me 3 ) 1256b 2-aminopyridin-6-yl- (CH 2 ) 3 NHS0 2 (2-pyridyl) 1257 2-aminopyridin-6-yl- (CH 2 )3 NHS0 2 (3-pyridyl) 1258 2-aminopyridin-6-yl-(CH 2 )3 NHS0 2 (4-pyridyl) 1259 2-aminopyridin-6-yl- (CH 2 ) 3 NHS0 i ,(2-thiazolyl) 1260 2-aminopyridin-6-yl-(CH 2 >3 NHS0 (4-isoxazolyl) 1261 2-aminopyridin-6-yl- ( CH 2 ) 3 NHΞ0^-[4- (3,5- 1262 2-aminopyridin-6-yl- (CH 2 ) 3 dimet hy l ) isoxazoly l ] 1263 2-aminopyridιn-6-yl- CH 2 >3 NHSO 6 H - (2-Br) 1264 2-aminopyridin-6-yl- CH 2 ) 3 NHSO C6H -(3-Br) 1265 2-aminopyridin-6-yl- CH 2 ) 3 NHSO ^ C6H4-(2-F) 1266 2-aminopyridin-6-yl- CH 2 ) 3 NHSO_C 6 H4~(3-F) 1267 2-aminopyridin-6-yl- CH 2 )3 NHSO ^ C 6 H4-(4-F) 1267a 2-aminopyridin-6-yl- CH 2 ) 3 NHS0 2 C 6 H 3 -(2,6-Cl 2 ) 1267b 2-aminopyridin-6-yl- CH 2 )3 NHS0 2 (2-naphthyl) 1267c 2-aminopyridin-6-yl- CH 2 ) 3 NHSθ2(l-naphthyl) 1267d 2-aminopyridin-6-yl- CH 2 ) 3 NHSθ2C6H4-(4-Ph) 1267e 2-aminopyridin-6-yl- CH 2 ) 3 NHS0 2 C 6 H 2 -(4-Ph-2, 6- dimethyl) 1267f 2-aminopyridin-6-yl- CH 2 >3 HS02C6H2-(4-Ph-2, 6- dichloro) I J 1267g 2-aminopyridιn-6-yl- CH 2 )3 NHS0 H=CHPh ι 1267h 2-aminopyridin-6-yl- CH 2 ) 3 NHS0 2 CH 2 Ph 1267j 2-aminopyridin-6-yl- CH 2 ) 3 NHSO ιi CH 2 CH=:CHPh 1267k 2-aminoρyridin-6-yl- CH 2 )3 NHS0 -n-Bu 1267m 2-aminopyridin-6-yl- CH 2 )3 NHSO^-i-Bu 1267n 2-aminoρyridin-6-yl- CH 2 ) 3 NHS0 2 NHPh 1267p 2-aminopyridιn-6-yl- CH 2 ) 3 NHS0 2 NHCeH4 - ( 2 -CH3 ) 1267q 2-aminopyridin-6-yl- CH 2 ) 3 NHSO2NHC6H4- (3-CH3) 1267r 2-aminoρyridin-6-yl- CH 2 )3 NHSO^NHC 6 H4- (4-CH3) 1267s 2-aminopyridin-6-yl- CH 2 ) 3 NHS0 2 NHC6C 3 - ( 2 , 6-Me ) NHSθ2NHC 6 C 2 -(2,4, 6- 1267t 2-aminopyridin-6-yl- (CH 2 ) 3 Me 3 ) NHSO 2 NH(2-naphthy1 ) 1267u 2-aminopyridin-6-yl- (CH 2 ) 3 NHSO NHH-naphthyl) 1267v 2-aminopyridin-6-yl- (CH ) 3 NHSθ2NHC 6 H4-(4-Ph) 1267w 2-aminopyridin-6-yl-(CH ) 3 NHSO2NHC6H2- (4-Ph-2, 6- 1267x 2-aminopyridin-6-yl-(CH 2 >3 dimethyl) NHSO2 HC6H2- (4-Ph-2, 6- 1267y 2-aminopyridin-6-yl-(CH 2 )3 dichloro) NHC0 2 CH 2 Ph 1268 2-aminopyridin-6-yl- (CH ) 3 NHCθ2n-Bu 1269 2-aminopyridin-6-yl- ( CH 2 ) 3 NHC0 2 i-Bu 1270 2-aminopyridin-6-yl- ( CH2>3 NHS0 2 Ph 1271 2-iminoazepin-7-yl- (CH 2 ) 3 NHS0 2 Ph ( 1274 imidazol-4-ylamino-(CH 2 ) 3 to NHSO2 (4-isoxazolyl) " 1279 2-iminoazepin-7-yl-(CH 2 ) 3 NHS0 2 (4-isoxazolyl) 1282 imidazol-4-ylamino- ( CH 2 ) 3 NHS0 2 -(4-(3,5- 1287 2-iminoazepin-7-yl- ( CH 2 ) 3 dimethyl) isoxazolyl] NHS0 2 -[4-(3,5- 1290 imidazol-4-ylaroino- ( CH 2 >3 dimethyl ) isoxazolyl ] 1295 imidazol-2-ylamino-(CH 2 ) 3 H 1296 pyridin-2-ylamino- ( CH2 ) 3 H 1297 imidazolin-2-ylamino-(CH 2 ) 3 H 1298 tetrahydropyrιmιdιn-2-ylamιno- ( CH2 ) 3 H H 3-pyrιdιnyl H 1299 benzimidazol-2-ylamino-(CH 2 ) 3 H H 3-pyrιdιnyl H 1300 2-amιnopyrιdιn-6-yl- (CH 2 ) 3 H H 3-pyrιdιnyl H 1301 2-ιmιnoazepιn-7-yl- (CH 2 )3 H H 3-pyrιdιnyl H 1304 ιmιdazol-4-ylamιno- (CH 2 )3 H H 3-pyrιdιnyl H 1309 imidazol-2-ylamino- (CH 2 )3 H H (3, 4-methylene- H dioxy)phenyl 1310 pyrιdιn-2-ylamιno- (CH )3 H H (3, 4-methylene- H dioxy)phenyl 1311 ιmιdazolιn-2-ylamino- (CH 2 )3 H H (3,4-methylene- H dioxy)phenyl 1312 tetrahydropyrιmιdιn-2-ylamιno-(CH ) 3 H H (3, 4-methylene- H dιoxy)phenyl t 1313 benzimidazol -2-ylamιno- ( CH ) 3 t H (3, 4-methylene- H dioxy(phenyl 1314 2-amιnopyπdιn-6-yl- (CH ) 3 H (3,4-methylene- H dioxy)phenyl 1315 2-ιmιnoazepm-7-yl- (CH 2 )3 H (3, 4-methylene- H dιoxy)ρhenyl 1318 ιmιdazol-4-ylamino-(CH ) 3 H (3, 4-methylene- H dioxy)phenyl 1323 ιmιdazol-2-ylamιno- (CH 2 )3 H H 3-pyridinyl NHSO a Ph 1324 pyrιdιn-2-ylamιno-(CH 2 )3 H H 3-pyrιdιnyl NHSOaPh 1325 imidazol-2-ylamino- (CH 2 ) 3 NHSO a Ph 1326 pyridin-2-ylamino- (CH )3 - NHSOaPh 1326a pyridin-2-ylamino-(CH 2 ) 2 CH(Ph ) NHS0 2 C6H2-(2,4,6-CH 3 )3 641.4 1326b pyridin-2-ylamino-(CH ) 2 CH{CH3) NHS0 2 C 6 H2-(2,4,6-CH3)3 579.4 1326c pyridin-2-ylaroino-CH 2 CH(CH3 ) CH 2 NHSθ2C 6 H 2 -(2,4,6-CH 3 )3 579.5 1326d pyridin-2-ylamino- (CH 2 )3 NHS0 2 C6H2-(2,4, 6-CH 3 )3 1326e pyridin-2-ylamino- (CH 2 ) 3 NHS0 C6H2-( , 4, 6-^ )3 1326f pyridin-2-ylamino-(CH 2 ) 3 NHS0 2 C 6 H2-(2,4,6-CH 3 )3 641.4 669.5 1326g pyridin-2-ylamino-(CH2) 3 NHS0 2 C 6 H2-(2,4,6-CH 3 )3 NHS0 C6H 2 -(2,4, 6-0^3)3 579.4 1326h pyridin-2-ylamino- ( CH 2 ) 3 1326i imidazol-2-ylamino- (CH ) 2 NHS0 2 C 6 H2-(2,4,6-CH 3 )3 568.3 NJ 1327 imidazol-2-ylamino- ( CH 2 ) 2 NHS0 2 Ph t CΛ I 1327a imidazol-2-ylamino- ( CH 2 ) 2 NHC0 2 CH2Ph 1327b imidazol-2-ylamino-carbonyl-(CH 2 ) 2 NHS0 2 C 6 H2-(2,4,6-CH3)3 568.5 1328 pyridin-2-ylamino- (CH 2 ) 2 NHS0 2 Ph 1328a pyridin-2-ylamino- (CH ) 2 NHC0 2 CH2Ph 1328b pyridin-2-ylamino-carbonyl- (CH 2 ) 2 NHS0 2 C6H2-(2,4, 6-CH3>3 1329 imidazolin-2-ylamino- (CH ) NHSOaPh NHC0 2 CH 2 Ph 494.3 1329a imidazolin-2-ylamino- ( CH2 ) 2 1330 tetrahydropyrimidin-2-ylamino-(CH2)2 NHS0 2 Ph 1330a tetrahydropyrimidin-2-ylamino-(CH 2 ) 2 NHC0 2 CH2 Ph 1331 benzimidazol-2-ylamino- ( CH 2 ) 2 H NHSO z Ph 1331a benzimidazol-2-ylamino- ( CH 2 ) 2 H NHC0 2 CH 2 Ph 1331b benzimidazol-2-ylamino-carbonyl- H NHSO2C6H2- (2,4,6-CH 3 ) 3 ( CH 2 ) 2 1332 2-aminopyridin-6-yl-(CH 2 ) 2 H NHS0 2 Ph 1332a 2-aminopyridin-6-yl-(CH 2 ) 2 H NHC0 2 CH 2 Ph 1333 2-iminoazepin-7-yl- ( CH 2 ) 2 H NHS0 2 Ph 1333a 2-iminoazepin-7-yl- (CH 2 ) 2 H NHC0 2 CH2Ph 1336 imidazol- -ylamino- (CH 2 )2 H NHS0 Ph 1336a imidazol-4-ylamino-(CH 2 ) 2 H NHC0 2 CH2Ph 1341 imidazol-2-ylamino-(CH 2 )4 H NHSOaPh 1341a imidazol-2-ylamino- (CH 2 ) H NHC0 2 CH2Ph 1342 pyridin-2-ylamino- (CH 2 ) H NHS0 2 Ph to J 1342a pyridin-2-ylamino- (CH2) H NHC0 2 CH2Ph I 1343 imidazolin-2-ylamino- (CH2)4 H NHS0 2 Ph 1343a imidazolin-2-ylamino- (CH 2 )4 H NHC0 2 CH2Ph 522 . 3 1344 tetrahydropyrimidin-2-ylamino-(CH 2 ) 4 H NHSθ 2 Ph 1344a tetrahydroρyrimidin-2-ylamino-(CH 2 ) 4 H NHC0 2 CH2Ph 1345 benzimidazol-2-ylamino- (CH ) 4 H NHS0 2 Ph 1345a benzimidazol-2-ylamino- (CH 2 ) H NHC0 CH2Ph 1346 2-aminopyridin-6-yl-(CH 2 ) H NHS0 2 Ph 1346a 2-aminopyridin-6-yl-(CH )4 H NHC0 2 CH2Ph 1347 2-iminoazepin-7-yl- (CH 2 )4 H NHS0 2 Ph 2-iminoazepin-7-yl- (CH 2 )4 NHC0 2 CH2Ph imidazol-4-y lamino- (CH 2 ) 4 NHSOaPh imidazol -4 -ylamino- (CH 2 )4 NHCO^CH^Ph imidazol -2 -ylaraino-CH 2 {o-C^H^ ) -CH 2 NHS0 2 -(l-naphthyl) imidazol-2-ylamino-CH 2 (o-C6H4) -CH 2 NHC0 CH2 h imidazol-2-ylaι_ino-CH 2 (0-C6H4) -CH 2 NHS0 2 CgC2-(2, 4, 6-Me3) pyridin-2-ylamino-CH 2 (o-C6H4) -CH NHSO - (1-naphthyl) pyridin-2-yl-UD.ino-CH 2 (o-C6H4) -CH 2 NHC0^CH 2 Ph pyridin-2-yl-unino-CH 2 (0-C6H4 ) -CH 2 HS0 C6C2~(2, 4, 6-MΘ3) imidazolin-2-ylamino-CH2 (0-C6H4 ) -CH2 H NHS0 2 - (1-naphthyl) imidazolin-2-ylamino-CH2 ( 0-C6H4 ) -CH 2 H NHC0^CH2P imidazolin-2-ylamino-CH 2 <o-CgH ) -CH 2 H NHS0 2 C6C2-(2, 4,6-Me 3 ) imidazolin-2-ylamino- (0-C6H4) -CH2 H NHS0 2 -(l-naphthyl) imidazolin-2-ylamino- (0-C6H4) -CH2 H NHCθ 2 CH2Ph imidazolin-2-y lamino- (0-C6H4) -CH2 H NHS0 2 C 6 C2-(2, 4, 6-Me 3 ) Table 2 Ex . 2002 ρyridin-2-ylamino-(CH2)3 NHC00CH 2 Ph 2003 imidazolin-2-yl amino-(CH2>3 NHC0 2 CH 2 C6H4- (2-CH3) 2004 tetrahydropyrimidιn-2-ylamino- (CH 2 )3 NHC0 2 CH 2 C6H4- (3-CH3 ) 2005 benzimidazol-2-ylamino-(CH 2 ) 3 NHCO2CH 2 C6H4- ( -CH3) 2006 2-aminopyridιn-6-yl-(CH2) 3 NHCO2CH2 (2-pyπdιnyl) 2007 2-iminoazepin-7-yl-(CH 2 )3 NHC0 2 CH 2 (3-pyridinyl) 2010 imidazol-4-ylamino-(CH ) 3 NHCθ2CH 2 (2-thιazolyl) 2015 ιmidazol-2-ylamino-(CH 2 ) 3 NHCO2CH2 (4-ιsoxazolyl) 2016 pyridin-2-ylamino-(CH 2 )3 NHC0 2 t.. ^ (2-thιenyl ) 2017 imidazolin-2-ylamino- ( CH 2 ) 3 2018 tetrahydropyrimidin-2-ylamino- (CH 2 ) 3 2019 benzimidazol-2-ylamino-(CH 2 )3 2020 2-aminopyridin-6-yl-(CH2) 3 2021 2-iminoazepin-7-yl-(CH 2 )3 2024 imidazol-4-ylamino-(CH 2 )3 2029 imidazol-2-ylamino-(CH 2 )3 2030 ρyridin-2-ylamino- (CH 2 ) 3 2031 imidazolin-2-ylamino- (CH 2 ) 3 2032 tetrahydropyrimidin-2-ylamino-(CH 2 )3 2033 benzimidazol-2-ylamino- (CH 2 )3 1 N 2034 2-aminopyridin-6-yl- (CH 2 ) 3 f 2035 2-iminoazepin-7-yl-(CH 2 )3 2038 imidazol-4-ylamino- (CH 2 >3 043 imidazol-2-ylamino-(CH 2 ) 3 2044 pyridin-2-ylamino- (CH 2 ) 3 2045 imidazol-2-ylamino- (CH 2 >3 2046 pyridin-2-ylamino-(CH )3 H H (3,4- H meth lenedioxy) phenyl 2 047 imidazolin-2-ylamino-(CH )3 H H (3,4- H methylenedioxy) phenyl 2048 tetrahydropyrimidin-2-ylamino-(CH2) 3 H H (3,4- H methylenedioxy) phenyl 2049 benzimidazol-2-ylamino-(CH2) H H (3,4- H meth lenediox ) phenyl 2050 2-aroinopyridin-6-yl-(CH2>3 H H (3,4- H 1 J methylenedioxy) 1 phenyl 2051 2-iminoazepin-7-yl-(CH2>3 H H (3,4- H methylenedioxy) phenyl 2054 imidazol-4-ylamino-(CH2)3 H H (3,4- H methylenedioxy) phenyl 2059 imidazol -2 -ylamino- (CH2 ) 3 H H 3 -pyrιdiny l H 2060 pyridin-2-ylamino- ( CH2>3 H H 3-pyridinyl H 2061 ιmιdazolιn-2-ylamιno-(CH 2 )3 2062 tetrahydropyrιmιdιn-2-ylamιno- (CH ) 3 2063 benzimidazol-2-ylaπιιno- (CH 2 ) 3 2064 2-amιnopyrιdιn-6-yl-(CH 2 ) 3 2065 2-ιmιnoazepιn-7-yl- CH 2 ) 3 2068 lmidazol- -ylamino- CH 2 ) 3 2073 ιmιdazolιn-2-ylamino-(CH 2 )3 508.3 2075 imidazol-2-ylamιno- CH 2 )3 2076 ιmιdazol-2-ylamιno- CH 2 )3 2077 ιmιdazol-2-ylamιno- CH 2 )3 2078 ιmιdazol-2-ylamιno- CH 2 )3 2079 ιmιdazol-2-ylamιno- CH 2 )3 2080 lmidazol-2-ylamino- CH 2 )3 NJ 2081 imidazol-2-ylamino- CH 2 )3 2082 imidazol-2-ylamino- CH 2 )3 2083 lmidazol-2-ylamino- CH 2 )3 2084 imidazol-2-ylammo- CH 2 )3 2085 ιmιdazol-2-ylamιno- CH 2 )3 2086 ιmιdazol-2-ylamιno- CH 2 )3 2087 ιmιdazol-2-ylamιno- CH 2 )3 20B8 ιmιdazol-2-ylamιno- CH 2 ) 3 2089 ιmιdazol-2-ylamιno- CH 2 )3 2090 imιdazol-2-ylamιno- CH 2 ) 3 2091 imidazol- 2-ylamino- CH 2 ) 3 NHSOaPh 2092 imidazol- 2-ylamino- CH 2 ) 3 NHS0 2 C6H -( -CH3) 2093 i idazol- 2-ylamino- CH 2 ) 3 NHS0 2 C 6 H3-(2,6-CH 3 )2 540.3 2094 imidazol- 2-ylamino- CH 2 )3 NHS0 2 C 6 H2-(2,4,6-CH 3 )3 554.4 2095 imidazol- 2-ylamino- CH 2 )3 NHS0 ( -pyridyl) 2096 imidazol- 2-ylamino- CH 2 )3 NHS0 2 (2-thienyl) 2097 imidazol- 2-ylamino- CH 2 )3 NHS0 2 (2-thιazolyl) 2098 imidazol- 2-ylaroino- CH 2 ) 3 NHS0 2 [4- (3,5- dimethyl) isoxazolyl] 2099 imidazol-2-ylamino- CH 2 ) NHS0 2 C6H4-(4-Br) 2100 imidazol-2-ylamino- CH 2 ) 3 NHSO^C6H - (4-F) 2101 imidazol-2-ylamino- CH 2 ) 3 NHS0 2 C6H3-(2, 6-Cl 2 ) 2102 imidazol-2-ylaroino- CH 2 ) 3 NHS0 2 ( 2 -naphthyl) imidazol-2-ylamino- l 2103 CH 2 ) 3 NHSθ 2 (1 -naphthyl) 562.4 J I 2104 imidazol-2-ylamino- CH 2 )3 NHS0 2 C6H4-4-Ph 588.4 2104a imidazol-2-ylamino- CH 2 ) 3 NHSθ2C6H4-4-(4- pyridyl) 2104b imidazol-2-ylamino- CH 2 ) 3 NHSθ2CgH4-4-(2- oxazolyl ) 2104c imidazol-2-ylamino- CH 2 ) 3 NHSO2C6H4-4-P- pyrazolyl) 2105 imidazol-2-ylamino- CH 2 )3 NHSθ 2 CgH2-4-Ph-2, 6- 616.3 dimethyl 2105a imidazol-2-ylamino- (CH2)3 NHS02C6H2-4-(3- pyridyl) -2, 6-dimeth l 2105b imidazol-2-ylamino- (CH 2 ) 3 NHS0 2 C6H 2 -4- (2-oxa- zolyl) -2, 6-dimethyl 2105c imidazol-2-ylamino-(CH 2 )3 NHS0 2 C6H2-4-(3-pyra- zolyl) -2, 6-dimethyl 2106 ιmidazol-2-yla-nino- ( CH 2 ) 3 NHS0 2 C6H2-4-Ph-2, 6- dichloro 2107 imidazol-2-ylamino-{CH 2 ) 3 NHSθ2C 6 H-4-Ph-2, 6- dimethy1-3-chloro 2108 imidazol-2-ylamino- (CH2) 3 NHS0 ; CH_Ph 2109 imidazol-2-ylamino- (CH2) 3 NHS0 -n-Bu 2110 imidazol-2-ylaroino- (CH 2 ) 3 NHS0 2 NHPh 2111 imidazol-2-ylamino-(CH2)3 NHSO 2 NHC6H4- (4-CH3) U- ^ 2112 imidazol-2-ylamino- (CH2) 3 NHSθ2NHC6C 3 -(2, 6-Me ) 2113 imidazol-2-ylamino- (CH 2 ) 3 NHSO2 HC6C2- (2,4,6- Me 3 ) 2114 ιmidazol-2-ylamino-(CH )3 NHS0 2 NH(3-pyridyl) 2115 imidazol-2-ylaroino- (CH 2 ) 3 NHS0 2 [4-(3,5- dimethyl ) isoxazolyl ] 2116 imidazol-2-ylamino-(CH2)3 NHSO2NHC6H - (4-Br) 2117 imidazol-2-ylamino- (CH 2 )3 HSθ2NHC6H4-(4-F) 2118 imidazol-2-ylamino-(CH 2 )3 NHS0 2 NH(2-naρhthyl) 2119 ιmιdazol-2-ylamιno- ( CH 2 ) 3 NHS0 2 NH(1-naphthy1 ) 2120 ιmidazol-2-ylamιno-(CH2)3 NHS0 2 NHC 6 H -(4-Ph) 2121 ιmιdazol-2-ylamino-(CH 2 )3 NHS0 2 NHC 6 H 2 -(4-Ph-2, 6- dimethyl) 2122 ιmιdazol-2-ylamino-(CH 2 )3 NHSθ2NHC 6 H 2 - (4-Ph-2, 6- dichloro) 2123 imidazol-2-ylamino NHSO , ,NHCH 2 Ph 2124 ιmιdazol -2-ylammo NHSO ^ NH-n-Bu 2125 pyπdιn-2-ylamιno- NHC0 2 CH „ C6H4- (3-CH3 ) 2126 pyrιdιn-2-ylamιno- NHCO2CH2 (3-pyridinyl ) 2127 pyrιdιn-2-ylamιno- NHC02CH,; (2-thιazolyl) 2128 pyrιdιn-2-ylamιno- NHC0 2 CH ^ (4-ιsoxazolyl) 2129 pyrιdin-2-ylamιno- NHCO21-BU NJ 2130 pyrιdιn-2-ylamιno- l NHCOPh 2132 pyridιn-2-ylammo- NHCOCH2CH2Ph 2133 pyrιdιn-2-ylamιno- NHCOCH ^ CHPh 2134 pyπdιn-2-ylamιno- NHCOCH 2 (3-pyridinyl) 2135 pyrιdιn-2 -ylamιno- NHCOCH 2 (2-thιenyl) 2136 pyndιn-2-ylamιno- NHCOCH2 (cyclohexyl ) 2137 pyrιdm-2-ylamιno- NHCOn-Bu 2138 ρyrιdιn-2-ylamino- NHCONHCH2Ph 2139 pyrιdin-2-ylamιno- NHS0 2 Ph 2140 pyridin ■2-ylamino- (CH 2 )3 NHSO..C6H4- (4-CH3) 2141 pyridin -2-ylamino- (CH 2 )3 NHSO2C6H3- (2, 6-CH 3 )2 2142 pyridin •2 -ylamino- (CH 2 ) 3 NHSO2C6H2- (2, 4, 6-CH 3 )3 565.4 2143 pyridin 2-ylamino- ( CH 2 )3 NHSθ 2 (3-pyridyl) 2144 pyridin •2-ylamino- (CH 2 ) 3 NHS0 2 (2-thιenyl) 2145 pyridin 2 -ylamino- ( CH 2 ) 3 NHS0^(2-thiazolyl) 2146 pyridin ■2-ylamino- (CH 2 )3 NHSO_.C6H4- (4-Br) 2147 pyridin •2-ylamino- ( CH 2 ) 3 (4-F) 2148 pyridin •2 -ylamino- (CH 2 )3 NHS0 2 C6H3-(2, 6-Cl 2 ) 2149 pyridin -2-ylaroino- ( CH 2 ) 3 NHS0 2 (2-naphthyl) 2150 pyridin -2 -ylamino- (CH 2 )3 NHS0_, (1-naphthyl) 2151 pyridin -2-ylamino- ( CH 2 ) 3 NHS0 2 C6H4-(4-Ph) 2151a pyridin -2-ylamino- (CH 2 ) 3 NHS02CgH4-4-(4- I t pyridyl) CO CJ> I 2151b pyridin-2-ylamino- (CH 2 ) 3 NHSO2C6H4- - is¬ oxazolyl) 2151c pyridin-2-yl-unino-(CH2)3 NHSθ2C6H4-4-(3- pyrazolyl) 2152 pyridin-2-ylamino- (CH 2 ) 3 NHSθ2C6H2-4-Ph-2,6- dimethyl 2152a pyridin-2-ylamino-(CH 2 )3 NHSθ2CgH2-4-(3- pyridyl)-2, 6-dimethyl 2152b pyridin-2-ylamino- CH 2 ) 3 NHS02C 6 H2-4-(2~oxa- zolyl) -2, 6-dimethyl 2152c pyridin-2-ylamino- CH 2 ) 3 NHSθ2CgH2-4-(3-pyra- zol l) -2, 6-dimethyl 2153 pyridin-2-ylamino- CH 2 ) 3 NHS0 2 C 6 H 2 -4-Ph-2, 6- dichloro 2154 pyridin-2-ylamino- CH 2 ) 3 NHSO^CH^Ph 2155 pyridin-2-ylamino- CH 2 ) 3 NHS0 -n-Bu 2156 p ridin-2-ylamino- CH 2 ) 3 NHS0 2 NHPh 2157 pyridin-2-ylamino- CH 2 ) 3 NHS0 2 NHC6H -(4-CH 3 ) 2158 pyridin-2-ylamino- CH 2 ) 3 NHS0 2 NHC6C 3 -(2,6-Me 2 ) 2159 pyridin-2-yla ino- CH 2 ) 3 NHSθ2NHC6C2-(2, 4,6- Me 3 ) NJ 2160 pyridin-2-ylamino- CH ) 3 NHS0 2 NH(3-pyrid 1) , 2161 pyridin-2-ylamino- CH 2 ) 3 NHSO^-[4-(3,5- dimethyl) isoxazolyl] 2162 pyridin-2-ylamino- CH 2 )3 NHS0 2 NHCgH4-(4-Br) 2163 pyridin-2-ylamino- CH 2 )3 NHS0 2 NHC6H4-(4-F) 2164 pyridin-2-ylamino- CH 2 )3 NHSO^NH(2-naphthyl) 2165 pyridin-2-ylamino- CH 2 )3 NHS0 2 NH) 1-naphthyl) 2166 pyridin-2-ylamino- CH 2 )3 NHSθ2NHC6H 4 -(4-Ph) 2167 pyridin-2-ylamino- CH 2 )3 NHS0 2 NHC6H2-(4-Ph-2, 6- dimethyl ) 2168 pyridin-2-ylamino- ( CH2 ) 3 NHS0 NHC 6 H - (4-Ph-2, 6- dichloro) 2169 pyridin-2-ylamino-(CH 2 )3 NHSO^NHCl^ h 2170 pyridin-2-ylamino- (CH 2 )3 NHS0 2 NH-n-Bu 2171 tetrahydropyrimidin-2-ylamino- NHC00CH2Ph 2172 tetrahydropyrimidin-2-ylamino- NHC02CH 2 C 6 H 4 -(4-CH3) 2173 tetrahydropyrimidin-2-ylamino- NHC0 2 CH (3 -pyridinyl) 2173 tetrahydropyriroidin-2-yla ino- NHCθ2CH^ ( 2 -thiazolyl) 2175 tetrahydropyrimidin-2-ylamino- NHC0 2 CH 2 (2-thienyl) 2176 te rahydropyrimidin-2-ylamino- NHCθ2n-Bu 2177 tetrahydropyrimidin-2-ylamino- NHS0 2 Ph 2178 tetrahydropyrimidin-2-ylamιno- NHS0 2 C 6 H 4 - (4-CH 3 ) 2179 tetrahydropyrimidin-2-ylamino- NHS0 C6H3-(2,6-Me 2 ) N te rahydropyrimidin-2-ylamino- J 2180 NHSθ2C6H 2 -(2,4, 6-Me3) 00 I 2181 tetrahydropyrimidin-2-ylamino- NHS0 2 ( 3 -pyridyl) 2182 tetrahydropyrimidin-2-ylamino- NHS0 2 (2-thienyl) 2183 te rahydropyrimidin-2-ylamino- NHSθ2(2-thiazolyl) 2184 tetrahydropyrimidin-2-ylamino- NHSO2C6H4- (2-Br) 2185 tetrahydropyrimidin-2-ylamino- NHS0 2 C6H4-(4-F) 2186 te rahydropyrimidin-2-ylamino- NHS02C6H3- ( 2,6-Cl2) 2187 tetrahydropyrimidin-2-ylamino- NHS0 2 (2 -naphthyl) 2188 tetrahydropyrimidin-2-ylamino- HSθ (l -naphthyl) 2189 tetrahydropy imidin-2-ylamino- NHS0 C6H -(4-Ph) 2189a tetrahydropyrimidin-2-ylamino- (CH2) 3 NHS0 2 C 6 H 4 -4- (4- pyridyl) 2189b tetrahydropyrimidin-2-ylamino- (CH2) 3 NHS0 2 C6H4-4-(2- oxazolyl) 2189c tetrahydropyrimidin-2-ylamino- (CH2)3 NHS0 2 C 6 H4-4- (3- pyrazolyl) 2190 tetrahydropyrimidin-2-ylamino- (CH2) 3 NHSθ 2 C6H2-4-Ph-2,6- dimethyl 2190a tetrahydropyrimidin-2-ylamino- (CH2) 3 NHS0 2 C 6 H 2 -4-(3- pyridyl) -2, 6-dimethyl 2190b tetrahydropyrimidin-2-ylamino- (CH2) 3 NHSO2C6H2-4- (2-oxa- zolyl) -2, 6-dimethyl 2190c tetrahydropyrimidin-2-ylamino- (CH2) 3 NHSO2C6H2-4- (3-pyra- I NJ l zolyl) -2, 6-dimethyl o , 2191 tetrahydιopyrimidin-2-ylamino- (CH2) 3 NHSθ2C6H2-4-Ph-2, 6- dichloro 2192 tetrahydropyrimidin-2-ylamino- (CH2) 3 NHS0 2 CH 2 Ph 2193 tetrahydropyrimidin-2-ylamino- (CH2) 3 NHS0 2 -n-Bu 2194 tetrahydropyrimidin-2-ylamino- (CH2) 3 NHS0 2 NHPh 2195 tetrahydropyrimidin-2-ylamino- (CH2)3 NHS0 NHC 6 H4-(4-CH3) 2196 tetrahydropyrimidin-2-ylamino- (CH2) 3 NHSO2NHC6C3- (2, 6-M 2) 2197 tetrahydropyrimidin-2-ylamino- (CH2) 3 NHSO2NHC6C2- (2,4,6- Me 3 ) 2198 tetrahydropyrimidin-2-ylamino- (CH2) 3 NHSO [4-(3, 5- dimethyl) isoxazolyl] 2199 tetrahydropyrimidin-2-ylamino- (CH 2 )3 NHS0.,NH<2-naphthyl) 2200 tetrahydropyrimidin-2-ylamino- (CH2)3 NHS0 2 NH(1-naphthyl) 2201 tetrahydropyrimidin-2-ylamino- (CH ) 3 NHS0 2 NHC6H -(4-Ph) 2202 tetrahydropyrimidin-2-ylamino- ( CH2 ) 3 NHS02NHC 6 H2-(4-Ph-2, 6- dimethyl) 2203 tetrahydropyrimidin-2-ylamino- ( CH2 ) 3 NHS0 2 NHC6H 2 -(4-Ph-2, 6- dichloro) 2204 tetrahydropyrimidin-2-ylamino-(CH 2 ) 3 NHS0 2 NHCH 2 Ph 2205 imidazolin-2-ylamino- (CH 2 ) 3 NHC0 2 CH 2 C6H4- (4-CH3) 2206 imidazolin-2-ylamino- (CH2) 3 NHCO2CH2 (3-pyridinyl) 2207 imidazolin-2-ylamino-(CH2) 3 NHCθ2CH 2 (2-thiazolyl) N 2208 imidazolin-2-ylamino- (CH 2 ) 3 NHCO2CH2 (2-thienyl) ? 2209 imidazolin-2-ylamino-(CH 2 ) 3 NHCθ2i-Bu 2210 imidazolin-2-ylamino-(CH 2 ) 3 NHS0 2 Ph 2211 imidazolin-2-ylamino-(CH 2 ) 3 NHS0 2 C6H4-(3-CH3) 2212 imidazolin-2-ylamino- (CH2)3 NHSθ2C6H 3 -(2,6-M β 2) 2213 imidazolin-2-ylamino-(CH2)3 NHSO2C6H2-(2,4,6-Me3 ) 2214 imidazolin-2-ylamino- (CH2)3 NHS0 2 (3-pyridyl) 2215 imidazolin-2-ylamino-(CH2) 3 NHS0 2 (2-thienyl) 2216 imidazolin-2-ylamino- (CH2) 3 NHS0 2 (2-thiazolyl) 2217 imidazol in-2 -ylamino- (CH 2 ) 3 NHSθ 2 -[4-(3,5- di ethyl) isoxazolyl] 2218 imidazol in-2 -ylamino- (CH 2 ) 3 NHS0 2 C 6 H -(3-Br) 2218 imidazolin-2-ylamino-(CH 2 )3 NHSO^C 6 H4-(4-F) 2219 imidazolin-2-ylamino- (CH 2 )3 NHS0 2 C 6 H3-(2,6-Cl 2 ) 2220 imidazolin-2-ylamino-(CH 2 ) 3 HSO^ (2-naphthyl) 2221 imidazolin-2-ylamino-(CH 2 )3 NHS0 2 (1-naphthyl) 2222 imidazolin-2-ylamino- (CH 2 ) 3 NHS0 C 6 H4-(4-Ph) 2222a imidazolin-2-ylamino- (CH )3 NHSO2C6H4-4-U- pyridyl) 2222b imidazolin-2-ylamino- (CH 2 ) 3 NHS02C 6 H4-4-(2- oxazolyl) 2222c imidazolin-2-ylamino- (CH 2 ) 3 NHSθ2C6H4- -(3- I t pyrazolyl) 2223 imidazolin-2-ylamino- (CH 2 )3 NHS0 2 C 6 H2-4-Ph-2, 6- dimethyl 2223a imidazolin-2-ylamino- (CH 2 )3 NHS0 2 C 6 H 2 -4-(3- pyridyl) -2, 6-dimethyl 2223b imidazolin-2-ylamino- (CH 2 )3 NHSθ2C6H 2 -4-(2-oxa- zolyl) -2, 6-dimethyl 2223c imidazolin-2-ylamino- (CH 2 ) 3 NHSO2C6H2-4- (3-pyra¬ zolyl) -2, 6-dimethyl NHSθ2C6H2- -Ph-2.6- 2224 imidazolin-2-ylamino- ( CH 2 ) 3 dichloio 2225 imidazolin-2-ylamino-(CH 2 )3 NHS0_CH.,Ph 2226 imidazolin-2-ylaroino-(CH 2 )3 NHS0 2 -n-Bu 2227 imidazolin-2-ylamino-(CH 2 )3 NHSO^NHPh 2228 imidazolin-2-ylamino- (CH )3 HS0 2 NHC6H4- {4-CH3) 2229 imidazolin-2-ylamino-(CH 2 )3 NHSO2NHC6C3-(2,6-Me2) 2230 imidazolin-2-ylamino-(CH )3 NHSO2NHC6C2- (2,4,6- Me 3 ) 2231 imidazolin-2-ylamino- (CH 2 ) 3 NHS0 2 NH(2-naphthy1) 2232 imidazolin-2-ylaroino- (CH2>3 NHS0 2 NH) 1-naphthy1) NHSθ2NHC 6 H4-(4-Ph) 2233 imidazolin-2-ylamino- ( CH2 ) 3 2234 imidazolin-2-ylamino- (CH2) 3 NHSθ2NHC6H2-4-Ph-2, 6- I t dimethyl tsj NHSθ2NHC6H2-4-Ph-2, 6- I 2235 imidazolin-2-ylamino- ( CH2 ) 3 dichloro NHSθ 2 NHCH 2 Ph 2236 imidazolin-2-ylamino- ( CH 2 ) 3 2237 benzimidazol-2-ylamino- (CH ) 3 NHS0 2 Ph 2238 benzimidazol-2-ylamino- (CH2 ) 3 NHS0 2 C6H4- (3-CH3) 2239 benzimidazol-2-ylamino- ( CH2 ) 3 HSθ2CeH3-(2,6-Me2) 2240 benzimidazol-2-ylamino- (CH2 ) 3 NHSO2C6H2- (2, 4, 6-Me3) 2241 benzimidazol-2-ylamino- (CH2 ) 3 NHS0 2 (4-py idyl) 2242 benzimidazol-2-ylamino- ( CH2 ) 3 NHSθ2(2-thienyl) 2243 benzimidazol-2-ylamino- CH 2 ) 3 NHS0 2 (2-thiazolyl) 2244 benzimidazol-2- lamino- CH 2 )3 NHSO j - [4-(3,5- dimeth 1) isoxazolyl ] 2245 benziroidazol- 2-ylamino- CH 2 )3 NHS0 C6H4-(3-Br) 2246 benzimidazol- 2-ylamino- CH 2 )3 HSO z C6H4-(3-F) 2247 benzi idazol- 2-ylamino- CH 2 ) 3 NHS02C6H3-(2,6-Cl2) 2248 benzimidazol- 2-ylamino- CH 2 )3 NHS0 2 (2-naphthyl) 2249 benzimidazol 2-ylamino- CH 2 ) 3 NHS0 2 (1-naphthyl) 2250 benzimidazol- 2-ylamino- CH 2 ) 3 NHS0 2 C6H4-(4-Ph) 2251 benzimidazol- 2-ylamino- CH 2 )3 NHSθ2C6H2-4- h-2, 6- dimethyl 2252 benzimidazol-2-ylamino- CH 2 ) 3 NHSθ2C6H2-4-Ph-2, 6- dichloro NI 2253 benziraidazol-2-ylamino- CH 2 )3 NHS0 2 CH 2 Ph ϊ 2254 benzimidazol-2-ylamino- CH 2 ) 3 NHSθ 2 -i-Bu 2255 benzimidazol-2-ylamino- CH 2 )3 NHS0 2 NHPh 2256 benzimidazol-2-ylamino- CH 2 )3 NHSO2NHC6H4- (4-CH3 ) 2257 benzimidazol-2-ylamino- CH 2 )3 NHSO2NHC6C3-(2,6-Mβ2) 2258 benzimidazol-2-ylamino- CH 2 )3 NHS0 2 NHC6C 2 -(2,4, 6- Me 3 ) 2259 benzimidazol-2-ylamino- CH 2 )3 NHS0 2 NH ( 2 - napht hy 1 ) 2260 benzimidazol-2-ylaroino- CH 2 )3 NHSθ 2 NH) 1-naphthyl ) 2261 benzimidazol-2-ylamino- CH 2 ) 3 NHS0 2 NHC 6 H -(4-Ph) 2262 benzimidazol-2-ylamino-(CH 2 ) 3 NHS0 2 NHC 6 H 2 -4-Ph-2, 6- di ethyl 2263 benzimidazol-2-ylamino-(CH2 ) 3 NHS0 NHC 6 H 2 -4-Ph-2, 6- dichloro 2264 benzimidazol-2-ylamino- (CH2) 3 NHSθ 2 NHCH Ph 2265 benzimidazol-2-yleunino-(CH 2 )3 NHC0 2 CH2Ph 2266 benzimidazol-2-yleunino-(CH 2 ) 3 NHCθ2i-Bu 2267 2-aminopyridin- 6-yl-(CH 2 ) 3 NHS0 2 C 6 H 4 -(4-CH3) 2268 2-aminopyridin- 6-yl- ( CH 2 >3 NHSO2C6H3- (2, 6-Me2) 2269 2-aminopyridin- 6-yl-(CH 2 ) 3 NHS0 2 C 6 H2-(2,4,6-Me 3 ) 2270 2-aminopyridin- 6-yl- ( CH 2 ) 3 NHS0 2 (3-pyridyl) 2271 2-aminopyridin- 6-yl-(CH 2 ) 3 NHS0 2 (2-thiazolyl) 2272 2-aminopyridin- 6-yl- ( CH 2 ) 3 NHSO2 (4-isoxazolyl) NJ 2273 2-ammopyridin- 6-yl- ( CH 2 ) 3 NHSO C6H4- (3-Br) ιP» I 2274 2-aminopyridin- 6-yl-(CH 2 ) 3 NHS0 2 C6H4-(3-F) 2275 2-aminopyridin- 6-yl- ( CH 2 ) 3 NHSθ2C6H3-(2,6-Cl 2 ) 2276 2-aminopyridin- 6-yl- ( CH 2 ) 3 NHS0 2 (2-naphthyl) 2277 2-aminopyridin- 6-yl- ( CH 2 ) 3 NHS0 2 (1-naphthyl) 2278 2-aminopyridin- 6-yl- ( CH ) 3 NHSθ2CgH4 - ( 4 -Ph ) 2279 2-aminopyridin- 6-yl- ( CH 2 ) 3 NHS0 2 C6H2 -4 -Ph-2 , 6 - dimethyl 2280 2-aroinopyridin-6-yl-(CH2) 3 HSθ2C6H2 - -Ph- 2 , 6 - dichloro 22 81 2-aminopyridin-6-yl-(CH 2 )3 NHS0 2 CH2 h 2282 2-aminopyridin-6-yl- (CH 2 )3 NHS0 2 -i-Bu 2283 2-aminopyridin-6-yl-(CH 2 )3 NHS0 2 NHPh 2284 2-aminopyridin-6-yl-(CH )3 NHSO 2 HC6H4- (4-CH3) 2285 2-aminopyridin-6-yl-(CH 2 )3 HS0 NHCeC3-(2,6-Me 2 ) 2 286 2-aminopyridin-6-yl-(CH )3 NHS0 2 NHC6C2- (2,4,6- Me 3 ) 2287 2-aminopyridin-6-yl-(CH 2 )3 NHS0 2 NH(2-naphthy1) 2288 2-aminopyridin-6-yl-(CH 2 >3 NHS0 2 NH) 1-naphthyl) 2289 2-euninopyridin-6-yl- (CH 2 >3 NHS02NHC6H4-( - h) 2290 2-aminopyridin-6-yl- (CH2) 3 NHSθ2NHC6H 2 -4-Ph-2, 6- dimethyl 2291 2-euninopyridin-6-yl-(CH2) 3 NHS0 2 NHC6H2-4-Ph-2, 6- I tj dichloro tn I 2292 2-euninopyridin-6-yl-(CH2)3 NHC0 2 n-Bu 2293 2-euninopyridin-6-yl-(CH2> 3 NHC0 2 i-Bu 2294 2-iminoazepin-7-yl- (CH2>3 NHS0 2 Ph 2295 imidazol-4-ylamino-(CH 2 )3 NHS0 2 Ph 2296 2-iminoazepin-7-yl- (CH2)3 NHS0 2 (4-isoxazolyl) 2297 imidazol-4-ylamino-(CH 2 ) 3 NHS0 2 (4-isoxazolyl) 2298 2-iminoazepin-7-yl-(CH 2 )3 NHS0 2 -[4-(3, 5- dimethyl) isoxazolyl) 2299 imidazol-4-ylamino- (CH 2 )3 2300 imidazol-2-yla-nino-(CH 2 )3 2301 pyridin-2-ylamino-(CH 2 )3 2302 imidazol-2-yla_nino-(CH )3 2303 pyridin-2-ylamino-(CH )3 2304 imidazol-2-ylamino-(CH ) 2 2305 imidazol-2-ylamino- ( CH 2 ) 2 2306 imidazol-2-ylamino-carbonyl- (CH ) 2307 pyr idin-2 -yleunino- (CH ) 2 2308 pyridin-2-yl-unino- (CH 2 ) 2 N 2309 pyridin-2-ylamino-carbonyl- ( CH 2 ) 2 2310 imidazolin-2-ylamino-(CH 2 ) 2311 imidazolin-2-ylamino-(CH 2 ) 2312 tetrahydropyrimidin-2-ylamino-(CH ) 2313 tetrahydropyrimidin-2-ylamino-(CH 2 ) 2314 benzimidazol-2-ylamino-(CH 2 ) 2 2315 benzimidazol-2-ylamino- (CH 2 ) 2 2316 benzimidazol-2-ylamino-carbonyl- (CH 2 ) 2 2317 2-aminopyridin-6-yl-(CH 2 ) 2 2318 2-aminopyridin-6-yl- (CH 2 ) 2 2319 2-iminoazepin-7-yl-(CH 2 ) 2 NHS0 2 Ph 2320 2-iminoazepin-7-yl-(CH 2 ) NHCO^CH 2 Ph 2321 imidazol-4-ylamino-(CH 2 ) 2 NHSOaPh 2322 imidazol-4-yl-unino-(CH 2 ) NHC0 2 CH2Ph 2323 imidazol-2-ylamino-(CH 2 )4 NHSOaPh 2324 imidazol-2-ylamino-(CH 2 ) NHC0 2 CH2Ph 2325 pyridin-2-ylamino-(CH 2 ) NHS0 2 Ph 2326 pyridin-2- lamino-(CH 2 ) NHC0 2 CH2Ph 2327 imidazolin-2-ylamino-(CH 2 )4 NHS0 2 Ph 2328 imidazolin-2-ylamino-(CH 2 ) 4 NHC0 2 CH2Ph 522 . 3 2329 tetrahydropyrimidin-2-ylamino- (CH 2 )4 NHS0 2 Ph 2330 tetrahydropyrimidin-2-ylamino- (CH 2 )4 NHC0 2 CH 2 Ph 2331 benzimidazol-2-ylamino- (CH 2 )4 NHS0 2 Ph NJ 2332 benzimidazol-2-ylaroino- (CH 2 )4 NHC0 2 CH 2 Ph V 2333 2-aroinopyridin-6-yl-(CH 2 )4 NHSOaPh 2334 2-aminopyridin-6-yl- (CH 2 )4 NHC0 2 CH 2 Ph 2335 2-iminoazepin-7-yl-(CH 2 )4 NHS0 2 Ph 2336 2-iminoazepin-7-yl- (CH 2 >4 NHC0 2 CH2Ph 2337 imidazol-4-ylamino-(CH2>4 NHS0 Ph 2338 imidazol-4-ylamino- (CH2>4 NHC0 2 CH2Ph 2339 imidazol-2-ylamino-CH 2 (o-C6H4) -CH2 NHS0 2 -(l-naphthyl) 2340 imidazol-2-ylamino-CH2(o-C6H4) -CH2 NHC0 2 CH2Ph 2341 imidazol-2-ylamino-CH 2 (o-C6H4) -CH 2 NHSθ 2 C6C 2 - ( 2 , 4 , 6 -Me 3 ) 2342 pyridin-2-ylamino-CH 2 (o-CgH4) -CH 2 NHS0 2 -(l-naphthyl) 2343 pyridin-2-ylamino-CH 2 (0-C6H4 ) -CH 2 NHC0 2 CH2Ph 2344 pyridin-2-ylamino-CH 2 (o-CfH4)-CH2 NHS0 C 6 C2-(2,4,6-Me 3 ) 2345 imidazolin-2-ylamino-CH 2 (o-C6H4)-CH 2 NHS0 2 -(l-naphthyl) 2346 imidazolin-2-ylamino-CH 2 (o-C3H4) -CH NHC0 2 CH2Ph 2347 imidazolin-2-yle_mino-CH (o-C6H4) -CH 2 NHSθ 2 C6C -(2,4, 6-Me 3 ) 2348 imidazolin-2-yleunino-(0-C13H4) -CH 2 NHS0 2 -(l-naphthyl) 2349 imidazolin-2-ylamino-(0-C13H4) -CH 2 NHC0 2 CH2Ph 2350 imidazolin-2-ylamino- (o-CgH > -CH 2 NHSθ2CgC2 -(2,4, 6-Mβ3 ) I t 00 I Table 3 3003 imidazolin-2-yl amino-(CH 2 )3 NHCO2CH2C6H4- (2-CH3) 3004 tetrahydropyrimidin-2-ylamino-(CH 2 ) 3 NHCO2CH2C6H4- O-CH3) 3005 benzimidazol-2-ylamino- (CH 2 ) 3 NHC0 CH 2 C6H - (4-CH 3 ) 3006 2-aminopyridin-6-yl- (CH 2 ) 3 NHC0 CH 2 (2-pyridinyl) 3007 2-iminoazepin-7-yl-(CH 2 ) 3 NHC0 2 CH 2 (3-pyridinyl) 3010 imidazol-4-ylamino- (CH 2 ) 3 NHCO2CH2 (2-thiazolyl) 3015 imidazol-2-ylamino-(CH ) 3 NHCO2CH2 (4-isoxazolyl) 3016 pyridin-2-ylamino-(CH 2 ) 3 NHCO2CH2 (2-thienyl) 3017 imidazolin-2-ylamino- (CH 2 ) 3 NHC0 2 n-Bu 3018 tetrahydropyrimidin-2-ylamino- (CH 2 ) 3 NHCθ2i-Bu 3019 benzimidazol-2-ylamino- (CH 2 ) 3 NHC0 2 t-Bu 3020 2-aminopyridin-6-yl- (CH 2 ) 3 NHS02Ph 3020a pyridin-2-ylamino-(CH2) 3 NHS0 2 Ph CcO 3020b imidazolin-2-yl amino-(CH2)3 NHS0 2 Ph 03 -2 3020c tetrahydropyrimidin-2-ylamino- (CH ) 3 NHS0 2 Ph H 3020d imidazol-2-ylamino- (CH 2 ) 3 NHS0 2 Ph C Hm 3021 2-iminoazepin-7-yl- (CH 2 ) 3 NHS0 2 C6H4-(2-CH 3 ) (A x 3021a imidazol-2-ylamino-(CH 2 ) 3 NHS0 2 C6H3-(2, 6-Me 2 ) mm , 3021b imidazol-2-ylamino-(CH2) 3 HSO2C6H2- (2, , 6-Me 3 ) H ro CJΠ 3021c imidazol-2-ylamino- (CH2) 3 NHSO2C6H2- (2, 6-Me2"4-Ph) c σ r 1 3021d pyridin-2-ylamino- (CH 2 ) 3 NHSO2C6H2- (2, 6-Me2~4-Ph) m ro 3021e imidazolin-2-yl amino-(CH2>3 NHSO2C6H2- (2, 6-Me 2 -4-Ph) 3021f tetrahydropyrimidin-2-ylamino- (CH 2 ) 3 NHSO2C6H2- (2, 6-Me2-4-Ph) 3021g imidazol-2-ylamino- (CH 2 ) 3 NHSO2C6H2- (2, 6-MΘ2-4- (3- pyridyl) ) 3021h imidazol-2-ylamino- (CH 2 ) 3 NHS02C6H2-(2, 6-Me2-4-(4- pyridyl) ) 3021i imidazol-2-ylamino- (CH2) 3 HSO2C6H2- (2, 6-Me 2 -4- (2- furyl) ) 3021j imidazol-2-ylamino-(CH2) 3 NHS0 2 C6H 2 -(2,6-Me2-4-(3- furyl) ) 3021k imidazol-2-ylamino- (CH2) 3 NHSO2C6H2- (2, 6-MΘ2-4- (5- pyrazolyl) ) 30211 pyridin-2-ylamino- (CH 2 ) 3 H NHSO2C6H2- (2, 4, 6-Me 3 ) 3021m pyridin-2-ylamino- (CH2) 3 H NHSO2C6H2- (2, 6-Me 2 -4- (3- pyridyl) ) CcO 3021n pyridin-2-ylamino- (CH2) 3 NHSO2C6H2- (2, 6-MΘ2-4- (4- CD 0) pyridyl) ) H 3021o pyridin-2-ylamino- (CH2) 3 NHS0 2 C6H2-(2, 6-Me2~4- (2- C Hm furyl) ) 0x) 3021p pyridin-2-ylamino- (CH2> 3 NHSO2C6H2- (2, 6-Me2~4- (3- mm I furyl) ) H t ι 3021q ρyridin-2-ylamino- (CH2) 3 HSO2C6H2- (2, 6-MΘ2-4- (5- cr- pyrazolyl) ) m 3021r imidazolin-2-yl amino-(CH2)3 NHSO2C6H2- (2, 4, 6-Me 3 ) 3021s imidazolin-2-yl amino- (CH2) 3 NHS02CgH2- (2, 6-Me 2 -4- (3- pyridyl) ) 3021t imidazolin-2-yl amino-(CH2)3 HS0 2 C6H2-( , 6-Me 2 -4-(4- pyridyl) ) 3021u imidazolin-2-yl amino-(CH 2 )3 NHSO2C6H2- (2, 6-MΘ2-4- (2- furyl)) NHS0 2 C6H2-(2,6-Me 2 -4-(3- 3021v imida zolin-2-yl amino- (CH2 > 3 furyl)) 3021w imidazolin-2-yl amino- (CH2 > 3 NHSO2C6H2- (2, 6-MΘ2-4- (5- pyrazolyl) ) 3024 imidazol-4-ylamino- (CH2 ) 3 NHSO2 (2-pyridyl) 3029 imidazol-2-ylamino-(CH2 ) 3 NHSO2 (4-isoχazolyl) NHS0 2 -[4-(3,5-dim- 3030 ρyridin-2-ylamino- (CH2 ) 3 CO ethyl) isoxazolyl] 00 l amino- (CH 2 ) 3 NHS0 2 -[4- (3,5-dim- CO 3030a imidazolin-2-y d ethyl) isoxazolyl] H C H 3030b tetrahydropyrimidin-2-ylamino- ( CH2 ) 3 NHS0 2 -[4-(3, 5-dim- ethyl) isoxazolyl] NHS0 2 -[4-(3,5-dim- 3030c imidazol-2-ylamino- ( CH2 ) 3 ethyl) isoxazolyl] NHS0 2 C6H4-(2-Br) 3031 imidazolin-2-ylamino- ( CH2 ) 3 3032 tetrahydropyrimidin-2-ylamino- ( CH 2 ) 3 NHSO2C6H4- (3-Br) 3033 benzimidazol-2-ylamino- (CH2 ) 3 NHS0 2 C6H4-(4-Br) 3034 2-aminopyridin-6-yl- (CH2 ) 3 HSO2C6H4- (2-F) NHS0 2 C6H4-(3-F) 3035 2-iminoazepin-7-yl- ( CH 2 ) 3 3038 imidazol-2-ylamino- ( CH2 ) 3 NHS0 2 (1-naphthyl) 3038a imidazol-2-ylamino- ( CH2 ) 3 NHS0 2 C6H3-(2, 6-CI2) 3038b imidazol-2-ylamino- ( CH2 ) 3 NHS0 2 C6H2- (2, 6-Cl2~4-Ph) 3043 imidazol-2-ylamino- (CH 2 ) 3 NHS0 2 -i-Bu 3044 pyridin-2-ylamino- (CH 2 ) 3 H H NHS0 2 -t-Bu 3045 imidazol-2-ylamino-(CH2) 3 H (3,4- H methylenedioxy)phenyl 3046 pyridin-2-ylamino-(CH2) 3 H (3,4- H methylenedioxy) phenyl 3047 imidazolin-2-ylamino-(CH2) 3 H (3,4- H methylenedioxy) phenyl 3048 tetrahydroρyrimidin-2-ylamino- (CH2) 3 H (3,4- H methylenedioxy)phenyl 3049 benzimidazol-2-ylamino-(CH2> 3 H (3,4- H methylenedioxy)phenyl co 3050 2-aminopyridin-6-yl-(CH2) 3 H (3,4- H Xmm methylenedioxy)phenyl H I 3 u 3051 2-iminoazepin-7-yl-(CH2) 3 (3,4- H ci I methylenedioxy) phenyl m- 3054 imidazol-4-ylamino-(CH2) 3 (3,4- H methylenedioxy)phenyl 3059 imidazol-2-ylamino- (CH2) 3 H 3-pyridinyl H 3060 pyridin-2-ylamino- (CH2) 3 H 3-ρyridinyl H 3061 imidazolin-2-ylamino- (CH 2 ) 3 H 3-pyridinyl H 3062 tetrahydroρyrimidin-2-ylamino- (CH2) 3 H 3-pyridinyl H 3063 benzimidazol-2-ylamino- (CH2) 3 H 3-pyridinyl H 3064 2-aminopyridin-6-yl- (CH2) 3 H 3-pyridinyl H 3065 2-iminoazepin-7-yl- (CH2) 3 H 3068 imidazol-4-ylamino- (CH 2 ) 3 H 3068a imidazol-2-ylamino-CH2 (0-C5H4) NHS0 2 -(l-naphthyl) 3068b imidazol-2-ylamino-CH2 (o-CgH 4 ) NHC0 2 CH2Ph 3068c imidazol-2-ylamino-CH2 (o-CgH4> NHS02CgC2- (2, 4, 6-Me3> 3068d pyridin-2-ylamino-CH2 (o-C H4) NHS0 2 - (1-naphthyl) 3068e pyridin-2-ylamino-CH2 (o-CgH4> NHC0 2 CH2Ph CcO 3068f pyridin-2-ylamino-CH2 (o-CgH4> NHS0 2 CgC2- (2, 4, 6-MΘ3) 09 3068g imidazolin-2-ylamino-CH2 (0-C6H4) NHS0 2 - (1-naphthyl) H 3 3068h imidazolin-2-ylamino-CH2 (0-C6H ) NHC0 2 CH2Ph C H imidazolin-2-ylamino-CH2 (o-CgH 4 ) NHS0 2 CgC2-(2,4, 6-Me3) m 3068i imidazolin-2-ylamino- (m-CgH 4 ) NHS0 - (1-naphthyl) imidazolin-2-ylamino- (m-CgH 4 ) NHC0 2 CH 2 Ph imidazolin-2-ylamino- ( -CgH4) NHS02C C2- (2, 4, 6-Me 3 ) imidazol-2-ylamino- (CH2) 3 NHC0 2 CH2Ph imidazol-2-ylamino- (CH 2 ) 3 NHC0 2 CH 2 CgH 4 - O-CH3) imidazol-2-ylamino- (CH2) 3 NHC0 2 CH 2 (3-ρyridinyl) 3078 imidazol-2-ylamino- (CH2) 3 NHCO2CH2 (2-thiazolyl) 3079 imidazol-2-ylamino- (CH2) 3 NHCO2CH2 (2-thienyl) 3080 imidazol-2-ylamino- (CH 2 ) 3 NHCO2CH2 (5-isoxazolyl) 3081 imidazol-2-ylamino- (CH2) 3 NHCθ2n-Bu 3082 imidazol-2-ylamino- (CH2) 3 NHCOPh 3083 imidazol-2-ylamino- (CH2) 3 NHCOCH 2 Ph 3084 imidazol- 2-ylamino- CH2 NHCOCH2CH2P 3085 imidazol- 2-ylamino- CH 2 NHCOCH=CHPh 3086 imidazol- 2-ylamino- CH2 NHCOCH 2 (3-ρyridinyl) 3087 imidazol- 2-ylamino- CH 2 NHCOCH 2 (2-thienyl) 3088 i idazol- 2-ylamino- CH 2 NHCOCH2 (cyclohexyl) 3089 imidazol- 2-ylamino- CH 2 NHCOn-Bu 3090 i idazol- 2-ylamino- CH 2 NHCONHCH 2 Ph CcO 3091 imidazol- 2-ylamino- CH 2 NHS0 2 Ph 09 CO 3092 imidazol- 2-ylamino- CH 2 NHS0 2 CgH4- (4-CH3) H 3093 imidazol- 2-ylamino- CH 2 NHS02CgH3-(2, 6-CH3)2 554 . 4 C H imidazol- 2-ylamino- m 3094 CH 2 NHS02C6H2-(2,4, 6-CH3) 3 568 . 4 co 3095 imidazol- 2-ylamino- CH 2 NHSO2 (3-pyridyl) xmm , 3096 imidazol- 2-ylamino- CH 2 NHSO2 (2-thienyl) H 3 o 3097 imidazol- 2-ylamino- CH2 NHS0 2 (2-thiazolyl) cr 1 3098 imidazol- 2-ylamino- CH 2 NHS0 2 [4- (3, 5- m dimethyl) isoxazolyl] 3099 imidazol-2-ylamino- CH2 NHS0 2 CgH 4 - (4-Br) 3100 imidazol-2-ylamino- CH 2 NHS0 2 CgH 4 - (4-F) 3101 imidazol-2-ylamino- CH 2 NHS02CgH 3 -(2, 6-CI2) 594 . 3 3102 imidazol-2-ylamino- CH2 NHS0 2 (2-naphthyl) 3103 imidazol-2-ylamino- CH2 NHS0 2 (1-naphthyl) 3104 imidazol-2-ylamino- CH 2 NHS02CgH 4 -(4-Ph) 3104a imidazol-2-ylamino- CH2 NHSO2C6H -4- (4-pyridyl) 3 1 04 b imidazol-2-ylamino- (CH2 ) 3 CH 3 H NHS02CgH 4 -4- (2-oxazolyl) 3104c imidazol-2-ylamino- (CH2) 3 CH 3 H NHS02C6H4-4-(3- pyrazolyl) 3105 imidazol-2-ylamino- (CH2) 3 CH 3 NHSθ2C H2~ (4-Ph-2, 6- 630.3 dimethyl) 3105a imidazol-2-ylamino-(CH2) 3 CH 3 NHS02CgH2-4- (3-pyridyl) - 2, 6-dimethyl CO CH3 NHS02C H2- - (2-oxa- c 3105b imidazol-2-ylamino- (CH2) 3 O zolyl) -2, 6-dimethyl O 3105c imidazol-2-ylamino- (CH 2 ) 3 CH 3 NHS02CgH 2 -4- (3-pyra- c H zolyl) -2, 6-dimethyl m co 3105d imidazol-2-ylamino- (CH2) 3 CH3 NHS02CgH2~4- (4-pyridyl) - x m 2, 6-dimethyl q I HS02C H2~ - (2-furyl) - 3 ui 3105e imidazol-2-ylamino- ( CH2 ) 3 CH 3 c I 2, 6-dimethyl fn 3105f imidazol-2-ylamino- (CH2) 3 CH3 NHS02C H2-4- (3-furyl) - 2, 6-dimethyl 3106 imidazol-2-ylamino- (CH2) 3 NHS02CgH2-(4-Ph-2,6- 670.3 dichloro) 3107 imidazol-2-ylamino-(CH2) 3 NHS02CgH-(4-Ph-2,6- dimethy1-3-chloro) 3108 imidazol-2-ylamino- (CH2> 3 NHS0 2 CH 2 Ph 3109 imidazol-2-ylamino- (CH2) 3 NHSθ2-n-Bu 3110 imidazol-2-ylamino- (CH2) 3 NHS0 NHPh 3111 imidazol-2-ylamino- (CH2) 3 NHS0 2 NHC6H 4 -(4-CH 3 ) 3112 imidazol-2-ylamino- (CH2) 3 NHS02NHCgC 3 - (2, 6-Me2) 3113 imidazol-2-ylamino- (CH2) 3 NHSθ2NHC C2- (2,4, 6-Me 3 ) 3114 imidazol-2-ylamino- (CH2) 3 NHS0 2 NH(3-pyridyl) 3115 imidazol-2-ylamino- (CH2) 3 NHS0 2 [4-(3,5- dimethyl) isoxazolyl] C cO 3116 imidazol-2-ylamino-(CH2) 3 NHS0 2 NHCgH 4 -(4-Br) 09 CO 311 imidazol-2-ylamino- (CH2) 3 NHS0 2 NHCgH4- (4-F) H 3118 imidazol-2-ylamino- (CH2) 3 NHS0 2 NH(2-naphthyl) C H 3119 imidazol-2-ylamino- (CH2) 3 NHS0 2 NH(l-naphthyl) m co 3120 imidazol-2-ylamino- (CH2) 3 NHS02NHCgH 4 -(4-Ph) x m 3121 imidazol-2-ylamino- (CH2) 3 NHS0 2 NHCgH2- (4-Ph-2, 6- I t n dimethyl) 30 -j c I 3122 imidazol-2-ylamino- (CH 2 ) 3 CH3 HS02NHC H2- (4-Ph-2, 6- m ro dichloro) cn 3123 imidazol-2-ylamino- (CH2) 3 NHS0 2 NHCH 2 Ph 3124 imidazol-2-ylamino-(CH2) 3 NHS0 2 NH-n-Bu 3125 pyridin-2-ylamino- (CH2) 3 NHC02CH 2 CgH4 - ( 3 -CH 3 ) 3126 pyridin-2-ylamino- (CH2) 3 NHCO2CH2 ( 3-ρy ridinyl ) 3127 pyridin-2-ylamino- (CH2) 3 NHCO2CH2 ( 2 -thia zolyl ) 3128 pyridin-2-ylamino-(CH2) 3 NHCO2CH2 ( 4 -isoxa zolyl ) 3129 pyridin-2-ylamino- (CH 2 ) 3 NHC02 i-Bu (CH 2 >3 NHCOPh (CH 2 >3 NHCOCH 2 Ph (CH 2 >3 NHCOCH2CH 2 Ph (CH 2 )3 NHCOCH=CHPh (CH 2 NHC0CH 2 (3-pyridinyl) )3 (CH 2 )3 NHCOCH 2 (2-thienyl) (CH 2 )3 NHCOCH2 (cyclohexyl) (CH 2 >3 NHCOn-Bu (CH 2 NHCONHCH 2 Ph )3 (CH 2 )3 NHS0 2 Ph (CH 2 ) 3 NHS0 2 CgH 4 - (4-CH3) (CH 2 )3 NHS02C H3~ (2, 6-CH3>2 (CH 2 >3 NHSO2C6H2- (2,4, 6-CH 3 ) 3 579 . 4 (CH 2 >3 NHS0 2 (3-pyridyl) (CH 2 >3 NHSO2 (2-thienyl) (CH 2 )3 NHS0 2 (2-thiazolyl) (CH 2 >3 NHS0 2 CgH 4 - (4-Br) (CH 2 NHS0 2 CgH4- (4-F) )3 (CH 2 )3 NHS02CgH3-(2, 6-Cl 2 ) (CH 2 >3 NHSO2 (2-naphthyl) (CH 2 )3 NHS0 2 (1-naphthyl) (CH 2 )3 NHS02CgH 4 -(4-Ph) (CH 2 NHS02C H4-4- (4-pyridyl) )3 3151b pyridin-2-ylamino- (CH2 ) 3 NHS0 2 CgH4-4- (2-oxazolyl) 3151c ρyridin-2 -ylamino- (CH 2 ) 3 NHS0 2 CgH4-4-(3- pyrazolyl) 3152 pyridin-2-ylamino- (CH2 ) 3 NHS02CgH 2 - (4-Ph-2, 6- di ethyl) 3152a pyridin-2-ylamino- (CH 2 ) 3 NHSO2C6H2-4- (3-pyridyl) - 2, 6-dimethyl CO c 3152b pyridin-2-ylamino- (CH2 ) 3 NHS0 2 CgH2-4- (2-oxa- 09 O zolyl) -2, 6-dimethyl H H 3152c pyridin-2-ylamino- (CH2 ) 3 HS02C H2-4- (3-pyra- C H m zolyl) -2, 6-dimethyl 3152d pyridin-2-ylamino- (CH2 ) 3 NHSO2C6H2-4- (4-pyridyl) - 2, 6-dimethyl 3152e pyridin-2-ylamino- (CH2 ) 3 NHS02C H2~4- (2-furyl) - 2, 6-dimethyl ro 3152f pyridin-2-ylamino- (CH2 ) 3 NHS0 2 CgH2-4- (3-furyl) - 2, 6-dimethyl 3153 pyridin-2-ylamino- (CH2) 3 NHS0 2 CgH2- (4-Ph-2, 6- dichloro) 3154 pyridin-2-ylamino- (CH2) 3 NHS0 2 CH 2 Ph 3155 ρyridin-2-ylamino- (CH2) 3 NHS0 2 -n-Bu 3156 pyridin-2-ylamino- (CH2) 3 NHS0 2 NHPh 3157 pyridin-2-ylamino- (CH2) 3 NHS0 2 NHCgH4- (4-CH3) 3158 pyridin-2-ylamino-(CH 2 ) 3 NHS0 2 NHC6C 3 -(2, 6-Me2> 3159 pyridin-2-ylamino- (CH2) 3 NHSθ2 HC C2- (2, 4, 6-Me 3 ) 3160 pyridin-2-ylamino- (CH 2 ) 3 NHS0 2 NH(3-pyridyl) 3161 pyridin-2-ylamino-(CH2) 3 NHS0 2 -[4-(3,5- dimethyl) isoxazolyl] 3162 pyridin-2-ylamino- (CH2) 3 NHS0 2 NHCgH4- (4-Br) 3163 pyridin-2-ylamino- (CH2) 3 NHS0 2 NHCgH4- (4-F) CcO 3164 pyridin-2-ylamino- (CH 2 ) 3 NHS0 2 NH(2-naphthyl) 09 O 3165 pyridin-2-ylamino- (CH2) 3 NHS0 2 NH) 1-naphthyl) H 3166 pyridin-2-ylamino- (CH2> 3 NHSO2NHC6H4- (4-Ph) C H rn 3167 pyridin-2-ylamino- (CH2) 3 NHSθ2NHC H2- (4-Ph-2, 6- o dimethyl) x m m 3168 pyridin-2-ylamino- (CH2) 3 CH 3 NHSθ2NHCgH2- (4-Ph-2, 6- H I t\- dichloro) o X 3169 pyridin-2-ylamino-(CH2) 3 NHS0 2 NHCH 2 Ph m 3170 ρyridin-2-ylamino- (CH 2 ) 3 NHS0 2 NH-n-Bu 3171 tetrahydropyrimidin-2-ylamino- NHC00CH2Ph 3172 tetrahydropy imidin-2-ylamino- NHCθ2CH 2 C H4 - ( 4 -CH ) 3173 etrahydropy imidin-2-ylamino- NHCO2CH2 ( 3-pyridinyl ) 3173 tetrahydropyrimidin-2-ylamino- NHCO2CH2 ( 2 -thiazolyl ) 3175 tetrahydropyrimidin-2- lamino- NHCO2CH2 ( 2 -th ienyl ) 3176 tetrahydropyrimidin-2-ylamino- NHCθ2n-Bu 3177 tetrahydropyrimidin-2-ylamino- NHSO∑Ph 3178 tetrahydropyrimidin-2- NHS02C6H4- (4-CH3) 3179 tetrahydropyrimidin-2- NHSθ2CgH3-(2, 6-Me2> 3180 tetrahydroρyrimidin-2- HS02C H2~ (2, 4, 6-Mβ3> 3181 tetrahydropyrimidin-2- NHS0 2 (3-pyridyl) 3182 tetrahydropyrimidin-2- NHSO2 (2-thienyl) 3183 tetrahydropyrimidin-2- NHS0 2 (2-thiazolyl) 3184 tetrahydropyrimidin-2- NHS0 2 CgH4- (2-Br) c CO 3185 tetrahydropyrimidin-2- NHS0 2 CgH4- (4-F) 09 O 3186 tetrahydropyrimidin-2- NHSθ2C H3-(2, 6-CI2) H H 3187 tetrahydropyrimidin-2- NHSO2 (2-naphthyl) C H m 3188 tetrahydropyrimidin-2- NHSO2 (1-naphthyl) co x 3189 tetrahydropyrimidin-2- NHSθ2CgH 4 -(4-Ph) m m 3189a tetrahydropyrimidin-2- HS02C H - - (4-pyridyl) -I i 3 f° 3189b tetrahydropyrimidin-2- NHS02CgH 4 -4- (2-oxazolyl) c oι r I 3189c tetrahydropyrimidin-2- NHSθ2CgH 4 -4- (3- m rcon pyrazolyl) 3190 tet ahydropyrimidin-2 NHS02C H2- (4-Ph-2, 6- dimethyl) 3190a tetrahydropy imidin-2 NHSO2C6H2 -4 - ( 3-pyridyl ) - 2 , 6-dimethyl NHSθ2C H2 -4 - (2 -oxa- zolyl ) -2 , 6-dimethyl 3190c tetrahydropyrimidin-2-ylamino-(CH2> 3 CH3 NHS0 2 CgH2-4- (3-pyra- zolyl) -2, 6-dimethyl 3190d tetrahydropyrimidin-2-ylamino- (CH2) 3 CH3 HS02C H2~4- (4-pyridyl) 2, 6-dimethyl 3190e tetrahydropyrimidin-2-ylamino- (CH 2 ) 3 CH 3 NHS0 2 CgH2-4-(2-furyl)- 2, 6-dimethyl 3190f tetrahydropyrimidin-2-ylamino- (CH2) 3 CH3 NHSθ2CgH2-4-(3-furyl)- CO 2, 6-dimethyl 09 CO 3191 tetrahydropyrimidin-2-ylamino-(CH2) 3 CH 3 NHS0 2 CgH2- (4-Ph-2, 6- H H dichloro) C mH 3192 tetrahydroρyrimidin-2-ylamino-(CH 2 ) NHS0 2 CH 2 Ph o x 3193 tetrahydropyrimidin-2-ylamino-(CH 2 ) 3 NHS0 2 -n-Bu mm 3194 tetrahydropyrimidin-2-ylamino- (CH2) 3 NHS0 2 NHPh 1 ^ 3195 tetrahydroρyrimidin-2-ylamino- (CH2) 3 NHS0 2 NHCgH 4 - (4-CH3) σs c l 3196 tetrahydropyrimidin-2-ylamino- (CH 2 ) 3 HS02NHC C3- (2, 6-Me2> 8 3197 tetrahydroρyrimidin-2-ylamino- (CH2) 3 NHS0 2 NHCgC2-(2, 4, 6-Me3> 3198 tetrahydropyrimidin-2-ylamino-(CH2) 3 NHS0 2 [4-(3,5- dimethyl) isoxazolyl] 3199 tetrahydropyrimidin-2-ylamino-(CH2) 3 NHS0 2 NH(2-naphthyl) 3200 tetrahydroρyrimidin-2-ylamino- (CH2) 3 NHS0 2 NH(l-naphthyl) 3201 tetrahydropyrimidin-2-ylamino-(CH2) 3 NHSθ2NHCgH4-(4-Ph) 3202 tetrahydroρyrimidin-2-ylamino- (CH2) 3 NHSO2NHC6H2- (4-Ph-2, 6- dimethyl) 3203 tetrahydropyrimidin-2-ylamino- (CH2) 3 CH3 HSθ2NHCgH2- (4-Ph-2, 6- dichloro) tetrahydropyrimidin-2 NHS0 2 NHCH 2 Ph imidazolin-2- lamino- NHC02CH 2 CgH 4 -.(4-CH3) imidazolin-2-ylamino- NHCO2CH2 (3-pyridinyl) imidazolin-2-ylamino- NHCO2CH2 (2-thiazolyl) imidazolin-2-ylamino- NHC0 2 CH 2 (2-thienyl) imidazolin-2-ylamino- NHCθ2i-Bu imidazolin-2-ylamino- NHS0 2 Ph imidazolin-2- 1amino- NHS0 2 CgH 4 - (3-CH 3 ) imidazolin-2-ylamino- NHS02CgH 3 -(2, 6-Me2) imidazolin-2-ylamino- NHS02C H2- (2, , 6-Me 3 ) imidazolin-2-ylamino- NHS0 (3-ρyridyl) imidazolin-2-ylamino- NHSO2 (2-thienyl) imidazolin-2-ylamino- NHS0 2 (2-thiazolyl) imidazolin-2-ylamino- NHS0 2 -[4-(3,5- dimethyl) isoxazolyl] 3218 imidazolin-2-ylamino- NHS0 2 CgH 4 - (3-Br) 3218a imidazolin-2-ylamino- NHS0 2 CgH 4 -(4-F) 3219 imidazolin-2-ylamino- NHS02CgH3-(2, 6-Cl 2 ) 3220 imidazolin-2-ylamino- NHS0 2 (2-naρhthyl) 3221 imidazolin-2-ylamino- NHS0 2 (1-naphthyl) 3222 imidazolin-2-ylamino- NHS02C6H4-( -Ph) 3222a imidazolin-2-ylamino- (CH2) 3 HS02C H4-4-(4-pyridyl) 3222b imidazolin-2-ylamino- (CH2) 3 NHSθ2C H4-4- (2-oxazolyl) 3222c imidazolin-2-ylamino- (CH2) 3 NHS02CgH 4 -4-(3- pyrazolyl) 3223 imidazolin-2-ylamino- (CH2) 3 NHSO2C6H2- (4-Ph-2, 6- dimethyl) 3223a imidazolin-2-ylamino- (CH2) 3 NHS0 2 CgH2-4-(3-pyridyl) - O 2, 6-dimethyl c 09 3223b imidazolin-2-ylamino- (CH2) 3 NHS02CgH2~4- (2-oxa- CO H zolyl) -2, 6-dimethyl H C H 3223c imidazolin-2-ylamino- (CH2) 3 NHS02C H2" - (3-pyra- m co zolyl) -2, 6-dimethyl x m 3223d imidazolin-2-ylamino- (CH2) 3 NHSθ2C H2-4- (4-pyridyl) - m H I ts 2, 6-dimethyl 3 c 3223e imidazolin-2-ylamino-(CH2) 3 NHS02CgH2"4-(2-furyl) - i- m 2, 6-dimethyl S! 3223f imidazolin-2-ylamino-(CH2) 3 NHSθ2CgH2- - (3-furyl) - 2, 6-dimethyl 3224 imidazolin-2-ylamino- (CH2) 3 NHS02CgH2-(4-Ph-2, 6- dichloro ) 3225 imidazolin-2-ylamino- (CH2) 3 NHSθ2CH 2 Ph 3226 imidazolin-2-ylamino- (CH2) 3 NHS0 -n-Bu 3227 imidazolin-2-ylamino-(CH2) 3 NHS0 2 NHPh 3228 xmidazolin-2-ylamino- (CH2) 3 NHSθ2NHCgH 4 - (4-CH 3 ) 3229 imidazolin-2-ylamino- (CH2) 3 NHS02NHCgC 3 -(2,6-Me2) 3230 imidazolin-2-ylamino- (CH2) 3 NHS02NHC C2- (2,4, 6-Me 3 ) 3231 imidazolin-2-ylamino- (CH2) 3 NHS0 2 NH (2-naphthyl) 3232 imidazolin-2-ylamino- (CH2) 3 NHS0 2 NH) 1-naρhthyl) 3233 imidazolin-2-ylamino- (CH2) 3 NHS02NHCgH4-(4-Ph) 3234 imidazolin-2-ylamino-(CH2) 3 NHSθ2 HC H2- (4-Ph-2, 6- CO dimethyl) c 09 3235 xmidazolin-2-ylamino- (CH2) 3 CH3 NHS02NHC H2- (4-Ph-2, 6- CO H dichloro) H C 3236 imidazolin-2-ylamino- (CH2) 3 NHS0 2 NHCH 2 Ph CO 3237 benzimidazol-2-ylamino- (CH2) 3 NHS0 Ph X m m 3238 benzimidazol-2-ylamino- (CH2) 3 NHS0 2 CgH4- (3-CH 3 ) 1 ^ 3239 benzimidazol-2-ylamino- (CH2) 3 NHS0 2 C6H 3 -(2, 6-Me2) x c 1 3240 benzimidazol-2-ylamino- (CH2) 3 NHS02CgH2-(2, 4, 6-Me 3 ) ro 3241 benzimidazol-2-ylamino- (CH2) 3 NHS0 2 (4-pyridyl) cn 3242 benzimidazol-2-ylamino- (CH2) 3 NHS02(2-thienyl) 3243 benzimidazol-2-ylamino- (CH 2 ) 3 NHS0 2 (2-thiazolyl) 3244 benzimidazol-2-ylamino- (CH2) 3 NHS0 2 -[4-(3,5- dimethyl) isoxazolyl] 3245 benzimidazol-2-ylamino- (CH2) 3 NHS0 2 CgH 4 - (3-Br) 3246 benzimidazol-2-ylamino- (CH2) 3 NHS0 2 CgH4- (3-F) 3247 benzimidazol-2-ylamino- (CH2) 3 NHS02CgH 3 -(2,6-Cl2) 3248 benzimιdazol-2-ylamxno- (CH2) 3 NHS0 (2-naphthyl) 3249 benzimidazol-2-ylamino-(CH2) 3 NHS0 2 (1-naphthyl) 3250 benzimidazol-2-ylamino- (CH2) 3 NHS02C6H4-( -Ph) 3251 benzimidazol-2-ylamino- (CH2) 3 NHSO2C6H2- (4-Ph-2, 6- dxmethyl) 3252 benzimxdazol-2-ylamino- (CH2) 3 CH 3 NHS02CgH2"(4-Ph-2,6- dxchloro) - (4-CH 3 ) - (2, 6-Me2) " (2, , 6-Me 3 ) aphthyl) aphthyl) -(4-Ph) -(4-Ph-2, 6- dxmethyl) 3263 benzxmιdazol-2-ylamxno- (CH2) 3 CH3 NHSO2 HC6H2- (4-Ph-2, 6- dxchloro) 3264 benzxmidazol-2-ylamxno- (CH2) 3 NHS0 2 NHCH 2 Ph 3265 benzimιdazol-2-ylamino- (CH2) 3 NHC02CH 2 Ph 3266 benzimidazol-2-ylamino- (CH2) 3 NHCO21-BU 3267 2-aminopyridin-6-yl- (CH2 NHS0 2 CgH 4 -(4-CH 3 ) 3268 2-aminopyridxn-6-yl- (CH2 NHS02CgH3-(2, 6-Me2> 3269 2-aminopyridin-6-yl-(CH2 NHS02CgH 2 -(2, 4, 6-Me3> 3270 2-aminopyridin-6-yl- (CH2 NHS0 2 (3-pyridyl) 3271 2-aminopyridin-6-yl-(CH2 NHS0 2 (2-thiazolyl) 3272 2-aminopyridin-6-yl-(CH 2 NHS0 2 (4-isoxazolyl) 3273 2-aminoρyridin-6-yl- (CH2 NHS0 2 CgH - (3-Br) O 3274 2-aminopyridin-6-yl- (CH2 NHS0 2 CgH 4 - (3-F) c 09 3275 2-aminopyridin-6-yl- (CH2 NHSO2C6H3- (2, 6-Cl 2 ) O H H 3276 2-aminoρyridin-6-yl- (CH2 NHS0 2 (2-naphthyl) C H 3277 2-aminopyridin-6-yl-(CH2 NHS0 2 (1-naρhthyl) rπ co 3278 2-aminopyridin-6-yl- (CH2 NHS02CgH 4 -(4-Ph) x m 3279 2-aminopyrxdin-6-yl- (CH2 NHS02CgH2-(4-Ph-2, 6- m 3 dimethyl) c 3280 2-aminopyridin-6-yl- (CH2 CH 3 NHS0 2 CgH 2 -(4-Ph-2, 6- r m ro dichloro) 3281 2-aminopyridin-6-yl- (CH2 NHS0 2 CH 2 Ph 3282 2-aminopyridin-6-yl- (CH2 NHS0 -i-Bu 3283 2-aminoρyridin-6-yl- (CH2 NHS0 2 NHPh 3284 2-aminopyridin-6-yl- (CH2 NHS0 2 NHCgH4- (4-CH3) 3285 2-aminopyridin-6-yl-(CH2 NHSθ2NHCgC3- (2, 6-Me2> 3286 2-aminopyridin-6-yl- (CH2 NHSθ2NHCgC2- (2,4, 6-Me3> 3287 2-aminopyridin-6-yl-(CH2 NHS0 2 NH(2-naphthyl) 3288 2-aminopyridin-6-yl-(CH2) 3 NHS0 2 NH) 1-naphthyl) 3289 2-aminopyridin-6-yl-(CH2) 3 NHS0 2 NHC6H4-(4-Ph) 3290 2-aminopyridin-6-yl-(CH2) 3 NHSO2NHC6H2- (4-Ph-2, 6- dimethyl) 3291 2-aminopyridin-6-yl- (CH 2 ) 3 CH 3 NHSO2NHC6H2- (4-Ph-2, 6- dichloro) 2-aminopyridin-6-yl- (CH2) 3 NHCθ2n-Bu 2-aminopyridin-6-yl-(CH2) 3 NHC0 2 i-Bu 2-iminoazepin-7-yl- (CH2) 3 NHS0 2 Ph imidazol-4-ylamino- (CH2) 3 NHS0 Ph 2-iminoazeρin-7-yl- (CH2) 3 NHS0 2 (4-isoxazolyl) imidazol-4-ylamino- (CH2) 3 NHS0 2 (4-isoxazolyl) 2-iminoazepin-7-yl- (CH2) 3 NHS0 2 -[4-(3,5- dimethyl) isoxazolyl] imidazol-4-ylamino- (CH2) 3 CH3 NHS0 2 -[4-(3,5- dimethyl) isoxazolyl] 3300 imidazol-2-ylamino- (CH2) 3 3301 ρyridin-2-ylamino-(CH2> 3 3302 imidazol-2-ylamino- (CH2) 3 3303 ρyridin-2-ylamino- (CH2) 3 3304 imidazol-2-ylamino- ( CH2 ) 2 3305 imidazol-2-ylamino-(CH2)2 NHC0 2 CH2Ph 3306 imidazol-2-ylamino-carbonyl- (CH 2 ) 2 NHSθ2CgH 2 - (2,4, 6-CH3) 3 3307 pyridin-2-ylamino- (CH2)2 NHS0 2 Ph 3308 pyridin-2-ylamino- (CH2)2 NHC0 2 CH2Ph 3309 pyridin-2-ylamino-carbonyl- (CH2) 2 NHSO2C6H2- (2, , 6-CH3) 3 3310 imidazolin-2-ylamino- (CH2)2 NHS0 2 Ph 3311 imidazolin-2-ylamino- (CH2) 2 NHC0 2 CH2Ph tetrahydroρyrimidin-2-ylamino- (CH2) 2 NHS0 Ph tetrahydropyrimidin-2-ylamino- (CH2) 2 NHC0 2 CH2Ph benzimidazol-2-ylamino- (CH2) 2 NHS0 Ph benzimidazol-2-ylamino- (CH2) 2 NHC0 2 CH2Ph benzimidazol-2-ylamino-carbonyl- (CH2) 2 NHS02CgH 2 - (2, 4, 6-CH3) 3 2-aminoρyridin-6-yl- (CH2)2 NHS0 2 Ph 2-aminopyridin-6-yl- (CH2)2 NHC0 2 CH2Ph 2-iminoazepin-7-yl- (CH2) 2 NHSθ2Ph 2-iminoazepin-7-yl- (CH2) 2 NHC0 2 CH2Ph imidazol-4-ylamino- (CH2) 2 NHS0 2 Ph imidazol-4-ylamino- (CH2) 2 NHC0 2 CH2Ph imidazol-2-ylamino- (CH2) 4 NHS0 2 Ph imidazol-2-ylamino- (CH2) NHC0 2 CH2Ph pyridin-2-ylamino- (CH2) 4 NHS0 2 Ph pyridin-2-ylamino- (CH2) 4 NHC0 2 CH2Ph imidazolin-2-ylamino- (CH2) 4 NHS0 2 Ph 3328 tetrahydropyrimidin-2-ylamino- (CH2) 4 NHS0 2 Ph 3329 tetrahydropyrimidin-2-ylamino- (CH2) 4 NHC0 2 CH Ph 3330 benzimidazol-2-ylamino- (CH2) 4 NHS0 2 Ph 3331 benzimidazol-2-ylamino- (CH2) 4 NHC0 2 CH 2 Ph 3332 2-aminopyridin-6-yl- (CH2) 4 NHS0 2 Ph 3333 2-aminopyridin-6-yl-(CH2) 4 NHC0 2 CH 2 Ph 3334 2-iminoazepin-7-yl- (CH2) 4 NHS0 2 Ph CO 33 2-iminoazepin-7-yl- (CH2) 4 NHC0 2 CH 2 Ph c 35 09 imidazol-4-ylamino-(CH2) 4 NHS0 2 Ph O 3336 -I imidazol-4-ylamino- (CH2) 4 H 3337 NHC0 2 CH2Ph C H 3338 imidazol-2-ylamino-(CH2) 3 NHS02C H2~ (2, , 6-CH 3 ) 3 m co 3339 pyridin-2-ylamino-(CH2) 3 NHS02CgH2~ (2, , 6-CH3) 3 655 . 3 xm 3340 imidazol-2-ylamino- (CH2) 3 NHS02CgH2~ (2, 4, 6-CH3) 3 N> 3341 imidazol-2-ylamino- (CH2) 3 NHS02CgH 2 - (2,4, 6-CH3) 3 ? 3342 imidazol-2-ylamino-(CH2) 3 NHS02CgH2~ (2, 4, 6-CH3) 3 3343 imidazol-2-ylamino-(CH2) 3 NHS0 2 CgH2- (2,4, 6-CH 3 ) 3 3344 imidazol-2-ylamino- (CH2) 3 HSθ2C H2- (2,4, 6-CH3) 3 3345 imidazol-2-ylamino-(CH2) 3 NHS02C H2- (2,4, 6-CH3) 3 3346 imidazol-2-ylamino- (CH 2 ) 3 NHS02C H2 " ( 2 , 4 , 6 -CH3 ) 3 3 47 imidazol-2-ylamino-(CH2) 3 NHSO2C6H2- (2, 4, 6-CH3) 3 3348 imidazol-2-ylamino- (CH2) 3 NHS02CgH2-(2,4,6-CH 3 ) 3 3349 imidazol-2-ylamino- (CH2) 3 NHS02C6H 2 -(2,6-CH 3 )2-4- Ph 3350 imidazol-2-ylamino- (CH2) 3 NHS02C6H2~(2, 6-CH 3 )2 ~ 4- Ph 3351 imidazol-2-ylamino- (CH2) 3 NHS02CgH2-(2, 6-CH 3 )2-4- CcO Ph 09 O 3352 imidazol-2-ylamino- (CH 2 ) 3 NHS02CgH2-(2, 6-CH 3 )2-4- H Ph C Hm S02C H2-(2, 6-CH 3 )2-4- S02CgH 2 -(2, 6-CH 3 )2-4- S02CgH 2 -(2, 6-CH 3 )2-4- 3356 imidazol-2-ylamino- (CH2) 3 NHS02CgH 2 - (2, 6-CH3) 2-4- Ph 3357 imidazol-2-ylamino- (CH2) 3 NHS02CgH2~(2, 6-CH3) 2 -4- Ph 3358 imidazol-2-ylamino-CH2 (0-C6H4 ) NHS0 2 - (1-naphthyl) 3359 imidazol-2-ylamino-CH2 (o-CgH4> NHC0 2 CH 2 Ph 3360 imidazol-2-ylamino-CH 2 (o-CgH 4 ) NHS02C6C2"(2, 4, 6-Me 3 ) 3361 pyridin-2-ylamino-CH2 (0-C6H4) NHS0 2 -(l-naphthyl) 3362 ρyridin-2-ylamino-CH2 (o-C H4> NHC0 2 CH2Ph 3363 pyridin-2-ylamino-CH2 (o-CgH 4 ) NHS0 2 CgC - (2, 4, 6-Me3) 3364 imidazolin-2-ylamino-CH2 (o-CgH 4 ) NHS0 2 -(l-naphthyl) 3365 imidazolin-2-ylamino-CH2 (o-CgH 4 ) NHC0 2 CH2Ph 3366 imidazolin-2-ylamino-CH2 (o-CgH ) HS02C C2" (2,4, 6-Me3) 3367 imidazolin-2-ylamino- (m-CgH ) NHS0 2 - (1-naρhthyl) 33g8 imidazolin-2-ylamino- (m-CgH 4 ) NHC0 2 CH2Ph 3369 imidazolin-2-ylamino-(m-CgH 4 ) NHS02C C2" (2, , 6-Me 3 ) Table 4 co x Ex . m I No . R 1 > 14 ιl5 MS NJ 3 H c c ~°o 4001 imidazol-2-ylamino- (CH2) 3 4002 pyridin-2-ylamino-(CH2) 3 NHCOOCH2Ph ro 4002a imidazolin-2-yl amino- (CH2) 3 NHCOOCH2Ph 4002b tetrahydropyrimidin-2-ylamino- (CH2) 3 NHC02CH 2 Ph 4002c xmidazol-2-ylamino- (CH2) 3 NHC02CH2Ph 4003 imidazolin-2-yl amino- (CH2> 3 HC02CH2C H 4 - (2-CH3) 4004 tetrahydropyrimidin-2-ylamino- (CH2) 3 HC02CH2C H4 ~ (3-CH 3 ) 4005 benzimidazol-2-ylamino- (CH2) 3 NHC02CH 2 CgH4- (4-CH 3 ) 4006 2-aminopyridin-6-yl- (CH2) 3 NHCO2CH2 (2-pyridinyl) 4007 2-iminoazepin-7-yl- (CH2) 3 NHC02CH 2 (3-pyridinyl) imidazol-4-ylamino-(CH2) 3 NHC0 2 CH 2 (2-thiazolyl) imidazol-2-ylamino- (CH 2 ) 3 NHC0 2 CH 2 (4-isoxazolyl) pyridin-2-ylamino- (CH 2 ) 3 NHC0 CH 2 (2-thienyl) imidazolin-2-ylamino- (CH2) 3 NHC0 2 n-Bu tetrahydropyrimidin-2-ylamino- (CH2) 3 NHC0 2 i-Bu benzimidazol-2-ylamino- (CH2) 3 NHC02t-Bu 2-aminopyridin-6-yl- (CH2) 3 NHS0 2 Ph pyridin-2-ylamino- (CH2) 3 NHS0 2 Ph imidazolin-2-yl amino-(CH2) 3 NHS0 2 Ph tetrahydropyrimidin-2-ylamino- (CH 2 ) 3 NHS0 2 Ph imidazol-2-ylamino- (CH2) 3 NHS0 2 Ph 2-iminoazepin-7-yl- (CH2) 3 NHS0 2 CgH 4 - (2-CH 3 ) imidazol-2-ylamino-(CH2) 3 NHS02CgH 3 -(2,6-Me2) imidazol-2-ylamino- (CH 2 ) 3 NHSO2C6H2- (2,4, 6-Me 3 ) imidazol-2-ylamino- (CH2) 3 NHS0 2 CgH2- (2, 6-Me2~4-Ph) pyrxdin-2-ylamino- (CH2) 3 NHSθ2CgH2" (2, 6-Me2~4-Ph) imidazolin-2-yl amino-(CH2>3 NHSO2C6H2- (2, 6-Me2"4-Ph) tetrahydropyrimidin-2-ylamino- (CH2) 3 NHS02CgH 2 - (2, 6-Me2"4-Ph) imidazol-4-ylamino- (CH 2 ) 3 NHS0 2 (2-pyridyl) imidazol-2-ylamino- (CH 2 ) 3 NHS0 2 (4-isoxazolyl) ρyridin-2-ylamino- (CH2) 3 NHS0 2 -[4-(3,5-dim- ethyl) isoxazolyl] 4030a imidazolin-2-yl amino- (CH2) 3 NHS0 2 -[4- (3, 5-dim- ethyl) isoxazolyl] 4030b tetrahydropyrimidin-2-ylamino- (CH2) 3 NHS0 2 -[4-(3,5-dim- ethyl) isoxazolyl] 4030c imidazol-2-ylamino- (CH2) 3 NHS0 2 -[4-(3,5-dim- ethyl) isoxazolyl] imidazolin-2-ylamino- (CH2) 3 NHS0 2 CgH 4 - (2-Br) tetrahydropyrimidin-2-ylamino- (CH2) 3 NHS0 C6H 4 - (3-Br) benzimidazol-2-ylamino- (CH2) 3 NHSO2C6H4- (4-Br) 2-aminopyridin-6-yl- (CH2) 3 NHS0 2 CgH 4 - (2-F) 2-iminoazeρin-7-yl- (CH2) 3 NHS0 2 CgH - (3-F) imidazol-2-ylamino- (CH2) 3 NHS0 (1-naphthyl) imidazol-2-ylamino- (CH2) 3 NHS0 2 CgH 3 ~ (2, 6-Cl 2 ) imidazol-2-ylamino- (CH2) 3 NHS0 2 C H2- (2, 6-Cl2-4-Ph) imidazol-2-ylamino- (CH2) 3 NHS02-i~Bu pyridin-2-ylamino- (CH2) 3 NHS0 2 -t-Bu imidazol-2-ylamino- (CH2) 3 3,4- H methylenedioxy)phenyl 4046 ρyridin-2-ylamino- (CH2) 3 (3,4- methylenedioxy)phenyl 4047 imidazolin-2-ylamino- (CH2) 3 (3,4- methylenedioxy)phenyl 4048 tet rahydropyrimidxn-2 -ylamino- (CH2 ) 3 4049 benzimxdazol -2 -ylamxno- (CH2 ) 3 4050 2-aminopyrxdxn- 6-yl- (CH2 ) 3 4051 2-xmxnoazepxn-7 -yl- (CH2 ) 3 CO c 09 CO 4054 xmxdazol-4-ylamιno- (CH 2 ) 3 H C H 4059 xmxdazol-2-ylamino- (CH2) 3 m 4060 pyπdιn-2-ylamιno-(CH2) 3 4061 xmxdazolxn-2-ylamxno- (CH2) 3 4062 tetrahydroρyrxmxdxn-2-ylamιno- (CH 2 ) 3 4063 benzimxdazol-2-ylamxno- (CH2) 3 4064 2-aminopyrxdxn-6-yl- (CH 2 ) 3 cn 4065 2-ιminoazepxn-7-yl- (CH2) 3 4068 imxdazol-4-ylamxno- (CH2) 3 4068a imxdazol-2-ylamino-CH2 (o-CgH 4 ) 4068b xmιdazol-2-ylamxno-CH2 (0-C6H4) 4068c ιmιdazol-2-ylamino-CH2 (o-CgH4> 4068d pyridxn-2-ylamxno-CH2 (o-CgH4> 4068e pyridιn-2-ylamino-CH2 (o-CgH4) 4068f pyridin-2-ylamino-CH 2 (o-CgH 4 ) HSθ2CgC2-(2, 4, 6-Me3> 4068g imidazolin-2-ylamino-CH2 (o-CgH 4 ) NHS0 2 -d-naphthyl) 4068h imidazolin-2-ylamino-CH2 (o-CgH 4 ) NHC0 2 CH2Ph 4068i imidazolin-2-ylamino-CH2 (o-CgH 4 ) NHS0 2 CgC2-(2,4, 6-Me3> 4068j imidazolin-2-ylamino- (m-CgH ) NHS0 2 -(l-naphthyl) 4068k imidazolin-2-ylamino- (m-CgH 4 ) NHC0 2 CH2Ph 40681 imidazolin-2-ylamino- (m-CgH ) NHS02CgC2- (2,4, 6-Me 3 ) 4075 imidazol-2-ylamino- (CH2) 3 NHC0 2 CH2Ph 4076 imidazol-2-ylamino- (CH2> 3 NHC0 2 CH 2 CgH 4 - (3-CH 3 ) 4077 imidazol-2-ylamino- (CH2) 3 NHCθ2CH 2 (3-pyridinyl) 4078 imidazol-2-ylamino- (CH2> 3 NHCO2CH2 (2-thiazolyl) CO X 4079 imidazol-2-ylamino- (CH2> 3 NHCθ2CH 2 (2-thienyl) mm 4080 imidazol-2-ylamino- (CH2) 3 NHCθ2CH 2 (5-isoxazolyl) I 3) ^ 4081 imidazol-2-ylamino- (CH2) 3 NHCθ2n-Bu c r i 4082 xmιdazol-2-ylamxno- (CH2) 3 m NHCOPh σro> 4083 imidazol-2-ylamino- (CH2) 3 NHCOCH 2 Ph 4084 imidazol-2-ylamino- (CH2) 3 NHCOCH2CH2P 4085 imidazol-2-ylamino- (CH2) 3 NHCOCH=CHPh 4086 imidazol-2-ylamino- (CH2) 3 NHCOCH 2 (3-pyridinyl) 4087 imidazol-2-ylamino- (CH2) 3 NHCOCH (2-thienyl) 4088 imidazol-2-ylamino- (CH2) 3 NHCOCH2 (cyclohexyl) 4089 imidazol-2-ylamino- (CH2) 3 NHCOn-Bu 4090 imidazol-2-ylamino- (CH2) 3 NHCONHCH2Ph 4091 imidazol-2-ylamino- CH 2 >3 NHS0 2 Ph 4092 imidazol-2-ylamino- CH 2 ) 3 NHS0 2 C6H4-(4-CH 3 ) 4093 imidazol-2-ylamino- CH 2 ) 3 NHS02CgH 3 - (2, 6-CH3) 2 4094 imidazol-2-ylamino- CH 2 ) 3 NHSθ2C H2- (2, 4, 6-CH3) 3 4095 imidazol-2-ylamino- CH 2 ) 3 NHS0 2 (3-pyridyl) 4096 imidazol-2-ylamino- CH 2 >3 NHS02(2-thienyl) 4097 imidazol-2-ylamino- CH 2 ) 3 NHS0 2 (2-thiazolyl) C cO 4098 imidazol-2-ylamino- CH 2 ) 3 NHS0 2 [4-(3,5- 09 di ethyl) isoxazolyl] CO 4099 imidazol-2-ylamino- CH 2 ) 3 NHS0 2 CgH4- (4-Br) c ylamino- CH 2 ) 3 NHS0 2 CgH -(4-F) m H 4100 imidazol-2- co 4101 imidazol-2-ylamino- CH 2 ) 3 NHS0 2 CgH3-(2, 6-Cl 2 ) Xm 4102 imidazol-2-ylamino- CH 2 )3 NHS0 2 (2-naphthyl) I 3 ^ 4103 imxdazol-2-ylamino- CH 2 ) 3 NHS0 2 (1-naphthyl) cr I 4104 imidazol-2-ylamino- CH 2 )3 NHS0 2 C6H 4 -(4-Ph) m ro 4104a imidazol-2-ylamino- CH 2 )3 NHS02CgH 4 -4- (4-pyridyl) 4104b imidazol-2-ylamino- CH 2 )3 NHS02CgH 4 -4- (2-oxazolyl) 4104c imidazol-2-ylamino- CH 2 )3 NHSθ2CgH 4 -4-(3- pyrazolyl) 4105 imidazol-2-ylamino- CH 2 ) 3 CH3 NHSO2C6H2- (4-Ph-2, 6- dimethyl) 4105a imidazol-2-ylamino- (CH2) 3 CH3 HS02C H2-4- (3-pyridyl) - 2, 6-dimethyl 4105b imidazol-2-ylamino- (CH2> 3 CH3 NHSθ2CgH2-4- (2-oxa- zolyl) -2, 6-dimethyl 4105c imidazol-2-ylamino- (CH2) 3 CH3 NHSθ2C H2-4- (3-pyra- zolyl) -2, 6-dimethyl 4106 imidazol-2-ylamino- (CH2) 3 CH 3 NHSO2C6H2- (4-Ph-2, 6- dichloro) 4107 imidazol-2-ylamino- (CH2) 3 CH3 NHS02CgH- (4-Ph-2, 6- chloro) - (4-CH 3 ) - (2, 6-Me 2 ) - (2, , 6-Me 3 ) yridyl) 5- oxazolyl) 4116 imidazol-2-ylamino- (CH2) 3 NHS0 2 NHCgH - (4-Br) 4117 imidazol-2-ylamino- (CH2) 3 NHS0 2 NHCgH ~ (4-F) 4118 imidazol-2-ylamino- (CH2) 3 NHS0 2 NH (2-naphthyl) 4119 imidazol-2-ylamino- (CH 2 ) 3 NHS0 2 NH (1-naρhthyl) 4120 imidazol-2-ylamino- (CH2) 3 NHS02NHC6H 4 -(4-Ph) 4121 imidazol-2-ylamino- (CH2 ) 3 CH3 HS02NHC H2~(4-Ph-2, 6- dimethyl) 4122 imidazol-2-ylamino-(CH2) 3 CH3 NHSθ2NHCgH2- (4-Ph-2, 6- dichloro) 4123 imidazol-2-ylamino- (CH 2 ) 3 NHSθ2NHCH 2 Ph 4124 imidazol-2-ylamino-(CH 2 ) 3 NHS0 NH-n-Bu 4125 pyridin-2-ylamino- (CH ) 3 NHCO2CH2C6H4- (3-CH3) CO c 4126 pyridin-2-ylamino- (CH 2 ) 3 NHC02CH 2 (3-pyridinyl) 09 CO 4127 pyridin-2-ylamino- (CH ) 3 NHCO2CH 2 (2-thiazolyl) H 4128 pyridin-2-ylamino- (CH ) 3 NHCO2CH2 (4-isoxazolyl) C H m 4129 pyridin-2-ylamino- (CH 2 ) 3 NHCθ2i-Bu o 4130 pyridin-2-ylamino-(CH2) 3 NHCOPh X m m 4131 pyridin-2-ylamino- (CH2) 3 NHCOCH 2 Ph H 1 NJ 3 CO 4132 pyridin-2-ylamino- (CH2) 3 HCOCH2CH2Ph c r I 4133 pyridin-2-ylamino- (CH2) 3 NHCOCH=CHPh ro 4134 pyridin-2-ylamino- (CH2) 3 NHCOCH 2 (3-pyridinyl) 01 4135 pyridin-2-ylamino- (CH 2 ) 3 NHCOCH 2 (2-thienyl) 4136 pyridin-2-ylamino- (CH 2 ) 3 NHCOCH2 (cyclohexyl) 4137 pyridin-2-ylamino- (CH2) 3 NHCOn-Bu 4138 pyridin-2-ylamino- (CH2) 3 NHCONHCH2Ph 4139 ρyridin-2-ylamino-(CH2) 3 NHS0 2 Ph 4140 pyridin-2-ylamino- (CH2) 3 NHS0 2 C gH 4 - ( 4-CH3 ) 4141 ρyridin-2-ylamino-(CH2) 3 NHS02CgH 3 - (2 , 6 -CH 3 ) 2 4142 pyridin-2-ylamino- ( CH 2 ) 3 NHS0 2 CgH2- (2,4, 6-CH3) 3 4143 pyridin-2-ylamino- ( CH 2 ) 3 NHS0 2 (3-ρyridyl) 4144 pyridin- 2-ylamino- ( CH 2 ) 3 NHSO2 (2-thienyl) 4145 pyridin-2-ylamino- ( CH 2 ) 3 NHS0 2 (2-thiazolyl) 4146 pyridin- 2-ylamino- ( CH 2 ) 3 NHS0 2 CgH4-(4-Br) 4147 pyridin- 2-ylamino- ( CH 2 ) 3 NHS0 2 CgH4~ (4-F) 4148 pyridin- 2-ylamino- ( CH 2 ) 3 NHSθ2C H3- (2, 6-CI2) cO 4149 pyridin- 2-ylamino- ( CH 2 ) 3 NHS0 2 (2-naphthyl) 09 CO 4150 pyridin-■2-ylamino- ( CH 2 ) 3 NHS0 2 (1-naphthyl) H H 4151 pyridin- 2-ylamino- ( CH 2 ) 3 NHS02CgH4-(4-Ph) C H m 4151a pyridin- 2-ylamino- ( CH 2 ) 3 HSO2C6H4-4- (4-pyridyl) co NHS0 2 CgH 4 -4- (2-oxazolyl) x 4151b pyridin-•2-ylamino- ( CH 2 ) 3 m 4151c pyridin-■2-ylamino- ( CH 2 ) 3 NHS02CgH 4 -4-(3- I pyrazolyl) 3D CO c 4152 pyridin-2-ylamino- (CH 2 ) 3 CH3 NHS02CgH2" (4-Ph-2, 6- m dimethyl) 4152a pyridin-2-ylamino- (CH2> 3 CH3 NHS0 CgH 2 -4- (3-pyridyl) ■ 2, 6-dimethyl 4152b pyridin-2-ylamino- (CH2) 3 CH3 NHS0 2 CgH2-4- (2-oxa- zolyl) -2, 6-dimethyl 4152c pyridin-2-ylamino- (CH2) 3 CH3 NHS02CgH2- - (3-ρyra- zolyl) -2, 6-dimethyl 4153 pyridin-2-ylamino- ( CH2 ) 3 CH 3 NHSθ2C H2- (4-Ph-2, 6- dichloro) 4154 pyridin-2-ylamino- CH 2 )3 NHS0 2 CH 2 Ph 4155 pyridin-2-ylamino- CH 2 )3 NHS0 2 -n-Bu 4156 pyridin-2-ylamino- CH 2 ) 3 NHS0 2 NHPh 4157 pyridin-2-ylamino- CH 2 ) 3 NHS0 2 NHC6H4-(4-CH 3 ) 4158 pyridin-2-ylamino- CH 2 )3 NHS02NHCgC 3 - (2, 6-Me2> CO c 4159 pyridin-2-ylamino- CH 2 ) 3 NHS0 2 NHCgC2-(2,4, 6-Me 3 ) 09 CO 4160 pyridin-2-ylamino- CH 2 ) 3 NHS0 2 NH (3-ρyridyl) H 4161 pyridin-2-ylamino- CH 2 ) 3 NHS0 2 -[4-(3,5- C -I m dimethyl) isoxazolyl] co X 4162 pyridin-2-ylamino- CH 2 )3 NHS0 2 NHCgH 4 - (4-Br) m 4163 pyridin-2-ylamino- CH 2 )3 NHS0 2 NHCgH 4 -(4-F) I 3 1, 4164 pyridin-2-ylamino- CH 2 ) 3 NHS0 2 NH (2-naphthyl) c rm- I 4165 pyridin-2-ylamino- CH 2 )3 NHS0 2 NH) 1-naphthyl) rcon 4166 pyridin-2-ylamino- CH 2 ) 3 NHS0 2 NHCgH 4 -(4-Ph) 4167 pyridin-2-ylamino- CH 2 ) 3 NHSθ2NHCgH 2 -(4-Ph-2, 6- dimethyl) 4168 pyridin-2-ylamino- CH 2 ) 3 CH3 NHSθ2NHC H2~ (4-Ph-2, 6- dichloro) 4169 pyridin-2-ylamino- CH ) 3 CH3 H NHS0 2 NHCH 2 Ph 4170 pyridin-2-ylamino- CH 2 ) 3 CH3 H NHS0 2 NH-n-Bu 4171 tetrahydropyrimidin-2-ylamino- (CH2) 3 CH3 H NHCOOCH 2 Ph tetrahydropyrimidin-2- NHCθ2CH 2 C H4- (4-CH3) tetrahydropyrimidin-2- NHCO2CH2 (3-pyridinyl) tetrahydropyrimidin-2- NHCO2CH2 (2-thiazolyl) tetrahydropyrimidin-2- NHCO2CH2 (2-thienyl) tetrahydropyrimidin-2- NHCθ2n-Bu tetrahydropyrimidin-2- NHS0 2 Ph tetrahydropyrimidin-2- NHS0 2 CgH 4 - (4-CH3) tetrahydropyrimidin-2- NHS0 2 CgH3-(2, 6-Me 2 ) tetrahydropyrimidin-2- NHS0 2 CgH2- (2, 4, 6-Me3> tetrahydropyrimidin-2- NHS0 2 (3-pyridyl) tetrahydropyrimidin-2- NHS0 2 (2-thienyl) tetrahydropyrimidin-2- NHS0 2 (2-thiazolyl) tetrahydropyrimidin-2- NHS0 2 C6H 4 - (2-Br) tetrahydropyrimidin-2- NHS0 2 C6H 4 - (4-F) te rahydropyrimidin-2- NHSθ2CgH 3 -(2, 6-CI2) tetrahydropyrimidin-2- NHS0 2 (2-naphthyl) tetrahydropyrimidin-2- NHS0 2 (1-naρhthyl) tetrahydropyrimidin-2- NHS02CgH 4 -(4-Ph) tetrahydropyrimidin-2- NHS02CgH 4 -4- (4-pyridyl) tetrahydropyrimidin-2- NHSθ2CgH 4 -4- (2-oxazolyl) tetrahydropyrimidin-2- NHSθ2CgH 4 -4-(3- pyrazolyl) 4190 tetrahydropyrimidin-2-ylamino- (CH2) 3 CH3 NHS02CgH2"(4-Ph-2, 6- dimethyl) 4190a tetrahydropyrimidin-2-ylamino- (CH2) 3 CH3 NHS0 2 CgH2~4- (3-pyridyl) 2, 6-dimethyl 4190b tetrahydropyrimidin-2-ylamino- (CH 2 ) 3 CH3 NHS02C H2-4- (2-oxa- zolyl) -2, 6-dimethyl 4190c tetrahydropyrimidin-2-ylamino- (CH 2 ) 3 CH3 NHSO2C6H2-4- (3-pyra- C cO zolyl) -2, 6-dimethyl 09 CO 4191 tetrahydropyrimidin-2-ylamino- (CH2) 3 CH3 NHS02CgH2-(4-Ph-2,6- H H dichloro) C H m 4192 tetrahydropyrimidin-2-ylamino- (CH2) 3 NHS0 2 CH 2 Ph co x 4193 tetrahydroρyrimidin-2-ylamino- (CH2) 3 NHS0 2 ~n-Bu mm 4194 tetrahydropyrimidin-2-ylamino- (CH2) 3 NHS0 2 NHPh H 3 ^ 4195 tetrahydropyrimidin-2-ylamino- (CH2) 3 NHS0 2 NHCgH4- (4-CH3) cι I 4196 tetrahydroρyrimidin-2-ylamino- (CH2) 3 NHS02NHC C3-(2, 6-Me2> m- n 4197 tetrahydropyrimidin-2-ylamino- (CH2) 3 NHS02NHC C2~ (2, 4, 6- e3> 4198 tetrahydropyrimidin-2-ylamino- (CH 2 ) 3 NHS0 2 [4-(3, 5- dimethyl) isoxazolyl] 4199 tetrahydroρyrimidin-2-ylamino- (CH ) 3 NHS0 2 NH (2-naphthyl) 4200 tetrahydropyrimidin-2-ylamino- (CH ) 3 NHS0 2 NH(l-naphthyl) 4201 tetrahydropyrimidin-2-ylamino- (CH ) 3 NHSθ2NHC H4- (4-Ph) 4202 tetrahydropyrimidin-2-ylamino- (CH 2 ) 3 NHS02NHC H2- (4-Ph-2, 6- dimethyl) 4203 tetrahydropyrimidin-2-ylamino- (CH2 ) 3 CH 3 NHSθ2NHCgH 2 - (4-Ph-2, 6- dichloro) tetrahydropyrimidin-2 -ylamino- (CH2) 3 CH 3 H NHS0 2 NHCH 2 Ph imidazolin-2-ylamino- (CH 2 >3 CH3 H NHC02CH CgH4_(4-CH3) imidazolin-2-ylamino- (CH 2 )3 CH3 H NHC02CH 2 (3-pyridinyl) imidazolin-2-ylamino- ( CH 2 )3 CH3 H NHCO2CH2 (2-thiazolyl) imidazolin-2-ylamino- ( CH 2 ) 3 CH3 H NHC02CH 2 (2-thienyl) imidazolin-2-ylamino- ( CH 2 ) 3 CH3 H NHCθ2i-Bu imidazolin-2-ylamino- (CH 2 )3 CH3 H NHS0 2 Ph imidazolin-2-ylamino- (CH 2 )3 CH3 H NHS0 2 CgH 4 -(3-CH3) imidazolin-2-ylamino- ( CH 2 ) 3 CH3 H HS02C6H3-(2,6-Me2) imidazolin-2-ylamino- (CH 2 ) 3 CH3 H NHSO2C6H2- (2,4, 6-Me3) imidazolin-2-ylamino- ( CH 2 ) 3 CH3 H NHS0 2 (3-pyridyl) imidazolin-2-ylamino- (CH 2 )3 CH3 H NHSO2 (2-thienyl) imidazolin-2-ylamino- (CH 2 ) 3 CH3 H NHS0 2 (2-thiazolyl) imidazolin-2-ylamino- (CH 2 )3 CH 3 H NHS0 2 -(4-(3,5- dimethyl) isoxazolyl] 4218 imidazolin-2-ylamino- (CH 2 ) 3 CH3 H NHS0 2 CgH 4 -(3-Br) 4218a imidazolin-2-ylamino- (CH2) 3 CH 3 H NHS0 2 CgH 4 -(4-F) 4219 imidazolin-2-ylamino- (CH2) 3 CH 3 H NHSθ2C H3~ (2, 6-CI2) 4220 imidazolin-2-ylamino- (CH2) 3 CH 3 H NHS0 2 (2-naphthyl) 4221 imidazolin-2-ylamino- (CH2) 3 CH3 H NHS0 2 (1-naphthyl) 4222 imidazolin-2-ylamino- (CH2) 3 CH3 H NHS02CgH 4 -(4-Ph) 4223 imidazolin-2-ylamino- (CH 2 ) 3 CH3 HSO2C6H2- (4-Ph-2, 6- dimethyl) 4224 imidazolin-2-ylamino- (CH2) 3 CH3 HS02C H2- (4-Ph-2, 6- dichloro) 4225 imidazolin -2-ylamino- (CH 2 )3 NHS0 2 CH 2 Ph 4226 imidazolin--2-ylamino- (CH 2 )3 NHS0 2 -n-Bu 4227 imidazolin--2-ylamino- (CH 2 )3 HSθ2NHPh CcO 4228 imidazolin -2-ylamino- (CH 2 )3 NHS0 2 NHCgH4- (4-CH3) 09 CO 4229 imidazolin -2-ylamino- (CH 2 )3 NHS02NHCgC 3 - (2, 6-Me2> H 4230 imidazolin -2-ylamino- (CH 2 )3 NHS02NHC C2- (2, 4, 6-Me 3 ) H NHS0 2 NH (2-naphthyl) m 4231 imidazolin -2-ylamino- (CH 2 ) 3 co 4232 imidazolin -2-ylamino- (CH 2 ) 3 NHS0 2 NH) 1-naphthyl) xm imidazolin -2-ylamino- NHS02NHCgH 4 -(4-Ph) =1 4233 (CH 2 ) 3 imidazolin -2-ylamino- NHSO2NHC6H2- (4-Ph-2, 6- .0 £ 4234 (CH 2 ) 3 c ON I dimethyl) im- 4235 imidazolin-2-ylamino- ( CH2> 3 CH 3 NHSO2NHC6H2- (4-Ph-2, 6- dichloro) 4236 imidazolin-2-ylamino- (CH2> 3 NHS0 2 NHCH 2 Ph 4237 benzimidazol-2-ylamino- (CH2) 3 NHS0 2 Ph 4238 benzimidazol-2-ylamino- (CH2 ) 3 NHS0 2 CgH 4 - (3-CH 3 ) 4239 benzimidazol-2-ylamino- (CH2) 3 NHSθ2C H3- (2, 6-Me2) 4240 benzimidazol-2-ylamino- (CH2) 3 NHS02CgH 2 -(2,4,6-Me3) 4241 benzimidazol-2-ylamino- (CH2 ) 3 NHS0 2 (4-pyridyl) 4242 benzimidazol-2-ylamino- (CH2) 3 CH3 NHSO2 (2-thienyl) 4243 benzimidazol-2-ylamino- (CH2) 3 CH 3 NHSO2 (2-thiazolyl) 4244 benzimidazol-2-ylamino- (CH2) 3 CH3 NHS0 2 -(4-(3,5- dimethyl) isoxazolyl] 4245 benzimidazol -2-ylamino- (CH 2 ) 3 CH3 H NHS0 2 CgH 4 - (3-Br) 4246 benzimidazol -2-ylamino- (CH 2 ) 3 CH 3 H NHS0 2 CgH 4 - (3-F) 4247 benzimidazol -2-ylamino- ( CH 2 ) 3 CH3 H HS02C6H3-(2, 6-CI2) C CH 3 cO 4248 benzimidazol -2-ylamino- ( CH 2 ) 3 H NHS0 2 (2-naρhthyl) 09 4249 benzimidazol -2-ylamino- (CH 2 ) 3 CH 3 CO H NHS0 2 (1-naρhthyl) 4250 benzimidazol -2-ylamino- ( CH 2 ) 3 CH 3 H NHSθ2CgH 4 -(4-Ph) H c 4250a benzimidazol -2-ylamino- (CH 2 )3 CH 3 H NHSθ2CgH 4 -4- (4-pyridyl) m co 4250b benzimidazol -2-ylamino- ( CH 2 ) 3 CH 3 H NHS02CgH 4 -4- (2-oxazolyl) x m 4250c benzimidazol -2-ylamino- (CH 2 ) 3 CH3 H NHS02CgH -4-(3- 3 1 NJ pyrazolyl) 3 CO cr 4251 benzimidazol-2-ylamino- (CH2) 3 CH3 HS02C H2- (4-Ph-2, 6- πt ro dimethyl) σ> 4251a benzimidazol-2-ylamino- (CH2) 3 CH3 NHS0 2 CgH 2 -4- (3-ρyridyl) - 2, 6-dimethyl) 4251b benzimidazol-2-ylamino- (CH2) 3 CH3 NHSθ2CgH2-4-(2-oxa- zolyl ) -2 , 6 -dimethyl ) 4251c benzxmidazol-2-ylamino- (CH2) 3 CH3 NHS02CgH2 - 4 - ( 3 -pyra- zo lyl ) -2 , 6-dimethyl ) 4252 benzimidazol-2-ylamino- (CH2 ) 3 CH3 NHS0 2 CgH2- (4-Ph-2, 6- dichloro) 4253 benzimidazo1-2- NHSθ2CH 2 P 4254 benzimidazo1-2- NHS0 -i-Bu 4255 benzimidazol-2- NHS0 2 NHPh 4256 benzimidazol-2- NHS0 2 NHCgH 4 - (4-CH3) 4257 benzimidazol-2- NHS02NHC C3~ (2, 6-MΘ2) O c 4258 benzimidazol-2- HS02NHC C2" (2, 4, 6-Me3> 09 4259 benzimidazol-2- NHS0 2 NH(2-naphthyl) 3 H 4260 benzimidazol-2- NHS0 2 NH) 1-naphthyl) C rHπ 4261 benzimidazol-2- NHS02NHC H4- (4-Ph) co benzimidazol-2- NHS0 2 NHCgH 2 - (4-Ph-2, 6- x 4262 m m dimethyl) H 1 3 ∞ 4263 benzimidazol-2-ylamino- (CH2) 3 CH3 NHS02NHC H2" (4-Ph-2, 6- c 00 1 1 dichloro) m- κ> 4264 benzimidazol-2-ylamino- (CH2) 3 NHS0 2 NHCH 2 Ph σ> 4265 benzimidazol-2-ylaraino- (CH2) 3 NHC02CH 2 Ph 4266 benzimidazol-2-ylamino- (CH2) 3 NHC02i-Bu 4267 2-aminopyridin-6-yl- (CH 2 ) 3 NHS0 2 CgH4-(4-CH 3 ) 4268 -aminopyridin-6-yl- (CH ) 3 NHSθ2CgH 3 - (2, 6-Me2) 4269 2-aminopyridin-6-yl- (CH 2 ) 3 NHS02C H2~ (2,4, 6-Me 3 ) 4270 2-aminopyridin-6-yl- (CH 2 ) 3 NHS0 2 (3-pyridyl) 4271 2-aminopyridin-6-yl- (CH2) 3 NHS0 2 (2-thiazolyl) 4272 2-aminopyridin-6~yl-(CH 2 NHSO2 (4-isoxazolyl) 4273 2-aminopyridin-6-yl-(CH2 NHS0 2 CgH4- (3-Br) 4274 2-aminopyridin-6-yl- (CH2 NHS0 2 CgH 4 -(3-F) 4275 2-aminopyridin-6-yl- (CH2 NHS0 2 CgH3-(2, 6-Cl 2 ) 4276 2-aminopyridin-6-yl- (CH2 NHSθ2(2-naphthyl) 4277 2-aminopyridin-6-yl- (CH2 NHS0 2 (l-naphthyl) 4278 2-aminopyridin-6-yl- (CH2 NHS0 2 CgH4-(4-Ph) 2-aminopyridin-6-yl- (CH2 HS02C H2- (4-Ph-2, 6- dimethyl) 2-aminopyridin-6-yl-(CH2 CH 3 NHS0 2 CgH2- (4-Ph-2, 6- dichloro) 2-aminopyridin-6-yl- (CH2 NHS0 2 CH 2 Ph 2-aminopyridin-6-yl- (CH 2 NHS0 2 -i-Bu 2-aminopyridin-6-yl- (CH 2 NHS0 2 NHPh 2-aminopyridin-6-yl- (CH2 NHS0 2 NHCgH4~ (4-CH3) 2-aminoρyridin-6-yl- (CH2 NHSO2 HC6C3- (2, 6-Me2) 2-aminopyridin-6-yl-(CH2 NHSO2NHC6C2-(2,4, 6-Me3) 2-aminopyridin-6-yl-(CH2 NHS0 2 NH (2-naphthyl) 2-aminopyridin-6-yl- (CH2 NHS0 2 NH) 1-naphthyl) 2-aminopyridin-6-yl- (CH2 NHS02NHC6H4-(4-Ph) 2-aminopyridin-6-yl- (CH 2 NHSθ2NHC H2- (4-Ph-2, 6- dimethyl) 4291 2-aminopyridin-6-yl- (CH2) 3 4292 2-aminopyridin-6-yl- (CH2) 3 4293 2-aminopyridin-6-yl- (CH2) 3 4294 2-iminoazepin-7-yl- (CH2) 3 4295 imidazol-4-ylamino- (CH 2 ) 3 4296 2-iminoazepin-7-yl- (CH2) 3 CcO 4297 imidazol-4-ylamino- (CH2) 3 09 O 4298 2-iminoazepin-7-yl- (CH 2 ) 3 H H m 4 299 imidazol-4-ylamino- (CH2) 3 4300 imidazol-2-ylamino- (CH2) 3 4301 pyridin-2-ylamxno- (CH2) 3 4302 imidazol-2-ylamino- (CH2) 3 o 4303 pyridin-2-ylamino- (CH2) 3 4304 imidazol-2-ylamino- ( CH2 ) 2 4305 imidazol-2-ylamino- ( CH2 ) 2 4 306 imidazol-2-ylamino-carbonyl- (CH2) 2 4307 pyridin-2-ylamino- ( CH2 ) 2 4308 pyridin-2-ylamino- ( CH 2 ) 2 4309 pyridin-2-ylamino-carbonyl-(CH2) 2 NHS02CgH 2 - (2, 4, 6-CH3) 3 4310 imidazolin-2-ylamino- ( CH2 ) 2 NHS0 2 Ph 4311 imidazolin-2-ylamino-(CH2) 2 NHC0 2 CH 2 Ph 4312 tetrahydropyrimidin-2-ylamino- (CH ) 2 NHS0 2 Ph 4313 tetrahydropyrimidin-2-ylamino~ (CH2) 2 NHC0 2 CH2Ph 4314 benzimidazol-2-ylamino- (CH2) 2 NHS0 2 Ph 4315 benzimidazol-2-ylamino- (CH2)2 NHC0 2 CH2Ph CcO 4316 benzimidazol-2-ylamino-carbonyl- (CH2) 2 NHS02CgH 2 -(2, 4, 6-CH3) 3 09 O 4317 2-aminopyridin-6-yl- ( CH2 ) 2 NHSθ2P H H 4318 2-aminopyridin-6-yl- ( CH2 ) 2 NHC0 2 CH2Ph C Hm 4319 2-iminoazepin-7-yl- ( CH2 ) 2 NHS0 2 Ph co x 4320 2-iminoazepin-7-yl- ( CH2 ) 2 NHC0 2 CH2Ph m 4321 imidazol-4-ylamino- ( CH2 ) 2 NHS0 2 Ph so 4322 imidazol-4-ylamino- ( CH2 ) 2 NHC0 2 CH2Ph c m 4323 imidazol-2-ylamino- (CH2) NHS0 2 Ph σi 4324 imidazol-2-ylamino- (CH2) 4 NHC0 2 CH2Ph 4325 pyridin-2-ylamino- (CH2) 4 NHS0 2 Ph 4326 ρyridin-2-ylamino-(CH2) 4 NHC0 2 CH2Ph 4327 imidazolin-2-ylamino- (CH2) 4 NHS0 2 Ph 4328 tetrahydropyrimidin-2-ylamino- (CH2) NHSθ2Ph 4329 tetrahydropyrimidin-2-ylamino- (CH2) NHC0 2 CH2Ph 4330 benzimidazol-2-ylamino- (CH2) 4 NHS0 2 Ph 4331 benzimidazol-2-ylamino- (CH2) 4 NHC0 2 CH2Ph 4332 2-aminoρyridin-6-yl- (CH2) 4 NHS02Ph 4333 2-aminopyridin-6-yl-(CH2) 4 NHC0 2 CH2Ph 4334 2-iminoazepin-7-yl-(CH2) 4 NHS0 2 Ph 4335 2-iminoazepin-7-yl- (CH2) 4 NHC0 2 CH2Ph 4336 imidazol-4-ylamino-(CH 2 ) 4 NHS0 2 Ph 433 imidazol-4-ylamino- (CH2) 4 NHC0 2 CH2Ph 4338 imidazol-2-ylamino-(CH2) 3 NHSO2C6H2- (2,4, 6-CH3) 3 CO c 4339 pyridin-2-ylamino- (CH2) 3 NHS02C6H2"(2, , 6-CH3) 3 09 CO 4340 imidazol-2-ylamino- (CH2) 3 NHS02C H2~ (2,4, 6-CH3) 3 H H 4341 imidazol-2-ylamino- (CH2) 3 NHSO2C6H2- (2,4, 6-CH3) 3 C H m 4342 imidazol-2-ylamino- (CH2) 3 NHS02C H2- (2, 4, 6-CH3) 3 co m m 4343 imidazol-2-ylamino-(CH2) 3 NHS02CgH 2 - (2,4, 6-CH3) 3 H 1 NJ CD NJ I m oi 4344 imidazol-2-ylamino- (CH2) 3 HSθ2C H2~ (2, 4, 6-CH3) 3 4345 imidazol-2-ylamino- (CH2) 3 HSθ2CgH2- (2,4, 6-CH3) 3 4346 imidazol-2-ylamino- (CH2) 3 NHSO2C6H2- (2, , 6-CH3) 3 4347 imidazol-2-ylamino-(CH2) 3 NHSO2C6H2- (2,4, 6-CH 3 ) 3 4348 imidazol-2-ylamino-(CH2) 3 NHS02C 6 H 2 -(2,4,6-CH 3 ) 3 4349 imidazol-2-ylamino- (CH2) 3 NHS0 2 CgH 2 -(2,6-CH3)2-4- 4350 imidazol-2-ylamino-(CH2) 3 NHSθ2CgH 2 - (2, 6-CH3) 2"4- Ph 4351 imidazol-2-ylamino- (CH2) 3 HSθ2C H2- (2, 6-CH3) 2-4- Ph 4352 imidazol-2-ylamino- (CH2> 3 NHS02CgH2"(2, 6-CH3> 2 - - Ph c CO 4353 imidazol-2-ylamino- (CH2> 3 NHS02CgH2- (2, 6-CH3) 2 -4- 09 Ph H a 4354 imidazol-2-ylamino- (CH2> 3 NHS02CgH 2 - (2, 6-CH3>2- - C H m Ph co x 4355 imidazol-2-ylamino- (CH2) 3 NHSθ2C H2- (2, 6-CH3) 2 -4- m m Ph H 1 3 [^ 4356 imidazol-2-ylamino- (CH2 ) 3 NHSθ2C H2- (2, 6-CH3) 2 -4- c o r 1 Ph m ro NHSθ2C H2- (2, 6-CH3) 2~4- σ> 4357 imidazol-2-ylamino- (CH2) 3 Ph 4358 imidazol-2-ylamino-CH2 (o-CgH 4 ) NHS0 2 -(l-naphthyl) 4359 imidazol-2-ylamino-CH2 (o-CgH ) NHC0 2 CH2Ph 4360 imidazol-2-ylamino-CH2 (o-CgH 4 ) NHS02CgC2- (2,4, 6-Me3> 4361 pyridin-2-ylamino-CH2 (o-CgH ) NHS0 2 - (1-naρhthyl) 4362 pyridin-2-ylamino-CH2 (o-CgH 4 ) NHC0 2 CH2Ph 4363 pyridin-2-ylamino-CH2 (o-CgH 4 ) NHS02CgC2 - (2 , 4 , 6-Me3 ) 4364 imidazolin-2-ylamino-CH2 (0-C6H4) NHS0 2 - (1-naphthyl) 4365 imidazolin-2-ylamino-CH2 (o-C H4) NHC0 2 CH2Ph 4366 imidazolin-2-ylamino-CH2 (0-C6H4) NHSθ2C6C 2 -(2,4,6-Me 3 ) 4367 imidazolin-2-ylamino-(m-CgH4> NHS0 2 -(l-naphthyl) 4368 imidazolin-2-ylamino-(m-CgH 4 ) NHC0 2 CH2Ph 4369 imidazolin-2-ylamino- (m-CgH 4 ) NHS02CgC 2 - (2,4, 6-Me3> CO 09 c H m co x m I NJ CD 31 c I m oi Table 5 Ex. No. ιl4 .15 MS 5001 ιmidazol-2-ylaπuno- (CH2) 3 H H 5002 pyrιdιn-2-ylamιno-(CH2) 3 H NHCOOCH2Ph I 5003 ιmιdazolin-2-yl amino- (CH2) 3 H NHC0 2 CH i CgH4-(2-CH 3 ) NJ SO cπ 5004 tetrahydropyrιmidin-2-ylamino- (CH2) 3 H NHCθ2CH_C H4 - ( 3 -CH3 ) I 5005 bβnzιmidazol-2-ylamιno- (CH 2 ) 3 H NHCθ2CH z C6H 4 - (4-CH 3 ) 5006 2-aminopyridin-6-yl- (CH2) 3 H HCO2CH (2-pyrιdιnyl) 5007 2-imιnoazepin-7-yl- (CH 2 )3 H NHC02CH_ (3 -pyridinyl) 5010 imidazol-4-ylamino- (CH2)3 H NHCO2CH2 (2-thιazolyl) 5015 ιmιdazol-2-ylamino- (CH2) 3 H NHCO2CH2 (4-ιsoxazolyl) 5016 pyridin-2-ylaπιino- (CH2)3 H NHCθ2CH2<2-thιenyl) 5017 imidazolιn-2-ylamιno-(CH2) 3 H NHCθ2n-Bu 5018 tetrahydropyrimιdιn-2-ylamino- (CH2)3 H NHCθ 2 ι-Bu 5019 benzimidazol-2-ylamιno- (CH2) 3 H NHCθ2t-Bu 5020 2-aπunopyrιdm-6-yl- (CH 2 )3 H NHSOaPh 5021 2-iminoazepm-7-yl- (CH 2 ) 3 H NHS0 2 C 6 H4-(2-CH3) 5024 imidazol-4- lamino-(CH 2 ) 3 H NHSO^l2-py idyl) 5029 imidazol-2-ylamino- (CH 2 ) 3 H NHSO (4-ιsoxazolyl) 5030 pyridin-2-ylamino-(CH 2 )3 H NHS0 2 -[4-(3,5- dimethyl) isoxazolyl] 5031 ιmidazolin-2-ylamino-(CH 2 ) H NHS0 2 CgH4-(2-Br) 5032 tetrahydropyrimidin-2-ylamιno- (CH 2 )3 H NHS0 2 CgH4-(3-Br) 5033 benzιmidazol-2-ylamιno- (CH 2 )3 H HSθ C 6 H4-(4-Br) 5034 2-aminopyridin-6-yl- (CH 2 )3 H NHSO C 6 H -(2-F) 5035 2-iminoazepin-7-yl- (CH 2 ) 3 H NHSθ 2 C 6 H 4 -(3-F) 5038 imidazol-4-ylamino- (CH 2 ) 3 H NHSO^d-naphthyl) 5043 imidazol-2-ylamino- (CH 2 )3 H NHSO - i -Bu I NJ pyridin-2-ylamιno-(CH2) 3 H NHS0 2 -t -Bu SO 5044 ON I 5045 imidazol-2-ylamino-(CH 2 )3 (3,4- H methylenedioxy)phenyl 5046 pyridin-2-ylamino-(CH 2 )3 (3,4- methylenedioxy)phenyl 5047 imidazolin-2-ylamino- (CH 2 ) 3 (3,4- methylenedioxy)phenyl 5048 tetrahydropyrimidin-2-ylamιno- (CH 2 ) 3 (3,4- methylenedioxy)phenyl 5049 benzιmιdazol-2-ylamιno- (CH2) 3 (3,4- methylenedioxy(phenyl 5050 2-amιnopyrιdin-6-yl- (CH2) 3 (3,4- methylenedioxy)pheny1 5051 2-ιmιnoazepιn-7-yl- (CH 2 >3 (3,4- methylenedioxy)pheny1 5054 ιmιdazol-4-ylamino-(CH 2 )3 (3,4- ethylenedioxy)phenyl 5059 ιmιdazol-2-ylamιno- (CH ) 3 3-pyrιdmyl H 5060 pyrιdιn-2-ylammo- (CH 2 )3 3-pyrιdιnyl H 5061 ιmιdazolιn-2-ylamino- (CH 2 ) 3 3-pyrιdιnyl H 5062 tetrahydropyrιmιdin-2-ylamino-(CH 2 ) 3 3-pyrldinyl H 5063 benzιmιdazol-2-ylamιno- (CH 2 ) 3 3-pyrιdιnyl H I t 5064 2-ammopyrιdιn-6-yl- (CH 2 ) 3 3-pyrιdιnyl H SO I 5065 2-ιmιnoazepιn-7-yl- (CH2)3 3-pyrιdιnyl H 5068 ιmιdazol-4-ylamιno- (CH 2 ) 3 3-pyrιdιnyl H 5069 ιmιdazol-2-ylaιtuno-CH 2 (0-C6H4) H NHSθ 2 -(l-naphthyl) 5070 ιmιdazol-2-ylamιno-CH2(o-CgH > H NHCθ 2 CH2P 5071 ιmιdazol-2-ylamino-CH2(o-CgH4) H NHSO2C6C2-(2,4,6-Me 3 ) 5072 pyrιdιn-2-ylamιno-CH2 (0-C6H4) H NHSθ 2 -(l-naphthyl) 5073 pyrιdιn-2-ylaraιno-CH 2 (o-CgH4) H NHC0 2 CH2Ph 5074 pyrιdιn-2-ylamιno-CH 2 (0-C6H ) H NHSO2C6C2 - ( 2 , 4 , 6 -Me 3 ) 5075 ιmιdazolιn-2-ylamιno-CH2(0-C6H4) H NHSθ 2 - ( l -naphthyl ) 5076 imidazolin-2-ylamino-CH2 (o-C H4) H NHCO z CH 2 Ph 5077 imidazolin-2-ylamino-CH 2 (o-CgH4) H NHSθ2C 6 C2-(2,4,6-Me 3 ) 5078 imidazol in-2-yleunino- (m-CgH4) H NHSO_ - ( 1 -naphthy 1 ) 5079 imidazolin-2-ylamino- (m-CgH4) H HCO CH2P 5080 imidazolin-2-ylaroino- (m-CgH4) H NHS02C 6 C 2 -(2,4,6-Me 3 ) I NJ SO Table 6 Ex . No . |H >15 MS 6001 imidazol-2-ylamino- (CH 2 )3 H H 6002 pyridin-2-ylamino- (CH 2 )3 H NHC00CH2Ph 6003 imidazolin-2-yl amino-(CH 2 )3 H HCO2CH2C6H4- (2-CH3) NJ SO 6004 tetrahydropyrimidin-2-ylamino- (CH 2 )3 H NHCO2CH 2 C6H4- (3-CH3 ) 6005 benzimidazol-2-ylamino-(CH 2 ) 3 H NHCθ2CH 2 C H4- (4-CH3) 6006 2-aminopyridin-6-yl- (CH 2 )3 H NHCO2CH2 (2-pyridinyl) 6007 2-iminoazepin-7-yl- (CH 2 ) 3 H NHC0 2 CH 2 (3-pyridinyl) 6010 imidazol-4-ylamino- (CH 2 ) 3 H NHCO2CH2 (2-thiazolyl) 6015 imidazol-2-ylamino-(CH 2 )3 H NHC0 2 CH 2 (4-isoxazolyl) 6016 pyridin-2-ylamino- (CH 2 )3 H NHCO2CH2 (2-thienyl) 6017 imidazolin-2-ylamino-(CH 2 ) 3 H NHCθ2n-Bu 6018 tetrahydropyrimidin-2-ylamino- (CH 2 )3 H NHC0 2 i-Bu 6019 benzimidazol-2-yl__mino-(CH 2 ) 3 H NHCθ2t-Bu 6020 2-aminopyridin-6-yl-(CH ) 3 H NHS0 2 Ph 6021 2-irainoazepin-7-yl-(CH 2 ) 3 H NHS0 2 CgH4- (2-CH3) 6024 imidazol-4-ylamino-(CH 2 )3 H NHS0 2 (2-pyridyl) 6029 imidazol-2-ylamino-(CH 2 ) 3 H NHS0 2 (4-isoxazolyl) 6030 ρyridin-2-ylamino-(CH )3 H NHS0 2 -[4-(3,5- di ethyl) isoxazolyl] 6031 imidazolin-2-y lamino- (CH 2 ) 3 H NHS0 2 CgH4-(2-Br) 6032 tetrahydropyr imidin-2 -yleunino- (CH 2 ) 3 H NHSθ 2 C6H4-(3-Br) 6033 benzimidazol-2-ylamino-(CH 2 )3 H NHSθ 2 CgH4- (4-Bt) 6034 2-aminopyridin-6-yl-(CH 2 )3 H NHS0 2 CgH4-(2-F) 6035 2-iminoazepin-7-yl- (CH 2 ) 3 H NHSθ 2 C6H4-(3-F) 6038 imidazol-4-ylamino-(CH 2 )3 H NHS0 2 (1-naphthyl) 6043 imidazol-2-ylamino- (CH 2 )3 H NHS0 2 -i-Bu I O 6044 pyridin-2-ylamino- (CH ) 3 o H NHS0 2 -t-Bu o I 6045 imidazol-2-ylamino- (CH2) 3 (3,4- H methylenedioxy)phenyl 6046 pyridin-2-ylamino- (CH 2 )3 (3,4- methylenedioxy)phenyl 6047 imidazolin-2-ylamino- (CH 2 )3 (3,4- methylenedioxy)pheny1 6048 tetrahydropyrimidin-2-ylamino-(CH 2 )3 (3,4- methylenedioxy)phenyl 6049 benzimidazol -2 -ylamino- (CH 2 ) 3 (3,4- methylenedioxy)pheny1 6050 2-aminopyridin-6-yl- (CH 2 ) 3 (3,4- methylenedioxy)phenyl 6051 2-iminoazepin-7-yl-(CH 2 >3 (3,4- methylenedioxy)phenyl 6054 imidazol- -ylamino-(CH 2 )3 (3,4- methylenedioxy)phen 1 6059 imidazol-2-ylamino- (CH 2 >3 3-pyrιdinyl H 6060 pyridin-2-ylamino-(CH )3 3-pyrιdιnyl H 6061 imidazolin-2-ylamino- (CH ) 3 3-pyridinyl H 6062 tetrahydropyπmidin-2-ylamino- (CH ) 3 3-pyridinyl H 6063 benzimidazol-2-ylamino- (CH 2 ) 3 3-pyridιnyl H I UJ 6064 2-aminopyridin-6-yl- (CH 2 ) 3 O 3-pyridinyl H 6065 2-iminoazepin-7-yl- (CH ) 3 3-pyrιdιnyl H 6068 imidazol-4-ylamino-(CH 2 )3 3-pyridinyl H 6069 imidazol-2-ylaroino-CH (o-C6H4) H NHS0 2 -(l-naphthyl) 6070 imidazol-2-ylamino-CH 2 (0-C6H4) H NHC0 2 CH 2 Ph 6071 imidazol-2-ylamino-CH (o-CgH4) H NHS0 CgC 2 -(2,4, 6-Me 3 ) 607 2 pyridin-2-ylamino-CH (o-CgH4> H NHSθ 2 -(l-naphthyl) 6073 pyridin-2-ylamino-CH 2 (o-CgH4) H NHC0 2 CH 2 Ph 6074 pyridin-2-ylamino-CH 2 (o-CgH4) H NHS0 2 C 6 C2 - ( 2 , 4 , 6 -Me 3 ) 6075 imidazolin-2-ylamino-CH 2 (0-C6H4) H NHS0 2 - ( 1 -naphthyl ) 6076 imidazolin-2-ylamino-CH (o-CgH4) H NHC0 2 CH2Ph 6077 imidazolin-2-ylaroino-CH (0-C5H4) H NHS0 2 CgC 2 -(2,4, 6-Me 3 ) 6078 imidazolin-2-ylamino-(m-CgH4) H NHSO ^ ,- (1 -naphthyl) 6079 imidazolin-2-ylamino- (m-CgH ) H NHCO > ,CH2P 6080 imidazolin-2-ylamino-(m-CgH ) H NHS0 2 C 6 C 2 -(2,4,6-Me3) I J CD NJ I Table 7 Ex. 7001 imidazol -2-ylamino- (CH 2 )i CH NHCθ 2 CH^Ph 7002 imidazol -2-ylamino- (CH 2 ) 3 CH NHCθ 2 n-Bu 7003 imidazol -2-ylamino- (CH 2 ) 3 CH NHC0 2 ι-Bu o Ul I 7004 imidazol -2-ylamino- (CH 2 )3 CH NHCOPh 7005 imidazol -2-ylamino- (CH 2 ) 3 N NHCOCH 2 h 7006 imidazol -2-ylamino- (CH 2 ) 3 CH NHCOCH 2 CH 2 Ph 7007 imidazol -2-ylamino- (CH 2 ) 3 CH NHCOCH=CHPh 7008 imidazol -2-ylamino- (CH 2 )3 CH NHCOn-Bu 7009 imidazol -2-ylamino- (CH 2 ) 3 CH NHS0 2 Ph 7010 imidazol -2-ylamino- (CH 2 ) 3 CH NHS0 2 C fa H 4 -(2-CHj) 7011 imidazol -2-ylamino- (CH 2 ) 3 N NHS0 2 C fa H 4 -(3-CHj) 7012 imidazol -2-ylamino- (CH 2 ) 3 CH NHSθ 2 C 6 H 4 -(4-CHj) 7013 imidazol-2-ylamino- CH 2 ) 3 CH NHSO^C e H J -(2,6-CH :t ) 2 7014 imidazol-2-ylamino- CH 2 )j CH NHS0 2 C t H 2 -(2,4,6-CH j ) j 7015 imidazol-2-yla ino- CH 2 ) 3 CH NHSO z (2-pyridyl) 7016 imidazol-2-yl-unino- CH 2 )j CH NHSO^l -pyridyl) 7017 imidazol-2-ylamino- CH 2 ) 3 N NHSO^f4-pyridyl) 7018 imidazol-2-ylamino- CH 2 ) 3 CH NHS0 z (2-thιenyl) 7019 imidazol-2-ylamino- CH 2 ) 3 CH NHSθ .l4- (3,5- di ethyl) isoxazolyl ] 7020 imidazol-2-ylamino- CH 2 ) 3 CH NHS0 C tj H ) -(2,6-Cl 2 ) 7021 imidazol-2-ylamino- CH 2 ) 3 CH NHS0 2 (2-naphthyl) 7022 imidazol-2-ylamino- CH 2 )j CH NHSO^d-naphthyl) 7023 imidazol-2-ylamino- CH 2 ) 3 CH NHS0 2 C H 4 -(4-Ph) 7024 iraidazol-2-ylamino- CH 2 )3 CH NHSO z C c H 2 -(4-Ph-2,6- I UJ CD dimethyl) *- I 7025 imidazol-2-ylamino- CH 2 ) 3 CH CH NHS0 2 C 6 H 2 -(4-Ph-2,6- dichloro) 7026 imidazol-2-ylamino- CH 2 ) 3 H CH N CH NHSθ 2 C 6 H 4 -4-(4-pyridyl) 7027 imidazol-2-ylamino- CH 2 ) 3 H N CH CH NHS0 2 C 6 H 4 -4-(4-pyridyl)- 2, 6-dimethyl 7028 imιdazol-2-ylamino- CH 2 )j CH CH NHS0 2 C fc H 4 -4-(4-pyπdyl) - 2, 6-dιchloro 7029 imidazol-2-ylamino- CH 2 ) 3 CH N CH NHS0 2 C 6 H 4 -4-(2-oxazolyl) 7030 imidazol-2-ylamino- (CH ) 3 CH CH NHS0 2 C t ,H, j -4-(2-oxazolyl) - 2, 6-dimethyl 7031 imidazol-2-ylamino- (CH 2 ) CH CH NHS0 2 C t ,H -4-(2-oxazolyl) - 2, 6-dichloro 7031a imidazol-2-ylaroino-(CH2> CH CH NHS0 2 C 0 H 4 -4-(3-pyridyl)- 2, 6-dimethyl 7031b imidazol-2-yl-unino-(CH 2 ) CH CH NHS0 2 C t ,H 4 -4- (2-furyl) -2,6- dimethyl 7031c imidazol-2-ylamino- (CH ) N CH CH NHS0 2 C D H 4 -4-(3-_uryl) -2,6- dimethyl 7031d imidazol-2-ylamino- (CH ) 3 CH CH NHS0 C t H 4 -4-(5-pyrazolyl) - 2, 6-dimethyl 7032 imidazol 2-ylamino- (CH 2 ) 3 CH NHSθ CH 2 Ph I J 7033 imidazol •2-ylaroino- (CH;,^ CH NHS0 2 -n-Bu o cn I 7034 imidazol •2-ylamino- (CH 2 )3 CH NHS0 2 NHPh 7035 imidazol -2-ylamino- (CH 2 ) 3 N NHS0 2 NHC έ H 3 -(2,6-Me2) 7036 imidazol -2-ylamino- (CH 2 ) 3 CH NHSθ 2 NHC 6 H 2 -(2,4,6-Me 3 ) 7037 imidazol -2-ylamino- (CH 2 )j CH NHS0 2 NH(2-naphthyl) 7038 imidazol -2-ylamino- (CH 2 ) 3 CH NHS0 2 NH(l-naphthyl) 7039 imidazol -2-ylamino- (CH 2 ) 3 CH NHS0 NHC 6 H 4 -(4-Ph) 7040 imidazol -2-ylamino- (CH 2 ) 3 CH NHS0 2 NHC b H 2 -(4-Ph-2, 6- dimethyl ) 7041 imidazol-2-ylamino-(CH 2 ) 3 CH CH N NHS0 2 NHC b H 2 -(4-Ph-2,6- dichloro) 7042 imidazol-2-ylamino-(CH )j CH NHS0 2 NHCH 2 Ph 7043 imidazol-2-ylamino- {CH 2 ) 3 CH NHS0 2 NH-n-Bu 7044 imidazol-2-ylamino-(CH 2 )3 CH NHS0 2 NH-i-Bu 7045 imidazol-2-ylamino-(CH 2 ) CH NHS0 2 NH-t-Bu 7046 pyridιn-2-yla-nino-{CH 2 )3 CH NHC0 2 CH 2 Ph 7047 pyπdιn-2-ylamino- (CH 2 ) 3 N NHC0 n-Bu 7048 pyrιdm-2-ylamino-(CH2) 3 CH NHC0 1-Bu 7049 pyridin-2-ylamino- (CH 2 ) 3 CH NHCOPh 7050 pyridin-2-ylamino- (CH ) 3 CH NHC0CH Ph 7051 pyπdin-2-ylamino- (CH 2 ) j CH NHC0CH 2 CH Ph 7052 pyridin-2 -ylamino- (CH 2 ) 3 CH NHCOCH=CHPh I C-> o 7053 pyridin-2-ylamino- (CH 2 ) j N NHCOn-Bu ON I 7054 pyrιdin-2-y lamino- (CH 2 ) 3 CH NHS0 2 Ph 7055 pyridin-2-ylamino-(CH 2 ) 3 CH NHS0 2 C 6 H 4 -(2-CHj) 7056 pyridin-2-ylaroino-(CH ) 3 N NHS0 2 C b H 4 -(3-CH 3 ) 7057 pyridιn-2-ylamino- (CH 2 ) 3 CH NHSO^C b H 4 -(4-CHj) 7058 pyridin-2-ylamino- (CH 2 ) 3 CH NHS0 2 C b H 3 -(2,6-CH 3 ) i i 7059 pyridin-2-ylamino-(CH2) 3 CH NHSθ 2 C b H^-(2, 4,6-CHj) 3 7060 pyridin-2-ylaroino- (CH 2 ) j CH NHS0 2 (2-pyπdyl) 7061 pyridιn-2-ylamino- (CH ) 3 CH NHS0 2 (3-pyridyl) 7062 pyridin-2-ylamino- (CH 2 )3 N NHS0 2 (4-pyridyl) 7063 pyridin-2-ylamino- (CH2 ) 3 CH NHS0 2 (2-thienyl) 7064 pyridin-2-ylamino- (CH 2 ) 3 CH NHS0 2 [4-(3,5- dimethyl) isoxazolyl] 7065 pyridin-2-yla-oino- (CH 2 ) 3 CH NHS0 2 C b Hj-(2,6-Cl 2 ) 7066 pyridin-2-ylamino- (CH 2 ) 3 CH NHS0 2 (2-naphth l) 7067 pyridin-2-yl_unino-(CH2)3 CH NHS0 2 (1-naphthyl) 7068 pyridin-2-ylamino-(CH 2 )3 CH NHS0 2 C b H 4 -(4-Ph) 7069 pyridin-2-ylamino- (CH 2 ) 3 CH NHSθ 2 C t H^-(4-Ph-2,6- dimethyl) 7070 pyridin-2-ylamino- (CH 2 ) CH CH NHS0 2 C b H 2 -(4-Ph-2,6- dichloro) 7071 ρyridin-2-ylamino- (CH 2 ) 3 H CH N CH NHS0 2 C b H 4 -4-(4-ρyridyl) 7072 pyridin-2-ylamino- (CH >3 H N CH CH NHS0 2 C H 4 -4-(4-pyridyl)- I CJ o 2, 6-dimethyl ^J I 7073 pyridin-2-ylamino- (CH 2 )3 CH CH NHS0 2 C b H 4 -4-(4-pyridyl)- 2, 6-dichloro 7074 pyridin-2-ylamino- (CH 2 ) 3 H CH N CH NHS0 2 C 6 H 4 -4-(2-oxazolyl) 7075 pyridin-2-ylamino- (CH 2 )3 H CH N CH NHS0 C b H 4 -4-(2-oxazolyl) - 2, 6-dimethyl 7076 pyridin-2-ylamino- (CH ) 3 CH CH NHS0 2 C fc H 4 -4-(2-oxazolyl) - 2, 6-dichloro 7076a pyridin-2-ylamino- (CH 2 )3 CH CH NHS0 2 C b H 4 -4-(3-pyridyl)- 2 , 6-dimethyl 7076b pyridin-2-ylamino- CH 2 ) 3 CH CH NHS0^C t H 4 -4-(2-furyl)-2,6- dimethyl 7076c pyridin-2-ylamino- CH 2 ) 3 N CH CH NHSO C ( H -4-(3-furyl) -2, 6- dimethyl 7076d pyridin-2-ylamino- CH 2 ) 3 CH CH NHS0 2 C b H 4 -4-(5-pyrazolyl) - 2, 6-dimethyl 7077 ρyridin-2-ylamino- CH 2 ) 3 NHS0 2 CH Ph 7078 pyridin-2- ylamino- CH 2 ) 3 CH NHS0 2 -n-Bu 7079 pyridin-2-ylamino- CH 2 ) 3 CH NHS0 NHPh 7080 pyridin-2-ylamino- CH 2 ) 3 CH NHS0 2 NHC c H J -(2, 6-Me 7081 pyridin-2- ylamino- CH 2 ) 3 CH NHS0 NHC b H_.-(2,4,6-Me 3 ) 7082 pyridin-2-ylamino- CH 2 )i CH NHSθ 2 NH(2-naphthyl) 7083 ρyridin-2-ylamino- CH ) 3 N NHS0 2 NH(1-naphthyl) I O pyridin-2-yla ino- o 7084 CH 2 ) 3 CH NHSO^NHC c ,H -(4-Ph) 00 I 7085 pyridin-2-ylaroino- CH 2 ) 3 CH NHSθ 2 NHC 6 H -(4-Ph-2, 6- dimethyl) 7086 pyridin-2-ylamino- CH 2 >3 CH CH NHS0 NHC 6 H 2 -(4-Ph-2, 6- dichloro) 7087 pyridin-2-ylamino- CH 2 ) 3 H CH NHS0 2 NHCH Ph 7088 pyridin-2-ylamino- CH 2 ) 3 H CH NHS0 2 NH-n-Bu 7089 pyridin-2-ylamino- CH 2 ) 3 H N NHSθ 2 NH-i-Bu 7090 pyridin-2-ylamino- CH 2 ) 3 H CH NHS0 2 NH-t-Bu 7091 tetrahydropyrimidin-2-ylamino- (CH >3 C H5 CH NHC0 2 CH 2 Ph 7092 tetrahydropyrimidin- 2-ylamino- CH 2 CH NHCO n-Bu 7093 tetrahydropyrimidin- 2-ylamιno- CH 2 CH NHCO z ι-Bu 7094 tet ahydropyri idin-2-ylamιno- CH 2 CH NHCOPh 7095 tetrahydropyrimid 2-ylamino- CH, N NHCOCH_Ph 7096 tetrahydropyrimidin 2-ylamino- CH 2 CH NHCOCH. H_Ph 7097 tetrahydropyrimidin 2-ylamino- CH Z CH NHCOCH=CHPh 7098 tetrahydropyrimidin 2-ylamino- CH 2 CH NHCOn-Bu 7099 tetrahydropyrimidin- 2-ylamino- CH CH NHSθ 2 Ph 7100 tetrahydropyrimidin- 2-ylamιno- CH 2 CH NHS0 2 C t H 4 -(2-CHj) 7101 tetrahydropyrimidm- 2-ylamino- CH 2 N NHS0 2 C b H -(3-CH j ) 7102 tetrahydropyrimidin 2-ylamino- CH 2 CH NHS0 2 C t ,H 4 -(4-CH 3 ) 7103 tetrahydropyrimidin- 2-ylamιno- CH CH NHS0 2 C b Hj-(2,6-CH J ) / 7104 tetrahydropyrimidiinn-2-ylamino- CH 2 CH NHSθ 2 C b H,-(2,4,6-CHj) 3 I co 7105 tetrahydropyrimidin-2-ylamino- o CH 2 CH NHSθ 2 (2-pyridyl) SO I 7106 tetrahydropyrimidin 2-ylamιno- CH CH NHS0 2 (3-pyridyl) 7107 tetrahydropyrimidin 2-ylamino- CH 2 N NHS0 2 (4-pyridyl) 7108 tetrahydropyrimidin 2-ylamino- CH 2 CH NHS0 2 (2-thienyl) 7109 tetrahydropyrimidin 2-ylamino- CH 2 CH NHS0 2 [4-(3,5- dimethyl) isoxazolyl J 7110 tetrahydropyrimidin-2-ylammo- CH 2 CH NHSθ 2 C 6 H 3 -(2,6-Cl 2 ) 7111 tetrahydropyrimidin-2-ylamino- CH 2 CH NHS0 2 (2-naphthyl) 7112 etrahydropyrimidin-2-ylamino- CH 2 CH NHS0 2 (1 -naphthyl) 7113 te rahydropyrimidin-2-ylamino- CH 2 CH NHS0 2 C 6 H 4 -(4-Ph) 7114 tetrahydropyrimidin-2-ylamino-(CH 2 )3 H CH N CH NHS0 2 C b H. : -(4-Ph-2,6- dimethyl) 7115 tetrahydropyrimidin-2-ylamino- (CH 2 )3 H CH CH NHSO C b H 2 -(4-Ph-2,6- dichloro) 7116 tetrahydropyrimidin-2-ylamino-(CH 2 ) 3 H CH N CH NHS0 2 C e H -4-(4-pyridyl) 7117 tetrahydropyrimidin-2-ylamino- (CH 2 ) 3 H N CH CH NHS0 2 C b H 4 -4-(4-pyridyl)- 2, 6-dimethyl 7118 tetrahydropyrimidin-2-ylamino- (CH 2 ) 3 H CH CH NHS0 2 C έ H -4-(4-pyridyl)- 2, 6-dichloro 7119 tetrahydropyrimidin-2-ylamino- (CH ) 3 H CH N CH NHS0 2 C b H -4-(2-oxazolyl) 7120 tetrahydropyrimidin-2-ylamino- (CH )3 H CH N CH NHS0 2 C b H 4 -4-(2-oxazolyl) - 2, 6-dimethyl 7121 tetrahydropyrimidin-2-ylamino- (CH 2 )3 H N CH CH NHS0 2 C b H -4-(2-oxazolyl)- I O 2, 6-dichloro 7121a tetrahydropyriroidin-2-ylamino- (CH 2 )3 H N CH CH NHS0 2 C b H 4 -4-(3-pyridyl)- 2, 6-dimethyl 7121b tetrahydropyrimidin-2-ylamino-(CH 2 )3 H N CH CH NHS0 2 C 6 H 4 -4-(2-fυryl) -2,6- dimethyl 7121c tetrahydropyrimidin-2-ylamino-(CH 2 )3 H N CH CH NHS0 2 C 6 H 4 -4-(3-furyl) -2.6- dimethyl 7121d tetrahydropyrimidin-2-ylamino-(CH 2 ) 3 H N CH CH NHS0 2 C 6 H 4 -4-(5-pyrazolyl) - 2, 6-dimethyl 7122 tetrahydropyrimidin-2-ylamino-(CH 2 )3 CH 3 CH N CH NHS0 2 CH 2 Ph X CJ X X X X X X X X X X X - -i - -i u υ cj u υ c j c j c j c j 0 0 0 0 0 0 0 0 0 0 0 0 0 c e c c c c c c c c c c c E E E E E E E E , E fl fl fl fl fl fl fl fl fl g ( εfl fl § fl fl ε -c~N ~rN —CN _C. _f. _fM. -t. _C. ^ >« >- >- >. - >, >. >. >, >, >. u u u υ u c u u i I i i i I i i i i I I I 0 O 0 0 O O O O C C C C C C C C C C C C C C C C C C C C C 7144 imidazol 2-ylamino- CH 2 )3 CH NHS0 2 Ph 7145 imidazol 2-ylamino- CH 2 )3 CH NHSO C b H 4 -(2-CH j ) 7146 imidazol 2-ylamino- CH 2 ) 3 N NHS0 C b H 4 -(3-CH J ) 7147 imidazolin- 2-yl.unino- CH 2 )3 CH NHSθ2C b H 4 -(4-CHj) 7148 imidazolin- 2-yleunino- CH 2 ) 3 CH NHS0 2 C-Hj-(2,6-CH j )_ 7149 imidazolin- 2-ylamino- CH 2 )3 CH NHSθ2C e H 2 -(2,4,6-CH )3 7150 imidazolin- 2-ylamino- CH 2 ) 3 CH NHS0 2 (2-pyrιdyl) 7151 imidazolin- 2-ylamino- CH 2 ) 3 CH NHS0 2 (3-pyridyl) 7152 imidazolin- 2-ylamino- CH 2 ) 3 N NHS0 (4-pyridyl) 7153 imidazolin 2-ylamino- CH 2 ) 3 CH NHS0 2 (2-thienyl) 7154 imidazolin- 2-ylaroino- CH 2 ) 3 CH NHSθ 2 [4-(3,5- di ethyl) isoxazolyl] 7155 imidazolin-2-ylamino- CH 2 ) 3 CH NHSθ2C b Hj-(2,6-Cl 2 ) I CO 7156 imidazo1in-2-ylamino- CH 2 )j CH NHS0 2 (2-naphthyl) 7157 imidazolin-2-ylamino- CH 2 ) 3 CH NHS0 2 (1-naphthyl) 7158 imidazolin-2-ylamino- CH 2 ) 3 CH NHSθ 2 C 6 H 4 -(4-Ph) 7159 imidazolin-2-ylamino- CH 2 ) 3 CH NHS0 2 C 6 H 2 -(4-Ph-2,6- dimethyl) 7160 imidazolin-2-ylaroino- CH 2 ) 3 CH CH NHSθ 2 C b H 2 -(4-Ph-2,6- dichloro) 7161 imidazolin-2-ylamino- CH 2 ) 3 H CH N CH NHS0 2 C 6 H 4 -4-(4-pyrιdyl) 7162 imidazolin-2-ylamino- CH 2 ) 3 H N CH CH NHS0 2 C 6 H -4-(4-pyridyl) 2, 6-dimethyl 7163 imidazolin-2-ylamino- (CH 2 ) 3 CH CH NHSO,C b H 4 -4-(4-pyridyl)- 2, 6-dichloro 7164 imidazolin-2-ylamino-(CH 2 )3 H CH N CH NHS0 2 C r ,H -4-(2-oxazolyl) 7165 iroidazolin-2-ylamino-(CH 2 ) 3 H CH N CH NHS02C o H 4 -4-(2-oxazolyl) - 2, 6-dimethyl 7166 imidazolin-2-ylamino-(CH 2 )3 CH CH NHS0 2 C b H 4 -4-(2-oxazolyl) - 2, 6-dichloro 7166a imidazolin-2-ylamino- (CH )3 CH CH NHS0 2 C t H 4 -4-(3-pyridyl)- 2, 6-dimethyl 7166b imidazolin-2-ylamino- (CH 2 )3 CH CH NHSθ2C b H 4 -4-(2--uryl)-2,6- dimethyl 7166c imidazolin-2-ylamino- (CH 2 ) 3 CH CH NHSθ 2 C c H 4 -4-(3-£uryl)-2, 6- dimethyl CH CH NHSθ 2 C D H 4 -4-(5-pyrazolyl) - 2, 6-dimethyl ylamino- (CH 2 ) 3 N NHS0 2 CH Ph ylamino-(CH 2 )3 CH NHS0 2 -n-Bu -ylamino-(CH 2 )3 CH NHS0 2 NHPh -ylamino-(CH 2 ) CH NHS0 2 NHC b H j -(2,6-Me 2 ) -ylamino- (CH 2 )3 CH NHSθ 2 NHC b H -(2,4,6-Me 3 ) -ylamino-(CH 2 )3 CH NHS0 2 NH( 2 -naphthyl) -ylamino-(CH 2 )3 N NHSθ 2 NH(l -naphthyl) -ylamino-(CH ) 3 CH NHSθ 2 NHC 6 H 4 - ( 4 - Ph ) 7175 imidazolin-2-ylamino- (CH, ) 3 CH CH NHSO ^ NHC t H_- (4-Ph-2, 6- dimethy 1 ) 7176 imidazolin-2-ylamino- (CH 2 ) j CH CH NHSO,NHC t H_- (4-Ph-2, 6- dichloro) 7177 imidazolin-2 -ylamino- (CH t ) Δ NHSO ^ NHCH_Ph 7178 imidazolin-2 -ylamino- (CH2 ) 3 NHSO NH-n-Bu 7179 imidazolin-2 -ylamino- (CH 2 ) 3 NHSO_NH-ι-Bu 7180 imidazolin-2 -ylamino- (CH 2 ) j NHSO,NH-t-Bu 7181 benzimidazol -2-y lamino- (CH 2 ) 3 NHCO,CH,Ph 7182 benzimidazol -2-ylamιno- (CH 2 ) 3 NHCO,n-Bu 7183 benzimidazol -2-ylamιno- (CH 2 ) 3 NHCO ^ i-Bu 7184 benzimidazol -2-ylamino- (CH ) 3 NHCOPh 7185 benzimidazol -2-ylamino- (CH 2 ) 3 NHCOCH j Ph I O 7186 benzimidazol -2-ylamιno- (CH,) j NHCOCH, CH 2 Ph I 7187 benzimidazol -2-ylamino- (CH2) 3 NHCOCH=CHPh 7188 benzimidazol -2-ylamino- (CH2) 3 NHCOn-Bu 7189 benzimidazol -2 -ylamino- (CH2) 3 NHS0 2 Ph 7190 benzimidazol -2 -ylami no- (CH2 ) 3 NHS0 2 C b H 4 -(2-CH 3 ) 7191 benzimidazol -2-ylamino- (CH2) 3 NHS0 2 C b H 4 -(3-CHj) 7192 benzimidazol -2-ylamιno- (CH2) NHSO,C t ,H 4 -(4-CH J ) 7193 benzimidazol -2-ylamino- (CH2 ) 3 NHS0 2 C b H 3 -(2,6-CH 3 ), 7194 benzimidazol -2-ylamino- (CH2) 3 NHS0 2 C b H 2 -(2,4,6-CHj)3 7195 benzimidazol -2-y lamino- (CH 2 ) 3 NHS0 2 ( 2 -pyridyl) 7196 benzimidazol-2-ylamino- NHS0 2 ( 3-pyridyl) 7197 benzimidazol-2-ylamino- NHS0 2 (4-pyridyl) 7198 benzimidazol-2-ylamino- NHSO, (2-thienyl) 7199 benzimidazol-2-ylamino- NHSO [4-(3,5- dimethyl) isoxazolyl ) 7200 benzimidazol-2-ylamino- NHS0 2 C b H J -(2,6-Cl 2 ) 7201 benzimidazol-2-ylamino- NHS0 2 (2-naphthyl) 7202 benzimidazol-2-ylamino- NHSO, (1-naphthyl) 7203 benzimidazol-2-ylamino- NHSO,C b H 4 -(4-Ph) 7204 benzimidazol-2-ylamino- NHS0 2 C tJ H2-(4-Ph-2,6- dimethyl ) 7205 benzimidazol-2-ylamino- CH 2 ). CH CH NHSθ 2 C b H,-(4-Ph-2,6- dichloro) I O 7206 benzimidazol-2-ylamino- NHS0 2 C b H 4 -4-(4-pyridyl) cn I 7207 benzimidazol-2-yla ino- NHS0 2 C c H 4 -4-(4-pyridyl) - 2, 6-dimethyl 7208 benzimidazol-2-ylaroino- CH 2 ) 3 CH CH NHS0 2 C b H 4 -4- (4-pyridyl) - 2, 6-dichloro 7209 benzimidazol-2-ylamino- NHS0 2 C b H 4 -4- (2-oxazolyl) 7210 benzimidazol-2-ylamino- NHS0 2 C b H 4 -4-(2-oxazolyl) - 2, 6-dimethyl 7211 benzimidazol-2-ylamino- (CH 2 ) 3 CH CH NHS0 C b H 4 -4- (2-oxazolyl) - 2, 6-dichloro 7211a benzimidazol-2-ylamino- (CH ) 3 CH CH NHS0 2 C b H 4 -4-(3-pyπdyl) - 2, 6-dimethyl 7211b benzimidazol-2-ylamino-(CH 2 CH CH NHS0 2 C b H 4 -4-(2-furyl) -2,6 dimethyl 7211c benzimidazol-2-ylamino- (CH 2 ) N CH CH NHS0 2 C b H 4 -4-(3-furyl)-2,6- dimethyl 7211d benzimidazol-2-ylamino-(CH ) 3 CH CH NHS0 2 C b H 4 -4-(5-pyrazolyl) - 2, 6-dimethyl 7212 benzimidazol CH NHSθ 2 CH,Ph 7213 benzimidazol CH NHSO,-n-Bu 7214 benzimidazol CH NHSO,NHPh 7215 benzimidazol N NHS0 2 NHC b Hj-(2,6-Me2) 7216 benzimidazol CH NHS0 2 NHC 6 H 2 -(2,4,6-Mβ3) I CO 7217 benzimidazol CH NHSθ 2 NH(2-naphthyl) OΛ I 7218 benzimidazol CH NHS0 2 NH(1-naphthyl) 7219 benzimidazol CH NHS0 2 NHC b H 4 -(4-Ph) 7220 benzimidazol CH NHS0 2 NHC b H 2 -(4-Ph-2,6- dimethyl) 7221 benzimidazol-2-ylamino- (CH 2 ) 3 CH CH N NHSθ2NHC b H 2 -(4-Ph-2,6- dichloro) 7222 benzimidazol-2-ylamino- (CH )3 CH NHSθ 2 NHCH 2 Ph 7223 benzimidazol-2-ylamino- (CH 2 >3 CH NHSθ 2 NH -n- Bu 7224 benzimidazol-2-ylamino-(CH 2 )3 CH NHS0 2 NH - 1 -Bu 7225 benzimidazol-2 -ylamino- (CH 2 )3 H N CH CH NHS0 2 NH-t-Bu 7226 2-aminopyridin H CH N CH NHCO,CH,Ph 7227 2-aminopyridin H CH CH N NHCO,n-Bu 7228 2-aminopyridin H N N CH NHC0 2 i-Bu 7229 2-aminopyridin H N CH CH NHCOPh 7230 2-aminopyridin H CH N CH NHCOCH,Ph 7231 2-aminopyridin H N CH CH NHCOCH,CH,Ph 7232 2-aminopyridin H CH N CH NHCOCH=CHPh 7233 2-aminopyrid n H CH CH N NHCOn-Bu 7234 2-aminopyridin H N CH CH NHS0,Ph 7235 2-aminopyrid n H CH N CH NHS0 C c H 4 -(2-CHj) 7236 2-aminopyrid n H CH CH N NHS0 2 C b H -(3-CHj) 7237 2-aminopyrid n H N N CH NHS0 2 C b H 4 -(4-CHj) I CO 7238 2-aminopyrid n H N CH CH NHS02C H 3 -(2,6-CHj) 2 7239 2-aminopyrid n H CH N CH NHSθ2C 0 H2-(2,4,6-CH )j 7240 2-aminopyridin H N CH CH NHSθ 2 (2-pyridyl) 7241 2-aminopyridin H CH N CH NHS0 2 (3-pyridyl) 7242 2-aminopyridin H CH CH N NHS0 2 (4-pyridyl) 7243 2-aminopyridin H N N CH NHS0 2 (2-thienyl) 7244 2-aminopyridin CH 3 N CH CH NHSθ2[4-(3,5- dimethy l ) isoxazoly l 1 7245 2--uninopyridin-6-yl- ( CH 2 ) 2 H CH N CH NHSθ 2 C b H 3 - ( 2 , 6 -Cl 2 ) 7246 2-aminopyridin-6-yl- ( CH2>2 H N CH CH NHSθ 2 ( 2 -naphthyl ) 7247 2-aminopyridin-6-yl- (CH ) 2 CH NHSO U-naphthyl) 7248 2-aminopyridin-6-yl- (CH 2 ) ;. CH NHS0 2 C b H 4 - (4-Ph) 7249 2-_minopyridin-6-yl-(CH 2 ) 2 CH NHS0 2 C b H 2 -(4-Ph-2, 6- dimethyl) 7250 2-aminopyridin-6-yl- (CH 2 ) 2 CH CH NHS0 2 C H,-(4-Ph-2,6- dichloro) 7251 2-aminopyridin-6-yl- ( CH 2 ) 2 H CH N CH NHSO,C b H 4 -4- (4-pyridyl) 7252 2-aminopyridin-6-yl- ( CH2 ) 2 H N CH CH NHSO C b H.,-4-(4-pyridyl)- 2, 6-dimethyl 7253 2-aminopyridin-6-yl- ( CH2 ) 2 CH CH NHS0 2 C b H 4 -4-(4-pyridyl)- 2, 6-dichloro 7254 2-aminopyridin-6-yl- ( CH 2 ) 2 H CH N CH NHSO,C b H 4 -4- (2-oxazolyl) 7255 2-aminopyridin-6-yl- ( CH2>2 H CH N CH NHS0 2 C b H 4 -4-(2-oxazolyl) - 2, 6-dimethyl oo I 7256 2-aminopyridin-6-yl-(CH2> 2 CH CH NHS0 C b H -4-(2-oxazolyl)- 2, 6-dichloro 7256a 2-aminopyridin-6-yl-(CH 2 ) 2 N CH CH NHS0 2 C 6 H 4 -4-(3-pyridyl)- 2, 6-dimethyl 7256b 2-aminopyridin-6-yl- (CH 2 ) 2 CH CH NHSθ 2 C 6 H 4 -4-(2-furyl)-2,6- dimethyl 7256c 2-aminopyridin-6-yl-(CH ) 2 CH CH NHS0 2 C 6 H 4 -4-(3-furyl)-2,6- dimethyl 7256d 2-aroinopyridin-6-yl- ( CH 2 ) 2 CH CH NHSO,C Ll H -4-(5-pyrazolyi; 2, 6-dimethyl 7257 2-aminopyridin- N 7258 2-aminopyridin- CH NHSO,-n-Bu 7259 2-aminopyridin- CH NHSO,NHPh 7260 2-aminopyridin- CH NHSO,NHC b Hj- (2, 6-Me,) 7261 2-aminopyridin- CH NHSO ^ NHC b H 2 -(2,4, 6-Me j ) 7262 2-aminopyridin- CH NHS0 2 NH(2-naphthyl) 7263 2-aminopyridin- N NHSO,NH(l-naphthyl) 7264 2-aminopyridin- CH NHSO,NHC b H 4 -(4-Ph) 7265 2-aminopyridin- CH NHSO,NHC b H,-(4-Ph-2,6- dimethyl) 7266 2-aminopyridin-6-yl- ( CH 2 ) 2 CH CH NHS0 2 NHC 6 H 2 -(4-Ph-2, 6- I O dichloro) co I 7267 2-aminopyridin-6-yl- ( CH2 ) 2 CH NHS0 2 NHCH 2 Ph 7268 2-_uninopyridin-6-yl- ( CH2 ) 2 CH NHSO,NH-n-Bu 7269 2-aminoρyridin-6-yl-(CH 2 ) 2 N NHS0 2 NH-i-Bu 7270 2-aminopyridin-6-yl- (CH 2 ) 2 CH NHSO,NH-t-Bu 7271 imidazol-2-ylamino-CH2(0-C6H4) -CH2 CH NHSθ 2 -(l-naphthyl) 7272 imidazol-2-ylamino-CH2(0-C6H4) -CH 2 CH NHC0 2 CH 2 Ph 7273 imidazol-2-ylamino-CH2 (0-C6H4) -CH2 CH NHS0 2 C6C2-(2,4,6- e3) 7274 pyridin-2-ylamino-CH2 (0-C6H4) -CH2 CH NHS0 2 -(1-naphthyl) 7275 pyridin-2-ylaunino-CH2(0-C6H4)-CH2 CH NHC0 2 CH 2 Ph 7276 pyridin-2-ylamino-CH2 (0-C6H4) -CH2 H CH NHS0 2 C 6 C2-(2,4,6-Me 3 ) 7277 imidazolin-2-ylamino-CH (0-C6H4) -CH 2 H CH NHS0 -(l-naphthyl) 7278 imidazol in-2-ylamino-CH2 (0-C6H4 ) -CH2 H CH NHC0 2 CH2Ph 7279 imidazolin-2-ylamino-CH2 (0-C6H4) -CH2 H CH NHSθ2CgC2-(2, 4, 6-Me 3 ) 7280 imidazolin-2-ylamino-(o-C6H4) -CH2 H CH NHSO,- (1 -naphthyl) 7281 imidazol in-2- lamino- (o-CgH4 ) -CH2 H CH NHC0,CH2Ph 7282 imidazolin-2-ylamino-(o-C6H4) -CH 2 H CH NHS0 2 C 6 C2-(2,4,6-Me3) I co NJ O I Table 8 Ex . No . R9 ι l 5 MS 8001 imidazol ■2-ylamino- ( CH 2 ) 3 N NHC0,CH,Ph 8002 imidazol 2-ylamino- (CH 2 »3 CH NHCθ2n-Bu 8003 imidazol -2-ylamino- (CH 2 ) j N NHC0 2 i-Bu 8004 imidazol •2-ylamino- ( CH 2 ) 3 CH NHCOPh 8005 imidazol •2-ylamino- ( CH 2 ) 3 N NHCOCH 2 Ph 8006 imidazol -2-ylamino- ( CH 2 ) 3 CH NHCOCH CH 2 Ph 8007 imidazol -2-ylamino- (CH 2 ) 3 N NHCOCH=CHPh 8008 imidazol -2-ylamino- (CH 2 ) j CH NHCOn-Bu 8009 imidazol -2-ylamino- ( CH 2 ) 3 N NHSO,Ph 8010 imidazol -2-ylamino- ( CH 2 ) 3 CH NHSθ 2 C b H 4 -(2-CHj) 8011 imidazol-2-ylamino- ( CH 2 ) 3 N NHS0 2 C b H 4 -(3-CHj) 8012 imidazol-2-ylamino- (CH 2 ) 3 CH NHS0 2 C 6 H 4 -(4-CHj) 8013 ιmιdazol-2-ylamino-(CH 2 )j CH 3 CH CH N NHSO,C 6 H J -(2,6-CH 3 ) 2 8014 ιmιdazol-2-ylamino- (CH 2 ) 3 H CH CH N NHS0 2 C t H,- ( 2,4,6-CH 3 )3 8015 imιdazol-2-ylamino-{CH 2 ) 3 CHj CH CH N NHSO_(2-pyrιdyl) 8016 imidazol-2-ylamino-(CH 2 )3 H N CH CH NHSO ^ (3-pyridyl) 8017 ιmιdazol-2-ylamino-(CH 2 ) 3 CH3 CH CH N NHSO,(4-pyrιdyl) 8018 ιmιdazol-2- lamino-(CH 2 ) 3 H N N CH NHS0 2 (2-thιenyl) 8019 imidazol-2-ylamino-(CH 2 )3 CH 3 CH CH N NHS0 2 [4-(3,5- dimethyl) isoxazolyl) 8020 ιmιdazol-2-ylamino-(CH 2 ) 3 H CH CH N NHSO,C b Hj-(2,6-Cl 2 ) 8021 imidazol-2-ylamιno- ( CH 2 >3 CH 3 CH CH N NHS0 2 (2-naphthyl) 8022 ιmidazol-2-ylamino- (CH ) 3 H CH CH N NHS0 2 (1-naphthyl) 8023 imidazol-2-ylamino- (CH 2 )3 CHj CH CH N NHS0_C b H -(4-Ph) 8024 imidazol-2-ylamιno-(CH 2 )3 H CH CH N NHSO,C fc H 2 -(4-Ph-2,6- I O ts di ethyl) 8025 ιmidazol-2-ylamιno- ( CH 2 ) 3 H CH CH N NHSθ 2 C b H 2 -(4-Ph-2,6- dichloro) 8026 ιmιdazol-2-ylamιno- (CH )3 CH 3 CH CH N NHS0 2 C 6 H 4 -4-(4-pyrιdyl) 8027 imidazol-2-ylamino- (CH 2 )3 CH 3 CH CH N NHS0 2 C 6 H 4 -4-(4-pyrιdyl)- 2, 6-dimethyl 8028 ιmidazol-2-ylamιno-(CH 2 )3 H N CH CH NHSθ 2 C b H 4 -4-(4-pyπdyl) - 2, 6-dιchloro 8029 ιmidazol-2-ylamιno- (CH 2 )3 CH 3 CH CH N NHS0 2 C 6 H -4-(2-oxazolyl) 8030 imidazol-2-ylamino-(CH 2 )3 CH 3 CH CH N NHS0 2 C 0 H 4 -4-(2-oxazolyl) - 2 , 6-dimethyl 8031 imidazol-2-ylamino- (CH 2 ) CH CH N NHSO ^ C b H 4 -4-(2-oxazolyl)- 2, 6-dιchloro 8031a imidazol-2-ylamino- (CH 2 ) 3 CH3 CH CH N NHSO,C b H 4 -4-(3-pyridyl) - 2, 6-dimethyl 8031b imidazol-2-ylamino-(CH 2 )3 CH CH N NHS0 2 C b H 4 -4-(2-furyl) -2, 6- dimethyl 8031c imidazol-2-ylamino- (CH 2 ) 3 CH CH N NHSθ C b H 4 -4-(3-furyl) -2, 6- dimethyl 8031d imidazol-2-ylamino- (CH ) 3 CH3 CH CH N NHSθ2C b H 4 -4-(5-pyrazolyl) 2, 6-dimethyl CH NHS0 2 CH 2 Ph I N NHS0 2 -n-Bu tsj CH NHS0 NHPh N NHS0 2 NHC 6 H3-(2,6-Me 2 ) CH NHSθ 2 NHC 6 H 2 -(2, ,6-Mβj) N NHSθ2NH(2-naphthyl) CH NHS0 2 NH(1-naphthyl) N NHSθ 2 NHC b H 4 -(4-Ph) CH NHSθ2NHC b H 2 -(4-Ph-2, 6- dimethyl ) 8041 imidazol -2-ylamino- ( CH2 ) 3 CH 3 CH CH N NHS0 2 NHC b H 2 -(4-Ph-2, 6- dichloro) 8042 imidazol-2-ylamino-(CH 2 )3 CH NHSO,NHCH_Ph 8043 imidazol-2-ylamino- ( CH 2 ) 3 N NHS0 2 NH-n-Bu 8044 imidazol-2-ylamino- ( CH2 ) 3 CH NHS0 NH-i-Bu 8045 imidazol-2-ylamino- ( CH 2 ) 3 N NHSO,NH-t-Bu 8046 pyridin-2-ylamino-(CH 2 )3 CH NHCO,CH,Ph 8047 pyridin-2-ylamino- ( CH 2 ) 3 N NHCO,n-Bu 8048 pyridin-2-ylamino-(CH2)3 CH NHC0 2 i-Bu 8049 pyridin-2-ylamino-(CH 2 )3 N NHCOPh 8050 pyridin-2-yl-unino-(CH )3 CH NHCOCH,Ph 8051 pyridin-2-ylamino- (CH 2 )j N NHCOCH 2 CH 2 Ph 8052 pyridin-2-ylamino-(CH 2 )3 CH NHCOCH=CHPh I 8053 pyridin-2-ylamino- (CH2)3 N NHCOn-Bu tsj 8054 pyridin-2-ylamino- (CH2) 3 N NHS0 2 Ph 8055 pyridin-2-ylamino-(CH2) 3 CH NHSθ 2 C b H -(2-CH 3 ) 8056 pyridin-2-ylamino-(CH 2 )3 N NHSθ 2 C b H -(3-CHj) 8057 pyridin-2-ylamino-(CH2>3 CH NHS0 2 C b H 4 -(4-CH 3 ) 8058 pyridin-2-ylamino- ( CH2> 3 N NHS0 2 C b H 3 -(2,6-CHj)2 8059 pyridin-2-ylamino- (CH2 ) 3 N NHSO,C 6 H 2 -(2,4,6-CH j ) 3 8060 pyridin-2-ylamino-(CH2>3 N NHS0 (2-pyridyl) 8061 pyridin-2-ylamino- ( CH2 ) 3 CH NHS0 2 (3-pyridyl) 8062 pyridin-2-ylamino- (CH2>3 N NHS0 (4-pyridyl) 8063 pyridin-2 -y lamino- (CH 2 ) 3 NHSO, (2-thienyl) 8064 pyridin-2 -ylamino- (CH 2 > 3 NHSO, [4- (3,5- dimethyl) isoxazolyl] 8065 pyridin-2-ylamino- (CH 2 ) 3 NHS0 2 C b Hj-(2,6-Cl 2 ) 8066 pyridin-2 -ylamino- (CH 2 ) 3 NHS0 2 (2-naphthyl) 8067 pyridin-2-ylamino-(CH )3 NHSO, (1-naphthyl) 8068 pyridin-2-ylamino-(CH2)3 NHS0 2 C b H 4 -(4-Ph) 8069 pyridin-2-ylamino- (CH 2 >3 NHS0,C L H,-(4-Ph-2,6- dimethyl) 8070 pyridin-2-ylamino- (CH 2 ) 3 CH CH NHS0 2 C o H 2 -(4-Ph-2, 6- dichloro) 8071 ρyridin-2-ylamino- (CH 2 >3 CHj CH CH NHS0 2 C c H 4 -4- (4-pyridyl) 8072 pyridin-2-ylamino-(CH 2 )3 CHj CH CH NHS0 2 C.H 4 -4-(4-pyridyl) - I l tsj 2, 6-dimethyl cn 8073 pyridin-2-ylamino- (CH 2 )3 CH CH NHS0 2 C b H 4 -4-(4-pyridyl)- 2, 6-dichloro 8074 pyridin-2-ylamino- (CH 2 )3 CH3 CH CH NHS0 2 C e H 4 -4- (2-oxazolyl) 8075 pyridin-2-ylamino- (CH 2 )3 CH3 CH CH NHS0,C b H 4 -4-(2-oxazolyl) - 2, 6-dimethyl 8076 pyridin-2-ylamino-(CH 2 )3 CH CH NHSθ 2 C 6 H -4- (2-oxazolyl) - 2, 6-dichloro 8076a pyridin-2-ylamino- (CH 2 ) 3 CH 3 CH CH NHS0 2 C b H 4 -4-(3-pyridyl) - 2 , 6-dimethyl 8076b ρyridin-2-ylamino- ( CH 2 ) 3 CH CH N NHS0 2 C o H 4 -4-(2-furyl)-2, 6- di ethyl 8076c pyridin-2-ylamino-(CH 2 )3 CH CH N NHS0 2 C b H 4 -4-(3-furyl)-2,6- dimethy1 8076d pyridin-2-ylamino-(CH 2 )3 CHj CH CH N NHS0 2 C c H 4 -4-(5-pyrazolyl) - 2, 6-dimethyl 8077 pyridin- -2-ylamino- (CH 2 ) 3 N NHS0 2 CH 2 Ph 8078 pyridin-2-ylamino- ( CH 2 ) 3 CH NHS0 2 -n-Bu 8079 pyr din-2-ylamino- (CH 2 ) 3 N NHS0 2 NHPh 8080 pyr din-2-ylamino- (CH 2 )3 CH NHS0 2 NHC c Hj-(2,6-Me2) 8081 pyridin-2-ylamino- (CH,) N NHSθ 2 NHC b H,-(2,4,6-Mej) 8082 pyr din-2-ylamino- (CH 2 ) 3 CH NHSO,NH(2-naphthyl) 8083 pyridin-2-ylamino- (CH 2 )j N NHSO,NH(l-naphthyl) I O pyridin-2-ylamino- (CH 2 )j CH NHS0,NHC b H 4 -(4-Ph) t 8084 ON I 8085 pyridin-2-ylamino- (CH 2 ) 3 N NHS0 2 NHC c H,-(4-Ph-2,6- dimethyl) 8086 pyridin-2-ylamino- (CH 2 ) 3 CH3 CH C H NHSO,NHC b H 2 -(4-Ph-2, 6- dichloro ) 8087 pyridin-2-ylamino-(CH ) 3 N NHSθ NHCH Ph 8088 pyridin-2-ylamino-(CH 2 ) 3 CH NHSθ 2 NH -n-Bu 8089 pyridin-2-ylamino- (CH 2 )3 N NHSθ 2 NH- i -Bu 8090 pyridin-2-ylamino- (CH 2 )3 CH NHSθ 2 NH - t -Bu 8091 tetrahydropyrimidin-2-ylamino- (CH2) 3 N NHC0 2 CH,Ph 8092 tetrahydropyrimidin-2-ylamino- CH, CH 3 CH N CH NHC0 2 n-Bu 8093 tetrahydropyrimidin-2-ylamino- CH 2 H CH CH N NHC0,i-Bu 8094 tetrahydropyrimidin-2-ylamino- CH 2 CHj N CH CH NHCOPh 8095 tetrahydropyrimidin-2-ylamino- CH 2 H CH CH N NHCOCH,Ph 8096 tetrahydropyrimidin-2-ylamino- CH 2 CHj N N CH NHCOCH_CH,Ph 8097 tetrahydropyrimidin-2-ylamino- CH 2 CH 3 CH CH N NHCOCH=CHPh 8098 tetrahydropyrimidin-2-ylamino- CH 2 H CH N CH NHCOn-Bu 8099 tetrahydropyrimidin-2-ylamino- CH 2 CH 3 CH CH N NHS0 2 Ph 8100 te rahydropyrimidin-2-ylamino- CH 2 H N CH CH NHS0 2 C & H -(2-CHj) 8101 tetrahydropyrimidin-2-ylamino- CH 2 H CH CH N NHS0 2 C b H 4 -(3-CHj) 8102 tetrahydropyrimidin-2-ylamino- CH 2 H N N CH NHSO,C b H 4 -(4-CHj) 8103 etrahydropyrimidin-2-ylamino- CH 2 CHj CH CH N NHS0 2 C c ,H,-(2,6-CHj) 2 8104 tetrahydropy imidin-2-ylamino- CH 2 H CH CH N NHS0 2 C t ,H 2 -(2,4,6-CHj) 3 I CO tj 8105 tetrahydropyrimidin-2-ylamino- CH CH CH CH N NHS0 2 (2-pyridyl) I 8106 te rahydropyrimidin-2-ylami o- CH 2 H N CH CH NHS0 2 (3-pyridyl) 8107 te rahydropy imidin-2-ylamino- CH 2 CH 3 CH CH N NHS0 2 (4-pyridyl) 8108 tetrahydropy imidin-2-ylamino- CH 2 H N N CH NHS0 (2-thienyl) 8109 te rahydropyrimidin-2-ylamino- CH 2 CH 3 CH CH N NHSθ 2 [4-(3,5- dimet hy l ) i soxazoly l ] 8110 tetrahydropyrimidin-2-ylamino- CH 2 j H CH CH N NHSθ 2 C 6 H j - ( 2 , 6 -Cl 2 ) 8111 tetrahydropyrimidin-2-ylamino- CH 2 3 CH 3 CH CH N NHS0 2 ( 2 - napht hy l ) 8112 tetrahydropyrimidin-2-yla ino- CH 2 3 H CH CH N NHS0 2 ( 1 -naphthyl ) 8113 tetrahydropyrimidin-2-yla ino- CH 2 3 CH 3 CH CH N NHS0 2 C 6 H 4 - ( 4 - Ph ) 8114 tetrahydropyrimidin-2-ylamino- ( CH 2 ) 3 H CH CH NHS0 2 C b H 2 - (4-Ph-2, 6- dimethyl) 8115 tetrahydropyrimidin-2-ylamino- (CH 2 ) 3 H CH CH NHSO,C b H 2 - (4-Ph-2, 6- dichloro) 8116 tetrahydropyrimidin-2-ylamino- (CH 2 ) CH 3 CH CH N NHS02C b H 4 -4-(4-pyridyl) 8117 tetrahydropyrimidin-2-ylamino- (CH ) j CH3 CH CH N NHS0 2 C b H -4-(4-pyridyl)- 2, 6-dimethyl 8118 tetrahydropyrimidin-2-ylamino- (CH 2 )3 H N CH CH NHS0 2 C b H 4 -4-(4-pyridyl) - 2, 6-dichloro 8119 tetrahydropyrimidin-2-ylamino- (CH )3 CH3 CH CH N NHSθ2C b H 4 -4-(2-oxazolyl) 8120 tetrahydropyrimidin-2-ylamino- (CH ) 3 CH3 CH CH N NHS0 C b H 4 -4-(2-oxazolyl) - 2, 6-dimethyl 8121 tetrahydropyrimidin-2-ylamino- (CH 2 )3 H CH CH NHSθ 2 C b H 4 -4-(2-oxazolyl) - I O 2, 6-dichloro t 00 I 8121a tetrahydropyrimidin-2-ylamino- (CH 2 >3 CH 3 CH CH NHS0 2 C b H 4 -4-(3-pyridyl) - 2, 6-dimethyl 8121b tetrahydropyrimidin-2-ylamino- (CH 2 >3 H CH CH NHSθ 2 C 6 H -4-(2-furyl)-2, 6- dimethyl 8121c tetrahydropyrimidin-2-ylamino- (CH 2 ) 3 H CH CH N NHS0 2 C b H 4 -4-(3-furyl) -2,6- dimethyl 8121d tetrahydropyrimidin-2-ylaroino-(CH 2 ) 3 CH3 CH CH NHS0 C 6 H 4 -4-(5-pyrazolyl) - 2, 6-dimethyl 8122 tetrahydropyrimidin-2-ylamino- (CH )3 H CH CH NHS0 2 CH 2 Ph 8123 tetrahydropyrimidin-2-ylamino- ( CH2 ) j H N NHSθ2-n-Bu 8124 tetrahydropyrimidin-2-ylamino- ( CH2 ) 3 H CH NHS0 2 NHPh 8125 tetrahydropyrimidin-2-ylamino- ( CH2 ) 3 CH3 N NHS0 2 NHC t ,H j -(2, 6-Me,) 8126 tetrahydropyrimidin-2-ylamino- ( CH2 ) j H CH NHS0 2 NHC c, H,-(2,4, 6-Mej) 8127 tetrahydropyrimidin-2-ylamino- ( CH2 ) 3 H N NHS0 2 NH(2-naphthyl) 8128 tetrahydropyrimidin-2-ylamino-(CH2 ) 3 CH 3 CH NHS0 2 NH(1-naphthyl) 8129 tetrahydropyrimidin-2-ylamino- ( CH2>3 H N NHS0 NHC b H 4 -(4-Ph) 8130 tetrahydropyrimidin-2-ylamino- ( CH2 ) j H CH NHS0 2 NHC H2-(4-Ph-2,6- dimethyl) 8131 tetrahydropyrimidin-2-ylamino- (CH 2 )3 CH3 CH CH N NHS0 NHC b H 2 -(4-Ph-2, 6- dichloro ) 8132 tetrahydropyrimidin-2-ylamino- (CH 2 )j H N N CH NHSO,NHCH 2 Ph 8133 tetrahydropyrimidin-2-ylamino-(CH 2 )3 H CH CH N NHS0 NH-n -Bu 8134 tetrahydropyrimidin-2-ylamino-(CH 2 ) 3 H CH N CH NHS0 2 NH - i -Bu SD 8135 tetrahydropyrimidin-2-ylamino- (CH 2 )3 CH3 CH CH N NHSθ 2 NH - t -Bu 8136 imidazolin-2-ylamino- (CH )3 H N CH CH NHCO,CH 2 Ph 8137 imidazolin-2-yl_mino-{CH 2 )3 CH3 CH CH N NHCθ 2 n -Bu 8138 imidazolin-2-ylamino-(CH 2 ) 3 H N N CH NHC0 i -Bu 8139 imidazolin-2-ylamino-(CH2 ) 3 CH3 CH CH N NHCOPh 8140 imidazolin-2-ylamino-(CH2 ) 3 H CH N CH NHCOCH 2 h 8141 imidazolin-2-ylamino- ( CH2 ) 3 CH3 CH CH N NHCOCH 2 CH, Ph 8142 imidazolin-2-ylamino-(CH 2 ) 3 CH3 N CH CH NHCOCH=CHPh 8143 imidazolin-2-ylamino-(CH2 ) 3 H CH CH N NHCOn-Bu 8144 imidazolin-2-ylamino- (CH 2 ) 3 CHj CH CH N NHSO,Ph 8145 imidazolin-2-ylamino- (CH, ) j H N CH CH NHSθ2C,.,H -(2-CHj) 8146 imidazolin-2-ylamino- (CH ) 3 H CH CH N NHS0 2 C C; H 4 - (3-CHj) 8147 imidazolin-2-ylamino- (CH 2 ) 3 H N N CH NHSO,C c ,H -(4-CHj) 8148 imidazolin-2-ylamino-(CH 2 )3 CH 3 CH CH N NHS0 2 C b Hj- (2,6-CHj) 2 8149 imidazolin-2-ylamino-(CH2 ) 3 H CH CH N NHSO,C b H 2 -(2,4,6-CHj) 8150 imidazolin-2-yla.mino-(CH2 ) 3 CH 3 CH CH N NHSO, (2-py idyl) 8151 imidazolin-2-ylamino- ( CH2 ) 3 H N CH CH NHSθ 2 (3-pyridyl) 8152 imidazolin-2-ylamino- (CH 2 )3 CH 3 CH CH N NHS0 2 (4-pyridyl) 8153 imidazolin-2-ylamino- (CH 2 )3 H N N CH NHSO, (2-thienyl) 8154 imidazolin-2-ylamino- (CH )3 CHj CH CH N NHS0 2 [4-(3,5- dimethyl) isoxazolyl] 8155 imidazolin-2-ylamino- ( CH 2 ) j H CH CH N NHSθ2C b H j -(2,6-Cl ) I CO 8156 imidazolin-2-ylamino- (CH )3 CH 3 CH CH N NHSO, (2-naphthyl) CO o I 8157 imidazolin-2-ylamino- ( CH 2 ) 3 H CH CH N NHS0 2 (1-naphthyl) 8158 imidazolin-2-ylamino- (CH 2 )3 CH3 CH CH N NHSθ2C b H -(4-Ph) 8159 imidazolin-2-ylamino- (CH 2 ) 3 H CH CH N NHS0 2 C b H 2 -(4-Ph-2,6- dimethyl) 8160 imidazolin-2-ylamino- (CH )3 CH CH N NHS0 2 C b H 2 -(4-Ph-2,6- dichloro) 8161 imidazolin-2-ylamino- ( CH 2 ) 3 CH 3 CH CH N NHSθ 2 C b H -4- (4-pyridyl) 8162 imidazolin-2-ylamino- ( CH >3 CH 3 CH CH N NHS0 2 C b H 4 -4-(4-pyridyl) 2 , 6-dimethyl 8163 imidazolin-2-ylamino-(CH 2 )3 CH CH NHSO,C b H 4 -4-(4-pyrιdyl) - 2, 6-dιchloro 8164 imidazolin-2-ylamino-(CH 2 ) j CH 3 CH CH N NHS0 2 C l; ,H -4-(2-oxazolyl) 8165 imidazolin-2-ylamino-(CH 2 ) 3 CHj CH CH N NHS0 2 C c H -4-(2-oxazolyl) - 2, 6-dimethyl 8166 imidazolin-2-yla_nino-(CH2)3 CH CH N NHS0 2 C b H -4-(2-oxazolyl) - 2, 6-dιchloro 8166a imidazolin-2-ylamino-(CH 2 ) CH- CH CH N NHS0 2 C b H 4 -4-(3-pyrιdyl)- 2, 6-dimethyl 8166b imidazolin-2-ylamino- (CH 2 >3 CH CH N NHSθ2C b H 4 -4-(2--uryl)-2,6- dimethyl 8166c imidazolin-2-ylamino-(CH 2 ) 3 CH CH N NHS0 2 C b H 4 -4-(3-furyl) -2,6- dimethyl CH 3 CH CH N NHS0 2 C b H 4 -4-(5-pyrazolyl)- 2, 6-dimethyl ■2-ylamino- (CH 2 )3 N lsJHS0 2 CH 2 Ph ■2-ylamino-(CH 2 )3 CH NHS0 2 -n-Bu ■2-ylamino- (CH >3 N NHS0 2 NHPh -2-ylamino- (CH 2 )j CH NHS0 NHC b H j -(2,6-Me,) -2-ylamino- (CH 2 )3 N NHS0 2 NHC fc H2-(2,4, 6-Mβj) -2-ylamino- (CH 2 ) 3 CH NHS0 2 NH(2-naphthyl) -2-ylamino- (CH >3 N NHS0 2 NH(1-naphthy1) -2-ylamino- (CH2) 3 CH NHS0 2 NHC b H - (4-Ph) 8175 imidazolin-2-ylamino- (CH ) 3 CH CH N NHSθ 2 NHC c H,-(4-Ph-2, 6 dimethyl) 8176 imidazolin-2-ylamino- (CH 2 )j CH, CH N CH NHS0 2 NHC c ,H,-(4-Ph-2,6- dichloro) 8177 imidazolin-2 -ylamino- (CH 2 )j N NHSθ 2 NHCH,Ph 8178 imidazolin-2 ■ ylamino- (CH 2 )3 CH NHS0 2 NH-n-Bu 8179 imidazolin-2 -ylamino- (CH 2 ) 3 N NHSθ 2 NH-i-Bu 8180 imidazolin-2 -ylamino- (CH 2 ) 3 CH NHSθ 2 NH-t-Bu 8181 benzimidazol -2-ylamino- (CH 2 ) 3 N NHCθ 2 CH,Ph 8182 benzimidazol -2-ylamino- (CH 2 ) 3 CH NHC0 2 n-Bu 8183 benzimidazol -2-ylamino- (CH 2 ) N NHC0 2 i-Bu 8184 benzimidazol -2-ylamino- (CH ) 3 CH NHCOPh 8185 benzimidazol -2-ylamino- (CH 2 ) 3 N NHC0CH 2 Ph I CJ 8186 benzimidazol -2-ylamino- CO (CH 2 )j CH NHCOCH, CH,Ph J I 8187 benzimidazol -2-ylamino- (CH 2 ) 3 N NHCOCH=CHPh 8188 benzimidazol -2-ylaraino- (CH 2 ) 3 CH NHCOn-Bu 8189 benzimidazol -2-ylamino- (CH 2 ) 3 N NHS0 2 Ph 8190 benzimidazol -2-ylamino- (CH 2 ) 3 CH NHΞθ 2 C 6 H 4 -(2-CH 3 ) 8191 benzimidazol -2-ylamino- (CH 2 ) 3 N NHS0 2 C 6 H 4 -(3-CH 3 ) 8192 benzimidazol -2-ylamino- (CH 2 ) 3 CH NHS0 2 C b H -(4-CHj) 8193 benzimidazol -2-ylamino- (CH 2 ) 3 N NHS0 2 C b H3-(2,6-CHj) 2 8194 benzimidazol -2-ylamino- (CH 2 ) 3 N NHS0 2 C 6 H2-(2,4,6-CH 3 )3 8195 benzimidazol -2-ylamino- (CH 2 ) 3 N NHS0 2 (2-pyridyl) 8196 benzimidazol-2-ylamino-(CH2 ) 3 NHSO, ( -pyridyl) 8197 benzimidazol-2-ylamino- (CH,) NHSO, (4-pyridyl) 8198 benzimidazol-2-ylamino-(CH 2 ) 3 NHSO_(2-thienyl) 8199 benzimidazol-2-ylamino-(CH 2 ) 3 NHSO, [4- (3,5- di ethyl) isoxazolyl] 8200 benzimidazol-2-ylamino- (CH ) NHSO,C Hj-(2,6-Cl2) 8201 benzimidazol-2- lamino- (CH 2 )3 NHS0 2 (2-naphthyl) 8202 benzimidazol-2-ylamino- (CH 2 ) 3 NHS0 (1-naphthyl) 8203 benzimidazol-2-ylamino- (CH 2 ) 3 NHS0 2 C 0 H 4 -(4-Ph) 8204 benzimidazol-2-ylamino-(CH 2 ) j NHSO,C b H2-(4-Ph-2,6- dimethyl) 8205 benzimidazol-2-ylamino- ( CH 2 ) 3 CH CH NHS0 2 C b H2-(4-Ph-2,6- dichloro) I Ul CH 3 CH CH N NHSO,C b H 4 -4- (4-pyrιdy1) CO 8206 benzimidazol-2-ylamino- (CH2)3 CO I 8207 benzimidazol-2-ylamino- (CH 2 ) 3 CH 3 CH CH N NHSθ2C b H 4 -4- (4-pyridyl) - 2, 6-dimethyl 8208 benzimidazol-2-ylamino- ( CH2 ) 3 CH CH NHS0 2 C b H -4-(4-pyridyl) - 2, 6-dichloro 8209 benzimidazol-2-ylamino-(CH2)3 CH 3 CH CH N NHSθ2C b H -4-(2-oxazolyl) 8210 benzimidazol-2-ylamino-(CH 2 ) 3 CH3 CH CH N NHS0 2 C b H 4 -4-(2-oxazolyl) 2, 6-dimethyl 8211 benzimidazol-2-ylamino- (CH 2 ) 3 CH CH N NHS0 2 C b H 4 -4-(2-oxazolyl) 2, 6-dichloro 8211a benzimidazol-2-ylamino-(CH2)3 CH CH CH N NHS0 2 C 0 H -4-(3-pyrιdyl) - 2, 6-dimethyl 8211b benzιmιdazol-2-ylamino- (CH2) j CH CH N NHSO,C b H -4-(2-furyl) -2, 6- dimethyl 8211c benzιmιdazol-2-ylamιno-(CH2)3 CH CH N NHSO,C b H 4 -4-(3-furyl) -2, 6- dimethyl 8211d benzιmιdazol-2-ylamιno- ( CH2 ) 3 CH 3 CH CH N NHS0 2 C c H -4-(5-pyrazolyl) - 2, 6-dimethyl 8212 benzimidazol ■2-ylamιno- (CH 2 )j H CH N CH NHSO,CH,Ph 8213 benzimidazol -2-ylamιno- (CH 2 )j H CH CH N NHS0 2 -n-Bu 8214 benzimidazol -2-ylamιno- ICH 2 ) 3 H N CH CH NHS0 2 NHPh 8215 benzimidazol -2-ylamιno- (CH 2 )j CH 3 CH CH N NHS0 2 NHC b H3-(2, 6-Me,) 8216 benzimidazol -2-ylamιno- (CH 2 )j H N N CH NHS0 2 NHC b H 2 -(2,4, 6-Mβj) I O 8217 benzimidazol -2-ylamιno- (CH ) 3 H CH CH N NHS0 2 NH(2-naphthyl) Ul 8218 benzimidazol -2-ylamιno- (CH 2 )3 CH 3 CH N CH NHS0 2 NH(1-naphthyl) 8219 benzimidazol -2-ylamιno- <CH 2 ) 3 H CH CH N NHS0 2 NHC 6 H 4 -(4-Ph) 8220 benzimidazol -2-ylamιno- (CH 2 )3 H N CH CH NHS0 2 NHC b H 2 -(4-Ph-2,6- dimethyl) 8221 benzimidazol-2-ylamιno-(CH 2 ) 3 CH3 CH CH N NHS0 2 NHC, b H2-(4-Ph-2,6- dichloro) 8222 benzιmιdazol-2-ylamino- (CH 2 )j CH NHS0 2 NHCH 2 Ph 8223 benzιmιdazol-2-ylamιno-(CH 2 )3 N NHS0 2 NH-n-Bu 8224 benzimιdazol-2-ylamιno-(CH )3 CH NHS0 2 NH-1-Bu 8225 benzimidazol-2-ylamino-(CH2>3 8226 2-aminopyridin-6-yl- CH 2 ) 2 8227 2-aminopyridin-6-yl- CH 2 ) 2 8228 2-aroinopyridin-6-yl- CH 2 ) 2 8229 2-aminopyridin-6-yl- CH 2 > 2 8230 2-aminopyridin-6-yl- CH 2 ) 2 8231 2-aminopyridin-6-yl- CH 2 ) 2 8232 2-aminopyridin-6-yl- CH 2 ) 2 8233 2-aminoρyridin-6-yl- CH 2 ) 2 8234 2-aminopyridin-6-yl- CH 2 ) 2 8235 2-aminopyridin-6-yl- CH 2 ) 2 8236 2-aminopyridin-6-yl- CH 2 ) 2 8237 2-aminopyridin-6-yl- CH 2 ) 2 I O 8238 2-aminopyridin-6-yl- CO CH 2 ) 2 cn I 8239 2-aminopyridin-6-yl- CH 2 ) 2 8240 2-aminopyridin-6-yl- CH 2 ) 2 8241 2-aminoρyridin-6-yl- CH 2 ) 2 8242 2-aminopyridin-6-yl- CH 2 ) 2 8243 2-aminopyrιdin-6-yl- CH 2 ) 2 8244 2-aminopyridin-6-yl- CH 2 ) 2 8245 2-aminopyridin-6-yl- CH 2 ) 2 8246 2-aminopyridin-6-yl CH 2 ) 2 8247 2-aminopyridin-6-yl - (CH ) 2 NHS0 2 (1-naphthyl) 8248 2-aminopyridin-6-yl- (CH ) NHS0 2 C b H -(4-Ph) NHSO,C b H 2 -(4-Ph-2,6- 8249 2-aminoρyridin-6-yl - (CH 2 ) 2 dimethyl) 8250 2-aminopyridin-6-yl- (CH ) 2 CH CH NHS0 2 C b H 2 -(4-Ph-2,6- dichloro) 8251 2-aminopyridin-6-yl- ( CH 2 ) 2 CH 3 CH CH NHSθ C b H 4 -4-(4-pyridyl) 8252 2-aminopyridin-6-yl- ( CH 2 ) 2 CH 3 CH CH NHS0 2 C b H 4 -4-(4-pyridyl) - 2, 6-dimethyl 8253 2-aminopyridin-6-yl- ( CH 2 ) 2 CH CH NHS0 2 C b H 4 -4-(4-pyridyl) - 2, 6-dichloro 8254 2-aminopyridin-6-yl- (CH 2 ) 2 CH3 CH CH NHS0 2 C b H 4 -4-(2-oxazolyl) 8255 2-aminopyridin-6-yl- (CH 2 ) 2 CH 3 CH CH NHS0 2 C 6 H 4 -4-(2-oxazolyl)- I co 2, 6-dimethyl Oi I 8256 2-aminopyridin-6-yl- (CH 2 ) CH CH NHS0 2 C 6 H 4 -4-(2-oxazolyl)- 2, 6-dichloro 8256a 2-aminopyridin-6-yl- ( CH ) 2 CH 3 CH CH NHS0 2 C 6 H 4 -4-(3-pyridyl) - 2, 6-dimethyl 8256b 2-aminopyridin-6-yl- ( CH 2 ) 2 CH CH NHS0 2 C b H 4 -4-(2-furyl) -2,6- dimethyl 8256c 2-aminopyridin-6-yl- ( CH 2 ) 2 CH CH N NHS0 2 C b H 4 -4- (3-furyl) -2, 6- di ethyl 8256d 2-aminopyridin-6-yl - (CH 2 > 2 CH3 CH CH N NHSO,C & H -4-(5-pyrazolyl) 2, 6-dimethyl 8257 2-aminopyridin-6-yl- ( CH 2 ) 2 N NHSθ 2 CH2Ph 8258 2-aminopyridin-6-yl-{CH 2 ) 2 CH NHS0 2 -n-Bu 8259 2-aminopyridin-6-yl-(CH >2 N NHS0 2 NHPh 8260 2-aminopyridin-6-yl-(CH 2 ) 2 CH NHS0 2 NHC 6 Hj-(2,6-Me,) 8261 2-aminopyridin-6-yl- ( CH 2 ) 2 N NHS0 2 NHC fe H,-(2, 4,6-Me 3 ) 8262 2-aminopyridin-6-yl- ( CH2 ) 2 CH NHΞ0 2 NH(2-naphthyl) 8263 2-aminopyridin-6-yl- ( CH 2 ) 2 N NHS0 2 NH(1-naphthyl) 8264 2-aminopyridin-6-yl- (CH 2 ) CH NHS0 2 NHC b H 4 -(4-Ph) 8265 2-aminopyridin-6-yl- ( CH 2 ) 2 N NHS0 NHC b H 2 -(4-Ph-2,6- dimethyl) 8266 2-aminopyridin-6-yl- ( CH 2 ) 2 CH 3 CH N CH NHS0 2 NHC b H 2 -(4-Ph-2,6- I CO dichloro) CO ~J I 8267 2-aminopyridin-6-yl- ( CH 2 ) 2 NHS0 2 NHCH Ph 8268 2-aminopyridin-6-yl- (CH 2 ) 2 NHS0 2 NH-n-Bu 8269 2-aminopyridin-6-yl- ( CH 2 ) 2 NHS0 2 NH-i-Bu 8270 2-aminopyridin-6-yl- ( CH 2 ) 2 NHS0 2 NH-t-Bu 8271 imidazol-2-ylamino-CH2 (0-C6H4) NHS0 2 -(1-naphthyl) 8272 imidazol-2-ylamino-CH2(0-C6H4 ) NHC0 2 CH 2 Ph 8273 imidazol-2-ylamino-CH2(0-C6H4 ) NHS0 2 C6C2- (2, 4, 6-Me3) 8274 pyridin-2-ylamino-CH2(0-C6H4) NHS0 2 -(1-naphthyl) 8275 pyridin-2-ylamino-CH2(0-C6H4 ) NHC0 2 CH 2 Ph 8276 pyridin-2-ylamino-CH2(0-C6H4) NHS02 6C 2 -(2,4,6-Me3) 8277 imidazolin-2-ylamino-CH2 (0-C6H4) NHS0 2 -(1-naphthyl) 8278 imidazolin-2-ylamino-CH2 (0-C6H4) NHC0 2 CH2Ph 8279 imidazolin-2-ylamino-CH2 (0-C6H4) NHS02C6C 2 -(2,4,6-Me3) 8280 imidazolin-2-ylamino-(m-CgH4) NHSθ2-d-naphthyl) 8281 imidazolin-2-ylamino-(m-C6H4) NHC0 2 CH2Ph 8282 imidazolin-2-yl-unino-(m-C6H4) NHSθ 2 C 6 C2-(2,4,6-Me 3 ) I CO O CD I

Claims: MXS. WHAT IS CLAIMED IS: A compound of Formula la: la and pharmaceutically acceptable salt forms thereof, wherein: X 1 , X 2 , X 3 , and X 4 are independently selected from nitrogen or carbon provided that at least two of X 1 , X 2 , X 3 and X 4 are carbon; R 1 is selected from: A and B are independently -CH 2 -, -0-, -N(R 2 )-, or -C(=0)-,- A 1 and B 1 are independently -CH 2 - or -N(R 3 )-; D is -N(R 2 )-, -0-, -S-, -C(=0)- or -S0 2 -; E-F is -C(R 4 )=C(R 5 )-, -N=C(R 4 )-, -C(R 4 )=N-, or -C ( R 4) 2 C ( R 5) 2 -; J, K, L and M are independently selected from -C(R 4 )-, -C(R 5 )- or -N-, provided that at least one of J, K, L and M is not -N-; R 2 is selected from: H, Ci-C δ alkyl, (Cχ-C 6 alkyl)carbonyl, (Ci-Cβ alkoxy) carbonyl; (Ci-Cβ alkyl)aminocarbonyl, 3 -C 6 alkenyl, C3-C cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl/ heteroaryl (Ci-Cβ alkyl)carbonyl, heteroarylcarbonyl, aryKCi-Cβ alkyl)-, (C 1 -C6 alkyl) carbonyl-, arylcarbonyl, Cι-C 6 alkylsulfonyl, arylsulfonyl, aryl (Cχ-C 6 alkyl) sulfonyl, heteroarylsulfonyl, heteroaryl (Ci-Ce alkyl) sulfonyl, aryloxycarbonyl, or aryl (Ci-C δ alkoxy) carbonyl, wherein said aryl groups are substituted with 0-2 substituents selected from the group consisting of C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo, CF 3 , and nitro; R 3 is selected from: H, Ci-Cg alkyl, C 3 -C- 7 cycloalkyl, C4-C11 cycloalkylalkyl, aryl, aryl(Cι-C 6 alkyl)-, or heteroaryl (Ci-Cβ alkyl) - ; R 4 and R 5 are independently selected from: H, C 1 -C 4 alkoxy, R R 3 , halogen, N0 2 , CN, CF 3 , Cι-C 6 alkyl, C 3 -C 6 alkenyl, C 3 -C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl (Ci-Cβ alkyl)-, (Ci-Ce alkyl) carbonyl, (Ci-Ce alkoxy)carbonyl, arylcarbonyl, or alternatively, when substituents on adjacent atoms, R 4 and R 5 can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups selected from: C1-C4 alkyl, C 1 -C 4 alkoxy, halo, cyano, ammo, CF3, or N0 2 ; U is selected from: - ( CH 2 ) n -, -(CH 2 ) n (CR 7 =CR 8 ) (CH 2 ) m -, -(CH 2 ) n (C»C) (CH 2 ) m -, -(CH 2 ) c Q(CH 2 ) m -, -(CH 2 ) n O(CH 2 ) m -, -(CH 2 ) n C(=0) (CH 2 ) m -, -(CH 2 ) n (C=0)N(R 6 ) (CH 2 ) m - -(CH 2 ) n N{R 6 ) (C=0) (CH 2 ) m -, or -(CH 2 ) n S(0) p (CH 2 ) m -; wherein one or more of the methylene groups in U is optionally substituted with R 7 ; Q is selected from 1, 2-cycloalkylene, 1, 2-phenylene, 1, 3-phenylene, 1, 4-phenylene, 2, 3-pyrιdinylene, 3 , 4-pyridinylene, 2 , -py id r.ylene, or 3,4- pyridazmylene; R 6 is selected from: H, C 1 -C 4 alkyl, or benzyl; R 7 and R 8 are independently selected from: H, Ci-Ce alkyl, C 3 -C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl(Cι-C6 alkyl)-, or heteroaryl (C0-C6 alkyl)-,. Rio 1S selected from: H, C 1 -C 4 alkoxy substituted with 0- 1 R 21 , N(R 6 ) 2 , halogen, N0 2 , CN, CF 3 , C0 2 R 17 , C(=0)R 17 , CONR 17 R 20 , -S0 2 R 17 , -S0 2 NR 17 R 20 , Ci-Cβ alkyl substituted with 0-1 R 15 or 0-1 R 21 , C 3 -C 6 alkenyl substituted with 0-1 R 15 or 0-1 R 21 , C3-C7 cycloalkyl substituted with 0-1 R 15 or 0-1 R 21 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 or 0-1 R 21 , aryl substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 , or aryl(Cι-C 6 alkyl)- substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 ; R 11 is selected from H, halogen, CF3, CN, N0 2 , hydroxy, NR 2 R 3 , C 1 -C 4 alkyl substituted with 0-1 R 21 , C1-C4 alkoxy substituted with 0-1 R 21 , aryl substituted with 0-1 R 21 , aryl(Cι-C 6 alkyl)- substituted with 0-1 R 21 , (C1-C 4 alkoxy) carbonyl substituted with 0-1 R 21 , (C 1 -C 4 alkyl) carbonyl substituted with 0-1 R 21 , C1-C4 alkylsulfonyl substituted with 0-1 R 21 , or C1-C 4 alkylaminosulfonyl substituted with 0-1 R 21 ; W s selected from: -(C(R 1 ) 2 ) q C(=0)N(R 13 )-, or -C ( =0 ) -N ( R 13) - ( C ( R 12) 2 ) q-; X is -C {R 12 ) (R 1 )-C(R 12 ) (R 15 )-; or alternatively, W and X can be taken together to be R 12 is selected from H, halogen, Ci-Cβ alkyl, C 2 -Ce alkenyl, C 2 -Cβ alkynyl, C 3 -C7 cycloalkyl, C 4 -C 10 cycloalkylalkyl, (C 1 -C 4 alkyl)carbonyl, aryl, or aryKCi-Cβ alkyl)-; R 13 is selected from H, Ci-Cβ alkyl, C3-C7 cycloalkylmethyl, or aryl(Cι-C6 alkyl)-; R 14 is selected from: H, Ci-Ce alkylthιo(Cι-C 6 alkyl)-, aryl ( Cι-Cιo alkylthioalkyl)-, aryl (C 1 -C 10 alkoxyalkyl) -, C1-C10 alkyl, C1-C 10 alkoxyalkyl, Ci-Cβ hydroxyalkyl, C2-C 10 alkenyl, C 2 -Cιo alkynyl, C3-C10 cycloalkyl, C 3 -C 10 cycloalkylalkyl, aryKCi-Cβ alkyl ) -, heteroaryl(Ci-Ce alkyl)-, aryl, heteroaryl, C0 2 R 17 , C(=0)R 17 , or CONR 17 R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 0-1 R 16 or 0-2 RU; R15 _s selected from: H, R 16 , Ci-Cio alkyl, Ci-Cio alkoxyalkyl, Ci-Cio alkyla inoalkyl, Ci-Cio dialkylammoalkyl, (Ci-Cio alkyl ) carbonyl, aryl(C 0 -C 6 alkyl) carbonyl, Ci-Cio alkenyl, C.-C.o alkynyl , C 3 -C 10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl (Cι-C 6 alkyl )- , heteroaryl (Ci-Cδ alkyl) -, aryl, heteroaryl, C0 2 R 17 , C(=0)R 17 , CONR 17 R 20 , S0 2 R 17 , or S0 2 NR 17 R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 0-2 R 11 ; Y is selected from: -COR 19 , -SO3H, -PO 3 H, tetrazolyl, -CONHM.SO . CF 3 , -C0NHSO 2 R 17 , -CONHSO 2 NHR 17 , -NHCOCF 3 , -NHCONHS0 2 R 17 , -NHS0 2 R 17 , -OP0 3 H 2 , -OSO 3 H, -PO 3 H 2 , -SO3H, -S0 2 NHCOR 17 , -S0 2 NHC0 2 R 17 , R 16 is selected from: -N(R 20 )-C(=O) -O-R 17 , -N(R 20 )-C(=O)-R 17 , -N(R 20 )-C(=O)-NH-R 17 , -N(R 20 )SO 2 -NR 20 R 17 ; R 17 is selected from: C 1 -C 10 alkyl, C 3 -C u cycloalkyl, aryl(Cι-C 6 alkyl ) -, (Cι-C 6 alkyl) aryl, heteroaryl (Cι-C 6 alkyl)-, ( Ci-Cβ alkyl ) heteroaryl, biaryl (C.-Cβ alkyl) -, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, C1-C4 alkoxy, aryl, heteroaryl, halo, cyano, ammo, CF 3 , and N0 2 ; R 18 is selected from: H, -C(=0)-0-R 17 , -C(=0)-R l7 , -C(=0)-NH-R 17 , -S0 2 -R 17 , or -SO 2 -NR 0 R 17 ; R 19 is selected from: hydroxy, C_-Cιo alkyloxy, C 3 -C 11 cycloalkyloxy, aryloxy, aryl (C.-Cβ alkoxy) -, C3-C10 alkylcarbonyloxyalkyloxy, C3-C 10 alkoxycarbonyloxyalkyloxy, C 2 -Cιo alkoxycarbonylalkyloxy, C 5 -C 10 cycloalkylcarbonyloxyalkyloxy, C 5 -C 10 cycloalkoxycarbonyloxyalkyloxy, C 5 -C 10 cycloalkoxycarbonylalkyloxy, C 7 -C 11 aryloxycarbonylalkyloxy, Cs-Cι 2 aryloxycarbonyloxyalkyloxy, C 8 - 12 arylcarbonyloxyalkyloxy, C 5 -C 10 alkoxyalkylcarbonyloxyalkyloxy, C 5 -C 10 (5-alkyl-l, 3-dιoxa-cyclopenten-2-one- yDmethyloxy, C 10 -C 14 (5-aryl-l, 3-dioxa-cyclopenten- 2-one-yl)methyloxy, or (R 11 ) (R 12 )N- (C1-C10 alkoxy) -; R 20 is selected from: H, Ci-Cβ alkyl, C3-C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl (Ci-Cβ alkyl) -, or heteroaryl (Ci-Cβ alkyl) - ; R21 1S selected from: COOH or NR 6 2 ; with the following provisos: (1) t, n, and q are chosen such that the number of atoms connecting R 1 and Y is in the range of 10-14; and (2) n and are chosen such that the value of n plus m is greater than one unless U is - i Cn; ; ^ ^ -n 2 ; „- . 2 . A compound of Claim 1 of the Formula la : R 10 la and pharmaceutically acceptable salt forms thereof, wherein: X 1 , X 2 , X 3 , and X 4 are independently selected from nitrogen or carbon provided that at least two of X 1 , X 2 , X 3 and X 4 are carbon; R 1 is selected frcm: A and B are independently -CH -, -0- , -N(R 2 )-, or -C(=0)-; A 1 and B 1 are independently -CH - or -N(R 3 )-; D is -N(R 2 )-, -0-, -S-, -C(=0)- or -S0 2 -; E-F s -C(R 4 )=C(R 5 )-, -N=C(R 4 )-, -C(R 4 )=N-, or -C ( R ) 2 C(R 5) 2 -; J, K, L and M are independently selected from -C(R4)-, -C(R 5 )- or -N-, provided that at least one of J, K, R 2 is selected from: H, Cι-C 6 alkyl, (Cχ-C ό alkyl)carbonyl, (Ci-Cβ alkoxy) carbonyl, Cι-C 6 alkylaminocarbonyl, C 3 -C 6 alkenyl, C 3 -C7 cycloalkyl, 4 -C 11 cycloalkylalkyl, aryl, heteroaryl (Ci-Cβ alkyl) carbonyl, heteroarylcarbonyl, aryl (Ci-Cβ alkyl)-, (Ci-Cβ alkyl)carbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, aryl(Cι-C6 alkyl)sulfonyl, heteroarylsulfonyl, heteroaryl (Ci- Cβ alkyl)sulfonyl, aryloxycarbonyl, or aryKCi-Cg alkoxy)carbonyl, wherein said aryl groups are substituted with 0-2 substituents selected from the group consisting of C1-C4 alkyl, C 1 -C 4 alkoxy, r.alo, CF 3 , and nitro, • R 3 is selected from: H, Cι-C 6 alkyl, C 3 -C 7 cycloalkyl, C4-C11 cycloalkylalkyl, aryl, aryl (Cι-C 6 alkyl) -, or heteroaryl (Ci-Cβ alkyl)-,. R 4 and R 5 are independently selected from: H, C_-C 4 alkoxy, NR 2 R 3 , halogen, N0 2 , CN, CF 3 , Cι-C δ alkyl, C 3 -C 6 alkenyl, C 3 -C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl (Cι-C 6 alkyl) -, C 2 -C? alkylcarbonyl, arylcarbonyl or alternatively, when substituents on adjacent atoms, R 4 and R 5 can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups selected from: C1-C4 alkyl, C 1 -C 4 alkoxy, halo, cyano, am o, CF3, or N0 2 ; U is selected from: - ( CH 2 ) n -« -(CH 2 )n(CR 7 =CR 8 ) (CH 2 ) m -, -lCH 2 ) t Q(CH 2 ) ι , - ( CH 2 ) nO ( CH 2 ) m-. -(CH 2 ) n N(R 6 ) (CH 2 ) m -, -(CH 2 ) n C(=0) (CH ) m -, or -(CH 2 )nS(0)p(CH 2 ) m -; wherein one or more of the methylene groups m U is optionally substituted with R 7 ; s selected from 1, 2-ther.yle.e, 1, 2-pheny_ene, 2,3- pyr d ylene, 3 , 4-tyr d:. -er.e, or 2,4- pyridiny_.ene; R 6 is selected from: H, C 1 -C 4 alkyl, or benzyl; R 7 and R 8 are independently selected from: H, Cι-C 6 alkyl, C3-C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryKCi-Cβ alkyl)-, or heteroaryl (Co-Cε alkyl)- ; R 10 is selected from: H, C 1 -C 4 alkoxy substituted with 0-1 R 21 , N(R 6 ) 2 , halogen, N0 2 , CN, CF 3 , C0 R 17 , C(=0)R 17 , C0NR 17 R 20 , -S0 2 R 17 , -S0 NR 17 R 20 , Cι-C 6 alkyl substituted with 0-1 R 15 or 0-1 R 21 , C 3 -C 6 alkenyl substituted with 0-1 R 15 or 0-1 R 21 , C 3 -C7 cycloalkyl substituted with 0-1 R 15 or 0-1 R 21 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 or 0-1 R 21 , aryl substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 , or aryKCi-Cβ alkyl)- substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 ; R 11 is selected from: H, halogen, CF 3 , CN, N0 2 , hydroxy, NR 2 R 3 , C 1 -C 4 alkyl substituted with 0-1 R 21 , C1-C4 alkoxy substituted with 0-1 R 21 , aryl substituted with 0-1 R 21 , aryl(Cι-C 6 alkyl)- substituted with 0-1 R 21 , (C 1 -C 4 alkoxy) carbonyl substituted with 0-1 R 21 , (C 1 -C 4 alkyl)carbonyl substituted with 0-1 R 21 , C 1 -C 4 alkylsulfonyl substituted with 0-1 R 21 , or C 1 -C4 alkylaminosulfonyl substituted with 0-1 R 21 ; W is -C ( =0 ) -N(R 13) - ( C ( R 12) 2 ) q-; X is -C(R 12 ) (R 14 )-C(R 12 ) (R 15 )-; alternatively, W and X can be taken together to be R 12 is H or Cι-C 6 alkyl; R 13 is selected from: H, Cι-C 6 alkyl, C3-C7 cycloalkyl ethyl, or aryl(Cι-C 6 alkyl)-; R 14 is selected from: H, Ci-Cβ alkylthioalkyl, aryl(Cι-Cιo alkylthioalkyl ) -, aryl (C1-C 10 alkoxyalkyl) -, C 1 -C 10 alkyl, C1-C10 alkoxyalkyl, Cι-C 6 hydroxyalkyl, C 2 -Cιo alkenyl, C2-C10 alkynyl, C 3 -C 10 cycloalkyl, C3-C10 cycloalkylalkyl, aryKCi-Cβ alkyl)-, heteroaryl (Ci-Cβ alkyl)-, aryl, heteroaryl, C0 R 17 , C(=0)R 17 , or CONR 17 R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be substituted independently with 0-1 R 16 or 0- 2 R U ; R 15 is selected from: H, R 16 , C1-C10 alkyl, Cι-C_ 0 alkoxyalkyl, C 1 -C 10 alkyla inoalkyl, C 1 -C 0 dialkylaminoalkyl, C 1 -C 10 alkylcarbonyl, aryl (Co-Ce alkyl)carbonyl, C 2 -C 10 alkenyl, C 2 -Cιo alkynyl ,C3-Cιo cycloalkyl, C 3 -C 10 cycloalkylalkyl, aryKCi-Cβ alkyl)-, heteroaryl (Ci-Cβ alkyl)-, aryl, heteroaryl, C0 2 R 17 , C(=0)R 17 , CONR 17 R 20 , S0 2 R 17 , or S0 2 NR 17 R 2 °, provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be substituted independently with 0-2 R u ; Y is selected from: -COR l9 , -SO 3 H, R 16 is selected from: -N(R 20 )-C(=O)-O-R 17 , -N(R 20 )-C(=O)-R 17 , -N(R 20 )-C(=O) -NH-R 17 , -N(R 20 )SO 2 -R 17 , or -N(R 20 )SO 2 -NR 0 R 17 ; R 17 is selected from: C1-C 1 0 alkyl, C3-C 11 cycloalkyl, aryl(Cι-C 6 alkyl)-, (Ci-Cβ alkyl)aryl, heteroaryl (Cι-C 6 alkyl)-, (Ci-Cβ alkyl) heteroaryl, biaryKCi-Cβ alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, heteroaryl, halo,cyano, amino, CF 3 , and N0 2 ; R 18 is selected from: H, -C(=0)-0-R 17 , -C(=0)-R 17 , -C(=0)-NH-R 17 , -S0 2 -R 17 , or -SO 2 -NR 20 R 17 ; R 19 is selected from: hydroxy, C1-C10 alkyloxy, C 3 -C 11 cycloalkyloxy, Cβ-Cio aryloxy, C 7 -C 11 aralkyloxy, C 3 -C 10 alkylcarbonyloxyalkyloxy, C 3 -C 10 alkoxycarbonyloxyalkyloxy, C 2 -Cιo alkoxycarbcnyialkyioxy, C5-C 1 0 cycloalkylcarbonyloxyalkyloxy, C5-C10 cycloalkoxycarbonyloxyalkyloxy, C5-C 1 0 cycloalkoxycarbonylalkyloxy, C7-C- .1 aryloxycarbonylalkyloxy, Ca-Cι 2 aryloxycarbonyloxyalkyloxy, Ca-Cι 2 arylcarbonyloxyalkyloxy, C5-C10 alkoxyalkylcarbonyloxyalkyloxy, C5-C 10 (5-alkyl-l, 3-dioxa-cyclopenten-2-one- yD ethyloxy, C 10 -C 4 (5-aryl-l, 3-dioxa-cyclopenten- 2-one-yl)methyloxy, or (R 11 ) (R 12 )N- (C -C 10 alkoxy)-; R 20 selected from: H, Ci-Cβ alkyl, C 3 -C7 cycloalkyl, C 4 - Cn cycloalkylalkyl, aryl(Cι-C δ alkyl)-, or heteroaryl (Ci-Cδ alkyl)-. R 21 is selected from COOH or NR 6 2l and 3. A compound of Claim 1 of the Formula Ila or lib: Ila Ub and pharmaceutically acceptable salt forms thereof wherein: Xi and X3 are independently selected from nitrogen or carbon; R 1 is selected from: wherein the above heterocycles are optionally substituted with 0-2 substituents selected from the group consisting of: NH 2 , halogen, N0 2 , CN, CF3, Ci- C 4 alkoxy, Ci-Cβ alkyl, and C3-C7 cycloalkyl; U is -(CH 2 ) n -, -(CH 2 ) L Q:CH ? : Π - or -C(=0) (CH 2 ) n -ι-/ wherein one of the methylene groups is optionally substituted with R 7 ; s selected rrorn 1, 2-crεr.yie:.e, 1, _ -p eny-eπe, 2, 3- pyr dmyleπe, 3 , 4-ty dιny J .er.e, or 2,4- pyrid ylene; R 6 is selected from: H, C 1 -C 4 alkyl, or benzyl; R7 is selected from: Ci-Cβ alkyl, C 3 -C 7 cycloalkyl, C 4 - C11 cycloalkylalkyl, aryl, aryl(Cι-C 6 alkyl) , heteroaryl, or heteroaryl (Cι-C 6 alkyl); R i o 1S selected from: H, C 1 -C 4 alkoxy substituted with 0-1 R 21 , halogen, C0 2 R 17 , C0NR 17 R 20 , Cι~C 6 alkyl substituted with 0-1 R 15 or 0-1 R 21 , C 3 -C 7 cycloalkyl substituted with 0-1 R 15 or 0-1 R 21 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 or 0-1 R 21 , or aryl (Ci-Cβ alkyl)- substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 ; RH 1S selected from: H, halogen, CF 3 , CN, N0 2 , hydroxy, NR 2 R 3 , C 1 -C 4 alkyl substituted with 0-1 R 21 , C1-C4 alkoxy substituted with 0-1 R 21 , aryl substituted with 0-1 R 21 , aryKCi-Cβ alkyl)- substituted with 0-1 R 21 , (C 1 -C 4 alkoxy)carbonyl substituted with 0-1 R 21 , (C 1 -C 4 alkyl)carbonyl substituted with 0-1 R 21 , C 1 -C 4 alkylsulfonyl substituted with 0-1 R 21 , or C 1 -C 4 alkylaminosulfonyl substituted with 0-1 R 21 ; X is -CH(R 14 )-CH(R 15 )-; R 13 IS H or CH ; R 14 is selected from: H, C 1 -C 10 alkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, halo, cyano, ammo, CF , and N0 2 ; R 15 is H or R 16 ; Y IS -COR 19 ; R 16 is selected from: -NH(R 20 )-C(=O)-O-R 17 , -N(R 20 )-C(=O)-R 17 , -N(R 20 )-C(=O) -NH-R 17 , -N(R 20 )SO 2 -R 17 , or -N(R 20 )SO -N(R 20 )R 17 ; R 17 is selected from: C 1 -C10 alkyl, C 3 -C 11 cycloalkyl, aryKCi-Cβ alkyl)-, (Ci-Cβ alkyl) aryl1 heteroaryl (Ci-Ce alkyl)-, (Ci-Cβ alkyl) heteroaryl, biaryl (C -Cβ alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, heteroaryl, halo, cyano, amino, CF 3 , and N0 2 ; R 19 is selected from: hydroxy, C1-C10 alkoxy, methylcarbonyloxymethoxy- , et nylcarbonyloxymethoxy- , t-butylcarbonyloxymethoxy- , cyclohexylcarbonyloxymethoxy- , 1- (methylcarbonyloxy) ethoxy- , 1- ( ethylcarbonyloxy) ethoxy- , 1- (t-butylcarbonyloxy) ethoxy- , 1- (cyclohexylcarbonyloxy) ethoxy- , i -propyl oxycarbonyloxymethoxy- , t-butyloxycarbonyioxymethoxy-, 1- (i-propyloxycarbonyloxy) ethoxy-, 1- (cyclohexyloxycarbonyloxy) ethoxy- , 1- ( C-butyloxycarbonyloxy) ethoxy-, dimethylaminoethoxy-, diethylammoethoxy-, (5-methyl-1, 3-dioxacyclopenten-2-on-4-yl) ethoxy-, (5- ( c-butyl) -1, 3-dioxacyclopenten-2-on-4- yl)methoxy-, (1, 3-dioxa-5-phenyl-cyclopenten-2-on-4-yl)methoxy-, or 1- (2- (2-methoxypropyl ) carbonyloxy) ethoxy-; R 20 is H or CH 3 ; R21 1S selected from COOH or NR 6 2 ; 4. A compound of Claim 1 of the Formula Ila or lib: and pharmaceutically acceptable salt forms thereof wherein: Xi and X3 are independently selected from nitrogen or carbon, provided that at least one of Xi and X 3 is carbon; P 1 is selected from: wherein the above heterocycles are optionally substituted with 0-2 substituents selected from the group consisting of: NH 2 , halogen, N0 2 , CN, CF 3 , C 1 -C 4 alkoxy, Ci-Ce alkyl, and C 3 -C7 cycloalkyl; U is -(CH 2 ) n -, -(CH 2 ' L Q;CH 2 , -,- or -C(=0) (CH 2 ) n -ι- wherein one of the methylene groups is optionally substituted with R 7 ; 0 s selected from 1,2-phenyler.e, 1, -pnenylene, 2,3- pyridinylene, 3,4-pyndmyler.e, or 2,4- pyr dinylene; R 6 is selected from: H, C 1 -C 4 alkyl, or benzyl; R7 is selected from: C_-Cό alkyl, C 3 -C7 cycloalkyl, C4-C11 cycloalkylalkyl, aryl, aryl(Cι-C ό alkyl; , heteroaryl, or heteroaryl (C1-C 0 alkyl); R 10 s selected from: H, C 1 -C 4 alkoxy substituted with 0-1 R 21 , halogen, C0 2 R 17 , C0NR 17 R 20 , Cι-C 6 alkyl substituted with 0-1 R 1 - or 0-1 R 21 , C 3 -C 7 cycloalkyl substituted with 0-1 R 15 or 0-1 R 21 , C4-C 11 cycloalkylalkyl substituted with 0-1 R 15 or 0-1 R 21 , or aryl(Cι-C ό alkyl)- substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 ; R 11 is selected from: H, halogen, CF 3 , CN, N0 2 , hydroxy, NR 2 R 3 , C 1 -C 4 alkyl substituted with 0-1 R 21 , C 1 -C 4 alkoxy substituted with 0-1 R 21 , aryl substituted with 0-1 R 21 , aryl(Cι-C 6 alkyl)- substituted with 0-1 R 21 , (C 1 -C 4 alkoxy) carbonyl substituted with 0-1 R 21 , (C 1 -C 4 alkyl)carbonyl substituted with 0-1 R 21 , C 1 -C 4 alkylsulfonyl substituted with 0-1 R 21 , or C 1 -C 4 alkyla inosulfonyl substituted with 0-1 R 21 ,-W W is -C(=0)-N(R 13 )-; X is -CH(R 1 )-CH(R 15 )-; R 13 is H or CH 3; R 14 is selected from: H, C 1 -C 10 alkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, C1-C4 alkoxy, aryl, halo, cyano, amino, CF3, and N0 2 ; R 15 is H or R 16 ; R 16 s selected from: -N(R 0 )-C(=O)-O-R 17 , -N(R 20 )-C(=O)-R 17 , -N(R 20 )-C(=O) -NH-R 17 , -N(R 0 )SO 2 -R 17 , or -N(R 20 )SO 2 -NR 20 R 1 "; R 17 is selected from: Ci-Cio alkyl, C3-C11 cycloalkyl, aryl(Cι-C 6 alkyl)-, (Cι-C 6 alkyl) aryl, heteroaryl (Ci-Cβ alkyl)-, (Cι-C 6 alkyl) heteroaryl, bιaryl(Cι-C 6 alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, heteroaryl, halo, cyano, ammo, CF 3 , and N0 2 ; R 19 is selected from: hydroxy, C1-C10 alkoxy, methylcarbonyloxymethoxy-, ethylcarbonyloxymethoxy-, t-butylcarbonyloxymethoxy-, cyclohexylcarbonyloxymethoxy-, 1- (methylcarbonyloxy)ethoxy-, 1- {ethylcarbonyloxy)ethoxy-, 1- (t-butylcarbonyloxy) ethoxy-, 1- (cyclohexylcarbonyloxy)ethoxy-, i-propyloxycarbonyloxymethoxy-, t-butyloxycarbonyloxymethoxy-, 1- (l-propyloxycarbonyloxy)ethoxy-, 1- (cyclohexyloxycarbonyloxy) ethoxy-, 1- ( t-butyloxycarbonyloxy)ethoxy-, dimethylaminoethoxy-, diethylaminoetnoxy- , ( 5-methyl-l, 3 -dιoxacyclopenten-2-on-4-yl) methoxy-, ( 5- ( t-butyl ) -l, 3-dιoxacyclopenten-2-on-4- yl) ethoxy-, ( 1,3 -dioxa- 5 -phenyl -cyclopenten-2 -on-4-yl ) methoxy- , or I- ( 2- ( 2 -methoxypropyDcarbonyloxy) ethoxy-; R 21 is selected from COOH or NR 6 2 ; t ≤ 'ι cr 1. 5. A compound of Claim 1 of Formula la and enantiomenc or diastenomeric forms thereof, and mixtures of enantiomeric or diastenomeric forms thereof, and pharmaceutically acceptable salt forms thereof, selected from the group consisting of: 3- [1- [3- (imidazolin-2-ylamino) ropyl] indazol-5- ylcarbonylammo]-2- (benzyloxycarbonylammo)- propionic acid, 3- [1-[3- (imidazolin-2-ylammo) ropyl]mdazol-5- y1carbonylamino] -2- (2,4,6-trιmethylbenzene- sulfonylamino)propionic acid, 3- [1-[3-(ιmιdazolιn-2-ylamino) ropyl] dazol-5- ylcarbonylammo] -2- (benzenesulfonylammo) propionic acid, 3- [1- [3- (imi azolin-2-ylamino) ropyl]ιndazol-5- ylcarbonylammo]-2-(2,6-dιchlorobenzene- sulfonylamino) ropionic acid, 3- [1- [3- (imidazolin-2-ylamino)propyl] indazol-5- ylcarbonyla o] -2- (3 , 5-dιmethylιsoxazol-4- ylsulfonylamino) propionic acid, 3- [1- [3- (ιmιdazolm-2-ylammo)propyl] mdazol-5- ylcarbonylammo] -2- (2, β-dimethylbenzene- sulfonylamino) ropionic acid, 3- [1- (3- (imidazolin-2-ylamino)propyl] mdazol-5- ylcarbonylammo] -2- (2 , 6-dimethyl-4-phenyl- benzenesulfonylammo)propionic acid, 3- [1- [3- (ιmιdazolιn-2-ylammo) propyl] ιndazol-5- ylcarbonylamino] -2- (4-phenylbenzenesul onyl¬ amino)propionic acid, 3- [1- [3- (tetrahydropyπmιd-2-ylamino)propyl] - mdazol-5-ylcarbonylammo] -2- (benzyloxy- carbonylammo)propionic acid, 3- [1- [3- (tetrahydropyrimid-2-ylamino)propyl] - mdazol-5-ylcarbonylamιno] -2- (2, 4, 6-trιmethyl- benzenesulfonylamino)propionic acid, 3- [1- [3- (tetrahydropyrιmιd-2-ylammo)propyl] - ιndazol-5-ylcarbonylammo] -2- (benzenesulfonyl¬ ammo) propionic acid, 3- [1- [3- (tetrahydropyrιmιd-2-ylamino)propyl] - mdazol-5-ylcarbonylamιno] -2- (2, 6-dιchloro- benzenesulfonylamino)propionic acid, 3- [1- [3- (tetrahydropyrιmιd-2-ylammo)propyl] - ndazol-5-ylcarbonylamιno] -2- (3 , 5-dιmethyl- ιsoxazol-4-ylsulfonylammo)propionic acid, 3- [1- [3- (tetrahydropyrιmιd-2-ylamino)propyl] - mdazol-5-ylcarbonylamιno]-2- (2, 6-dιmethyl- benzenesulfonylammo)propionic acid, 3- [1- [3- (tetrahydropyrιmιd-2-ylam o)propyl] - ιndazol-5-ylcarbonylamιno] -2- (2, 6-dιmethyl-4- phenylbenzenesulfonylamino)propionic acid, 3- [1- [3- (tetrahydropyrιmιd-2-ylamιno)propyl] - indazol-5-ylcarbonylammo] -2- (4-phenylbenzene- sulfonylamino)propionic acid, 3- [1- [3- (ιmιdazol-2-ylamino) ropyl] ιndazol-5-yl- carbonylamino] -2- (benzyloxycarbonylammo) - propionic acid, 3- [1- [3- ( ιmιdazol-2-ylammo)propyl] ιndazol-5-yl- carbonylammo] -2- (2,4, 6-trιmethylbenzene- sulfonylamino)propionic acid, 3- [1- [3- (imidazol-2-ylamino) propyl] mdazol-5-yl- carbonylammo] -2- (benzenesulfonylammo) - propionic acid, 3- [1- [3- (imidazol-2-ylamino) ropyl] mdazol-5-yl- carbonyla mo] -2- (2, 6-dιchlorobenzene- sulfonylamino) ropionic acid, 3- [1- [3- (imidazol-2-ylammo)propyl] indazol-5-yl¬ carbonylammo] -2- (3, 5-dιmethylιsoxazol-4- ylsulfonylamino)propionic acid, 3- [1- [3- (imidazol-2-ylamino)propyl] indazol-5-yl¬ carbonylammo] -2- (2, 6-dιmethylbenzene- sulfonylamino)propionic acid, 3- [1- [3- (imidazol-2-ylammo)propyl] mdazol-5-yl- carbonylammo] -2- (2,6-dιmethyl-4-phenyl- benzenesulfonylammo)propionic acid, 3- [1- [3- (imidazol-2-ylamino)propyl] ιndazol-5-yl- carbonylamino] -2- (4-phenylbenzenesulfonyl- amino)propionic acid, 3- [1- [3- (pyridin-2-ylamino)propyl] mdazol-5-yl¬ carbonylammo] -2- (benzyloxycarbonylammo) - propionic acid, 3- [1- [3- (pyridin-2-ylamino)propyl] mdazol-5-yl- carbonylamino] -2- (2,4, 6-trιmethylbenzene- sulfonylamino)propionic acid, 3- [1- (3- (pyridin-2-ylamino)propyl] mdazol-5-yl- carbonylamino] -2- (benzenesulfonylammo) - propionic acid, 3- [1- [3- (pyridin-2-ylam o)propyl] mdazol-5-yl- carbonylammo] -2- (2, 6-dιchlorobenzene- sulfonylamino)propionic acid, 3- [1- [3- (pyr dιn-2-ylammo) propyl] mdazol-5-yl- carbonylam c] -2- (3 , 5-dιmethylιsoxazol-4- ylsulfonylamino) propionic acid, 3- [1- [3- (pyrιdιn-2-ylamιno)propyl] ιndazol-5-yl- carbonylammo] -2- (2, 6-dιmethylbeπzene- sulfonylamino) propionic acid, 3- [1- [3- (pyridin-2-ylamino)propyl] ιndazol-5-yl- carbonylamino] -2- (2, 6-dimethyl-4-phenyl- benzenesulfonylammo)propionic acid, 3- [1- [3- (pyrid -2-ylammo)propyl] mdazol-5-yl- carbonylammo] -2- (4-phenylbenzenesulfonyl¬ amino) propionic acid, 3- [1- [3- (imidazolm-2-ylamino)propyl] mdazol-4- ylcarbonylammo] -2- (benzyloxycarbonylammo) - propionic acid, 3- [1- [3- (ιmιdazolιn-2-ylammo)propyl]ιndazol-4- ylcarbonylammo] -2- (2 ,4, 6-trιmethylbenzene- sulfonylammo)propionic acid, 3- [1- [3- (imidazolin-2-ylamino)propyl] mdazol-4- ylcarbonylammo] -2- (benzenesulfonylammo) propionic acid, 3- [1- [3- (imidazolin-2-ylammo)propyl] ιndazol-4- ylcarbonyla ino] -2- (2, 6-dichlorobenzene- sulfonylamino)propionic acid, 3- [1- [3- (imidazolin-2-ylamino)propyl] mdazol-4- ylcarbonylammo] -2- (3 , 5-dimethylιsoxazol-4- ylsulfonylamino) propionic acid, 3- [1- [3- (ιmidazolιn-2-ylamιno)propyl] ιndazol-4- ylcarbonylamino] -2- (2, 6-dimethylbenzene- sulfonylamino)propionic acid, 3- [1- [3- (imidazolιn-2-ylamino)propyl] mdazol-4- ylcarbonylamino] -2- (2, 6-dιmethyl-4-phenyl- benzenesulfonylamino)propionic acid, 3- [1- [3- (imidazolιn-2-ylamino)propyl] mdazol-4- ylcarbonylammo] -2- (4-phenylbenzenesulfonyl¬ amino)propionic acid, 3- [1- [3- ( tetrahydropyrιmιd-2-ylammo) propyl] - mdazol-4-ylcarbonylammo] -2- (benzyloxy¬ carbonylammo)propionic acid, 3- [1- [3- ( tetrahydropyrimid-2-ylammo)propyl] - indazol-4-ylcarbonylammo] -2- (2,4, 6-tπmethyl- benzenesulfonylamino)propionic acid, 3- [1- [3- (tetrahydropyrlmid-2-ylammo)propyl] - mdazol-4-ylcarbonylamιno] -2- (benzenesu-ionyl- a ino) propionic acid, 3- [1- {3- (tetrahydropyrimid-2-ylamino)propyl] - mdazol-4-ylcarbonylamιno] -2- (2, 6-dιchloro- benzenesulfonylamino)propionic acid, 3- [1- [3- (tetrahydropyrlmid-2-ylammo)propyl] - mdazol-4-ylcarbonylammo] -2- (3 , 5-dιmethyl- soxazol-4-ylsulfonylammo) ropionic acid, 3- [1- [3- (tetrahydropyrimid-2-ylammo)propyl] - ιndazol-4-ylcarbonylamιno] -2- (2, 6-dιmethyl- benzenesulfonylamino)propionic acid, 3- [1- [3- (tetrahydropyrimid-2-ylamino)propyl] - ιndazol-4-ylcarbonylamιno] -2- (2, 6-dιmethyl-4- phenylbenzenesulfonylamino)propionic acid, 3- [1- [3- (tetrahydropyrιmιd-2-ylamino)propyl] - ιndazol-4-ylcarbonylamιno] -2- (4-phenylbenzene- sulfonylamino)propionic acid, 3- [1- [3- (ιmιdazol-2-ylamιno)propyl] mdazol-4-yl- carbonylamino] -2- (benzyloxycarbonylammo) - propionic acid, 3- [1- [3- (ιmιdazol-2-ylammo)propyl] ιndazol-4-yl- carbonylamino] -2- (2,4, 6-trιmethylbenzene- sulfonylamino)propionic acid, 3- [1- [3- (ιmιdazol-2-ylam o)propyl] mdazol-4-yl- carbonylamino] -2- (benzenesulfonylammo) - propionic acid, 3- [1- [3- (imidazol-2-ylammo)propyl] indazol-4-yl- carbonylammo] -2- (2, 6-dichlorobenzene- sulfonylamino) propionic acid, 3- [1- [3- (ιmιdazol-2-ylamino) propyl] ιndazol-4-yl- carbonylam o] -2- (3 , 5-dimethylιsoxazol-4- ylsulfonylamino) ropionic acid, 3- [1- [3- (ιmιdazol-2-ylammo)propyl] ιndazol-4-yl- carbonylammo] -2- (2, β-dimethylbenzene- sul onylamino)propionic acid, 3- [1- [3- (ιmidazol-2-ylammo)propyl] mdazol-4-yl¬ carbonylammo] -2- (2, 6-dimethyl-4-phenyl- benzenesulfonylamino)propionic acid, 3- [1- [3- (ιmidazol-2-ylamino) ropyl] indazol-4-yl- carbonylammo] -2- (4-phenylbenzenesulfonyl¬ amino)propionic acid, 3- [1- [3- (pyridin-2-ylamino)propyl] indazol-4-yl- carbonylamino] -2- (benzyloxycarbonylammo) - propionic acid, 3- [1- [3- (pyridin-2-ylamino)propyl] indazol-4-yl- carbonylamino] -2- (2, 4, 6-trimethylbenzene- sulfonylamino)propionic acid, 3- [1- [3- (pyridin-2-ylammo)propyl] indazol-4-yl- carbonylamino] -2- (benzenesulfonylamino) - propionic acid, 3- [1- [3- (pyridin-2-ylamino) ropyl] indazol-4-yl- carbonyla ino] -2- (2, 6-dichlorobenzene- sulfonylamino)propionic acid, 3- [1- [3- (pyridin-2-ylamino)propyl] indazol-4-yl- carbonylamino] -2- (3, 5-dimethylisoxazol-4- ylsulfonylamino)propionic acid, 3- [1- [3- (pyridin-2-ylamino)propyl] mdazol-4-yl- carbonylamino] -2- (2, 6-dimethylbenzene- sulfonylamino)propionic acid, 3- [1- [3- (pyridin-2-ylamino)propyl] indazol-4-yl- carbonylamino]-2- (2, 6-dimethyl-4-pheny1- benzenesulfonylamino(propionic acid, and 3- [1- [3- (pyridin-2-ylamino)propyl] indazol-4-yl- carbonylamino] -2- (4-phenylbenzenesulfonyl¬ amino)propionic acid; and ester forms thereof, said ester being selected from the group consisting of: methyl, ethyl, isopropyl, n-butyl, isobutyl, benzyl, methylcarbonyloxymethyl, ethylcarbonyloxymethyl, tert-butylcarbonyloxymethyl, cyclohexylcarbonyloxymethyl, tert-butyloxycarbonyloxymethyl, dimethylaminoethyl, diethylaminoethyl, mo phol moet yl , py roi dmcethyl , and tr πiethyla monioethyl . 6 . A compound of Formula lb: lb and pharmaceutically acceptable salt forms thereof, wherein: X 1 , X 2 , X 3 , and X 4 are independently selected from nitrogen or carbon provided that at least two of X 1 , X 2 , X 3 and X 4 are carbon; R 1 is selected from: _ U(NR 6 ) __ , A and B are independently -CH -, -0-, -N(R 2 )-, or -C(=0)-; A 1 and B 1 are independently -CH 2 - or -N(R 3 )-; D IS -N(R 2 )-, -0-, -S-, -C(=0)- or -S0 -; -C(R ) 2 C(R 5 ) 2 -; J, K, L and M are independently selected from: -C(R 4 )-, -C(R 5 )- or -N-, provided that at least one of J, K, L and M is not -N-; R 2 is selected from: H, Ci-Cβ alkyl, (Ci-Cβ alkyl) carbonyl, (Ci-Cβ alkoxy) carbonyl; (Ci-Cβ alkyl)aminocarbonyl, C 3 -C 6 alkenyl, C 3 -C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, heteroaryl (Ci-Cβ alkyl)carbonyl, heteroarylcarbonyl, aryl Ci-Cβ alkyl, (Ci-Cβ alkyl) carbonyl, or arylcarbonyl, alkylsulfonyl, arylsulfonyl, aryl(Cι-C 6 alkyl) sulfonyl, heteroarylsulfonyl, heteroaryl ( Ci-Cβ alkyl)sulfonyl, aryloxycarbonyl, or aryKCi-Ce alkoxy) carbonyl, wherein said aryl groups are substituted with 0-2 substituents selected from the group consisting of C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo, CF 3 , and nitro; R 3 is selected from: H, Ci-Cβ alkyl, C 3 -C 7 cycloalkyl, C4-C11 cycloalkylalkyl, aryl, aryKCi-C ό alkyl)-, or heteroaryl (Ci-Cδ alkyl)-,- R 4 and R 5 are independently selected from: H, C 1 -C 4 alkoxy, NR 2 R 3 , halogen, N0 2 , CN, CF 3 , Ci-Cβ alkyl, C3-C 6 alkenyl, C3-C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl (Ci-Cβ alkyl)-, (Ci-Cβ alkyl) carbonyl, (Ci-Cβ alkoxy)carbonyl, arylcarbonyl, or alternatively, when substituents on adjacent atoms, R 4 and R 5 can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups selected from: C1-C 4 alkyl, C 1 -C 4 alkoxy, halo, cyano, amino, CF3, or N0 2 ; U is selected from: - (CH 2 ) n - - - (CH 2 ) n (CR 7 =CR θ ) ( CH 2 ) m - - (CH 2 ) n (C= ) (CH 2 ) m - - (CH 2 ) tQ (CH 2 ) m - -(CH 2 ) n 0(CH ) rn -, - (CH 2 ) n N(R 6 ) (CH 2 ) m -, -(CH 2 ) n C(=0) (CH 2 ) m -, - (CH 2 ) n (C=0)N(R 6 ) (CH 2 ) m - - (CH 2 ) n N(R ό ) (C=0) (CH 2 ) m -, or - !CH 2 ) n S(0)p(CH 2 ) m -; wherein one of the methylene groups is optionally substituted with R 7 ; Q s selected from: 1, 2-cycloalkylene, 1, 2-phenylene, 1, 3-phenylene, 1, 4-phenylene, 2, 3-pyridmylene, 3, 4-pyridinylene, 2 , 4-pyridir.ylene, or 3,4- pyridazmylene; R 6 is selected from: H, C 1 -C 4 alkyl, or benzyl; R 7 and R 8 are independently selected from: H, Cχ-C 6 alkyl, C 3 -C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl(Cι-C6 alkyl)-, or heteroaryl (Co-Cβ alkyl)-,. R 9 is selected from: H, C0 2 R 17 , C(=0)R 17 , CONR 17 R 20 , -S0 2 R 17 , -S0 2 NR 17 R 20 , Ci-C δ alkyl substituted with 0-1 R 15 or 0-1 R 21 , C 3 -C 6 alkenyl substituted with 0-1 R 15 or 0-1 R 21 , C 3 -C7 cycloalkyl substituted with 0-1 R 15 or 0-1 R 21 , C -Cu cycloalkylalkyl substituted with 0-1 R 15 or 0-1 R 21 , aryl substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 , or aryl(Cι-C 6 alkyl)- substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 ; R 11 is selected from H, halogen, CF 3 , CN, N0 2 , hydroxy, NR 2 R 3 , C 1 -C 4 alkyl substituted with 0-1 R 21 , C1-C4 alkoxy substituted with 0-1 R 21 , aryl substituted with 0-1 R 21 , aryl (Cι-C 6 alkyl)- substituted with 0-1 R 21 , (C 1 -C 4 alkoxy)carbonyl substituted with 0-1 R 21 , ( C1-C4 alkyl ) carbonyl substituted with 0-1 R 21 , C1-C4 alkylsulfonyl substituted with 0-1 R 21 , or C1-C4 alkylaminosulfonyl substituted with 0-1 R 21 ; w is selected from: - (C(R 12 ) 2 ) q C(=0)N(R 13 )-, or -C(=0)-N(R 13 )-(C(R 12 ) 2 ) q -; X is -C(R 12 ) (R 4 )-C(R 12 ) (R15) - ; or alternatively, W and X can be taken together to be R 12 is selected from: H, halogen, Ci-Cβ alkyl, C 2 -Cβ alkenyl, C 2 -C δ alkynyl, C 3 -C 7 cycloalkyl, C 4 -C 10 cycloalkylalkyl, (C 1 -C 4 alkyl)carbonyl, aryl, or aryKCi-Cβ alkyl)-; R 13 is selected from: H, Ci-Cβ alkyl, C 3 -C7 cycloalkylmethyl, or aryKCi-Cβ alkyl)-; Ri4 i S selected from: H, Ci-Cβ alkylthio(Cι-C 6 alkyl)-, aryl(Cι-Cιo alkylthioalkyl)-, aryl (C 1 -C 10 alkoxyalkyl) -, C1-C10 alkyl, C 1 -C 10 alkoxyalkyl, Ci-Cβ hydroxyalkyl, C2-C1 0 alkenyl, C 2 -Cιo alkynyl, C3-C10 cycloalkyl, C3-C1 0 cycloalkylalkyl, aryKCi-Cβ alkyl)-, heteroaryl (Ci-Cβ alkyl) -, aryl, heteroaryl, C0 R 17 , C(=0)R 17 , or CONR 17 R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 0-1 R 16 or 0-2 R 11 ; R 15 is selected from: H, R 16 , Ci-Cio alkyl, Ci-Cio alkoxyalkyl, Ci-Cio alkylaminoalkyl, Ci-Cio dialkylaminoalkyl, (Ci-Cio alkyl) carb ' -yl, aryl (C O -CΘ alkyl) carbonyl, Ci-Cio alkenyl, Ci-Cio alkynyl ,C 3 -Cιo cycloalkyl, C3-C10 cycloalkylalkyl, aryl (Cι~C 6 alkyl) -, heteroaryl (Cι-C 6 alkyl) -, aryl, heteroaryl, C0 2 R 17 , C(=0)R 17 , C0NR 1 R 20 , S0 R 17 , or S0 2 NR 17 R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 0-2 R 11 ; Y is selected from: -COR 19 , -SO 3 H, -PO 3 H, tetrazolyl, -CONHNHS0 2 CF 3 , -C0NHΞ0 2 R 17 , -C0NHS0 2 NHR 17 , -NHCOCF 3 , -NHC0NHS0 2 R 17 , -NHS0 2 R 17 , -OP0 3 H 2 , -OSO 3 H, -P0 3 H 2 , -SO 3 H, -S0 2 NHCOR 17 , -S0 2 NHC0 2 R 17 , R 16 is selected from: -N(R 0 )-C(=O)-O-R 17 , -N(R 20 )-C(=O)-R 17 , -N(R 20 )-C(=O)-NH-R 17 , -N(R 0 )SO 2 -R 17 , or -N(R 20 )Sθ2-NR 20 R 17 ; R 17 is selected from: C 1 -C 10 alkyl, C 3 -C 11 cycloalkyl, aryl(Cι-C 6 alkyl)-, (Ci-Cβ alkyl)aryl, ' heteroaryl (Ci-Cβ alkyl ) -, ( Ci-Cβ alkyl)heteroaryl, biaryl (Cι-C 6 alkyl) - , heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, C1-C4 alkoxy, aryl, heteroaryl, halo, cyano, amino, CF 3 , and N0 ; 15 is selected from: H, -C(=0)-0-R 17 , -C(=0) -R 17 , -C(=0)-NH-R 17 , -S0 2 -R 17 , or -SO 2 -NR 20 R 17 ; R 19 is selected from hydroxy, C 1 -C 10 alkyloxy, C3-C 11 cycloalkyloxy, aryloxy, aryl (Ci-Cβ alkoxy) -, C3-C 1 0 alkylcarbonyloxyalkyloxy, C 3 -C 10 alkoxycarbonyloxyalkyloxy, C 2 -Cιo alkoxycarbonylalkyloxy, C5-C 10 cycloalkylcarbonyloxyalkyloxy, C5-C 10 cycloalkoxycarbonyloxyalkyloxy, C 5 -C 10 cycloalkoxycarbonylalkyloxy, C7-C 11 aryloxycarbonylalkyloxy, C 8 -Cι aryloxycarbonyloxyalkyloxy, CΘ-CI 2 arylcarbonyloxyalkyloxy, C 5 -C 10 alkoxyalkylcarbonyloxyalkyloxy, C 5 -C 10 (5-alkyl-l, 3-dioxa-cyclopenten-2-one- yDmethyloxy, C 10 -C 14 (5-aryl-l, 3-dioxa-cyclopenten- 2-one-yl)methyloxy, or (R 11 ) (R 12 )N- (C 1 -C 1 0 alkoxy) -; R 20 is selected from: H, Cι-C 6 alkyl, C 3 -C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl (Ci-Cβ alkyl) -, or heteroaryl (Ci-Cβ alkyl) - ; 21 _s selected from COOH or NR 6 2 ; and with the following provisos: (1) t, n, m and q are chosen such that the number of atoms connecting R 1 and Y is in the range of 10-14; and (2) n and are chosen such that the value of n plus m is greater than one r.lε≤≤ * is 7. A compound of Claim 6 of Formula lb: lb and pharmaceutically acceptable salt forms thereof, wherein: X 1 , X 2 , X 3 , and X 4 are independently selected from nitrogen or carbon provided that at least two of X 1 , X 2 , X 3 and X 4 are carbon; R 1 is selected f rom : A and B are independently -CH 2 -, -0-, -N(R 2 )-, or -C(=0)-; A 1 and B 1 are independently -CH - or -N(R 3 )-; D is -N(R 2 )-, -0-, -S-, -C(=0)- or -S0 2 -; -C(R ) 2 C(R 5 ) 2 -; J, K, L and M are independently selected from -C(R 4 )-, -C(R 5 )- or -N-, provided that at least one of J, K, L and M is not -N-; R 2 is selected from: H, C . -C δ alkyl, (Ci-Cβ alkyl)carbonyl, (Cι-C 6 alkoxy)carbonyl, C . -C ό alkylaminocarbonyl, C 3 -C 6 alkenyl, C 3 -C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, heteroaryl (Ci-Cβ alkyl)carbonyl, heteroarylcarbonyl, aryl (Ci-Cβ alkyl)-, (C.-Cβ alkyl) carbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, aryKCi-Cβ alkyl(sulfonyl, heteroarylsulfonyl, heteroaryl (Ci-Cβ alkyl) sulfonyl, aryloxycarbonyl, aryKCi-Cβ alkoxy) carbonyl, wherein said aryl groups are substituted with 0-2 substituents selected from the group consisting of C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo, CF 3 , and nitro; R 3 is selected from: H, Ci-Cβ alkyl, C 3 -C 7 cycloalkyl, 4-C 11 cycloalkylalkyl, aryl, aryl (Cι-C 6 alkyl) -, or heteroaryl (Ci-Ce alkyl)-,. R 4 and R 5 are independently selected from: H, C 1 -C 4 alkoxy, NR 2 R 3 , halogen, N0 2 , CN, CF 3 , Cι-C 6 alkyl, C3-C6 alkenyl, C3-C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl (Cτ . -C 6 alkyl) -, C -C 7 alkylcarbonyl, arylcarbonyl or alternatively, when substituents on adiacent atoms, R 4 and R 5 can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic r ng being optionally substituted with 0-2 groups selected from: C1-C4 alkyl, C 1 -C 4 alkoxy, halo, cyano, ammo, CF3, or N0 2; U is selected from: - ( CH 2 ) n-. -(CH 2 ) π (CR 7 =CR 8 ) (CH 2 ) m - -cCH 2 )cQ(CH 2 ).„-, -(CH2) n O(CH 2 ) m -, -(CH 2 ) n N(R 6 ) (CH 2 ) m -, -(CH 2 ) n C(=0) (CH 2 ) m -ι °r -(CH 2 ) n S ( 0 ) p ( CH 2 ) m-; wherein one of the methylene groups is optionally substituted with R 7 ; C s selected frc- 1 , -cr.er.yier.e, 1, 3-p.eny-er.e, 2,3- pyndinylene, 3 , 4- yr idmyler.e, cr 2,4- cyridiny.ene; R 6 s selected from: H, C 1 -C 4 alkyl, or benzyl; R 7 and R 8 are independently selected from: H, Ci-Ce alkyl, C3-C7 cycloalkyl, C -C π cycloalkylalkyl, aryl, aryl(Cι-C 6 alkyl)-, or heteroaryl (C 0 -C 6 alkyl)-,. R 9 is selected from: H, C0 2 R 1_7 , C(=0)R 17 , C0NR 17 R 20 , -S0 2 R 17 , -SC 2 NR 17 R 20 , Ci-Cβ alkyl substituted with 0-1 R 15 or 0-1 R 21 , C 3 -C 6 alkenyl substituted with 0-1 R 15 or 0-1 R 21 , C 3 -C7 cycloalkyl substituted with 0-1 R 15 or 0-1 R 21 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 or 0-1 R 21 , aryl substituted w th 0-1 R 15 or 0-2 R 11 or 0-1 R 21 , or aryKCi-C δ alkyl)- substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 ; R 11 is selected from: H, halogen, CF 3 , CN, N0 2 , hydroxy, NR 2 R 3 , C 1 -C 4 alkyl substituted with 0-1 R 21 , C1-C4 alkoxy substituted with 0-1 R 21 , aryl substituted with 0-1 R 21 , aryl(Cι-C 6 alkyl)- substituted with 0-1 R 21 , (C 1 -C 4 alkoxy)carbonyl substituted with 0-1 R 21 , (C1-C 4 alkyl)carbonyl substituted with 0-1 R 21 , C 1 -C 4 alkylsulfonyl substituted with 0-1 R 21 , or C 1 -C 4 alkylaminosulfonyl substituted with 0-1 R 21 ; W is -C(=0) -N(R 13) - ( C ( R 12) 2 ) q -; X is -C(R 12 ) (R 14 )-C(R 12 ) (R 15 )-; alternatively, W and X can be taken together to be R 12 s H or Cι-C 6 alkyl; R 13 is selected from: H, Ci-C ό alkyl, C3-C7 cycloalkylmethyl, or aryl(Cι-C 6 alkyl)-; R 14 is selected from: H, Cχ-C 6 alkylthioalkyl, aryl(Cι-Cιo alkylthioalkyl)-, aryl (Cι-C 10 alkoxyalkyl) -, C 1 -C 10 alkyl, C 1 -C 1 0 alkoxyalkyl, Ci-Cβ hydroxyalkyl , C 2 -Cχo alkenyl, C 2 -Cιo alkynyl, C3-C 10 cycloalkyl, C 3 -C 10 cycloalkylalkyl, aryKCi-Cβ alkyl)-, heteroaryl (Ci-Cβ alkyl)-, aryl, heteroaryl, C0 2 R 17 , C(=0)R 17 , or CONR 17 R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently R 15 is selected from: H, R 16 , C 1 -C 10 alkyl, C 1 -C 1 0 alkoxyalkyl, C 1 -C 10 alkylaminoalkyl, C 1 -C 10 dialkylammoalkyl, C 1 -C 10 alkylcarbonyl , aryl (Co-Cβ alkyl) carbonyl, C 2 -Cιo alkenyl, C 2 -Cι 0 alkynyl ,C3-Cιo cycloalkyl, C 3 -C 10 cycloalkylalkyl, aryKCi-Cβ alkyl)-, heteroaryl (Ci-Cβ alkyl)-, aryl, heteroaryl, C0 2 R 17 , C(=0)R 17 , CONR 17 R 20 , S0 2 R 17 , or S0 NR 17 R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 0-2 R 11 ; Y is selected from: -COR 19 , -SO 3 H, R 10 is selected from: -N(R 20 )-C(=O) -O-R 17 , -N(R 20 )-C(=O)-R 17 , -N(R 20 )-C(=O) -NH-R 17 , -N(R 20 )SO 2 -R 17 , or -N(R 20 )SO 2 -NR 20 R 17 ; R 17 is selected from: Ci-Cio alkyl, C3-C11 cycloalkyl, aryl(Cι-C 6 alkyl)-, ( Ci-Cβ alkyl ) ry # heteroaryl (Cι-C 6 alkyl)-, (Cι-C 6 alkyl) heteroaryl, biaryKCi-Cβ alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, heteroaryl, halo, cyano, ammo, CF 3 , and N0 2 ; R 18 is selected from: H, -C(=0)-0-R 17 , -C(=0)-R 17 , -C(=0)-NH-R 17 , -SO2-R 17 , or -SO 2 -NR 20 R 17 ; R 19 is selected from hydroxy, C1-C10 alkyloxy, C 3 -C 1 1 cycloalkyloxy, Cβ-Cio aryloxy, C 7 -C1 1 aralkyloxy, C 3 -C 10 alkylcarbonyloxyalkyloxy, C 3 -C 10 alkoxycarbonyloxyalkyloxy, C 2 -Cχo alkoxycarbonylalkyloxy, C5-C 1 0 cycloalkyicarbonyloxyalkyloxy, C 5 -C 10 cycloalkoxycarbonyloxyalkyloxy, C5-C 1 0 cycloalkoxycarbonylalkyloxy, C7-C 11 aryloxycarbonylalkyloxy, 8 - 12 aryloxycarbonyloxyalkyloxy, Ca~Cι 2 arylcarbonyloxyalkyloxy, C5-C 1 0 alkoxyalkylcarbonyloxyalkyloxy, C 5 -C 10 (5-alky1-1, 3-dioxa-cyclopenten-2-one- yDmethyloxy, C10-C14 (5-aryl-l, 3-dιoxa-cyclopenten- 2-one-yl)methyloxy, or (R 11 ) (R 12 ) N- (C 1 -C 10 alkoxy)-; 20 selected from: H, Ci-Cβ alkyl, C 3 -C7 cycloalkyl, C 4 - C 11 cycloalkylalkyl, aryl(Cι-C 6 alkyl)-, or heteroaryl (Ci-Cβ alkyl)-,. R21 1S selected from COOH or NR 6 2 ; and A compound of Claim 6 of the Formula lie or lid: and pharmaceutically acceptable salt forms thereof, wherein: Xi and X3 are independently selected from nitrogen or carbon; R 1 is selected from: « "-0. --'- $ : UNR HJQ wherein the above heterocycles are optionally substituted with 0-2 substituents selected from the group consisting of: NH 2 , halogen, N0 , CN, CF3, Ci- C 4 alkoxy, Ci-Cβ alkyl, and C3-C7 cycloalkyl; U is -(CH 2 ) n -, -(CH 2 ) L Q:CH 2 : n - or -C(=0) (CH 2 ) n -ι-< wherein one of the methylene groups is optionally substituted with R 7 ; Q s selected from 1 , 2-tr.εr-yIe:.e, 1, -pheny..ene, 2,3- pyndinylene, 3 , 4-tyr dmyler.e, or 2,4- pyridinyle e; R δ is selected from: H, C 1 -C 4 alkyl, or benzyl; R7 is selected from: Ci-C δ alkyl, C 3 -C 7 cycloalkyl, C - C1 1 cycloalkylalkyl, aryl, aryKCi-Cβ alkyl) , heteroaryl, or heteroaryl (Ci-Cβ alkyl); R 9 IS selected from: H, -Ξ0 2 R 17 , -S0 2 NR 17 R 20 , C . -Cβ alkyl substituted with 0-1 R 15 or 0-1 R 21 , C 3 -C7 cycloalkyl substituted with 0-1 R 15 or 0-1 R 21 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 or 0-1 R 21 , aryl substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 , or aryl(Cι-C 6 alkyl)- substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 ; R 11 is selected from: H, halogen, CF 3 , CN, N0 2 , hydroxy, NR 2 R 3 , C 1 -C 4 alkyl substituted with 0-1 R 21 , C1-C 4 alkoxy substituted with 0-1 R 21 , aryl substituted with 0-1 R 21 , aryKCi-Ce alkyl)- substituted with 0-1 R 21 , (C 1 -C 4 alkoxy) carbonyl substituted with 0-1 R 21 , (C 1 -C 4 alkyl) carbonyl substituted with 0-1 R 21 , C 1 -C 4 alkylsulfonyl substituted with 0-1 R 21 , or C 1 -C 4 alkylaminosulfonyl substituted with 0-1 R 21 ; W is -C(=0)-N(R 13 )-; X is -CH(R 1 )-CH(R 15 )-; R 13 is H or CH 3; R 14 is selected from: H, C 1 -C 10 alkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with 3-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, halo, cyano, ammo, CF 3 , and N0 2 ; Y IS -COR 19 ; R lδ is selected from: -NH(R 20 ) -C(=0)-0-R 17 , -N(R 20 )-C(=O)-R 17 , -N(R 20 )-C(=O)-NH-R 17 , -N(R 20 )SO 2 -R 17 , or -N(R 20 )SO 2 -N(R 20 )R 17 ; R 17 is selected from: C1-C10 alkyl, C3-C 11 cycloalkyl, aryl(Cι-C 6 alkyl)-, ( Ci-Cβ alkyl)aryl, heteroaryl (Cι-C 6 alkyl)-, (C_-C 6 alkyl) heteroaryl, bιaryl(Cι-C 6 alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, heteroaryl, halo, cyano, am o, CF 3 , and N0 ; R 19 is selected from: hydroxy, C 1 -C 10 alkoxy, methylcarbonyloxymethoxy-, ethylcarbonyloxymethoxy-, t-butylcarbonyloxymethoxy-, cyclohexylcarbonyloxymethoxy-, 1- (methylcarbonyloxy)ethoxy-, 1- (ethylcarbonyloxy)ethoxy-, 1- (t-butylcarbonyloxy) ethoxy-, 1- (cyclohexylcarbonyloxy)ethoxy-, 1-propyloxycarbonyloxymethoxy-, t-butyloxycarbonyloxymethoxy-, 1- (i-propyloxycarbonyloxy) ethoxy-, 1- (cyclohexyloxycarbonyloxy) ethoxy- , 1- ( t-butyloxycarbonyloxy) ethoxy-, dimethylammoethoxy-, diethylaminoethoxy-, (5-methyl-1, 3-dioxacyclopenten-2-on-4-yl)methoxy-, (5- ( -butyl) -1,3-dioxacyclopenten-2-on-4- yl)methoxy-, (1, 3-dioxa-5-phenyl-cyclopenten-2-on-4-yl)methoxy-, or 1- (2- (2-methoxypropyl)carbonyloxy) ethoxy-; R 20 is H or CH 3 ; R 21 is selected from COOH or NR 6 2 ; and n is 1-4; and t or 9. A compound of Claim 6 of the Formula He or lid: and pharmaceutically acceptable salt forms thereof, wherein: Xi and X3 are independently selected from nitrogen or carbon, provided that at least one of Xi and X 3 is carbon; R 1 is selected from: — UNR wherein the above heterocycles are optionally substituted with 0-2 substituents selected from the group consisting of: NH 2 , halogen, N0 2 , CN, CF3, Ci- C 4 alkoxy, Ci-Cβ alkyl, and C 3 -C7 cycloalkyl: U is -(CH 2 ) n -, - 'CHj cQ.CHpln- or -C (=0) (CH 2 ) n -i ~ - wherein one of the methylene groups is optionally substituted with R 7 ; Q is selected from 1, -phenylene, 1, 3-phenylene, 2,3- pyπdinylene, 3 , 4-pyr Jιnyleπe, or 2,4- pyrιdιny_.ene; 6 1S selected from: H, C 1 -C 4 alkyl, or benzyl; R7 is selected from: Cι-C_ alkyl, C 3 -C7 cycloalkyl, C - C11 cycloalkylalkyl, aryl, aryKCi-Ce alkyl) , heteroaryl, cr heteroaryl (Ci-C δ alkyl) ; R 9 is selected from: H, -30 2 R 17 , -S0 NR 17 R 20 , Cι-C 6 alkyl substituted with 0-1 R 15 or 0-1 R 21 , C 3 -C7 cycloalkyl substituted w th 0-1 R 15 or 0-1 R 21 , C4-C1 1 cycloalkylalkyl substituted with 0-1 R 15 or 0-1 R 21 , aryl substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 , or aryKCi-Cβ alkyl)- substituted with 0-1 R 15 or 0-2 R 1 or 0-1 R 2 ,- R 11 s selected from H, halogen, CF 3 , CN, N0 2 , hydroxy, NR 2 R 3 , C 1 -C 4 alkyl substituted with 0-1 R 21 , C 1 -C 4 alkoxy substituted with 0-1 R 21 , aryl substituted with 0-1 R 21 , aryKCi-Ce alkyl)- substituted with 0-1 R 21 , (C 1 -C 4 alkoxy)carbonyl substituted with 0-1 R 21 , (C 1 -C 4 alkyl) carbonyl substituted with 0-1 R 21 , C 1 -C 4 alkylsulfonyl substituted with 0-1 R 21 , or C 1 -C 4 alkylaminosulfonyl substituted with 0-1 R 21 ,-W X is -CH(R 1 )-CH(R 15 )-; R 13 is H or CH 3; R 14 is selected from: H, C1-C 10 alkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C4 alkyl, C1-C4 alkoxy, aryl, halo, cyano, amino, CF 3 , and N0 ; Y IS -COR 19 ; R 16 is selected from: -N(R 20 )-C(=O) -O-R 17 , -N(R 20 )-C(=O)-R 17 , -N(R 20 )-C(=O) -NH-R 17 , -N(R 20 )SO 2 -R 17 , or -N(R 20 )SO 2 -NR 20 R 17 ; R 17 is selected from: Ci-Cio alkyl, C3-C11 cycloalkyl, aryl(Cι-C 6 alkyl)-, ( Ci-Cβ alkyl ) aryl, heteroaryl (Cι-C 6 alkyl)-, (Cι-C 6 alkyl ) heteroaryl, biaryKCi-Cβ alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, heteroaryl, halo, cyano, amino, CF 3 , and N0 ; > 19 is selected from: hydroxy, C 1 -C10 alkoxy, methylcarbonyloxymethoxy-, ethylcarbonyloxymethoxy-, ε-butylcarbonyloxymethoxy-, cyclohexylcarbonyloxymethoxy-, 1- (methylcarbonyloxy) ethoxy-, 1- (ethylcarbonyloxy)ethoxy-, 1- (t-butylcarbonyloxy) ethoxy-, 1- (cyclohexylcarbonyloxy)ethoxy-, i-propyloxycarbonyloxymethoxy-, t-butyloxycarbonyloxymethoxy-, 1- (i-propyloxycarbonyloxy)ethoxy-, 1- (cyclohexyloxycarbonyloxy) ethoxy-, 1- (t-butyloxycarbonyloxy)ethoxy-, dimethylammoethoxy-, diethylammoethoxy-, ( 5-methyl-1,3-dιoxacyclopenten-2-on-4-yl)methoxy-, (5- (t-butyl) -1, 3-dιoxacyclopenten-2-on-4- yl)methoxy-, ( 1, 3-dιoxa-5-phenyl-cyclopenten-2-on-4-yl)methoxy-, or 1- (2-(2-methoxypropyl)carbonyloxy)ethoxy-; R 21 is selected from COOH or NR 6 2 ; and l S ; Or -; c i≤ j cr 1. 10. A compound of Claim 6 of Formula lb and enantiomeric or diastenomeric forms thereof, and mixtures of enantiomeric or diastenomeric forms thereof, and pharmaceutically acceptable salt forms thereof, selected from the group consisting of: 3-(3-[3- (imidazol n-2-ylamino)propyl]mdazol-6- ylcarbonylammo] -2- (benzyloxycarbonylammo)- propionic acid, 3- [l-methyl-3- [3- (ιmιdazolm-2-ylamιno)propyl]- mdazol-6-ylcarbonylamιno]-2- (2,4,6-tπmethyl- benzenesulfonylamino)propionic acid, 3- [3-[3-(imidazolin-2-ylamino)propyl]indazol-6- ylcarbonylammo]-2-(benzenesulfonylammo) propionic acid, 3- [l-methyl-3- [3-(ιmιdazolιn-2-ylamιno)propyl]- dazol-6-ylcarbonylammo]-2-(2,6-dιchloro- benzenesulfonylammo)propionic acid, 3- [3- [3- (ιmιdazolm-2-ylammo)propyl] mdazol-6- ylcarbonylammo] -2- (3, 5-dιmethylιsoxazol-4- ylsulfonylamino) propionic acid, 3- [l-methyl-3- [3- (ιmιdazolm-2-ylammo)propyl] - indazol-6-ylcarbonylammo] -2- (2, 6-dimethyl- benzenesulfonylamino)propionic acid, 3- [3- [3- (imidazolin-2-ylam o)propyl] mdazol-6- ylcarbonylammo] -2- (2, 6-dιmethyl-4-phenyl- benzenesulfonylajnino)propionic acid, 3- [l-methyl-3- [3- (imidazolin-2-ylamino)propyl] - ιndazol-6-ylcarbonylammo]-2- (4-phenylbenzene- sulfonylamino)propionic acid, 3- [3- [3- (tetrahydropyrιmιd-2-ylammo)propyl] - ιndazol-6-ylcarbonylamιno] -2- (benzyloxy- carbonylammo)propionic acid, 3- [l-methyl-3- [3- (tetrahydropyrιmιd-2-ylamino)- propyl] ιndazol-6-ylcarbonylammo] -2- (2,4,6- trimethylbenzenesulfonylamino)propionic acid, 3- [3- [3- (tetrahydropyπmιd-2-ylammo)propyl]- indazol-6-ylcarbonylammo] -2- (benzenesulfonyl¬ ammo) propionic acid, 3- [l-methyl-3- [3- (tetrahydropyπmιd-2-ylammo) - propyl] ιndazol-6-ylcarbonylammo]-2- (2,6- dichlorobenzenesulfonylamino)propionic acid, 3- [3- [3- (tetrahydropyrιmιd-2-ylammo)propyl] - mdazol-6-ylcarbonylammo]-2-(3, 5-dimethyl- ιsoxazol-4-ylsulfonylammo)propionic acid, 3- [l-methyl-3- [3- (tetrahydropyπmιd-2-ylamιno)- propyl]mdazol-6-ylcarbonylammo] -2- (2,6- dimethylbenzenesulfonylamino)propionic acid, 3- [3- [3- (tetrahydropyrimid-2-ylammo)propyl] - mdazol-6-ylcarbonylammo]-2-(2, 6-dιmethyl-4- phenylbenzenesulfonylamino)propionic acid, 3- [l-methyl-3-[3- (tetrahydropyrιmιd-2-ylamιno)- propyl] -mdazol-6-ylcarbonylammo] -2-(4- phenylbenzenesulfonylamino)propionic acid, 3- [3- [3- (ιmιdazol-2-ylamino) propyl] mdazol-6-yl- carbonylammo] -2- (benzyloxycarbonylammo) - propionic acid, 3- [l-methyl-3- [3- (ιmιdazol-2-ylammo)propyl] - dazol-6-ylcarbonylammo] -2- (2, 4, 6-trιmethyl- benzenesulfonylamino)propionic acid, 3- [3- [3- (ιmιdazol-2-ylamιno) propyl] ιndazol-6-yl- carbonylamino] -2- (benzenesulfonylammo) - propionic acid, 3- [l-methyl-3- [3- (imidazol-2-ylammo)propyl] - indazol-6-ylcarbonylammo] -2- (2, 6-dιchloro- benzenesulfonylamino)propionic acid, 3- [3- [3- (imidazol-2-ylamino)propyl] mdazol-6-yl- carbonylamino] -2- (3, 5-dιmethylιsoxazol-4- ylsulfonylamino)propionic acid, 3- [l-methyl-3- [3- (imidazol-2-ylamino)propyl] - ιndazol-6-ylcarbonylammo] -2- (2, 6-dιmethyl- benzenesulfonylamino)propionic acid, 3- [3- [3- (imidazol-2-ylamino)propyl] mdazol-6-yl- carbonylammo] -2- (2, 6-dιmethyl-4-phenyl- benzenesulfonylamino)propionic acid, 3- [l-methyl-3- [3- (ιmιdazol-2-ylammo)propyl] - dazol-6-ylcarbonylammo] -2- (4-phenylbenzene- sulfonylamino)propionic acid, 3- [3- [3- (pyridm-2-ylammo) propyl] ιndazol-6-yl- carbonylamino] -2- (benzyloxycarbonylammo) - propionic ac d, 3- [l-methyl-3- [3- (pyridιn-2-ylammo)propyl] mdazol- 6-ylcarbonylamino] -2- (2,4, 6-tπmethylbenzene- sulfonylamino)propionic acid, 3- [3- [3- (pyrid -2-ylamino)propyl] mdazol-6-yl- carbonylamino] -2- (benzenesulfonylammo) - propionic acid, 3- [l-methyl-3- [3- (pyridm-2-ylamino)propyl] indazol- 6-ylcarbonylam o] -2- (2, 6-dichlorobenzene- sulfonylamino)propionic acid, 3- [3- [3- (pyrιdιn-2-yiam no)propylj ιndazol-5-yl- carbonylamino] -2- (3, 5-dιmethylιsoxazol-4- ylsulfonylammo)propionic acid, 3- [ l-methyl-3- [3- (pyrιdιn-2-ylamino)propyl]mdazol- 6-ylcarbonylamιno] -2- (2, 6-dιmethylbenzene- sulfonylamino)propionic acid, 3- [3- [3- (pyrιdιn-2-ylammo)propyl] mdazol-6-yl- carbonylamino] -2- (2, 6-dimethyl-4-phenyl- benzenesulfonylamino)propionic acid, 3- [l-methyl-3- [3- (pyridm-2-ylamino)propyl] mdazol- 6-ylcarbonylammo] -2- (4-phenylbenzenesulfonyl¬ amino)propionic acid, 3- [3- [3- (imidazolin-2-ylammo)propyl]indazol-7- ylcarbonylammo] -2- (benzyloxycarbonylammo) - propionic acid, 3- [l-methyl-3- [3- (ιmιdazolιn-2-ylamιno)propyl] - mdazol-7-ylcarbonylammo] -2- (2,4,6- tnmethylbenzenesulfonylamino)propionic acid, 3- [3- [3- (imidazolin-2-ylamino)propyl]mdazol-7- ylcarbonylammo] -2- (benzenesulfonylammo) propionic acid, 3- [l-methyl-3- [3- (imidazolin-2-ylamino)propyl] - indazol-7-ylcarbonylammo] -2- (2,6-dιchloro- benzenesulfonylamino)propionic acid, 3- [3- [3- (imidazolin-2-ylamino)propyl] mdazol-7- ylcarbonylammo] -2- (3,5-dιmethylιsoxazol-4- ylsulfonylamino)propionic acid, 3- [l-methyl-3-[3- (ιmιdazolm-2-ylamino)propyl] - indazol-7-ylcarbonylamιno]-2- (2,6-dιmethyl- benzenesulfonylammo)propionic acid, 3- [3-[3- (ιmιdazolιn-2-ylamino)propyl]mdazol-7- ylcarbonylamino] -2-(2,6-dimethyl-4-phenyl¬ benzenesulfonylamino)propionic acid, 3- [l-methyl-3-[3- (imidazolin-2-ylamino)propyl] - ιndazol-7-ylcarbonylammo]-2- (4-phenylbenzene- sulfonylamino)propionic acid, 3- [3- [3- (tetrahydropyr mιd-2-ylamιno) propyl] - ιndazoi-7-ylcarbonylammo] -2- (benzyloxy¬ carbonylammo)propionic acid, 3- [l-methyl-3- [3- (tetrahydropyrιmιd-2-ylamιno) - propyl] mdazol-7-ylcarbonylammo] -2- (2, 4, 6- trimethylbenzenesulfonylamino) propionic acid, 3- [3- [3- (tetrahydropyr mid-2-ylamino)propyl] - indazol-7-ylcarbonylammo] -2- (benzenesulfonyl¬ ammo) propionic acid, 3- [l-methyl-3- [3- (tetrahydropyrimid-2-ylamino) - propyl] ιndazol-7-ylcarbonylammo] -2- (2, 6- dichlorobenzenesulfonylamino)propionic acid, 3- [3- [3- (tetrahydropyrιmιd-2-ylamιno)propyl] - mdazol-7-ylcarbonylammo] -2- (3, 5-dιmethyl- isoxazol-4-ylsulfonylamino)propionic acid, 3- [l-methyl-3- [3- (tetrahydropyrimid-2-ylamino) - propyl] mdazol-7-ylcarbonylammo] -2- (2, 6- dimethylbenzenesulfonylamino)propionic acid, 3- [3- [3- (tetrahydropyrimid-2-ylam o)propyl] - mdazol-7-ylcarbonylammo] -2- (2, 6-dιmethyl-4- phenylbenzenesulfonylamino)propionic acid, 3- [l-methyl-3- [3- (tetrahydropyrimid-2-ylamino) - propyl] mdazol-7-ylcarbonylammo] -2- (4- phenylbenzenesulfonylamino)propionic acid, 3- [3- [3- (imidazol-2-ylammo)propyl] mdazol-7-yl- carbonylamino] -2- (benzyloxycarbonylammo) - propionic acid, 3- [l-methyl-3- [3- (imidazol-2-ylamino)propyl] - indazol-7-ylcarbonylammo] -2- (2,4, 6-trιmethyl- benzenesulfonylammo)propionic acid, 3- [3- [3- (ιmιdazol-2-ylamιno)propyl] mdazol-7-yl- carbony1ammo] -2- (benzenesulfonylammo) - propionic acid, 3- [l-methyl-3- [3- (imidazol-2-ylamino)propyl] - dazol-7-ylcarbonylammo] -2- (2, 6-dιchloro- benzenesulfonylamino)propionic acid, 3- [3- [3- (imidazol-2-ylamino) ropyl] ιndazol-7-yi- carbcnylamino] -2- (3, 5-dιmethylιsoxazol-4- ylsulfonylamino)propionic acid, 3- [l-methyl-3- [3- (imidazol-2-ylammo)propyl] - mdazol-7-ylcarbonylammo] -2- (2, 6-dιmethyl- benzenesulfonylamino)propionic acid, 3- [3- [3- (ιmιdazol-2-ylamino)propyl] mdazol-7-yl- carbonylamino] -2- (2, 6-dιmethyl-4-phenyl- benzenesulfonylamino)propionic acid, 3- [l-methyl-3- [3- (imidazol-2-ylamino)propyl] - indazol-7-ylcarbonylammo] -2-(4-phenylbenzene- sulfonylamino)propionic acid, 3- [3- [3- (pyrid -2-ylamino)propyl] mdazol-7-yl- carbonylamino] -2- (benzyloxycarbonylammo) - propionic acid, 3- [l-methyl-3- [3- (pyridin-2-ylamino)propyl] mdazol- 7-ylcarbonylammo]-2- (2,4,6-tπmethylbenzene- sulfonylamino)propionic acid, 3- [3- [3- (pyridin-2-ylamino)propyl] mdazol-7-yl- carbonylammo] -2- (benzenesulfonylammo) - propionic acid, 3- [l-methyl-3- [3- (pyridin-2-ylamino)propyl] indazol- 7-ylcarbonylammo]-2- (2,6-dιchlorobenzene- sulfonylamino)propionic acid, 3- [3- [3- (pyridm-2-ylamino)propyl]ιndazol-7-yl- carbonylamino]-2- (3,5-dιmethylιsoxazol-4- ylsulfonylamino)propionic acid, 3- [l-methyl-3-[3-(pyridm-2-ylammo)propyl]mdazol- 7-ylcarbonylamιno]-2- (2,6-dιmethylbenzene- sulfonylamino)propionic acid, 3- [3- [3- (pyrid -2-ylamino)propyl] mdazol-7-yl- carbonylamino] -2- (2,6-dimethyl- -phenyl- benzenesulfonylammo)propionic acid, and 3- [l-methyl-3- [3-(pyπdm-2-ylammo)propyl]indazol- 7-ylcarbonylammo]-2- (4-phenylbenzenesulfonyl¬ amino)propionic acid; and ester forms thereof, said esters being chosen from the group consisting of: methyl, ethyl, isopropyl, n-butyl, isobutyl, benzyl, methylcarbonyloxymethyl, ethylcarbonyloxymethyl, tert-butylcarbonyloxymethyl, cyclohexylcarbonyloxymethyl, tert-butyloxycarbonyloxymethyl, di ethylammoethyl, and diethylaminoethyl. 11. A compound of Formula Ic: IC and pharmaceutically acceptable salt forms thereof, wherein: X 1 , X 2 , X 3 , and X 4 are independently selected from nitrogen or carbon provided that at least two of X 1 , X 2 , X 3 and X 4 are carbon; R 1 is selected from: A and B are independently -CH 2 -, -0- , -N(R 2 )-, or -C(=0)-; A 1 and B 1 are independently -CH 2 - or -N(R 3 )-,- D is -N(R 2 )-, -0-, -S-, -C(=0)- or -S0 2 -,- E-F is -C(R )=C(R 5 )-, -N=C(R 4 )-, -C(R 4 )=N-, or -C(R 4 ) 2 C(R 5 ) 2 -; J, K, L and M are independently selected from -C(R 4 )-, -C(R 5 )- or -N-, provided that at least one of J, K, L and M is not -N-; R 2 is selected from: H, Ci-Cβ alkyl, (Ci-Cβ alkyl)carbonyl, (Ci-Cβ alkoxy) carbonyl; (Ci-Cβ alkyl)aminocarbonyl, C 3 -C 6 alkenyl, C3-C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, heteroaryl (Ci-C δ alkyl(carbonyl, heteroarylcarbonyl, aryl Cι-C 6 alkyl, (Ci-Ce alkyl) carbonyl, cr arylcarbonyl, Ci-Cg alkylsulfonyl, aryisulfonyi, aryKCi-Cβ alkyl)sulfonyl, he eroarylsulfonyl, heteroaryl (Ci-Cβ alkyl)sulfonyl, aryloxycarbonyl, or aryKCi-Cό alkoxy) carbonyl, wherein said aryl groups are substituted with 0-2 substituents selected from the group consisting of C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo, CF 3 , and nitro; R 3 is selected from: H, C -Cβ alkyl, C 3 -C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl(Cι-C 6 alkyl)-, or heteroaryl (Ci-Ce alkyl) - ■ R 4 and R 5 are independently selected from: H, C 1 -C 4 alkoxy, NR 2 R 3 , halogen, N0 , CN, CF 3 , Ci-Cβ alkyl, C 3 -C 6 alkenyl, C 3 -C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl (C_-C 6 alkyl)-, (Ci-Cβ alkyl) carbonyl, (Ci-Cβ alkoxy)carbonyl, arylcarbonyl, or alternatively, when substituents on adjacent atoms, R 4 and R 5 can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups selected from: C1-C4 alkyl, C 1 -C 4 alkoxy, halo, cyano, ammo, CF3, or N0 2 ; U is selected from: -(CH 2 ) n -, -(CH 2 ) n (CR 7 =CR 8 ) (CH 2 ) m - -(CH 2 ) n (CaC) (CH 2 ) m - -(CH 2 ) Q(CH 2 ) m - -(CH 2 ) n O(CH 2 ) πι - / -(CH 2 ) n N(R 6 ) (CH 2 ) m -, -(CH 2 ) n C(=0) (CH 2 ) m -, -(CH 2 ) n (C=0)N(R 6 ) (CH 2 ) m - -(CH 2 ) n N(R 6 ) (C=0) (CH 2 ) m -, or -(CH 2 ) n S(0) p (CH 2 ) m -; wherein one of the methylene groups is optionally substituted with R 7 ; Q is selected from 1, 2-cycloalkylene, 1, 2-phenylene, 1, 3-phenylene, 1, 4-phenylene, 2, 3-pyrιdinylene, 3, 4-pyridmylene, 2 , 4-pyπamyiene, or 3,4- pyridazmylene; R 6 is selected from: H, C 1 -C 4 alkyl, or benzyl; R 7 and R 8 are independently selected from: H, Ci-Ce alkyl, C 3 -C 7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl (Ci-Cβ alkyl)-, or heteroaryl (Co-Cβ alkyl)-,- R 9 is selected from: H, C0 2 R 17 , C(=0)R 17 , CONR 17 R 20 , -S0 2 R 17 , -S0 2 NR 17 R 20 , Ci-Cβ alkyl substituted with 0-1 R 15 or 0-1 R 21 , C3-C 6 alkenyl substituted with 0-1 R 15 or 0-1 R 21 , C 3 -C7 cycloalkyl substituted with 0-1 R 15 or 0-1 R 21 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 or 0-1 R 21 , aryl substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 , or aryKCi-Ce alkyl)- substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 ; R 11 is selected from H, halogen, CF 3 , CN, N0 2 , hydroxy, NR 2 R 3 , C 1 -C 4 alkyl substituted with 0-1 R 21 , C1-C4 alkoxy substituted with 0-1 R 21 , aryl substituted with 0-1 R 21 , aryKCi-Cβ alkyl)- substituted with 0-1 R 21 , (C 1 -C 4 alkoxy) carbonyl substituted with 0-1 R 21 , (C 1 -C4 alkyl) carbonyl substituted with 0-1 R 21 , C1-C4 alkylsulfonyl substituted with 0-1 R 21 , or C1-C4 alkylaminosulfonyl substituted with 0-1 R 21 ; W s selected from: - (C(R 12 ) 2 ) q C(=0)N(R 13 )-, or -C(=0)-N(R 13 )-(C(R 12 ) 2 ) q -; X is -C(R 12 ) (R 1 )-C(R 12 ) (R 15 )-; or alternatively, W and X can be taken together to be R 12 is selected from: H, halogen, Ci-Cβ alkyl, C 2 -C 6 alkenyl, C -Ce alkynyl, C3-C7 cycloalkyl, C 4 -C 10 cycloalkylalkyl, (C 1 -C 4 alkyl)carbonyl, aryl, or aryKCi-Cβ alkyl)-; R 13 is selected from: H, Ci-Cβ alkyl, C 3 -C7 cycloalkylmethyl, or aryKC . -Cβ alkyl) - R 14 is selected from: H, Ci-Ce alkylthio(Cι-C 6 alkyl)-, aryl(Cι-C_o alkylthioalkyl)-, aryl (C 1 -C 1 0 alkoxyalkyl) -, C1-C10 alkyl, C 1 -C 10 alkoxyalkyl, Ci-Cβ hydroxyalkyl, C2-C1 0 alkenyl, C 2 -Cιo alkynyl, C3-C10 cycloalkyl, C 3 -C 10 cycloalkylalkyl, aryKCi-Cβ alkyl ) -, heteroaryl (Ci-Cβ alkyl) -, aryl, heteroaryl, C0 2 R 17 , C(=0)R 17 , or C0NR 17 R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 0-1 R 16 or 0-2 R 11 ; R 15 is selected from: H, R 16 , Ci-Cio alkyl, Ci-Cio alkoxyalkyl, i-Cio alkylaminoalkyl, Ci-Cio dialkyla moalkyl, ( Ci-Cio alkyl ) carbonyl, aryl(Co-C ό alky ; carbonyl, i-Cio alkenyl, Ci-Cio alkynyl ,C 3 -Cιo cycloalkyl, C3-C10 cycloalkylalkyl, aryl (Cι-C 6 alkyl) -, heteroaryl (Cι-C 6 alkyl) -, aryl, heteroaryl, C0 R 1 , C(=0)R 17 , CONR 17 R 20 , S0 2 R 17 , or Ξ0 2 NR 17 R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 0-2 R 11 , Y is selected from: -COR 19 , -SO 3 H, -PO 3 H, tetrazolyl, -C0N?NHS0 2 CF 3 , -C0NHS0 2 R 17 , -C0NHS0 2 NHR 17 , -NHCOCF 3 , -NHCONHS0 2 R 17 , -NHS0 2 R 17 , -0P0 3 H 2 , -OSO 3 H, -Pθ 3 H 2 , -SO 3 H, -S0 NHCOR 17 , -S0 2 NHC0 2 R 17 , R 16 is selected from: -N(R 20 )-C(=O)-O-R 17 , -N(R 20 )-C(=O)-R 17 , -N(R 20 )-C(=O) -NH-R 17 , -N(R 20 )SO 2 -R 17 , or -N(R 20 )SO 2 -NR 20 R 17 R 17 is selected from: C 1 -C 10 alkyl, C 3 -C 11 cycloalkyl, aryl(Cι-C 6 alkyl ) -, (Ci-Cβ alkyl)aryl, heteroaryl (Ci-Cβ alkyl ) -, ( Ci-Cβ alkyl)heteroaryl, biaryl (Ci-Cβ alkyl) - . heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, C1-C4 alkoxy, aryl, heteroaryl, halo, cyano, amino, CF 3 , and N0 ; R 1 is selected from: H, -C(=0)-0-R 17 , -C(=0)-R 17 , -C(=0) -NH-R 17 , -S0 -R 17 , or -SO 2 -NR 20 R 1" ; R 19 is selected from hydroxy, C 1 -C 10 alkyloxy, C3-C11 cycloalkyloxy, aryloxy, aryKCi-Cβ alkoxy)-, C3-C10 alkylcarbonyloxyalkyloxy, C 3 -C 10 alkoxycarbonyloxyalkyloxy, C 2 -Cιo alkoxycarbonylalkyloxy, C5-C 10 cycloalkylcarbonyloxyalkyloxy, C5-C 10 cycloalkoxycarbonyloxyalkyloxy, C 5 -C 10 cycloalkoxycarbonylalkyloxy, C7-C 11 aryloxycarbonylalkyloxy, Cg-Cι 2 aryloxycarbonyloxyalkyloxy, Cβ-Cι 2 arylcarbonyloxyalkyloxy, C 5 -C 10 alkoxyalkylcarbonyloxyalkyloxy, 5 -C 10 (5-alkyl-l, 3-dioxa-cyclopenten-2-one- yDmethyloxy, C 10 -C 14 (5-aryl-l,3-dioxa-cyclopenten- 2-one-yDme hyloxy, or (R 11 ) (R 12 )N- (C 1 -C 1 0 alkoxy)-; R 20 is selected from: H, Ci-Cβ alkyl, C3-C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl (C_-C 6 alkyl) -, or heteroaryl (C -Ce alkyl) - ; R 21 is selected from COOH or NR 6 2 ; m is 0-4; with the following provisos: (1 ) z , n, m and q are chosen such that the number of atoms connecting R 1 and Y is in the range of 10-14; and (2) n and are chosen such that the value of n plus m is greater than one unless U is - ' rt 2 ; ! . >-n?)-n- . 12. A compound of Claim 11 of the Formula Ic Ic and pharmaceutically acceptable salt forms thereof wherein: X 1 , X 2 , X 3 , and X 4 are independently selected from nitrogen or carbon provided that at least two of X 1 , X 2 , X 3 and X 4 are carbon; R 1 is selected from: A and B are independently -CH 2 -, -0-, -N(R 2 )-, or -C(=0)-; A 1 and B 1 are independently -CH 2 - or -N(R 3 )-; D is -N(R 2 )-, -0-, -S-, -C(=0)- or -S0 2 -; -C(R ) 2 C(R 5 ) 2 -; J, K, L and M are independently selected from: -C(R 4 )-, -C(R 5 )- or -N-, provided that at least one of J, K, R 2 is selected from: H, Ci-Cδ alkyl, (Ci-Cβ alkyl)carbonyl, (Ci-Cβ alkoxy)carbonyl, Ci-Cβ alkylaminocarbonyl, C 3 -C 6 alkenyl, C3-C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, heteroaryl (Ci-Cβ alkyl)carbonyl, heteroarylcarbonyl, aryl (Ci-Cβ alkyl)-, (Ci-Ce alkyl) carbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, aryl(Cι-C6 alkyl)sulfonyl, heteroarylsulfonyl, heteroaryl (Cχ-Cβ alkyl) sulfonyl, aryloxycarbonyl, aryKCi-Ce alkoxy)carbonyl, wherein said aryl groups are substituted with 0-2 substituents selected from the group consisting of C 1 -C 4 alkyl, C1-C 4 alkoxy, halo, CF 3 , and nitro; R 3 is selected from: H, Cι-C 6 alkyl, C 3 -C7 cycloalkyl, C4-C11 cycloalkylalkyl, aryl, aryl (Cι-C 6 alkyl) -, or heteroaryl (C . -Ce alkyl)-,- R 4 and R 5 are independently selected from: H, C 1 -C 4 alkoxy, NR 2 R 3 , halogen, N0 2 , CN, CF 3 , \ -C 6 alkyl, C3-C 6 alkenyl, C3-C7 cycloalkyl, C 4 -C 1 . cycloalkylalkyl, aryl, aryl (Cι-C 6 alkyl) -, C 2 -C 7 alkylcarbonyl, arylcarbonyl or alternatively, when substituents on adjacent atoms, R 4 and R 5 can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring beinςr optionally substituted with 0-2 groups selected from: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo, cyano, amiro, CF 3 , or N0 2; U is selected from: -(CH 2 ) n -, -(CH 2 )n(CR 7 =CR θ ) (CH 2 ) m - -(CH 2 )_Q(CH 2 )-,,-, -(CH 2 ) n O(CH 2 ) m -, -(CH 2 ) n N(R 6 ) (CH 2 ) m-. -(CH 2 ) n C(=0) (CH 2 ) m -, or -(CH 2 ) n S(0) p (CH 2 ) m -; wherein one of the methylene groups is optionally substituted with R 7 ; Q is selected frc:n 1, 2-cr-enyle:.6, 1, j -pheny _ene, 2,3- pyrid ylene, 3 , 4-cyr idmyieπe, or 2,4- pyridinylene; R 6 is selected from: H, C_-C 4 alkyl, or benzyl; R 7 and R 8 are independently selected from: H, Ci-C ό alkyl, C3-C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryKCi-Cβ alkyl)-, or heteroaryl (C 0 -C 0 alkyl)-,. R 9 is selected from: H, C0 2 R 17 , C(=0)R 17 , CONR 17 R 20 , -S0 R 17 , -S0 2 NR 17 R 20 , Cι-C 6 alkyl substituted with 0-1 R 15 or 0-1 R 21 , C 3 -C 6 alkenyl substituted with 0-1 R 15 or 0-1 R 21 , C 3 -C7 cycloalkyl substituted with 0-1 R 15 or 0-1 R 21 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 or 0-1 R 21 , aryl substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 , or aryl(Cι-C 6 alkyl)- substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 ; RH i S selected from: H, halogen, CF 3 , CN, N0 2 , hydroxy, NR 2 R 3 , C 1 -C 4 alkyl substituted with 0-1 R 21 , C1-C4 alkoxy substituted with 0-1 R 21 , aryl substituted with 0-1 R 21 , arγl(Cι-C 6 alkyl)- substituted with 0-1 R 21 , (C 1 -C 4 alkoxy)carbonyl substituted with 0-1 R 21 , (C 1 -C 4 alkyl) carbonyl substituted with 0-1 R 21 , C 1 -C4 alkylsulfonyl substituted with 0-1 R 21 , or C1-C4 alkylaminosulfonyl substituted with 0-1 R 21 ; W is -C(=0)-N(R 13 )-(C(R 12 ) ) q -; X is -C(R 12 ) (R 14 )-C(R 12 ) (R 15 )-; alternatively, and X can be taken together to be R 1Z s H or Ci-C ό alkyl; R 13 is selected from: H, C \ -C ό alkyl, C3-C7 cycloalkylmethyl, or aryl(Cι-C 6 alkyl)-; R 14 is selected from: H, Cι-C 6 alkylthioalkyl, aryl(Cι-Cιo alkylthioalkyl)-, aryl(C_-Cιo alkoxyalkyl)-, C 1 -C 10 alkyl, C -C 1 0 alkoxyalkyl, Cι-C 6 hydroxyalkyl, C -Cιo alkenyl, C -Cι 0 alkynyl, C 3 -C 10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl(Cι-C 6 alkyl)-, heteroaryl (Ci-Cβ alkyl)-, aryl, heteroaryl, C0 R 17 , C(=0)R 17 , or CONR 17 R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 0-1 R 16 or 0-2 R 11 ; R 15 is selected from: H, R 16 , C 1 -C 10 alkyl, C 1 -C10 alkoxyalkyl, C 1 -C 10 alkylam oalkyl , C 1 -C 10 dialkylaminoalkyl, C 1 -C 10 alkylcarbonyl, aryl(Co-C 6 alkyl ) carbonyl , C 2 -Cιo alkenyl, C -Cιo alkynyl ,C 3 -Cιo cycloalkyl, C 3 -C 10 cycloalkylalkyl, aryl(Cι-C 6 alkyl)-, heteroaryl (Ci-Cβ alkyl)-, aryl, heteroaryl, C0 2 R 17 , C(=0)R 17 , CONR 17 R 20 , S0 2 R 17 , or S0 NR 17 P 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 0-2 R 11 ,- Y is selected from: -COR 19 , -SO 3 H, R 17 is selected from: Ci-Cio alkyl, C3-C11 cycloalkyl, aryKCi-Cβ alkyl)-, (Ci-Cβ alkyl)aryl, heteroaryl (Cι-C 6 alkyl)-, (Ci-Cβ alkyl)heteroaryl, biaryl(Cι-C 6 alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, heteroaryl, halo,cyano, amino, CF 3 , and N0 2 ; R 18 is selected from: H, -C(=0)-0-R 17 , -C(=0)-R 17 , -C(=0)-NH-R 17 , -S0 2 -R 17 , or -SO 2 -NR 20 R 17 ; R 19 is selected from: hydroxy, C 1 -C 1 0 alkyloxy, C 3 -C 11 cycloalkyloxy, CΘ-CIO aryloxy, C 7 -C 11 aralkyloxy, C 3 -C 10 alkylcarbonyloxyalkyloxy, C 3 -C 10 alkoxycarbonyloxyalkyloxy, C 2 -Cιo alkoxycarbonylalkyloxy, C5-C10 cycloaikyicarbonyloxyalkyloxy, C5-C10 cycloalkoxycarbonyloxyalkyloxy, C5-C 1 0 cycloalkoxycarbonylalkyloxy, C7-C 11 aryloxycarbonylalkyloxy, Cg-Cχ aryloxycarbonyloxyalkyloxy, C^-Cι 2 arylcarbonyloxyalkyloxy, C5-C10 alkoxyalkylcarbonyloxyalkyloxy, C5-C10 (5-alkyl-1, 3-dιoxa-cyclopenten-. -one- yDmethyloxy, C10-C14 (5-aryl-l, 3-dιoxa-cyclopenten- 2-one-yl)methyloxy, or (R 11 ) (R 12 ) N- (C 1 -C 10 alkoxy)-; R 20 selected from: H, Cι-C 6 alkyl, C 3 -C7 cycloalkyl, C 4 - C 11 cycloalkylalkyl, aryl(Cι-C 6 alkyl)-, or heteroaryl (Ci-Ce alkyl)-,. R21 1S selected from COOH or NR 6 2 ; and 13. A compound of Claim 11 of the Formula He or Ilf: He Ilf and pharmaceutically acceptable salt forms thereof, wherein: R 1 is selected from: — D : UNRfi H O wherein the above heterocycles are optionally substituted with 0-2 substituents selected from the group consisting of: NH 2 , halogen, N0 2 , CN, CF 3 , C 1 -C 4 alkoxy, C -Cβ alkyl, and C3-C7 cycloalkyl; U is -(CH 2 ) n -, - vCH 2 ) . QJCH^ m - or -C(=0) (CH 2 ) n _ι-, wherein one of the methylene groups is optionally substituted with R 7 ; Q is selected from I,2-phenylene, 1, -phenylene, 2,3- pyridinylene, 3,4-pyridinylene, or 2,4- pyridinylene; R 6 is selected from: H, C 1 -Z 4 alkyl, or benzyl; R7 is selected from: Cι-C 6 alkyl, C 3 -C 7 cycloalkyl, C4-C11 cycloalkylalkyl, aryl, aryl(Cι-C 6 alkyl), neteroaryl, or heteroaryl (Ci-Cβ alkyl); R 9 is selected from: H, -S0 2 R 17 , -S0 2 NR 17 R 20 , Cι-C 6 alkyl substituted with 0-1 R 15 or 0-1 R 21 , C 3 -C 7 cycloalkyl substituted with 0-1 R 15 or 0-1 R 21 , C4-C11 cycloalkylalkyl substituted with 0-1 R 15 or 0-1 R 21 , aryl substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 , or aryKCi-Ce alkyl)- substitu-ed with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 ; R 11 is selected from H, halogen, CF 3 , CN, N0 2 , hydroxy, NR 2 R 3 , C 1 -C 4 alkyl substituted with 0-1 R 21 , C 1 -C 4 alkoxy substituted with 0-1 R 21 , aryl substituted with 0-1 R 21 , aryl(Cι-C 6 alkyl)- substi uted with 0-1 R 21 , (C 1 -C 4 alkoxy) carbonyl substitαted with 0-1 R 21 , (C 1 -C 4 alkyl) carbonyl substituted ith 0-1 R 21 , C 1 -C 4 alkylsulfonyl substituted with 0-1 R 21 , or C 1 -C 4 alkyla mosulfonyl substituted with 0-1 R 21 ; X is -CH(R 14 )-CH(R 15 )-; R 14 is selected from: H, C 1 -C 10 alkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl groups are optιonal..y substituted with 0-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, C1-C4 alkoxy, aryl, halo, cyano, ammo, CF3, and N0 ; R 17 is selected from: Ci-Cio alkyl, C3-C11 cycloalkyl, aryl(Cι-C 6 alkyl)-, (Ci-Cβ alkyl) aryl, heteroaryl (Ci-Cβ alkyl)-, (Ci-Ce alkyl) heteroaryl, bιaryl(Cι-C6 alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, heteroaryl, halo, cyano, amino, CF 3 , and N0 2 ; R 19 is selected from: hydroxy, C 1 -C 1 0 alkoxy, methylcarbonyloxymethoxy-, ethylcarbonyloxymethoxy- , C-butylcarbonyloxymethoxy-, cyclohexylcarbonyloxymethoxy- , 1- (methylcarbonyloxy)ethoxy-, 1- (ethylcarbonyloxy)ethoxy-, 1- (t-butylcarbonyloxy) ethoxy- , 1- (cyclohexylcarbonyloxy)ethoxy-, i-propyloxycarbonyloxymethoxy-, t-butyloxycarbonyloxymethoxy-, 1- (i-propyloxycarbonyloxy) ethoxy-, 1- (cyclohexyloxycarbonyloxy) ethoxy-, 1- ( c-butylcxycarbonyioxy)ethoxy-, dimethyla inoethoxy- , diethylammoethoxy-, ( 5-methyl-l, 3-dioxacyclopenten-2-on-4-yDmethoxy-, (5- ( -butyl) -1, 3-dioxacyclopenten-2-cn-4- yl)methoxy-, (1, 3-dioxa-5-phenyl-cyclopenten-2-on-4-yl)methoxy-, or 1- (2- (2-methoxypropyl) carbonyloxy) ethoxy-; R 21 is selected from COOH or NR 6 2 ; and n is 1-4; and t. is 0 cr 1. 14. A compound of Claim 11 of the Formula He or Ilf: and pharmaceutically acceptable salt forms thereof, wherein: R 1 is selected from: wherein the above heterocycles are optionally substituted with 0-2 substituents selected from the group consisting of: NH 2 , halogen, N0 2 , CN, CF 3 , C 1 -C 4 alkoxy, Cι-C 6 alkyl, and C 3 -C7 cycloalkyl: U is -(CH 2 ) n -, - ;CH 2 ) -Q' H-./ I ,- or -C (=0) (CH 2 ) n -χ-, wherein one of the methylene groups is optionally substituted with R 7 ; Q s selected from 1, -phenylene, 1, -phenylene, 2,3- pyridinylene, 3 , 4-pyr dιnyler.e, or 2,4- pyridinylene; R 6 selected from: H, C 1 -C 4 alkyl, or benzyl; R7 is selected from Ci-Cβ alkyl, C 3 -C7 cycloalkyl, C4-C11 cycloalkylalkyl, aryl, aryKCi-Cβ alkyl), heteroaryl, or heteroaryl (Ci-Cβ alkyl); R 9 is selected from: H, -S0 2 R 17 , -S0 2 NR 17 R 20 , Cχ-C 6 alkyl substituted with 0-1 R 15 or 0-1 R 21 , C 3 -2 7 cycloalkyl substituted with 0-1 R 15 or C-l R 21 , C4-C11 cycloalkylalkyl substituted with 0-1 R 15 or 0-1 R 21 , aryl substituted with 0-1 R 15 cr 0-2 R 11 or 0-1 R 21 , or aryl(Cι-C 6 alkyl)- substituted with 0-1 R 15 or 0-2 R 11 or 0-1 R 21 ; R 11 is selected from H, halogen, CF 3 , CN, N0 2 , hydroxy, NR 2 R 3 , C 1 -C 4 alkyl substituted with 0-1 R 21 , C 1 -C 4 alkoxy substituted with 0-1 R 21 , aryl substituted with 0-1 R 21 , aryl(Cι-Cδ alkyl)- substituted with 0-1 R 21 , (C 1 -C4 alkoxy) carbonyl substituted with 0-1 R 21 , (C 1 -C 4 alkyl) carbonyl substituted with 0-1 R 21 , C 1 -C 4 alkylsulfonyl substituted with 0-1 R 21 , or C 1 -C 4 alkylaminosulfonyl substituted with 0-1 R 21 ;W is -C(=0)-N(R 13 )-; R 14 is selected from: H, C 1 -C 10 alkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, C1-C4 alkoxy, aryl, halo, cyano, amino, CF3, and N0 2 ; R 15 is H or R 16 ; R lδ s selected from: -NH(R 20 )-C(=O)-O-R 17 , -N(R 0 )-C(=O)-R 17 , -N(R 20 )-C(=O)-NH-R 17 , -N(R 20 )SO 2 -R 17 , or -N(R 20 )SO 2 -NR 20 R 17 ; R 17 is selected from: Ci-Cio alkyl, C3-C11 cycloalkyl, aryl(Cι-C 6 alkyl)-, (Ci-Cβ alkyl) aryl, heteroaryl (Ci-Cβ alkyl)-, (Cι-C 6 alkyl ) heteroaryl, biaryKCi-Cβ alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, heteroaryl, halo, cyano, amino, CF 3 , and N0 2 ; R 19 is selected from: hydroxy, Cχ-Cιo alkoxy, methylcarbonyloxymethoxy-, ethylcarbonyloxymethoxy-, t-butylcarbonyloxymethoxy-, cyclohexylcarbonyloxymethoxy-, 1- (methylcarbonyloxy)ethoxy-, 1- (ethylcarbonyloxy)ethoxy-, 1- (t-butylcarbonyloxy) ethoxy-, 1- (cyclohexylcarbonyloxy) ethoxy-, i-propyloxycarbonyloxymethoxy-, t-butyloxycarbonyloxymethoxy-, 1- (i-propyloxycarbonyloxy)ethoxy-, 1- (cyclohexyloxycarbonyloxy)ethoxy-, 1- ( t-butyloxycarbonyloxy)ethoxy-, dimethylaminoethoxy-, diethylaminoethoxy-, (5-methyl-1,3-dioxacyclopenten-2-on-4-yDmethoxy-, ( 5- ( t-butyl) -1, 3-dιoxacyclopenten-2-on-4- yl) ethoxy- , ( 1, 3-dιoκa-5-phenyl-cyclopenten-2-on-4-yl)methoxy- , or 1- (2- (2-methoxypropyl) carbonyloxy) ethoxy-; R 21 is selected from COOH or NR 6 ; and .Tl 13 J Cl _.; 15. A method for the treatment of cancer metastasis, diabetic retinopathy, neovascular glaucoma, thrombosis, restenosis, osteoporosis, or macular degeneration which comprises administering to a host in need of such treatment a therapeutically effective amount of a compound of Claim 1-14. 16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a coτipound of Claim 1-14.

Inventors: BATT DOUGLAS GUY, JADHAV PRABHAKAR KONDAJI, PETRAITIS JOSEPH JAMES, BATT, DOUGLAS, GUY, JADHAV, PRABHAKAR, KONDAJI, PETRAITIS, JOSEPH, JAMES
Applicants: BATT DOUGLAS GUY, DU PONT MERCK PHARMA, JADHAV PRABHAKAR KONDAJI, PETRAITIS JOSEPH JAMES, BATT, DOUGLAS, GUY, JADHAV, PRABHAKAR, KONDAJI, PETRAITIS, JOSEPH, JAMES, THE DU PONT MERCK PHARMACEUTICAL COMPANY
Application year: 1996
Main classification: C07D403
IPC codes: A61K31, A61P7, A61P19, A61P27, A61P35, A61P43, C07D401, C07D403, C07D405, C07D409, C07D413, C07D417, C07D471, C07D487